# Supplementary Information

A Quantitative Basis for Antiretroviral Therapy for HIV-1 Infection

Benjamin L. Jilek[1], Melissa Zarr[2], Maame E. Sampah[1], S. Alireza Rabi[1], Cynthia K. Bullen[1], Jun Lai[1], Lin Shen[1,2] and Robert F. Siliciano[1,2,3]

Departments of Medicine[1] and Pharmacology and Molecular Sciences[2], Johns Hopkins University School of Medicine, and Howard Hughes Medical Institute[3], Baltimore MD

Figure S1. Dose-response curves for the PIs DRV (a), LPV (b), NFV (c), and RTV (d) in primary CD4$^+$ T cells. Thin colored lines represent curves obtained in CD4$^+$ T cells from different donors. The thick orange line is the mean curve. The pink shaded region represents the actual clinical concentration range for the relevant drugs.

Figure S2. Extrapolation of median effect plots. **(A)** Plots of logarithmic measures of inhibition based on the critical subset model with parameters chosen to fit the dose response curve of the NNRTI efavirenz (see L. Shen et al, *Sci. Trans. Med.* 3, 91ra63, 2011). Specifically, in this example, $n_T = 4 \pm 1$, $c = 3$, and $K_d = 0.018$ µM. Note that even at extremely high levels of inhibition, these plots do not inflect downward. **(B)** Plots of logarithmic measures of inhibition based on the critical subset model with parameters chosen to fit the lower portion of dose response curve for the PI lopinavir (see L. Shen et al, *Sci. Trans. Med.* 3, 91ra63, 2011). Specifically, in this example, $n_T = 12 \pm 5$, $c = 2$ and $K_d = 0.0068$ µM. Note that even at extremely high levels of inhibition, these plots do not inflect downward. In fact, experimental PI dose response curves inflect upward due to the combined effects of protease inhibition on multiple downstream steps in the virus life cycle.

Figure S3 presents a 19×19 matrix of drug-drug combinations. Each cell contains two P values: the top value corresponds to the Bliss model and the bottom value to the Loewe model. Values >0.05 are in bold. Cell colors indicate: Synergy (bright green), Bliss (light green), Int. (yellow), Loewe (orange), Antag. (red), ND (gray).

	AZT	d4T	3TC	FTC	ddI	TDF	ABC	NVP	ETR	EFV	RAL	ELV	RTV	ATV	DRV	LPV	NFV	ENF	MVC
AZT		0.0008 / 0.9802	0.0041 / 0.0000	0.0000 / 0.0000	0.0140 / 0.0029	0.0001 / 0.0000	0.0021 / 0.0004	0.0547 / 0.0183	0.0116 / 0.0061	0.0000 / 0.0000	0.1981 / 0.0000	0.3341 / 0.0000	0.1778 / 0.0095	0.0027 / 0.0381	0.0025 / 0.0066	0.1515 / 0.0098	0.3241 / 0.0450	0.2952 / 0.0000	0.3562 / 0.0001
d4T	0.0008 / 0.9802		0.0513 / 0.0026	0.0045 / 0.0006	0.0011 / 0.0012	0.0017 / 0.0005	0.0101 / 0.0011	0.0418 / 0.0011	0.0117 / 0.0017	0.0008 / 0.0004	0.0949 / 0.0000	0.6133 / 0.0001	0.0920 / 0.0049	0.0077 / 0.0542	0.6706 / 0.0444	0.0019 / 0.0094	0.1820 / 0.0217	0.2954 / 0.0000	0.5409 / 0.0037
3TC	0.0041 / 0.0000	0.0513 / 0.0026		0.0140 / 0.4799	0.0015 / 0.0945	0.1327 / 0.0005	0.0014 / 0.0133	0.0103 / 0.0020	0.0194 / 0.0183	0.0000 / 0.0000	0.9681 / 0.0000	0.0345 / 0.0000	0.0014 / 0.0156	0.0000 / 0.0000	0.0944 / 0.0192	0.0495 / 0.0245	0.0978 / 0.0173	0.5965 / 0.0000	0.0372 / 0.0025
FTC	0.0000 / 0.0000	0.0045 / 0.0006	0.0140 / 0.4799		0.0211 / 0.0800	0.0051 / 0.0681	0.0099 / 0.7581	0.0146 / 0.0029	0.0104 / 0.0076	0.0040 / 0.0000	0.8500 / 0.0066	0.7611 / 0.0008	0.0079 / 0.0008	0.0000 / 0.0000	0.0004 / 0.0003	0.0001 / 0.0000	0.1667 / 0.0078	0.0142 / 0.0003	0.1747 / 0.0029
ddI	0.0140 / 0.0029	0.0011 / 0.0012	0.0015 / 0.0945	0.0211 / 0.0800		0.0016 / 0.4263	0.0017 / 0.0038	0.1683 / 0.0001	0.0047 / 0.2775	0.0001 / 0.0000	0.5521 / 0.0048	0.4496 / 0.0021	0.0075 / 0.0539	0.0753 / 0.0043	0.0002 / 0.0000	0.0595 / 0.0065	0.0109 / 0.0036	0.0546 / 0.0001	0.1348 / 0.0017
TDF	0.0001 / 0.0000	0.0017 / 0.0005	0.1327 / 0.0005	0.0051 / 0.0681	0.0016 / 0.4263		0.0022 / 0.9874	0.9329 / 0.0217	0.0068 / 0.0668	0.0854 / 0.0008	0.4843 / 0.0052	0.5159 / 0.0005	0.0096 / 0.0096	0.0000 / 0.0000	0.0000 / 0.0012	0.0004 / 0.0000	0.0256 / 0.0279	0.0236 / 0.0005	0.0034 / 0.0002
ABC	0.0021 / 0.0004	0.0101 / 0.0011	0.0014 / 0.0133	0.0099 / 0.7581	0.0017 / 0.0038	0.0022 / 0.9874		0.0274 / 0.0003	0.0100 / 0.0376	0.2376 / 0.0068	0.1376 / 0.0001	0.8620 / 0.0008	0.0053 / 0.0324	0.0098 / 0.0025	0.1277 / 0.0015	0.0644 / 0.0223	0.2907 / 0.0056	0.0507 / 0.0001	0.0140 / 0.0001
NVP	0.0547 / 0.0183	0.0418 / 0.0011	0.0103 / 0.0020	0.0146 / 0.0029	0.1683 / 0.0001	0.9329 / 0.0217	0.0274 / 0.0003		0.0017 / 0.0190	0.0305 / 0.6342	0.4601 / 0.0017	0.1182 / 0.0223	0.0846 / 0.0718	0.0200 / 0.0001	0.0034 / 0.0043	0.3090 / 0.0028	0.4324 / 0.0006	0.1394 / 0.0011	0.0196 / 0.0057
ETR	0.0116 / 0.0061	0.0117 / 0.0017	0.0194 / 0.0183	0.0104 / 0.0076	0.0047 / 0.2775	0.0068 / 0.0668	0.0100 / 0.0376	0.0017 / 0.0190		0.0499 / 0.3854	0.0672 / 0.0000	0.1922 / 0.0044	0.0883 / 0.0474	0.1507 / 0.0039	0.6379 / 0.0006	0.2210 / 0.0064	0.0111 / 0.0064	0.4843 / 0.0039	0.0419 / 0.0051
EFV	0.0000 / 0.0000	0.0008 / 0.0004	0.0000 / 0.0000	0.0040 / 0.0000	0.0001 / 0.0000	0.0854 / 0.0008	0.2376 / 0.0068	0.0305 / 0.6342	0.0499 / 0.3854		0.2924 / 0.0061	0.6194 / 0.0013	0.1041 / 0.0001	0.1970 / 0.0105	0.0590 / 0.0016	0.3444 / 0.0000	0.1484 / 0.0039	0.1559 / 0.0000	0.0035 / 0.0105
RAL	0.1981 / 0.0000	0.0949 / 0.0000	0.9681 / 0.0000	0.8500 / 0.0066	0.5521 / 0.0048	0.4843 / 0.0052	0.1376 / 0.0001	0.4601 / 0.0017	0.0672 / 0.0000	0.2924 / 0.0061		0.0078 / 0.7004	0.7567 / 0.0034	0.1012 / 0.0002	0.5038 / 0.0008	0.0121 / 0.0001	0.0137 / 0.0002	0.1368 / 0.0006	0.0371 / 0.0075
ELV	0.3341 / 0.0000	0.6133 / 0.0001	0.0345 / 0.0000	0.7611 / 0.0008	0.4496 / 0.0021	0.5159 / 0.0005	0.8620 / 0.0008	0.1182 / 0.0223	0.1922 / 0.0044	0.6194 / 0.0013	0.0078 / 0.7004		0.1939 / 0.0000	0.0897 / 0.0001	0.9202 / 0.0001	0.0319 / 0.0001	0.0659 / 0.0038	0.7744 / 0.0116	0.9409 / 0.0219
RTV	0.1778 / 0.0095	0.0920 / 0.0049	0.0014 / 0.0156	0.0079 / 0.0008	0.0075 / 0.0539	0.0096 / 0.0096	0.0053 / 0.0324	0.0846 / 0.0718	0.0883 / 0.0474	0.1041 / 0.0001	0.7567 / 0.0034	0.1939 / 0.0000		0.0132 / 0.0062	0.9944 / 0.0050	0.0018 / 0.0030	0.0028 / 0.1053	0.0160 / 0.2053	ND
ATV	0.0027 / 0.0381	0.0077 / 0.0542	0.0000 / 0.0000	0.0000 / 0.0000	0.0753 / 0.0043	0.0000 / 0.0000	0.0098 / 0.0025	0.0200 / 0.0001	0.1507 / 0.0039	0.1970 / 0.0105	0.1012 / 0.0002	0.0897 / 0.0001	0.0132 / 0.0062		0.0470 / 0.0050	0.0004 / 0.0100	0.0207 / 0.0296	0.0494 / 0.0016	ND
DRV	0.0025 / 0.0066	0.6706 / 0.0444	0.0944 / 0.0192	0.0004 / 0.0003	0.0002 / 0.0000	0.0000 / 0.0012	0.1277 / 0.0015	0.0034 / 0.0043	0.6379 / 0.0006	0.0590 / 0.0016	0.5038 / 0.0008	0.9202 / 0.0001	0.9944 / 0.0050	0.0470 / 0.0050		0.0522 / 0.1461	0.4917 / 0.0568	0.0149 / 0.8353	ND
LPV	0.1515 / 0.0098	0.0019 / 0.0094	0.0495 / 0.0245	0.0001 / 0.0000	0.0595 / 0.0065	0.0004 / 0.0000	0.0644 / 0.0223	0.3090 / 0.0028	0.2210 / 0.0064	0.3444 / 0.0000	0.0121 / 0.0001	0.0319 / 0.0001	0.0018 / 0.0030	0.0004 / 0.0100	0.0522 / 0.1461		0.0172 / 0.1256	0.0105 / 0.0039	ND
NFV	0.3241 / 0.0450	0.1820 / 0.0217	0.0978 / 0.0173	0.1667 / 0.0078	0.0109 / 0.0036	0.0256 / 0.0279	0.2907 / 0.0056	0.4324 / 0.0006	0.0111 / 0.0064	0.1484 / 0.0039	0.0137 / 0.0002	0.0659 / 0.0038	0.0028 / 0.1053	0.0207 / 0.0296	0.4917 / 0.0568	0.0172 / 0.1256		0.3974 / 0.0002	ND
ENF	0.2952 / 0.0000	0.2954 / 0.0000	0.5965 / 0.0000	0.0142 / 0.0003	0.0546 / 0.0001	0.0236 / 0.0005	0.0507 / 0.0001	0.1394 / 0.0011	0.4843 / 0.0039	0.1559 / 0.0000	0.1368 / 0.0006	0.7744 / 0.0116	0.0160 / 0.2053	0.0494 / 0.0016	0.0149 / 0.8353	0.0105 / 0.0039	0.3974 / 0.0002		0.0590 / 0.0010
MVC	0.3562 / 0.0001	0.5409 / 0.0037	0.0372 / 0.0025	0.1747 / 0.0029	0.1348 / 0.0017	0.0034 / 0.0002	0.0140 / 0.0001	0.0196 / 0.0057	0.0419 / 0.0051	0.0035 / 0.0105	0.0371 / 0.0075	0.9409 / 0.0219	ND	ND	ND	ND	ND	0.0590 / 0.0010	

Synergy	Bliss	Int.	Loewe	Antag	ND

Figure S3. *P* values for differences between experimentally observed inhibition by combinations of two drugs and predictions of the Bliss (top) and Loewe (bottom) models. Comparisons are based on a paired analysis transformed inhibition values, $\log[(1-f_u)/f_u]$, for individual donors at concentrations giving the best separation between the predictions of the two models. *P* values >0.05 are in **bold**. Combinations giving inhibition consistent with a single model are indicated in light green (Bliss) or orange (Loewe). Combinations for which the experimental inhibition was significantly greater than the predictions of either model are indicated in bright green (synergy). Intermediate inhibition consistent with neither or both models is indicated in yellow. Antagonism, defined as inhibition significantly below the predictions of both models, was not observed in this analysis. As described above, MVC-PI combinations could not be done (ND).

Figure S4. Individual variation in combination effects for pairs of antiretroviral drugs. For each combination, combined effects were examine in cells from 4-12 different donors and characterized as fitting the Loewe or Bliss models, showing synergy or antagonism, or an intermediate pattern as described in **Fig. 2f**. For each combination, a pie chart reflects the fraction of individuals showing each mode of interaction. For a statistical analysis of this individual variation, see **Supplementary Fig. S3**. Because of the lower levels of infection achieved with R5-tropic pseudoviruses, PI-MVC combinations could not be analyzed.

Figure S5. Relationship between predicted and experimental values of IIP_{1+2+3} for three different prediction methods. Ten selected three drug combinations were tested at concentrations chosen to maximize the difference between the Loewe and Bliss predictions while remaining within the dynamic range of the assay. Experimental three drug inhibition was compared to three drug predictions of the Loewe and Bliss models made using the equations in **Fig. 3** and to a 3 drug prediction based on a weighted average of the pairwise *DI* index values determined from two drug trials within each experiment. The dotted line represents a perfect correlation between predicted and experimental values. The *DI* index method consistently predicted experimentally results more accurately than either of the standard models. Note that the Bliss model consistently overestimates the combined effect except for one regimen (NVP/ENF/RAL, arrow) specifically chosen because all of the pairwise 2 drug interactions followed this model (**Fig. 2f**).

Legend:

△ Gilead 934   ● Scan   ◆ ACTG 298

▲ Merck 035   ● Dupont 006   ● CNAAB 3005

▲ CNA 3014   ● ESS 30009   ● CNA 30024

◆ EFV 30021   ◆ CNA 30021   ■ ACTG 1542

◆ MERIT   ■ STARTMRK   ▲ DuPont 006

■ Gilead 903   ● CLASS   ● 2NN

■ Gilead FTC 301A   ● ACTG 5095   △ BMS 034

▲ BMS AI 424424-007   ■ CASTLE   ● BMS 089

● ALERT   ■ CNA 3005   ■ AB M02-418

▼ AB M98-863   ◆ KLEAN   ● ARTEMIS

△ ACTG 5142   ■ GEMINI   ◆ INITIO

▲ SOLO   ◆ NEAT   ◆ BMS 008

◆ Agouron 542   ▲ BMS 007   ◆ AL 454-152

△ Atlantic   ● AI 454-148   ◆ ACTG 384

◆ NAHWP   ◆ Combine

Figure S6. Relationship between clinical outcome and $IIP_{\text{ave}_{1+2+3}}$ values. Clinical outcome is based on results of published comparative clinical trials of regimens comprised of 19 commonly used antiretroviral drugs, for which sufficient pharmacokinetic and pharmacodynamic data were available to calculate $IIP_{\text{ave}_{1+2+3}}$ using the *DI* index method. The % of patients in each arm plasma HIV-1 RNA levels below 50 copies/ml at 48 weeks in an intent-to-treat analysis is plotted against the estimated $IIP_{\text{ave}_{1+2+3}}$ of the regimen. Early regimens for which virologic suppression was not achieved are indicated as $< 20\%$. For statistical analysis, results from each arm are considered independently. Clinical trial results are compiled in *Medical Management of HIV Infection*, J.D. Bartlett, J. E. Gallant, and P.A. Pham, editors, Knowledge Source Solutions, Durham NC, 2009. This source contains original references for trial results.

Figure S7. Defining m' and IC_{50}'. For dose-response curves that inflect upward at drug concentrations below the clinical concentration range ($C_{min}<D<C_{max}$, pink shaded area), the behavior of the dose-response curve in the clinical concentration range was estimated using the median-effect model (dotted orange line, Equation 2), with parameters m' and IC_{50}' chosen using region of the measured dose-response curve closest to the clinical concentration range as described in Supplementary Information, Methods. m^* is the slope of a best fit line through the data points for which $\log[(1-f_u)/f_u] < 0$. When the dose-response curves inflect, IC_{50}' is expected to differ from IC_{50}. For curves that inflect upward, $m' > m^*$.

SupplementaryTable S1. Mean IC_{50} and m values for antiretroviral drugs.

Drug	Class	IC_{50} (μM) [a]	$\log IC_{50}$ ± SD [a]	IC_{50}' (μM) [b]	$\log IC_{50}'$ ± SD [b]	m ± SD [c]	m' ± SD [d]	m^* ± SD [e]	P for m' vs. m^*	n [f]
AZT	NRTI	1.7594	0.25 ± 0.62	1.7447	0.24 ± 0.64	0.62 ± 0.18	0.62 ± 0.21	0.60 ± 0.43	0.3654	45
d4T	NRTI	1.0966	0.04 ± 0.33	1.0832	0.03 ± 0.37	1.25 ± 0.22	0.84 ± 0.20	0.85 ± 0.44	0.6760	44
3TC	NRTI	0.0558	-1.25 ± 0.22	0.0557	-1.25 ± 0.23	0.97 ± 0.11	1.13 ± 0.25	1.12 ± 0.27	0.9786	49
FTC	NRTI	0.0112	-1.95 ± 0.30	0.0284	-1.55 ± 0.47	0.92 ± 0.12	1.22 ± 0.33	1.06 ± 0.55	0.0934	54
ABC	NRTI	0.0594	-1.23 ± 0.23	0.0777	-1.11 ± 0.65	0.85 ± 0.08	1.05 ± 0.23	1.22 ± 0.23	**0.0078** [g]	40
ddI	NRTI	0.1368	-0.86 ± 0.36	1.8086	0.26 ± 0.26	1.12 ± 0.15	2.25 ± 0.88	1.35 ± 0.76	**0.0151**	34
TDF	NRTI	0.0138	-1.86 ± 0.95	0.0130	-1.89 ± 0.64	0.92 ± 0.17	0.42 ± 0.13	ND [h]	ND [h]	46
EFV	NNRTI	0.0058	-2.24 ± 0.13	0.0146	-1.83 ± 0.18	1.69 ± 0.23	2.56 ± 0.50	1.40 ± 0.61	**<0.0001**	34
NVP	NNRTI	0.0891	-1.05 ± 0.18	0.2262	-0.65 ± 0.22	1.55 ± 0.18	2.36 ± 0.62	1.13 ± 0.62	**<0.0001**	28
ETR	NNRTI	0.0055	-2.26 ± 0.10	0.0112	-1.95 ± 0.13	1.85 ± 0.17	2.98 ± 0.45	0.95 ± 0.61	**<0.0001**	24
ATV	PI	0.0163	-1.79 ± 0.11	0.0183	-1.74 ± 0.07	2.18 ± 0.25	3.52 ± 0.41	0.98 ± 0.50	**<0.0001**	30
DRV	PI	0.0264	-1.58 ± 0.07	0.0259	-1.59 ± 0.06	2.14 ± 0.27	4.12 ± 0.42	0.76 ± 0.33	**<0.0001**	34
LPV	PI	0.0684	-1.16 ± 0.06	0.0702	-1.15 ± 0.04	2.07 ± 0.24	3.22 ± 0.31	1.32 ± 0.54	**<0.0001**	26
NFV	PI	0.3056	-0.51 ± 0.09	0.3433	-0.46 ± 0.06	1.93 ± 0.36	3.14 ± 0.64	1.07 ± 0.66	**<0.0001**	20
RTV	PI	0.1531	-0.82 ± 0.09	0.1742	-0.76 ± 0.06	2.14 ± 0.26	3.17 ± 0.22	1.36 ± 0.56	**<0.0001**	19
RAL	InSTI	0.0428	-1.37 ± 0.26	0.0418	-1.38 ± 0.27	0.98 ± 0.12	0.91 ± 0.13	1.00 ± 0.35	0.1599	33
EVG	InSTI	0.0632	-1.20 ± 0.33	0.0595	-1.23 ± 0.31	0.93 ± 0.12	0.87 ± 0.26	0.80 ± 0.51	0.7043	35
ENF	FI	0.0253	-1.60 ± 0.24	0.0207	-1.68 ± 0.33	1.57 ± 0.21	1.64 ± 0.29	0.94 ± 0.34	**<0.0001**	23
MVC	CRA	0.0010	-2.99 ± 0.65	0.0013	-2.89 ± 0.94	0.61 ± 0.17	0.68 ± 0.18	0.60 ± 0.30	0.6198	12

[a]Geometric mean IC_{50} values obtained from n individual donors/drug. IC_{50} values followed a log normal distribution. The standard deviation (SD) is given for log transformed IC_{50} values.

[b]Geometric mean IC_{50}' values obtained from n individual donors/drug. IC_{50}' values were determined from m' and the y-intercept of a linear regression line best representing the dose-response curve in the clinical concentration range as described in Methods. IC_{50}' values are expected to differ from actual IC_{50} values in cases where the median-effect plots are non-linear. IC_{50}' values follow a log normal distribution. SD is given for log transformed IC_{50}' values.

[c]Mean and SD of the slopes obtained from n individual donors/drug. For each donor, the slope was computed using linear regression analysis of median-effect plots covering the entire dynamic range of the infectivity assay.

[d]Mean and SD of m' values obtained from n individual donors/drug . m' is the slope of a linear regression line best representing the median-effect plot in the clinical concentration range (see Methods).

[e]Mean and SD of $m*$ values obtained from n individual donors/drug . $m*$ is the slope of a linear regression line through the region median-effect plot for which $D<IC_{50}$.

[f]n is the number of donors analyzed for a given drug.

[g]P values <0.05 are in bold

[h]The extremely shallow nature of the TDF dose response curve in and below the clinical concentrations range precluded accurate measurement of $m*$.

Supplementary Table S2. Statistical significance of differences in *m′* values for different antiretroviral drugs[a].

	AZT	d4T	3TC	FTC	ABC	ddI	TDF	EFV	NVP	ETR	ATV	DRV	LPV	NFV	RTV	RAL	EVG	ENF	MVC
AZT	■	2.3×10^{-06}	1.1×10^{-17}	2.1×10^{-15}	3.5×10^{-13}	2.8×10^{-15}	9.2×10^{-05}	9.7×10^{-27}	1.5×10^{-18}	2.7×10^{-25}	7.8×10^{-32}	1.6×10^{-25}	1.3×10^{-38}	1.1×10^{-14}	1.0×10^{-29}	9.1×10^{-11}	2.3×10^{-03}	5.3×10^{-19}	**0.3268[b]**
d4T	2.3×10^{-06}	■	1.6×10^{-08}	6.2×10^{-09}	5.0×10^{-05}	6.9×10^{-13}	7.3×10^{-16}	3.1×10^{-24}	1.1×10^{-16}	1.4×10^{-23}	5.1×10^{-30}	2.3×10^{-24}	4.2×10^{-36}	8.3×10^{-14}	1.2×10^{-27}	5.0×10^{-02}	**0.7745**	1.6×10^{-14}	1.4×10^{-02}
3TC	1.1×10^{-17}	1.6×10^{-08}	■	**0.0541**	**0.1052**	1.6×10^{-09}	1.3×10^{-26}	2.2×10^{-21}	3.1×10^{-14}	1.8×10^{-22}	1.0×10^{-29}	2.5×10^{-23}	6.6×10^{-36}	7.8×10^{-13}	1.8×10^{-28}	3.1×10^{-06}	9.2×10^{-04}	7.9×10^{-08}	2.3×10^{-07}
FTC	2.1×10^{-15}	6.2×10^{-09}	**0.0541**	■	2.1×10^{-03}	1.3×10^{-07}	1.3×10^{-20}	4.0×10^{-20}	4.1×10^{-13}	6.9×10^{-24}	3.2×10^{-33}	2.6×10^{-24}	2.2×10^{-38}	5.7×10^{-13}	4.2×10^{-33}	4.0×10^{-07}	2.4×10^{-05}	4.6×10^{-04}	2.0×10^{-09}
ABC	3.5×10^{-13}	5.0×10^{-05}	**0.1052**	2.1×10^{-03}	■	1.6×10^{-10}	5.6×10^{-21}	1.6×10^{-22}	4.4×10^{-15}	2.9×10^{-23}	1.6×10^{-30}	7.0×10^{-24}	9.1×10^{-37}	3.0×10^{-13}	2.9×10^{-29}	4.2×10^{-03}	1.9×10^{-02}	1.0×10^{-09}	6.0×10^{-06}
ddI	2.8×10^{-15}	6.9×10^{-13}	1.6×10^{-09}	1.3×10^{-07}	1.6×10^{-10}	■	7.5×10^{-17}	9.9×10^{-04}	1.1×10^{-02}	9.0×10^{-09}	1.5×10^{-15}	2.0×10^{-17}	3.3×10^{-13}	2.3×10^{-07}	1.1×10^{-11}	5.3×10^{-12}	2.9×10^{-12}	6.5×10^{-04}	2.1×10^{-14}
TDF	9.2×10^{-05}	7.3×10^{-16}	1.3×10^{-26}	1.3×10^{-20}	5.6×10^{-21}	7.5×10^{-17}	■	1.3×10^{-27}	1.6×10^{-19}	2.2×10^{-25}	2.3×10^{-31}	6.8×10^{-26}	1.0×10^{-37}	4.5×10^{-15}	2.9×10^{-28}	3.0×10^{-22}	3.0×10^{-06}	1.2×10^{-21}	8.8×10^{-04}
EFV	9.7×10^{-27}	3.1×10^{-24}	2.2×10^{-21}	4.0×10^{-20}	1.6×10^{-22}	9.9×10^{-04}	1.3×10^{-27}	■	**0.5890**	2.5×10^{-04}	1.2×10^{-12}	1.5×10^{-13}	4.7×10^{-10}	7.2×10^{-04}	3.7×10^{-08}	1.0×10^{-22}	5.3×10^{-23}	4.5×10^{-14}	2.8×10^{-24}
NVP	1.5×10^{-18}	1.1×10^{-16}	3.1×10^{-14}	4.1×10^{-13}	4.4×10^{-15}	1.1×10^{-02}	1.6×10^{-19}	**0.5890**	■	3.4×10^{-04}	1.5×10^{-10}	3.8×10^{-13}	3.6×10^{-08}	4.6×10^{-04}	8.9×10^{-07}	8.4×10^{-16}	5.4×10^{-17}	3.6×10^{-09}	3.2×10^{-18}
ETR	2.7×10^{-25}	1.4×10^{-23}	1.8×10^{-22}	6.9×10^{-24}	2.9×10^{-23}	9.0×10^{-09}	2.2×10^{-25}	2.5×10^{-04}	3.4×10^{-04}	■	1.5×10^{-05}	1.3×10^{-08}	4.9×10^{-03}	**0.3755**	**0.0777**	4.4×10^{-22}	4.0×10^{-25}	1.4×10^{-19}	1.1×10^{-24}
ATV	7.8×10^{-32}	5.1×10^{-30}	1.0×10^{-29}	3.2×10^{-33}	1.6×10^{-30}	1.5×10^{-15}	2.3×10^{-31}	1.2×10^{-12}	1.5×10^{-10}	1.5×10^{-05}	■	1.7×10^{-03}	2.0×10^{-02}	2.1×10^{-02}	3.6×10^{-04}	6.6×10^{-28}	4.0×10^{-31}	2.0×10^{-28}	1.0×10^{-29}
DRV	1.6×10^{-25}	2.3×10^{-24}	2.5×10^{-23}	2.6×10^{-24}	7.0×10^{-24}	2.0×10^{-17}	6.8×10^{-26}	1.5×10^{-13}	3.8×10^{-13}	1.3×10^{-08}	1.7×10^{-03}	■	6.5×10^{-06}	2.6×10^{-05}	2.9×10^{-07}	1.5×10^{-23}	1.5×10^{-26}	2.8×10^{-22}	3.2×10^{-26}
LPV	1.3×10^{-38}	4.2×10^{-36}	6.6×10^{-36}	2.2×10^{-38}	9.1×10^{-37}	3.3×10^{-13}	1.0×10^{-37}	4.7×10^{-10}	3.6×10^{-08}	4.9×10^{-03}	2.0×10^{-02}	6.5×10^{-06}	■	**0.3148**	**0.1285**	8.9×10^{-33}	9.6×10^{-31}	5.2×10^{-30}	2.5×10^{-29}
NFV	1.1×10^{-14}	8.3×10^{-14}	7.8×10^{-13}	5.7×10^{-13}	3.0×10^{-13}	2.3×10^{-07}	4.5×10^{-15}	7.2×10^{-04}	4.6×10^{-04}	**0.3755**	2.1×10^{-02}	2.6×10^{-05}	**0.3148**	■	**0.8333**	2.6×10^{-13}	4.2×10^{-15}	2.9×10^{-11}	3.6×10^{-15}
RTV	1.0×10^{-29}	1.2×10^{-27}	1.8×10^{-28}	4.2×10^{-33}	2.9×10^{-29}	1.1×10^{-11}	2.9×10^{-28}	3.7×10^{-08}	8.9×10^{-07}	**0.0777**	3.6×10^{-04}	2.9×10^{-07}	**0.1285**	**0.8333**	■	2.6×10^{-24}	1.5×10^{-26}	4.3×10^{-26}	3.4×10^{-24}
RAL	9.1×10^{-11}	5.0×10^{-02}	3.1×10^{-06}	4.0×10^{-07}	4.2×10^{-03}	5.3×10^{-12}	3.0×10^{-22}	1.0×10^{-22}	8.4×10^{-16}	4.4×10^{-22}	6.6×10^{-28}	1.5×10^{-23}	8.9×10^{-33}	2.6×10^{-13}	2.6×10^{-24}	■	**0.4354**	7.6×10^{-13}	7.2×10^{-04}
EVG	2.3×10^{-03}	**0.7745**	9.2×10^{-04}	2.4×10^{-05}	1.9×10^{-02}	2.9×10^{-12}	3.0×10^{-06}	5.3×10^{-23}	5.4×10^{-17}	4.0×10^{-25}	4.0×10^{-31}	1.5×10^{-26}	9.6×10^{-31}	4.2×10^{-15}	1.5×10^{-26}	**0.4354**	■	2.1×10^{-10}	3.7×10^{-02}
ENF	5.3×10^{-19}	1.6×10^{-14}	7.9×10^{-08}	4.6×10^{-04}	1.0×10^{-09}	6.5×10^{-04}	1.2×10^{-21}	4.5×10^{-14}	3.6×10^{-09}	1.4×10^{-19}	2.0×10^{-28}	2.8×10^{-22}	5.2×10^{-30}	2.9×10^{-11}	4.3×10^{-26}	7.6×10^{-13}	2.1×10^{-10}	■	7.6×10^{-14}
MVC	**0.3268**	1.4×10^{-02}	2.3×10^{-07}	2.0×10^{-09}	6.0×10^{-06}	2.1×10^{-14}	8.8×10^{-04}	2.8×10^{-24}	3.2×10^{-18}	1.1×10^{-24}	1.0×10^{-29}	3.2×10^{-26}	2.5×10^{-29}	3.6×10^{-15}	3.4×10^{-24}	7.2×10^{-04}	3.7×10^{-02}	7.6×10^{-14}	■

[a] *P* values for the differences in *m′* between pairs of antiretroviral drugs based on the analysis of cells from ~35 donors/drug. *m′* is the slope of a linear regression line best representing the median-effect plot in the clinical concentration range (see Methods). Values of *m′* are given in **Supplementary Table S1**. *P* values are not corrected for multiple comparisons because each comparison between a particular pair of antiretroviral drugs is unique. As shown in **Supplementary Table S1**, slopes within a class are similar but can be very different between classes. For example, PIs have much higher slopes than NRTIs. The differences are highly significant (range of *P* values: 2.3×10^{-07} - 1.3×10^{-38} for 35 NRTI-PI comparisons) and remain so even after correction for multiple comparisons.

[b] Differences that did <u>not</u> achieve statistical significance are in **bold**.

Supplementary Table S3. Calculation of IIP_{ave} values for single drugs.

Drug	Class	Dose (mg)	Dosing interval τ (hr)	C_{max}[a] (µM)	$t_{1/2}$[b] (hr)	$IIP_{ave} \pm SD$[c]
AZT	NRTI	300	12	4.45	8.5	0.41 ± 0.23
d4T	NRTI	40	12	2.32	3.5	0.28 ± 0.13
3TC	NRTI	300	24	15.29	10	2.44 ± 0.50
FTC	NRTI	200	24	6.80	39	2.70 ± 0.85
ABC	NRTI	600	24	13.45	18	2.03 ± 0.59
ddI	NRTI	400	24	39.37	18	2.21 ± 1.07
TDF	NRTI	300	24	1.06	180	0.89 ± 0.46
EFV	NNRTI	600	24	12.97	47.5	7.45 ± 1.31
NVP	NNRTI	400	24	25.16	21.5	4.67 ± 1.48
ETR	NNRTI	200	12	1.62	41	6.35 ± 1.00
ATV/r[d]	PI	300/100[d]	24	6.26	8.6	7.28 ± 1.46
DRV/r[d]	PI	600/100[d]	12	14.79	15	10.55 ± 2.10
LPV/r[d]	PI	400/100[d]	12	15.58	9.9	7.01 ± 0.67
NFV	PI	1250	12	7.04	4.25	2.81 ± 0.67
RTV[e]	PI	100	24	1.36	4.8	0.92 ± 0.17
RAL	InSTI	400	12	4.50	9.5	1.83 ± 0.38
EVG/c[f]	InSTI	150	24	5.94	9.15	1.51 ± 0.33
ENF	FI	90	12	1.11	3.8	2.07 ± 0.69
MVC	CRA	300	12	0.56	16	1.71 ± 0.89

[a]C_{max} values were taken from published pharmacokinetic studies summarized in by Acosta et al. (Acosta, E. P., Gerber, J. G. & Kuritzkes, D. R. in HIV Third Edition pp115-136. Libman, H.and Makadon, H.J. Eds. American College of Physicians, 2007) or package insert information.

[b]$t_{1/2}$ values were taken from published pharmacokinetic studies cited above. For NRTIs, $t_{1/2}$ is for the intracellular triphosphate form.

[c]Mean and SD of IIP_{ave} values calculated for individual donors as described in Supplemental Information, Methods. Individual variability in pharmacodynamics parameters gives rise to some variability in IIP_{ave}. However, the differences in IIP_{ave} values for different drugs are highly significant for most comparisons (**Supplementary Table S4**). This analysis does not consider individual variation in pharmacokinetics,

which is likely to provide additional variation. Nevertheless, the striking multilog differences in IIP_{ave}

provide insight into the general activity of these drugs in populations of patients.

[d]Pharmacokinetic data are for coadminstration (boosting) with 100 mg RTV.

[e]The C_{max} for RTV is for the 100 mg dose used for pharmacokinetic boosting.

[f]Pharmacokinetic data are for coadminstration (boosting) with cobicistat.

Supplementary Table S4. Statistical significance of differences in IIP_{ave} values for different antiretroviral drugs[a].

	AZT	d4T	3TC	FTC	ABC	ddI	TDF	EFV	NVP	ETR	ATV	DRV	LPV	NFV	RTV[c]	RAL	EVG	ENF	MVC
AZT	■	7.8×10^{-04}	1.7×10^{-36}	1.9×10^{-27}	3.4×10^{-21}	5.7×10^{-12}	2.4×10^{-05}	1.0×10^{-26}	1.7×10^{-17}	2.9×10^{-20}	7.4×10^{-22}	6.8×10^{-25}	8.9×10^{-29}	5.3×10^{-13}	1.5×10^{-12}	3.6×10^{-24}	6.7×10^{-24}	$4.0\times1^{0-11}$	3.6×10^{-04}
d4T	7.8×10^{-04}	■	5.7×10^{-35}	8.0×10^{-28}	8.6×10^{-22}	1.2×10^{-12}	3.9×10^{-07}	1.5×10^{-26}	1.3×10^{-17}	4.4×10^{-20}	7.3×10^{-22}	6.3×10^{-25}	1.6×10^{-27}	4.3×10^{-13}	2.4×10^{-14}	2.2×10^{-23}	6.8×10^{-24}	1.4×10^{-11}	1.6×10^{-04}
3TC	1.7×10^{-36}	5.7×10^{-35}	■	**0.0537[b]**	8.2×10^{-10}	**0.2148**	5.3×10^{-19}	2.8×10^{-23}	6.7×10^{-11}	2.7×10^{-17}	2.4×10^{-18}	2.1×10^{-22}	2.4×10^{-29}	3.5×10^{-02}	9.9×10^{-28}	2.5×10^{-08}	2.6×10^{-16}	3.1×10^{-02}	1.8×10^{-02}
FTC	1.9×10^{-27}	8.0×10^{-28}	**0.0537**	■	2.5×10^{-10}	1.8×10^{-02}	6.4×10^{-20}	2.2×10^{-24}	1.1×10^{-09}	3.3×10^{-18}	9.3×10^{-19}	5.1×10^{-23}	2.5×10^{-33}	**0.5926**	6.3×10^{-22}	5.7×10^{-09}	4.3×10^{-14}	1.3×10^{-03}	2.9×10^{-03}
ABC	3.4×10^{-21}	8.6×10^{-22}	8.2×10^{-10}	2.5×10^{-10}	■	1.0×10^{-02}	5.8×10^{-09}	9.8×10^{-26}	3.6×10^{-14}	1.4×10^{-19}	2.3×10^{-20}	8.6×10^{-24}	1.7×10^{-32}	3.5×10^{-07}	1.9×10^{-12}	**0.2223**	4.0×10^{-02}	3.1×10^{-02}	**0.9861**
ddI	5.7×10^{-12}	1.2×10^{-12}	**0.2148**	1.8×10^{-02}	1.0×10^{-02}	■	1.5×10^{-08}	1.2×10^{-26}	8.0×10^{-12}	1.4×10^{-20}	3.0×10^{-21}	1.8×10^{-25}	3.0×10^{-29}	1.1×10^{-02}	1.4×10^{-08}	4.7×10^{-02}	3.7×10^{-04}	**0.5602**	**0.1233**
TDF	2.4×10^{-05}	3.9×10^{-07}	5.3×10^{-19}	6.4×10^{-20}	5.8×10^{-09}	1.5×10^{-08}	■	1.3×10^{-28}	1.7×10^{-17}	3.2×10^{-22}	1.1×10^{-22}	1.9×10^{-25}	1.7×10^{-35}	2.2×10^{-12}	**0.7729**	5.1×10^{-11}	6.7×10^{-07}	2.9×10^{-08}	9.4×10^{-03}
EFV	1.0×10^{-26}	1.5×10^{-26}	2.8×10^{-23}	2.2×10^{-24}	9.8×10^{-26}	1.2×10^{-26}	1.3×10^{-28}	■	2.9×10^{-12}	6.3×10^{-04}	**0.6368**	1.1×10^{-09}	**0.1017**	7.1×10^{-23}	7.9×10^{-26}	9.1×10^{-25}	3.9×10^{-25}	2.9×10^{-26}	2.2×10^{-16}
NVP	1.7×10^{-17}	1.3×10^{-17}	6.7×10^{-11}	1.1×10^{-09}	3.6×10^{-14}	8.0×10^{-12}	1.7×10^{-17}	2.9×10^{-12}	■	1.1×10^{-06}	6.0×10^{-10}	2.1×10^{-19}	1.7×10^{-11}	1.5×10^{-08}	3.7×10^{-16}	1.8×10^{-13}	1.6×10^{-14}	1.3×10^{-12}	2.3×10^{-09}
ETR	2.9×10^{-20}	4.4×10^{-20}	2.7×10^{-17}	3.3×10^{-18}	1.4×10^{-19}	1.4×10^{-20}	3.2×10^{-22}	6.3×10^{-04}	1.1×10^{-06}	■	7.6×10^{-03}	9.0×10^{-14}	9.2×10^{-03}	4.4×10^{-17}	1.6×10^{-19}	1.1×10^{-18}	5.5×10^{-19}	2.7×10^{-20}	2.8×10^{-13}
ATV	7.4×10^{-22}	7.3×10^{-22}	2.4×10^{-18}	9.3×10^{-19}	2.3×10^{-20}	3.0×10^{-21}	1.1×10^{-22}	**0.6368**	6.0×10^{-10}	7.6×10^{-03}	■	8.8×10^{-10}	**0.3713**	2.2×10^{-18}	5.1×10^{-21}	1.0×10^{-19}	3.4×10^{-20}	5.7×10^{-21}	2.6×10^{-16}
DRV	6.8×10^{-25}	6.3×10^{-25}	2.1×10^{-22}	5.1×10^{-23}	8.6×10^{-24}	1.8×10^{-25}	1.9×10^{-25}	1.1×10^{-09}	2.1×10^{-19}	9.0×10^{-14}	8.8×10^{-10}	■	1.3×10^{-11}	2.4×10^{-23}	3.0×10^{-24}	2.5×10^{-23}	1.2×10^{-23}	7.4×10^{-25}	3.8×10^{-23}
LPV	8.9×10^{-29}	1.6×10^{-27}	2.4×10^{-29}	2.5×10^{-33}	1.7×10^{-32}	3.0×10^{-29}	1.7×10^{-35}	**0.0107**	1.7×10^{-11}	9.2×10^{-03}	**0.3713**	1.3×10^{-11}	■	1.2×10^{-23}	2.2×10^{-28}	3.8×10^{-30}	1.7×10^{-29}	1.4×10^{-28}	1.2×10^{-12}
NFV	5.3×10^{-13}	4.3×10^{-13}	3.5×10^{-02}	**0.5926**	3.5×10^{-07}	1.1×10^{-02}	2.2×10^{-12}	7.1×10^{-23}	1.5×10^{-08}	4.4×10^{-17}	2.2×10^{-18}	2.4×10^{-23}	1.2×10^{-23}	■	3.7×10^{-11}	2.6×10^{-06}	2.1×10^{-08}	1.1×10^{-03}	1.6×10^{-03}
RTV[c]	1.5×10^{-12}	2.4×10^{-14}	9.9×10^{-28}	6.3×10^{-22}	1.9×10^{-12}	1.4×10^{-08}	**0.7729**	7.9×10^{-26}	3.7×10^{-16}	1.6×10^{-19}	5.1×10^{-21}	3.0×10^{-24}	2.2×10^{-28}	3.7×10^{-11}	■	7.4×10^{-16}	1.3×10^{-11}	4.0×10^{-08}	1.1×10^{-02}
RAL	3.6×10^{-24}	2.2×10^{-23}	2.5×10^{-08}	5.7×10^{-09}	**0.2223**	4.7×10^{-02}	5.1×10^{-11}	9.1×10^{-25}	1.8×10^{-13}	1.1×10^{-18}	1.0×10^{-19}	2.5×10^{-23}	3.8×10^{-30}	2.6×10^{-06}	7.4×10^{-16}	■	3.7×10^{-04}	**0.1355**	**0.6572**
EVG	6.7×10^{-24}	6.8×10^{-24}	2.6×10^{-16}	4.3×10^{-14}	4.0×10^{-02}	3.7×10^{-04}	6.7×10^{-07}	3.9×10^{-25}	1.6×10^{-14}	5.5×10^{-19}	3.4×10^{-20}	1.2×10^{-23}	1.7×10^{-29}	2.1×10^{-08}	1.3×10^{-11}	3.7×10^{-04}	■	9.6×10^{-04}	**0.4516**
ENF	4.0×10^{-11}	1.4×10^{-11}	3.1×10^{-02}	1.3×10^{-03}	3.1×10^{-02}	**0.5602**	2.9×10^{-08}	2.9×10^{-26}	1.3×10^{-12}	2.7×10^{-20}	5.7×10^{-21}	7.4×10^{-25}	1.4×10^{-28}	1.1×10^{-03}	4.0×10^{-08}	**0.1355**	9.6×10^{-04}	■	**0.2329**
MVC	3.6×10^{-04}	1.6×10^{-04}	1.8×10^{-02}	2.9×10^{-03}	**0.9861**	**0.1233**	9.4×10^{-03}	2.2×10^{-16}	2.3×10^{-09}	2.8×10^{-13}	2.6×10^{-16}	3.8×10^{-23}	1.2×10^{-12}	1.6×10^{-03}	1.1×10^{-02}	**0.6572**	**0.4516**	**0.2329**	■

[a]*P* values for the differences in IIP_{ave} between pairs of antiretroviral drugs based on the analysis of cells from ~35 donors/drug. IIP_{ave} values are given in

Supplementary Table S3.

[b]Differences that did <u>not</u> achieve statistical significance are in **bold**.

[c]IIP_{ave} values for RTV are based on concentrations achieved with the 100 mg qd boosting dose.

Supplementary Table S5. Mean and SD of *DI* index values for drug combinations[a].

	AZT	d4T	3TC	FTC	ddI	TDF	ABC	NVP	ETR	EFV	RAL	ELV	RTV	ATV	DRV	LPV	NFV	ENF	MVC[b]
AZT		0.00 ±0.18	1.64 ±0.29	2.07 ±0.27	2.30 ±0.52	2.82 ±0.72	2.52 ±0.48	2.30 ±0.60	3.75 ±0.68	4.23 ±0.75	1.06 ±0.09	1.15 ±0.28	0.78 ±0.26	0.34 ±0.13	0.63 ±0.05	1.36 ±0.44	1.21 ±0.69	1.20 ±0.47	0.94 ±0.14
d4T	0.00 ±0.18		1.68 ±0.45	1.68 ±0.14	2.92 ±0.61	3.24 ±0.57	2.02 ±0.52	1.87 ±0.48	1.80 ±0.28	2.61 ±0.17	1.29 ±0.36	1.16 ±0.36	0.72 ±0.24	0.36 ±0.22	0.88 ±0.50	0.63 ±0.25	0.65 ±0.50	1.07 ±0.20	0.91 ±0.32
3TC	1.64 ±0.29	1.68 ±0.45		0.07 ±0.18	0.24 ±0.39	0.78 ±0.63	0.20 ±0.13	0.55 ±0.18	0.24 ±0.16	0.45 ±0.19	1.01 ±0.11	1.25 ±0.20	0.37 ±0.12	0.40 ±0.30	0.62 ±0.27	0.49 ±0.25	0.62 ±0.37	1.10 ±0.45	1.75 ±0.54
FTC	2.07 ±0.27	1.68 ±0.14	0.07 ±0.18		0.31 ±0.26	0.33 ±0.20	0.03 ±0.05	0.63 ±0.10	0.19 ±0.09	0.46 ±0.06	1.08 ±0.45	1.06 ±0.23	0.53 ±0.18	0.56 ±0.19	0.50 ±0.22	0.62 ±0.25	0.74 ±0.26	0.75 ±0.24	1.16 ±0.18
ddI	2.30 ±0.52	2.92 ±0.61	0.24 ±0.39	0.31 ±0.26		-0.05 ±0.13	0.21 ±0.10	0.82 ±0.37	-0.04 ±0.06	0.55 ±0.14	0.91 ±0.28	1.17 ±0.32	0.26 ±0.19	0.71 ±0.20	0.49 ±0.17	0.74 ±0.18	0.63 ±0.34	0.82 ±0.23	1.12 ±0.11
TDF	2.82 ±0.72	3.24 ±0.57	0.78 ±0.63	0.33 ±0.20	-0.05 ±0.13		-0.03 ±0.30	1.03 ±0.24	0.16 ±0.11	0.71 ±0.40	1.19 ±0.45	0.97 ±0.08	0.47 ±0.17	0.42 ±0.12	0.45 ±0.12	0.50 ±0.23	0.47 ±0.24	0.65 ±0.50	1.43 ±0.10
ABC	2.52 ±0.48	2.02 ±0.52	0.20 ±0.13	0.03 ±0.05	0.21 ±0.10	-0.03 ±0.30		0.62 ±0.21	0.17 ±0.10	0.76 ±0.89	0.90 ±0.13	1.04 ±0.36	0.41 ±0.19	0.55 ±0.13	0.78 ±0.20	0.54 ±0.27	0.82 ±0.46	0.77 ±0.53	1.33 ±0.21
NVP	2.30 ±0.60	1.87 ±0.48	0.55 ±0.18	0.63 ±0.10	0.82 ±0.37	1.03 ±0.24	0.62 ±0.21		-0.12 ±0.09	0.07 ±0.16	1.14 ±0.29	1.82 ±0.60	0.80 ± 0.00	0.64 ±0.46	0.43 ±0.31	0.87 ±0.23	1.08 ±0.15	0.84 ±0.26	1.64 ±0.27
ETR	3.75 ±0.68	1.80 ±0.28	0.24 ±0.16	0.19 ±0.09	-0.04 ±0.06	0.16 ±0.11	0.17 ±0.10	-0.12 ±0.09		0.19 ±0.29	0.84 ±0.23	0.88 ±0.16	0.53 ±0.33	0.78 ±0.21	0.99 ±0.63	0.82 ±0.24	1.49 ±0.13	0.92 ±0.47	1.80 ±0.48
EFV	4.23 ±0.75	2.61 ±0.17	0.45 ±0.19	0.46 ±0.06	0.55 ±0.14	0.71 ±0.40	0.76 ±0.89	0.07 ±0.16	0.19 ±0.29		1.30 ±0.45	1.07 ±0.20	0.81 ±0.21	0.74 ±0.45	0.70 ±0.26	0.93 ±0.21	1.27 ±0.26	0.89 ±0.27	1.67 ±0.12
RAL	1.06 ±0.09	1.29 ±0.36	1.01 ±0.11	1.08 ±0.45	0.91 ±0.28	1.19 ±0.45	0.90 ±0.13	1.14 ±0.29	0.84 ±0.23	1.30 ±0.45		0.04 ±0.13	0.97 ±0.32	1.52 ±0.73	1.12 ±0.40	1.32 ±0.25	1.90 ±0.40	1.14 ±0.15	1.36 ±0.20
ELV	1.15 ±0.28	1.16 ±0.36	1.25 ±0.20	1.06 ±0.23	1.17 ±0.32	0.97 ±0.08	1.04 ±0.36	1.82 ±0.60	0.88 ±0.16	1.07 ±0.20	0.04 ±0.13		1.25 ± 0.25	1.51 ±0.54	1.04 ±0.24	1.57 ±0.48	1.32 ±0.21	0.98 ±0.34	1.05 ±0.32
RTV	0.78 ±0.26	0.72 ±0.24	0.37 ±0.12	0.53 ±0.18	0.26 ±0.19	0.47 ±0.17	0.41 ±0.19	0.80 ±0.00	0.53 ±0.33	0.81 ±0.21	0.97 ±0.32	1.25 ±0.25		0.33 ±0.13	1.04 ±0.38	0.58 ±0.05	0.22 ±0.16	0.16 ±0.16	ND
ATV	0.34 ±0.13	0.36 ±0.22	0.40 ±0.30	0.56 ±0.19	0.71 ±0.20	0.42 ±0.12	0.55 ±0.13	0.64 ±0.46	0.78 ±0.21	0.74 ±0.45	1.52 ±0.73	1.51 ±0.54	0.33 ± 0.13		0.27 ±0.36	0.45 ±0.11	0.44 ±0.26	0.81 ±0.15	ND
DRV	0.63 ±0.05	0.88 ±0.50	0.62 ±0.27	0.50 ±0.22	0.49 ±0.17	0.45 ±0.12	0.78 ±0.20	0.43 ±0.31	0.99 ±0.63	0.70 ±0.26	1.12 ±0.40	1.04 ±0.24	1.04 ± 0.38	0.27 ±0.36		0.40 ±0.44	0.80 ±0.56	0.05 ±0.30	ND
LPV	1.36 ±0.44	0.63 ±0.25	0.49 ±0.25	0.62 ±0.25	0.74 ±0.18	0.50 ±0.23	0.54 ±0.27	0.87 ±0.23	0.82 ±0.24	0.93 ±0.21	1.32 ±0.25	1.57 ±0.48	0.58 ±0.05	0.45 ±0.11	0.40 ±0.44		0.29 ±0.28	0.60 ±0.31	ND
NFV	1.21 ±0.69	0.65 ±0.50	0.62 ±0.37	0.74 ±0.26	0.63 ±0.34	0.47 ±0.24	0.82 ±0.46	1.08 ±0.15	1.49 ±0.13	1.27 ±0.26	1.90 ±0.40	1.32 ±0.21	0.22 ±0.16	0.44 ±0.26	0.80 ±0.56	0.29 ±0.28		1.17 ±0.36	ND
ENF	1.20 ±0.47	1.07 ±0.20	1.10 ±0.45	0.75 ±0.24	0.82 ±0.23	0.65 ±0.50	0.77 ±0.53	0.84 ±0.26	0.92 ±0.47	0.89 ±0.27	1.14 ±0.15	0.98 ±0.34	0.16 ±0.16	0.81 ±0.15	0.05 ±0.30	0.60 ±0.31	1.17 ±0.36		1.59 ±0.42
MVC	0.94 ±0.14	0.91 ±0.32	1.75 ±0.54	1.16 ±0.18	1.12 ±0.11	1.43 ±0.10	1.33 ±0.21	1.64 ±0.27	1.80 ±0.48	1.67 ±0.12	1.36 ±0.20	1.05 ±0.32	ND	ND	ND	ND	ND	1.59 ±0.42	

[a]Each combination was tested in cells from 4-12 donors, and the *DI* was computed for each donor according to Equation 5 using the drug concentrations giving the highest difference between the Loewe and Bliss predictions.

[b]ND = not done. Because of the lower levels of infection achieved with R5-tropic pseudoviruses, PI-MVC combinations could not be analyzed.

Table S6. IIP_{ave} values for three drug regimens and component single drugs and drug pairs.

Regimen[a]			IIP_{ave}																
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTb	d4T	ddIb	0.37	0.25	0.75	0.45	0.83	0.82	0.88	0.62	1.11	0.99	1.36	0.45	1.50	1.32	2.06
AZTt	d4T	ddIb	0.39	0.25	0.75	0.47	0.84	0.82	0.89	0.64	1.14	0.99	1.39	0.47	1.54	1.32	2.09
AZTb	d4T	TDF	0.37	0.25	0.86	0.45	0.87	0.87	0.89	0.62	1.23	1.11	1.48	0.45	1.91	1.65	2.61
AZTt	d4T	TDF	0.39	0.25	0.86	0.47	0.87	0.87	0.89	0.64	1.25	1.11	1.50	0.47	1.98	1.65	2.66
AZTb	d4T	ddIq	0.37	0.25	0.84	0.45	0.91	0.90	0.96	0.62	1.21	1.09	1.46	0.45	1.60	1.43	2.18
AZTt	d4T	ddIq	0.39	0.25	0.84	0.47	0.92	0.90	0.97	0.64	1.23	1.09	1.48	0.47	1.64	1.43	2.21
d4T	ddIb	TDF	0.25	0.75	0.86	0.82	0.87	1.06	1.08	0.99	1.11	1.61	1.85	1.34	1.65	0.98	2.91
AZTb	ddIb	TDF	0.37	0.75	0.86	0.83	0.87	1.06	1.07	1.11	1.23	1.61	1.97	1.51	1.91	0.98	2.90
d4T	ddIq	TDF	0.25	0.84	0.86	0.90	0.87	1.10	1.12	1.09	1.11	1.70	1.95	1.45	1.65	1.03	3.05
AZTt	ddIb	TDF	0.39	0.75	0.86	0.84	0.87	1.06	1.07	1.14	1.25	1.61	2.00	1.55	1.98	0.98	2.97
AZTb	ddIq	TDF	0.37	0.84	0.86	0.91	0.87	1.10	1.11	1.21	1.23	1.70	2.07	1.61	1.91	1.03	3.03
AZTt	ddIq	TDF	0.39	0.84	0.86	0.92	0.87	1.10	1.12	1.23	1.25	1.70	2.09	1.66	1.98	1.03	3.09
AZTb	d4T	EVG/c	0.37	0.25	1.41	0.45	1.42	1.42	1.42	0.62	1.78	1.66	2.03	0.45	1.83	1.69	2.07
AZTt	d4T	EVG/c	0.39	0.25	1.41	0.47	1.42	1.42	1.43	0.64	1.81	1.66	2.06	0.47	1.86	1.69	2.09
d4T	TDF	EVG/c	0.25	0.86	1.41	0.87	1.42	1.43	1.44	1.11	1.66	2.27	2.52	1.67	1.69	2.24	3.29
AZTb	d4T	RAL	0.37	0.25	1.69	0.45	1.69	1.69	1.69	0.62	2.05	1.94	2.30	0.45	2.07	2.00	2.37
d4T	ddIb	EVG/c	0.25	0.75	1.41	0.82	1.42	1.60	1.60	0.99	1.66	2.16	2.41	1.34	1.69	2.25	2.90
AZTt	d4T	RAL	0.39	0.25	1.69	0.47	1.69	1.69	1.69	0.64	2.08	1.94	2.33	0.47	2.10	2.00	2.39
AZTb	d4T	MVC	0.37	0.25	1.72	0.45	1.72	1.73	1.73	0.62	2.09	1.97	2.34	0.45	2.06	1.95	2.26
AZTb	TDF	EVG/c	0.37	0.86	1.41	0.87	1.42	1.43	1.44	1.23	1.78	2.27	2.64	1.92	1.83	2.24	3.39
AZTt	d4T	MVC	0.39	0.25	1.72	0.47	1.72	1.73	1.73	0.64	2.12	1.97	2.36	0.47	2.09	1.95	2.27
AZTt	TDF	EVG/c	0.39	0.86	1.41	0.87	1.42	1.43	1.44	1.25	1.81	2.27	2.67	1.99	1.86	2.24	3.45
d4T	ddIq	EVG/c	0.25	0.84	1.41	0.90	1.42	1.62	1.62	1.09	1.66	2.25	2.50	1.45	1.69	2.36	3.06
AZTb	ddIb	EVG/c	0.37	0.75	1.41	0.83	1.42	1.60	1.60	1.11	1.78	2.16	2.53	1.51	1.83	2.25	2.96
AZTt	ddIb	EVG/c	0.39	0.75	1.41	0.84	1.42	1.60	1.60	1.14	1.81	2.16	2.55	1.55	1.86	2.25	3.00
AZTb	ddIq	EVG/c	0.37	0.84	1.41	0.91	1.42	1.62	1.62	1.21	1.78	2.25	2.62	1.61	1.83	2.36	3.10
AZTt	ddIq	EVG/c	0.39	0.84	1.41	0.92	1.42	1.62	1.62	1.23	1.81	2.25	2.65	1.66	1.86	2.36	3.14
AZTb	d4T	ABCb	0.37	0.25	1.91	0.45	1.91	1.92	1.92	0.62	2.28	2.16	2.53	0.45	2.84	2.41	3.26
AZTt	d4T	ABCb	0.39	0.25	1.91	0.47	1.91	1.92	1.92	0.64	2.31	2.16	2.56	0.47	2.91	2.41	3.31
d4T	TDF	RAL	0.25	0.86	1.69	0.87	1.69	1.69	1.69	1.11	1.94	2.55	2.80	1.67	2.00	2.71	3.63
d4T	ddIb	RAL	0.25	0.75	1.69	0.82	1.69	1.83	1.83	0.99	1.94	2.43	2.68	1.34	2.00	2.38	3.12
d4T	ddIb	MVC	0.25	0.75	1.72	0.82	1.73	1.83	1.83	0.99	1.97	2.47	2.72	1.34	1.95	2.54	3.13
d4T	TDF	MVC	0.25	0.86	1.72	0.87	1.73	1.73	1.73	1.11	1.97	2.58	2.83	1.67	1.95	2.95	3.65
AZTb	TDF	RAL	0.37	0.86	1.69	0.87	1.69	1.69	1.69	1.23	2.05	2.55	2.91	1.92	2.07	2.71	3.67
d4T	ddIq	RAL	0.25	0.84	1.69	0.90	1.69	1.85	1.85	1.09	1.94	2.53	2.77	1.45	2.00	2.47	3.27
ddIb	TDF	EVG/c	0.75	0.86	1.41	1.06	1.60	1.43	1.61	1.61	2.16	2.27	3.02	1.03	2.25	2.24	2.83
AZTb	ddIb	RAL	0.37	0.75	1.69	0.83	1.69	1.83	1.83	1.11	2.05	2.43	2.80	1.51	2.07	2.38	3.11
AZTt	TDF	RAL	0.39	0.86	1.69	0.87	1.69	1.69	1.69	1.25	2.08	2.55	2.94	1.99	2.10	2.71	3.73
AZTt	ddIb	RAL	0.39	0.75	1.69	0.84	1.69	1.83	1.83	1.14	2.08	2.43	2.83	1.55	2.10	2.38	3.15
d4T	ddIq	MVC	0.25	0.84	1.72	0.90	1.73	1.85	1.85	1.09	1.97	2.56	2.81	1.45	1.95	2.64	3.28
d4T	ddIq	MVC	0.25	0.84	1.72	0.90	1.73	1.85	1.85	1.09	1.97	2.56	2.81	1.45	1.95	2.64	3.28
AZTb	ddIb	MVC	0.37	0.75	1.72	0.83	1.72	1.83	1.83	1.11	2.09	2.47	2.84	1.51	2.06	2.54	3.19
AZTb	TDF	MVC	0.37	0.86	1.72	0.87	1.72	1.73	1.73	1.23	2.09	2.58	2.95	1.92	2.06	2.95	3.77
AZTt	ddIb	MVC	0.39	0.75	1.72	0.84	1.72	1.83	1.83	1.14	2.12	2.47	2.86	1.55	2.09	2.54	3.23
AZTt	TDF	MVC	0.39	0.86	1.72	0.87	1.72	1.73	1.73	1.25	2.12	2.58	2.97	1.99	2.09	2.95	3.82
ddIq	TDF	EVG/c	0.84	0.86	1.41	1.10	1.62	1.43	1.62	1.70	2.25	2.27	3.11	1.07	2.36	2.24	2.91
AZTb	ddIq	RAL	0.37	0.84	1.69	0.91	1.69	1.85	1.85	1.21	2.05	2.53	2.89	1.61	2.07	2.47	3.24
AZTb	d4T	ENF	0.37	0.25	2.07	0.45	2.07	2.07	2.07	0.62	2.44	2.32	2.69	0.45	2.51	2.33	2.74
AZTt	ddIq	RAL	0.39	0.84	1.69	0.92	1.69	1.85	1.85	1.23	2.08	2.53	2.92	1.66	2.10	2.47	3.28
AZTb	ddIq	MVC	0.37	0.84	1.72	0.91	1.72	1.85	1.85	1.21	2.09	2.56	2.93	1.61	2.06	2.64	3.32
AZTt	d4T	ENF	0.39	0.25	2.07	0.47	2.07	2.07	2.07	0.64	2.46	2.32	2.71	0.47	2.54	2.33	2.76
AZTt	ddIq	MVC	0.39	0.84	1.72	0.92	1.72	1.85	1.85	1.23	2.12	2.56	2.95	1.66	2.09	2.64	3.36
AZTb	d4T	ABCq	0.37	0.25	2.14	0.45	2.14	2.14	2.14	0.62	2.51	2.39	2.76	0.45	3.07	2.64	3.49
AZTt	d4T	ABCq	0.39	0.25	2.14	0.47	2.14	2.14	2.14	0.64	2.54	2.39	2.78	0.47	3.13	2.64	3.54
d4T	TDF	ABCb	0.25	0.86	1.91	0.87	1.92	1.92	1.92	1.11	2.16	2.77	3.02	1.67	2.41	1.88	3.81
d4T	ddIb	ABCb	0.25	0.75	1.91	0.82	1.92	2.04	2.04	0.99	2.16	2.66	2.91	1.34	2.41	2.17	3.40
AZTb	TDF	ABCb	0.37	0.86	1.91	0.87	1.91	1.92	1.92	1.23	2.28	2.77	3.14	1.92	2.84	1.88	4.23
d4T	ddIq	ABCb	0.25	0.84	1.91	0.90	1.92	2.06	2.06	1.09	2.16	2.75	3.00	1.45	2.41	2.20	3.56
AZTb	ddIb	ABCb	0.37	0.75	1.91	0.83	1.91	2.04	2.04	1.11	2.28	2.66	3.03	1.51	2.84	2.17	3.72
AZTt	TDF	ABCb	0.39	0.86	1.91	0.87	1.91	1.92	1.92	1.25	2.31	2.77	3.17	1.99	2.91	1.88	4.29
AZTt	ddIb	ABCb	0.39	0.75	1.91	0.84	1.91	2.04	2.04	1.14	2.31	2.66	3.05	1.55	2.91	2.17	3.77
ddIb	TDF	RAL	0.75	0.86	1.69	1.06	1.83	1.69	1.83	1.61	2.43	2.55	3.29	1.03	2.38	2.71	3.11
ddIb	TDF	MVC	0.75	0.86	1.72	1.06	1.83	1.73	1.83	1.61	2.47	2.58	3.33	1.03	2.54	2.95	3.45
AZTb	ddIq	ABCb	0.37	0.84	1.91	0.91	1.91	2.06	2.06	1.21	2.28	2.75	3.12	1.61	2.84	2.20	3.87
AZTt	ddIq	ABCb	0.39	0.84	1.91	0.92	1.91	2.06	2.06	1.23	2.31	2.75	3.15	1.66	2.91	2.20	3.92
AZTb	d4T	3TCb	0.37	0.25	2.30	0.45	2.30	2.31	2.31	0.62	2.67	2.55	2.92	0.45	2.91	2.72	3.28
d4T	EVG/c	MVC	0.25	1.41	1.72	1.42	1.73	1.84	1.84	1.66	1.97	3.14	3.39	1.70	1.95	3.20	3.44
ddIq	TDF	RAL	0.84	0.86	1.69	1.10	1.85	1.69	1.85	1.70	2.53	2.55	3.38	1.07	2.47	2.71	3.19

Regimen[a]			IIP$_{ave}$															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTt	d4T	3TCb	0.39	0.25	2.30	0.47	2.30	2.31	2.31	0.64	2.70	2.55	2.95	0.47	2.95	2.72	3.32
d4T	TDF	ENF	0.25	0.86	2.07	0.87	2.07	2.08	2.08	1.11	2.32	2.93	3.18	1.67	2.33	2.62	3.67
ddIq	TDF	MVC	0.84	0.86	1.72	1.10	1.85	1.73	1.85	1.70	2.56	2.58	3.42	1.07	2.64	2.95	3.54
d4T	ddIb	ENF	0.25	0.75	2.07	0.82	2.07	2.24	2.24	0.99	2.32	2.82	3.07	1.34	2.33	2.71	3.36
AZTb	d4T	3TCq	0.37	0.25	2.35	0.45	2.35	2.35	2.35	0.62	2.72	2.60	2.97	0.45	2.95	2.77	3.33
AZTt	d4T	3TCq	0.39	0.25	2.35	0.47	2.35	2.35	2.35	0.64	2.74	2.60	2.99	0.47	2.99	2.77	3.36
AZTb	EVG/c	MVC	0.37	1.41	1.72	1.42	1.72	1.84	1.84	1.78	2.09	3.14	3.51	1.84	2.06	3.20	3.58
AZTb	TDF	ENF	0.37	0.86	2.07	0.87	2.07	2.08	2.08	1.23	2.44	2.93	3.30	1.92	2.51	2.62	3.83
AZTt	EVG/c	MVC	0.39	1.41	1.72	1.42	1.72	1.84	1.84	1.81	2.12	3.14	3.53	1.87	2.09	3.20	3.60
d4T	ddIb	ABCq	0.25	0.75	2.14	0.82	2.14	2.24	2.24	0.99	2.39	2.89	3.14	1.34	2.64	2.38	3.62
d4T	TDF	ABCq	0.25	0.86	2.14	0.87	2.14	2.14	2.14	1.11	2.39	3.00	3.25	1.67	2.64	2.11	3.98
AZTt	TDF	ENF	0.39	0.86	2.07	0.87	2.07	2.08	2.08	1.25	2.46	2.93	3.32	1.99	2.54	2.62	3.89
d4T	ddIq	ENF	0.25	0.84	2.07	0.90	2.07	2.26	2.26	1.09	2.32	2.91	3.16	1.45	2.33	2.79	3.50
AZTb	ddIb	ENF	0.37	0.75	2.07	0.83	2.07	2.24	2.24	1.11	2.44	2.82	3.18	1.51	2.51	2.71	3.46
AZTt	ddIb	ENF	0.39	0.75	2.07	0.84	2.07	2.24	2.24	1.14	2.46	2.82	3.21	1.55	2.54	2.71	3.50
d4T	ddIq	ABCq	0.25	0.84	2.14	0.90	2.14	2.25	2.26	1.09	2.39	2.98	3.23	1.45	2.64	2.40	3.77
AZTb	ddIb	ABCq	0.37	0.75	2.14	0.83	2.14	2.24	2.24	1.11	2.51	2.89	3.26	1.51	3.07	2.38	3.95
AZTb	TDF	ABCq	0.37	0.86	2.14	0.87	2.14	2.14	2.14	1.23	2.51	3.00	3.37	1.92	3.07	2.11	4.40
AZTt	ddIb	ABCq	0.39	0.75	2.14	0.84	2.14	2.24	2.24	1.14	2.54	2.89	3.28	1.55	3.13	2.38	4.00
AZTb	ddIq	ENF	0.37	0.84	2.07	0.91	2.07	2.26	2.26	1.21	2.44	2.91	3.28	1.61	2.51	2.79	3.59
AZTt	TDF	ABCq	0.39	0.86	2.14	0.87	2.14	2.14	2.14	1.25	2.54	3.00	3.39	1.99	3.13	2.11	4.47
AZTt	ddIq	ENF	0.39	0.84	2.07	0.92	2.07	2.26	2.26	1.23	2.46	2.91	3.30	1.66	2.54	2.79	3.63
ddIb	TDF	ABCb	0.75	0.86	1.91	1.06	2.04	1.92	2.04	1.61	2.66	2.77	3.52	1.03	2.17	1.88	2.14
d4T	ABCb	EVG/c	0.25	1.91	1.41	1.92	1.42	2.02	2.02	2.16	1.66	3.33	3.58	2.42	1.69	3.39	4.18
d4T	RAL	MVC	0.25	1.69	1.72	1.69	1.73	1.94	1.94	1.94	1.97	3.41	3.66	2.01	1.95	3.94	4.06
AZTb	ddIq	ABCq	0.37	0.84	2.14	0.91	2.14	2.25	2.25	1.21	2.51	2.98	3.35	1.61	3.07	2.40	4.10
AZTt	ddIq	ABCq	0.39	0.84	2.14	0.92	2.14	2.25	2.25	1.23	2.54	2.98	3.37	1.66	3.13	2.40	4.15
ddIq	TDF	ABCb	0.84	0.86	1.91	1.10	2.06	1.92	2.06	1.70	2.75	2.77	3.61	1.07	2.20	1.88	2.16
d4T	3TCb	ddIb	0.25	2.30	0.75	2.31	0.82	2.39	2.40	2.55	0.99	3.05	3.30	2.72	1.32	2.55	3.64
AZTb	ABCb	EVG/c	0.37	1.91	1.41	1.91	1.42	2.02	2.02	2.28	1.78	3.33	3.70	2.84	1.83	3.39	4.68
d4T	3TCb	TDF	0.25	2.30	0.86	2.31	0.87	2.30	2.31	2.55	1.11	3.16	3.41	2.72	1.65	2.97	4.15
AZTb	RAL	MVC	0.37	1.69	1.72	1.69	1.72	1.94	1.94	2.05	2.09	3.41	3.78	2.08	2.06	3.94	4.10
AZTb	RAL	MVC	0.37	1.69	1.72	1.69	1.72	1.94	1.94	2.05	2.09	3.41	3.78	2.08	2.06	3.94	4.10
AZTb	d4T	ddIEC	0.37	0.25	2.56	0.45	2.56	2.56	2.56	0.62	2.93	2.81	3.18	0.45	3.40	3.29	4.11
AZTt	ABCb	EVG/c	0.39	1.91	1.41	1.91	1.42	2.02	2.02	2.31	1.81	3.33	3.72	2.91	1.86	3.39	4.73
AZTt	RAL	MVC	0.39	1.69	1.72	1.69	1.72	1.94	1.94	2.08	2.12	3.41	3.80	2.11	2.09	3.94	4.13
AZTt	d4T	ddIEC	0.39	0.25	2.56	0.47	2.56	2.56	2.56	0.64	2.95	2.81	3.20	0.47	3.46	3.29	4.16
d4T	3TCq	ddIb	0.25	2.35	0.75	2.35	0.82	2.44	2.44	2.60	0.99	3.10	3.34	2.77	1.32	2.59	3.68
d4T	3TCb	ddIq	0.25	2.30	0.84	2.31	0.90	2.41	2.41	2.55	1.09	3.14	3.39	2.72	1.43	2.58	3.79
d4T	3TCq	TDF	0.25	2.35	0.86	2.35	0.87	2.35	2.35	2.60	1.11	3.21	3.46	2.77	1.65	3.02	4.19
AZTb	3TCb	ddIb	0.37	2.30	0.75	2.30	0.83	2.39	2.39	2.67	1.11	3.05	3.42	2.91	1.50	2.55	3.69
ddIb	EVG/c	MVC	0.75	1.41	1.72	1.60	1.83	1.84	1.94	2.16	2.47	3.14	3.88	2.25	2.54	3.20	4.09
AZTb	3TCb	TDF	0.37	2.30	0.86	2.30	0.87	2.30	2.30	2.67	1.23	3.16	3.53	2.91	1.91	2.97	4.27
AZTt	3TCb	ddIb	0.39	2.30	0.75	2.30	0.84	2.39	2.39	2.70	1.14	3.05	3.44	2.95	1.54	2.55	3.73
TDF	EVG/c	MVC	0.86	1.41	1.72	1.43	1.73	1.84	1.84	2.27	2.58	3.14	4.00	2.25	2.95	3.20	4.35
AZTt	3TCb	TDF	0.39	2.30	0.86	2.30	0.87	2.30	2.30	2.70	1.25	3.16	3.56	2.95	1.98	2.97	4.32
d4T	3TCq	ddIq	0.25	2.35	0.84	2.35	0.90	2.45	2.45	2.60	1.09	3.19	3.44	2.77	1.43	2.62	3.83
AZTb	3TCq	ddIb	0.37	2.35	0.75	2.35	0.83	2.44	2.44	2.72	1.11	3.10	3.46	2.95	1.50	2.59	3.74
ddIb	TDF	ENF	0.75	0.86	2.07	1.06	2.24	2.08	2.24	1.61	2.82	2.93	3.68	1.03	2.71	2.62	3.12
AZTb	3TCb	ddIq	0.37	2.30	0.84	2.30	0.91	2.41	2.41	2.67	1.21	3.14	3.51	2.91	1.60	2.58	3.82
AZTt	3TCq	ddIb	0.39	2.35	0.75	2.35	0.84	2.44	2.44	2.74	1.14	3.10	3.49	2.99	1.54	2.59	3.77
AZTb	3TCq	TDF	0.37	2.35	0.86	2.35	0.87	2.35	2.35	2.72	1.23	3.21	3.58	2.95	1.91	3.02	4.31
d4T	ENF	EVG/c	0.25	2.07	1.41	2.07	1.42	2.20	2.20	2.32	1.66	3.48	3.73	2.34	1.69	3.46	3.81
ddIq	EVG/c	MVC	0.84	1.41	1.72	1.62	1.85	1.84	1.96	2.25	2.56	3.14	3.98	2.36	2.64	3.20	4.19
AZTt	3TCb	ddIq	0.39	2.30	0.84	2.30	0.92	2.41	2.41	2.70	1.23	3.14	3.54	2.95	1.64	2.58	3.86
AZTt	3TCq	TDF	0.39	2.35	0.86	2.35	0.87	2.35	2.35	2.74	1.25	3.21	3.60	2.99	1.98	3.02	4.36
d4T	ABCb	RAL	0.25	1.91	1.69	1.92	1.69	2.10	2.11	2.16	1.94	3.60	3.85	2.42	2.00	3.45	4.45
d4T	ABCb	MVC	0.25	1.91	1.72	1.92	1.73	2.07	2.08	2.16	1.97	3.64	3.89	2.42	1.95	4.16	4.67
ddIb	TDF	ABCq	0.75	0.86	2.14	1.06	2.24	2.14	2.24	1.61	2.89	3.00	3.75	1.03	2.38	2.11	2.34
AZTb	3TCq	ddIq	0.37	2.35	0.84	2.35	0.91	2.45	2.45	2.72	1.21	3.19	3.56	2.95	1.60	2.62	3.86
d4T	ABCq	EVG/c	0.25	2.14	1.41	2.14	1.42	2.20	2.20	2.39	1.66	3.56	3.81	2.65	1.69	3.62	4.44
ddIq	TDF	ENF	0.84	0.86	2.07	1.10	2.26	2.08	2.26	1.70	2.91	2.93	3.77	1.07	2.79	2.62	3.18
AZTt	3TCq	ddIq	0.39	2.35	0.84	2.35	0.92	2.45	2.45	2.74	1.23	3.19	3.58	2.99	1.64	2.62	3.90
AZTb	ENF	EVG/c	0.37	2.07	1.41	2.07	1.42	2.20	2.20	2.44	1.78	3.48	3.85	2.51	1.83	3.46	4.00
AZTb	ABCb	RAL	0.37	1.91	1.69	1.91	1.69	2.10	2.10	2.28	2.05	3.60	3.97	2.84	2.07	3.45	4.89
AZTt	ENF	EVG/c	0.39	2.07	1.41	2.07	1.42	2.20	2.20	2.46	1.81	3.48	3.88	2.54	1.86	3.46	4.03
AZTb	ABCb	MVC	0.37	1.91	1.72	1.91	1.72	2.07	2.07	2.28	2.09	3.64	4.00	2.84	2.06	4.16	5.20
AZTb	ABCb	MVC	0.37	1.91	1.72	1.91	1.72	2.07	2.07	2.28	2.09	3.64	4.00	2.84	2.06	4.16	5.20
ddIq	TDF	ABCq	0.84	0.86	2.14	1.10	2.25	2.14	2.25	1.70	2.98	3.00	3.84	1.07	2.40	2.11	2.36
AZTt	ABCb	RAL	0.39	1.91	1.69	1.91	1.69	2.10	2.10	2.31	2.08	3.60	3.99	2.91	2.10	3.45	4.94

Regimen[a]			IIP[ave]														
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTt	ABCb	MVC	0.39	1.91	1.72	1.91	1.72	2.07	2.07	2.31	2.12	3.64	4.03	2.91	2.09	4.16	5.24
AZTb	ABCq	EVG/c	0.37	2.14	1.41	2.14	1.42	2.20	2.20	2.51	1.78	3.56	3.93	3.07	1.83	3.62	4.96
AZTb	d4T	NFVt	0.37	0.25	2.76	0.45	2.76	2.76	2.76	0.62	3.12	3.01	3.37	0.45	3.20	2.92	3.31
AZTt	ABCq	EVG/c	0.39	2.14	1.41	2.14	1.42	2.20	2.20	2.54	1.81	3.56	3.95	3.13	1.86	3.62	5.01
AZTt	d4T	NFVt	0.39	0.25	2.76	0.47	2.76	2.76	2.76	0.64	3.15	3.01	3.40	0.47	3.23	2.92	3.34
ddIb	RAL	MVC	0.75	1.69	1.72	1.83	1.83	1.94	2.03	2.43	2.47	3.41	4.16	2.38	2.54	3.94	4.52
AZTb	d4T	FTC	0.37	0.25	2.79	0.45	2.79	2.79	2.79	0.62	3.16	3.04	3.41	0.45	3.55	3.21	3.91
ddIb	ABCb	EVG/c	0.75	1.91	1.41	2.04	1.60	2.02	2.13	2.66	2.16	3.33	4.07	2.17	2.25	3.39	3.78
TDF	ABCb	EVG/c	0.86	1.91	1.41	1.92	1.43	2.02	2.02	2.77	2.27	3.33	4.19	1.89	2.24	3.39	3.65
TDF	RAL	MVC	0.86	1.69	1.72	1.69	1.73	1.94	1.94	2.55	2.58	3.41	4.27	2.71	2.95	3.94	5.04
AZTb	d4T	NFVb	0.37	0.25	2.80	0.45	2.80	2.80	2.80	0.62	3.17	3.05	3.42	0.45	3.25	2.96	3.36
AZTt	d4T	FTC	0.39	0.25	2.79	0.47	2.79	2.79	2.79	0.64	3.18	3.04	3.43	0.47	3.60	3.21	3.95
d4T	ddIEC	TDF	0.25	2.56	0.86	2.56	0.87	2.56	2.56	2.81	1.11	3.42	3.67	3.29	1.65	2.51	4.76
AZTt	d4T	NFVb	0.39	0.25	2.80	0.47	2.80	2.80	2.80	0.64	3.19	3.05	3.44	0.47	3.28	2.96	3.38
d4T	ENF	RAL	0.25	2.07	1.69	2.07	1.69	2.29	2.29	2.32	1.94	3.76	4.01	2.34	2.00	3.96	4.28
ddIq	RAL	MVC	0.84	1.69	1.72	1.85	1.85	1.94	2.05	2.53	2.56	3.41	4.25	2.47	2.64	3.94	4.62
d4T	ENF	MVC	0.25	2.07	1.72	2.07	1.73	2.26	2.26	2.32	1.97	3.79	4.04	2.34	1.95	4.70	4.60
3TCb	ddIb	TDF	2.30	0.75	0.86	2.39	2.30	1.06	2.39	3.05	3.16	1.61	3.91	2.55	2.97	0.98	3.06
ddIq	ABCb	EVG/c	0.84	1.91	1.41	2.06	1.62	2.02	2.14	2.75	2.25	3.33	4.17	2.20	2.36	3.39	3.86
d4T	3TCb	EVG/c	0.25	2.30	1.41	2.31	1.42	2.35	2.35	2.55	1.66	3.72	3.97	2.72	1.69	4.06	4.56
d4T	ABCq	RAL	0.25	2.14	1.69	2.14	1.69	2.26	2.26	2.39	1.94	3.83	4.08	2.65	2.00	3.68	4.72
AZTb	ddIEC	TDF	0.37	2.56	0.86	2.56	0.87	2.56	2.56	2.93	1.23	3.42	3.79	3.41	1.91	2.51	4.61
d4T	ABCq	MVC	0.25	2.14	1.72	2.14	1.73	2.23	2.23	2.39	1.97	3.87	4.11	2.65	1.95	4.41	4.95
AZTt	ddIEC	TDF	0.39	2.56	0.86	2.56	0.87	2.56	2.56	2.95	1.25	3.42	3.81	3.46	1.98	2.51	4.67
3TCq	ddIb	TDF	2.35	0.75	0.86	2.44	2.35	1.06	2.44	3.10	3.21	1.61	3.95	2.59	3.02	0.98	3.11
d4T	3TCq	EVG/c	0.25	2.35	1.41	2.35	1.42	2.39	2.39	2.60	1.66	3.76	4.01	2.77	1.69	4.10	4.61
3TCb	ddIq	TDF	2.30	0.84	0.86	2.41	2.30	1.10	2.41	3.14	3.16	1.70	4.00	2.58	2.97	1.03	3.10
AZTb	ENF	RAL	0.37	2.07	1.69	2.07	1.69	2.29	2.29	2.44	2.05	3.76	4.13	2.51	2.07	3.96	4.38
AZTb	ENF	MVC	0.37	2.07	1.72	2.07	1.72	2.26	2.26	2.44	2.09	3.79	4.16	2.51	2.06	4.70	4.81
AZTb	3TCb	EVG/c	0.37	2.30	1.41	2.30	1.42	2.35	2.35	2.67	1.78	3.72	4.09	2.91	1.83	4.06	4.71
AZTt	ENF	RAL	0.39	2.07	1.69	2.07	1.69	2.29	2.29	2.46	2.08	3.76	4.15	2.54	2.10	3.96	4.41
AZTt	ENF	MVC	0.39	2.07	1.72	2.07	1.72	2.26	2.26	2.46	2.12	3.79	4.19	2.54	2.09	4.70	4.84
AZTt	3TCb	EVG/c	0.39	2.30	1.41	2.30	1.42	2.35	2.35	2.70	1.81	3.72	4.11	2.95	1.86	4.06	4.74
AZTb	ABCq	RAL	0.37	2.14	1.69	2.14	1.69	2.26	2.26	2.51	2.05	3.83	4.20	3.07	2.07	3.68	5.17
AZTb	ABCq	MVC	0.37	2.14	1.72	2.14	1.72	2.23	2.23	2.51	2.09	3.87	4.23	3.07	2.06	4.41	5.49
AZTt	ABCq	RAL	0.39	2.14	1.69	2.14	1.69	2.26	2.26	2.54	2.08	3.83	4.22	3.13	2.10	3.68	5.22
AZTt	ABCq	MVC	0.39	2.14	1.72	2.14	1.72	2.23	2.23	2.54	2.12	3.87	4.26	3.13	2.09	4.41	5.54
3TCq	ddIq	TDF	2.35	0.84	0.86	2.45	2.35	1.10	2.45	3.19	3.21	1.70	4.05	2.62	3.02	1.03	3.14
AZTb	3TCq	EVG/c	0.37	2.35	1.41	2.35	1.42	2.39	2.39	2.72	1.78	3.76	4.13	2.95	1.83	4.10	4.76
AZTt	3TCq	EVG/c	0.39	2.35	1.41	2.35	1.42	2.39	2.39	2.74	1.81	3.76	4.16	2.99	1.86	4.10	4.79
TDF	ENF	EVG/c	0.86	2.07	1.41	2.08	1.43	2.20	2.20	2.93	2.27	3.48	4.34	2.63	2.24	3.46	4.07
ddIb	ABCb	RAL	0.75	1.91	1.69	2.04	1.83	2.10	2.20	2.66	2.43	3.60	4.35	2.17	2.38	3.45	3.74
ddIb	ABCb	MVC	0.75	1.91	1.72	2.04	1.83	2.07	2.17	2.66	2.47	3.64	4.38	2.17	2.54	4.16	4.38
ddIb	ENF	EVG/c	0.75	2.07	1.41	2.24	1.60	2.20	2.33	2.82	2.16	3.48	4.23	2.71	2.25	3.46	4.19
TDF	ABCb	RAL	0.86	1.91	1.69	1.92	1.69	2.10	2.10	2.77	2.55	3.60	4.46	1.89	2.71	3.45	3.94
TDF	ABCb	MVC	0.86	1.91	1.72	1.92	1.73	2.07	2.07	2.77	2.58	3.64	4.50	1.89	2.95	4.16	4.69
ddIb	ABCq	EVG/c	0.75	2.14	1.41	2.24	1.60	2.20	2.29	2.89	2.16	3.56	4.30	2.38	2.25	3.62	3.98
TDF	ABCq	EVG/c	0.86	2.14	1.41	2.14	1.43	2.20	2.20	3.00	2.27	3.56	4.42	2.11	2.24	3.62	3.84
d4T	TDF	NFVt	0.25	0.86	2.76	0.87	2.76	2.76	2.76	1.11	3.01	3.62	3.87	1.67	2.92	3.16	4.02
d4T	FTC	ddIb	0.25	2.79	0.75	2.79	0.82	2.85	2.85	3.04	0.99	3.54	3.79	3.21	1.32	3.06	4.12
d4T	3TCb	RAL	0.25	2.30	1.69	2.31	1.69	2.39	2.40	2.55	1.94	3.99	4.24	2.72	2.00	4.00	4.76
d4T	3TCb	MVC	0.25	2.30	1.72	2.31	1.73	2.36	2.36	2.55	1.97	4.03	4.28	2.72	1.95	5.28	5.36
d4T	ABCb	ENF	0.25	1.91	2.07	1.92	2.07	2.41	2.41	2.16	2.32	3.98	4.23	2.42	2.33	3.61	4.62
ddIq	ABCb	RAL	0.84	1.91	1.69	2.06	1.85	2.10	2.22	2.75	2.53	3.60	4.44	2.20	2.47	3.45	3.81
ddIq	ABCb	MVC	0.84	1.91	1.72	2.06	1.85	2.07	2.18	2.75	2.56	3.64	4.48	2.20	2.64	4.16	4.46
ddIq	ENF	EVG/c	0.84	2.07	1.41	2.26	1.62	2.20	2.34	2.91	2.25	3.48	4.32	2.79	2.36	3.46	4.29
d4T	ddIb	NFVt	0.25	0.75	2.76	0.82	2.76	2.92	2.92	0.99	3.01	3.50	3.75	1.34	2.92	3.29	3.80
d4T	FTC	TDF	0.25	2.79	0.86	2.79	0.87	2.79	2.79	3.04	1.11	3.65	3.90	3.21	1.65	3.07	4.43
ddIq	ABCq	EVG/c	0.84	2.14	1.41	2.25	1.62	2.20	2.30	2.98	2.25	3.56	4.40	2.41	2.36	3.62	4.06
d4T	TDF	NFVb	0.25	0.86	2.80	0.87	2.80	2.80	2.80	1.11	3.05	3.66	3.91	1.67	2.96	3.20	4.05
d4T	3TCq	RAL	0.25	2.35	1.69	2.35	1.69	2.44	2.44	2.60	1.94	4.04	4.29	2.77	2.00	4.04	4.80
d4T	3TCq	MVC	0.25	2.35	1.72	2.35	1.73	2.41	2.41	2.60	1.97	4.07	4.32	2.77	1.95	5.32	5.41
d4T	3TCq	MVC	0.25	2.35	1.72	2.35	1.73	2.41	2.41	2.60	1.97	4.07	4.32	2.77	1.95	5.32	5.41
d4T	FTC	ddIq	0.25	2.79	0.84	2.79	0.90	2.86	2.86	3.04	1.09	3.63	3.88	3.21	1.43	3.10	4.26
AZTb	TDF	NFVt	0.37	0.86	2.76	0.87	2.76	2.76	2.76	1.23	3.12	3.62	3.98	1.92	3.20	3.16	4.36
AZTb	3TCb	RAL	0.37	2.30	1.69	2.30	1.69	2.39	2.39	2.67	2.05	3.99	4.36	2.91	2.07	4.00	4.80
AZTb	FTC	ddIb	0.37	2.79	0.75	2.79	0.83	2.85	2.85	3.16	1.11	3.54	3.90	3.55	1.50	3.06	4.38
d4T	ddIb	NFVb	0.25	0.75	2.80	0.82	2.80	2.96	2.96	0.99	3.05	3.55	3.80	1.34	2.96	3.33	3.83
AZTb	3TCb	MVC	0.37	2.30	1.72	2.30	1.72	2.36	2.36	2.67	2.09	4.03	4.40	2.91	2.06	5.28	5.53
AZTb	ABCb	ENF	0.37	1.91	2.07	1.91	2.07	2.41	2.41	2.28	2.44	3.98	4.35	2.84	2.51	3.61	5.21

Regimen[a]			IIP_{ave}														
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTt	TDF	NFVt	0.39	0.86	2.76	0.87	2.76	2.76	2.76	1.25	3.15	3.62	4.01	1.99	3.23	3.16	4.41
d4T	ddIq	NFVt	0.25	0.84	2.76	0.90	2.76	2.93	2.93	1.09	3.01	3.60	3.84	1.45	2.92	3.35	3.92
AZTt	3TCb	RAL	0.39	2.30	1.69	2.30	1.69	2.39	2.39	2.70	2.08	3.99	4.38	2.95	2.10	4.00	4.83
AZTt	FTC	ddIb	0.39	2.79	0.75	2.79	0.84	2.85	2.85	3.18	1.14	3.54	3.93	3.60	1.54	3.06	4.42
AZTt	3TCb	MVC	0.39	2.30	1.72	2.30	1.72	2.36	2.36	2.70	2.12	4.03	4.42	2.95	2.09	5.28	5.56
AZTt	ABCb	ENF	0.39	1.91	2.07	1.91	2.07	2.41	2.41	2.31	2.46	3.98	4.38	2.91	2.54	3.61	5.26
AZTb	ddIb	NFVt	0.37	0.75	2.76	0.83	2.76	2.92	2.92	1.11	3.12	3.50	3.87	1.51	3.20	3.29	4.04
AZTb	FTC	TDF	0.37	2.79	0.86	2.79	0.87	2.79	2.79	3.16	1.23	3.65	4.02	3.55	1.91	3.07	4.77
AZTt	ddIb	NFVt	0.39	0.75	2.76	0.84	2.76	2.92	2.92	1.14	3.15	3.50	3.90	1.55	3.23	3.29	4.07
d4T	ddIEC	EVG/c	0.25	2.56	1.41	2.56	1.42	2.60	2.60	2.81	1.66	3.97	4.22	3.29	1.69	4.20	5.51
AZTt	FTC	TDF	0.39	2.79	0.86	2.79	0.87	2.79	2.79	3.18	1.25	3.65	4.04	3.60	1.98	3.07	4.83
AZTb	TDF	NFVb	0.37	0.86	2.80	0.87	2.80	2.80	2.80	1.23	3.17	3.66	4.03	1.92	3.25	3.20	4.40
AZTb	3TCq	RAL	0.37	2.35	1.69	2.35	1.69	2.44	2.44	2.72	2.05	4.04	4.40	2.95	2.07	4.04	4.85
AZTb	3TCq	MVC	0.37	2.35	1.72	2.35	1.72	2.41	2.41	2.72	2.09	4.07	4.44	2.95	2.06	5.32	5.57
AZTb	FTC	ddIq	0.37	2.79	0.84	2.79	0.91	2.86	2.86	3.16	1.21	3.63	4.00	3.55	1.60	3.10	4.52
AZTt	TDF	NFVb	0.39	0.86	2.80	0.87	2.80	2.80	2.80	1.25	3.19	3.66	4.05	1.99	3.28	3.20	4.46
AZTt	3TCq	RAL	0.39	2.35	1.69	2.35	1.69	2.44	2.44	2.74	2.08	4.04	4.43	2.99	2.10	4.04	4.88
d4T	ddIq	NFVb	0.25	0.84	2.80	0.90	2.80	2.98	2.98	1.09	3.05	3.64	3.89	1.45	2.96	3.40	3.95
AZTt	3TCq	MVC	0.39	2.35	1.72	2.35	1.72	2.41	2.41	2.74	2.12	4.07	4.47	2.99	2.09	5.32	5.61
AZTb	ddIb	NFVb	0.37	0.75	2.80	0.83	2.80	2.96	2.96	1.11	3.17	3.55	3.91	1.51	3.25	3.33	4.08
AZTt	FTC	ddIq	0.39	2.79	0.84	2.79	0.92	2.86	2.86	3.18	1.23	3.63	4.02	3.60	1.64	3.10	4.56
AZTb	ddIq	NFVt	0.37	0.84	2.76	0.91	2.76	2.93	2.93	1.21	3.12	3.60	3.96	1.61	3.20	3.35	4.16
ddIb	ENF	RAL	0.75	2.07	1.69	2.24	1.83	2.29	2.40	2.82	2.43	3.76	4.50	2.71	2.38	3.96	4.47
3TCb	ddIb	EVG/c	2.30	0.75	1.41	2.39	2.35	1.60	2.43	3.05	3.72	2.16	4.46	2.55	4.06	2.25	4.33
AZTt	ddIb	NFVb	0.39	0.75	2.80	0.84	2.80	2.96	2.96	1.14	3.19	3.55	3.94	1.55	3.28	3.33	4.12
TDF	ENF	RAL	0.86	2.07	1.69	2.08	1.69	2.29	2.29	2.93	2.55	3.76	4.62	2.63	2.71	3.96	4.65
ddIb	ENF	MVC	0.75	2.07	1.72	2.24	1.83	2.26	2.37	2.82	2.47	3.79	4.54	2.71	2.54	4.70	5.11
TDF	ENF	MVC	0.86	2.07	1.72	2.08	1.73	2.26	2.26	2.93	2.58	3.79	4.65	2.63	2.95	4.70	5.38
AZTt	ddIq	NFVt	0.39	0.84	2.76	0.92	2.76	2.93	2.93	1.23	3.15	3.60	3.99	1.66	3.23	3.35	4.19
ddIb	ABCq	RAL	0.75	2.14	1.69	2.24	1.83	2.26	2.35	2.89	2.43	3.83	4.58	2.38	2.38	3.68	3.93
3TCb	TDF	EVG/c	2.30	0.86	1.41	2.30	2.35	1.43	2.35	3.16	3.72	2.27	4.58	2.97	4.06	2.24	4.64
ddIb	ABCq	MVC	0.75	2.14	1.72	2.24	1.83	2.23	2.32	2.89	2.47	3.87	4.61	2.38	2.54	4.41	4.58
d4T	3TCb	ABCb	0.25	2.30	1.91	2.31	1.92	2.47	2.47	2.55	2.16	4.22	4.47	2.72	2.41	2.82	4.98
AZTb	ddIEC	EVG/c	0.37	2.56	1.41	2.56	1.42	2.60	2.60	2.93	1.78	3.97	4.34	3.41	1.83	4.20	5.34
TDF	ABCq	RAL	0.86	2.14	1.69	2.14	1.69	2.26	2.26	3.00	2.55	3.83	4.69	2.11	2.71	3.68	4.11
TDF	ABCq	MVC	0.86	2.14	1.72	2.14	1.73	2.23	2.23	3.00	2.58	3.87	4.72	2.11	2.95	4.41	4.87
AZTt	ddIEC	EVG/c	0.39	2.56	1.41	2.56	1.42	2.60	2.60	2.95	1.81	3.97	4.37	3.46	1.86	4.20	5.38
3TCq	ddIb	EVG/c	2.35	0.75	1.41	2.44	2.39	1.60	2.47	3.10	3.76	2.16	4.51	2.59	4.10	2.25	4.38
AZTb	ddIq	NFVb	0.37	0.84	2.80	0.91	2.80	2.98	2.98	1.21	3.17	3.64	4.01	1.61	3.25	3.40	4.20
d4T	ABCq	ENF	0.25	2.14	2.07	2.14	2.07	2.53	2.53	2.39	2.32	4.21	4.46	2.65	2.33	3.82	4.89
3TCb	ddIq	EVG/c	2.30	0.84	1.41	2.41	2.35	1.62	2.44	3.14	3.72	2.25	4.56	2.58	4.06	2.36	4.42
3TCq	TDF	EVG/c	2.35	0.86	1.41	2.35	2.39	1.43	2.39	3.21	3.76	2.27	4.62	3.02	4.10	2.24	4.69
ddIq	ENF	RAL	0.84	2.07	1.69	2.26	1.85	2.29	2.41	2.91	2.53	3.76	4.60	2.79	2.47	3.96	4.56
ddIq	ENF	MVC	0.84	2.07	1.72	2.26	1.85	2.26	2.38	2.91	2.56	3.79	4.63	2.79	2.64	4.70	5.21
AZTt	ddIq	NFVb	0.39	0.84	2.80	0.92	2.80	2.98	2.98	1.23	3.19	3.64	4.03	1.66	3.28	3.40	4.23
d4T	3TCq	ABCb	0.25	2.35	1.91	2.35	1.92	2.51	2.51	2.60	2.16	4.26	4.51	2.77	2.41	2.86	5.02
ddIq	ABCq	RAL	0.84	2.14	1.69	2.25	1.85	2.26	2.36	2.98	2.53	3.83	4.67	2.41	2.47	3.68	4.00
ddIq	ABCq	MVC	0.84	2.14	1.72	2.25	1.85	2.23	2.33	2.98	2.56	3.87	4.70	2.41	2.64	4.41	4.67
AZTb	3TCb	ABCb	0.37	2.30	1.91	2.30	1.91	2.47	2.47	2.67	2.28	4.22	4.59	2.91	2.84	2.82	5.55
3TCq	ddIq	EVG/c	2.35	0.84	1.41	2.45	2.39	1.62	2.48	3.19	3.76	2.25	4.60	2.62	4.10	2.36	4.46
AZTt	3TCb	ABCb	0.39	2.30	1.91	2.30	1.91	2.47	2.47	2.70	2.31	4.22	4.61	2.95	2.91	2.82	5.61
AZTb	ABCq	ENF	0.37	2.14	2.07	2.14	2.07	2.53	2.53	2.51	2.44	4.21	4.58	3.07	2.51	3.82	5.51
AZTt	ABCq	ENF	0.39	2.14	2.07	2.14	2.07	2.53	2.53	2.54	2.46	4.21	4.61	3.13	2.54	3.82	5.56
AZTb	3TCq	ABCb	0.37	2.35	1.91	2.35	1.91	2.51	2.51	2.72	2.28	4.26	4.63	2.95	2.84	2.86	5.59
d4T	ddIEC	MVC	0.25	2.56	1.72	2.56	1.73	2.62	2.62	2.81	1.97	4.28	4.53	3.29	1.95	4.48	5.84
d4T	ddIEC	RAL	0.25	2.56	1.69	2.56	1.69	2.66	2.66	2.81	1.94	4.25	4.50	3.29	2.00	4.11	5.78
AZTt	3TCq	ABCb	0.39	2.35	1.91	2.35	1.91	2.51	2.51	2.74	2.31	4.26	4.66	2.99	2.91	2.86	5.65
ABCb	EVG/c	MVC	1.91	1.41	1.72	2.02	2.07	1.84	2.14	3.33	3.64	3.14	5.05	3.39	4.16	3.20	5.51
3TCb	ddIb	RAL	2.30	0.75	1.69	2.39	2.39	1.83	2.47	3.05	3.99	2.43	4.74	2.55	4.00	2.38	4.20
3TCb	ddIb	MVC	2.30	0.75	1.72	2.39	2.36	1.83	2.44	3.05	4.03	2.47	4.77	2.55	5.28	2.54	5.30
3TCb	ddIb	MVC	2.30	0.75	1.72	2.39	2.36	1.83	2.44	3.05	4.03	2.47	4.77	2.55	5.28	2.54	5.30
d4T	EVG/c	NFVt	0.25	1.41	2.76	1.42	2.76	2.82	2.82	1.66	3.01	4.17	4.42	1.70	2.92	4.61	4.55
ddIb	ABCb	ENF	0.75	1.91	2.07	2.04	2.24	2.41	2.51	2.66	2.82	3.98	4.73	2.17	2.71	3.61	3.94
3TCb	TDF	RAL	2.30	0.86	1.69	2.30	2.39	1.69	2.39	3.16	3.99	2.55	4.85	2.97	4.00	2.71	4.82
FTC	ddIb	TDF	2.79	0.75	0.86	2.85	2.79	1.06	2.85	3.54	3.65	1.61	4.40	3.06	3.07	0.98	3.26
3TCb	TDF	MVC	2.30	0.86	1.72	2.30	2.36	1.73	2.36	3.16	4.03	2.58	4.89	2.97	5.28	2.95	5.92
d4T	3TCb	ABCq	0.25	2.30	2.14	2.31	2.14	2.56	2.56	2.55	2.39	4.45	4.70	2.72	2.64	2.93	5.26
TDF	ABCb	ENF	0.86	1.91	2.07	1.92	2.08	2.41	2.41	2.77	2.93	3.98	4.84	1.89	2.62	3.61	3.73
d4T	3TCb	ENF	0.25	2.30	2.07	2.31	2.07	2.63	2.63	2.55	2.32	4.37	4.62	2.72	2.33	4.55	5.14
d4T	FTC	EVG/c	0.25	2.79	1.41	2.79	1.42	2.80	2.80	3.04	1.66	4.20	4.45	3.21	1.69	4.28	4.93

Regimen[a]			IIP$_{ave}$													
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTb	ddIEC	MVC	0.37	2.56	1.72	2.56	1.72	2.62	2.62	2.93	2.09	4.28	4.65	3.41	2.06	4.48	5.63
AZTb	ddIEC	MVC	0.37	2.56	1.72	2.56	1.72	2.62	2.62	2.93	2.09	4.28	4.65	3.41	2.06	4.48	5.63
AZTb	ddIEC	RAL	0.37	2.56	1.69	2.56	1.69	2.66	2.66	2.93	2.05	4.25	4.61	3.41	2.07	4.11	5.47
ddIb	TDF	NFVt	0.75	0.86	2.76	1.06	2.92	2.76	2.92	1.61	3.50	3.62	4.36	1.03	3.29	3.16	3.60
AZTt	ddIEC	MVC	0.39	2.56	1.72	2.56	1.72	2.62	2.62	2.95	2.12	4.28	4.68	3.46	2.09	4.48	5.68
AZTt	ddIEC	RAL	0.39	2.56	1.69	2.56	1.69	2.66	2.66	2.95	2.08	4.25	4.64	3.46	2.10	4.11	5.52
3TCq	ddIb	RAL	2.35	0.75	1.69	2.44	2.44	1.83	2.51	3.10	4.04	2.43	4.78	2.59	4.04	2.38	4.24
3TCq	ddIb	MVC	2.35	0.75	1.72	2.44	2.41	1.83	2.49	3.10	4.07	2.47	4.82	2.59	5.32	2.54	5.34
3TCb	ddIq	RAL	2.30	0.84	1.69	2.41	2.39	1.85	2.48	3.14	3.99	2.53	4.83	2.58	4.00	2.47	4.27
3TCb	ddIq	MVC	2.30	0.84	1.72	2.41	2.36	1.85	2.45	3.14	4.03	2.56	4.87	2.58	5.28	2.64	5.40
d4T	3TCq	ABCq	0.25	2.35	2.14	2.35	2.14	2.59	2.59	2.60	2.39	4.49	4.74	2.77	2.64	2.96	5.30
3TCq	TDF	RAL	2.35	0.86	1.69	2.35	2.44	1.69	2.44	3.21	4.04	2.55	4.90	3.02	4.04	2.71	4.86
d4T	3TCq	ENF	0.25	2.35	2.07	2.35	2.07	2.67	2.67	2.60	2.32	4.42	4.67	2.77	2.33	4.60	5.19
3TCq	TDF	MVC	2.35	0.86	1.72	2.35	2.41	1.73	2.41	3.21	4.07	2.58	4.93	3.02	5.32	2.95	5.96
d4T	EVG/c	NFVb	0.25	1.41	2.80	1.42	2.80	2.88	2.88	1.66	3.05	4.22	4.47	1.70	2.96	4.65	4.59
FTC	ddIq	TDF	2.79	0.84	0.86	2.86	2.79	1.10	2.86	3.63	3.65	1.70	4.49	3.10	3.07	1.03	3.29
ddIq	ABCb	ENF	0.84	1.91	2.07	2.06	2.26	2.41	2.52	2.75	2.91	3.98	4.82	2.20	2.79	3.61	4.00
AZTb	EVG/c	NFVt	0.37	1.41	2.76	1.42	2.76	2.82	2.82	1.78	3.12	4.17	4.54	1.84	3.20	4.61	4.97
ddIb	TDF	NFVb	0.75	0.86	2.80	1.06	2.96	2.80	2.96	1.61	3.55	3.66	4.41	1.03	3.33	3.20	3.64
AZTb	3TCb	ABCq	0.37	2.30	2.14	2.30	2.14	2.56	2.56	2.67	2.51	4.45	4.81	2.91	3.07	2.93	5.87
AZTb	3TCb	ENF	0.37	2.30	2.07	2.30	2.07	2.63	2.63	2.67	2.44	4.37	4.74	2.91	2.51	4.55	5.34
AZTb	FTC	EVG/c	0.37	2.79	1.41	2.79	1.42	2.80	2.80	3.16	1.78	4.20	4.57	3.55	1.83	4.28	5.36
AZTt	EVG/c	NFVt	0.39	1.41	2.76	1.42	2.76	2.82	2.82	1.81	3.15	4.17	4.56	1.87	3.23	4.61	5.00
ddIq	TDF	NFVt	0.84	0.86	2.76	1.10	2.93	2.76	2.93	1.70	3.60	3.62	4.45	1.07	3.35	3.16	3.65
3TCq	ddIq	RAL	2.35	0.84	1.69	2.45	2.44	1.85	2.52	3.19	4.04	2.53	4.88	2.62	4.04	2.47	4.31
AZTt	3TCb	ABCq	0.39	2.30	2.14	2.30	2.14	2.56	2.56	2.70	2.54	4.45	4.84	2.95	3.13	2.93	5.93
AZTt	3TCb	ENF	0.39	2.30	2.07	2.30	2.07	2.63	2.63	2.70	2.46	4.37	4.77	2.95	2.54	4.55	5.37
AZTt	FTC	EVG/c	0.39	2.79	1.41	2.79	1.42	2.80	2.80	3.18	1.81	4.20	4.60	3.60	1.86	4.28	5.40
3TCq	ddIq	MVC	2.35	0.84	1.72	2.45	2.41	1.85	2.50	3.19	4.07	2.56	4.91	2.62	5.32	2.64	5.44
ddIEC	TDF	EVG/c	2.56	0.86	1.41	2.56	2.60	1.43	2.60	3.42	3.97	2.27	4.83	2.51	4.20	2.24	4.33
AZTb	3TCq	ABCq	0.37	2.35	2.14	2.35	2.14	2.59	2.59	2.72	2.51	4.49	4.86	2.95	3.07	2.96	5.92
AZTb	3TCq	ENF	0.37	2.35	2.07	2.35	2.07	2.67	2.67	2.72	2.44	4.42	4.79	2.95	2.51	4.60	5.39
AZTb	EVG/c	NFVb	0.37	1.41	2.80	1.42	2.80	2.88	2.88	1.78	3.17	4.22	4.58	1.84	3.25	4.65	5.01
d4T	ddIEC	ABCb	0.25	2.56	1.91	2.56	1.92	2.74	2.74	2.81	2.16	4.47	4.72	3.29	2.41	3.11	6.14
AZTt	3TCq	ABCq	0.39	2.35	2.14	2.35	2.14	2.59	2.59	2.74	2.54	4.49	4.88	2.99	3.13	2.96	5.97
AZTt	3TCq	ENF	0.39	2.35	2.07	2.35	2.07	2.67	2.67	2.74	2.46	4.42	4.81	2.99	2.54	4.60	5.42
ddIq	TDF	NFVb	0.84	0.86	2.80	1.10	2.98	2.80	2.98	1.70	3.64	3.66	4.50	1.07	3.40	3.20	3.69
AZTt	EVG/c	NFVb	0.39	1.41	2.80	1.42	2.80	2.88	2.88	1.81	3.19	4.22	4.61	1.87	3.28	4.65	5.04
3TCb	ddIb	ABCb	2.30	0.75	1.91	2.39	2.47	2.04	2.55	3.05	4.22	2.66	4.96	2.55	2.82	2.17	3.07
ABCb	RAL	MVC	1.91	1.69	1.72	2.10	2.07	1.94	2.20	3.60	3.64	3.41	5.32	3.45	4.16	3.94	5.99
ABCb	RAL	MVC	1.91	1.69	1.72	2.10	2.07	1.94	2.20	3.60	3.64	3.41	5.32	3.45	4.16	3.94	5.99
ENF	EVG/c	MVC	2.07	1.41	1.72	2.20	2.26	1.84	2.32	3.48	3.79	3.14	5.21	3.46	4.70	3.20	5.94
d4T	FTC	RAL	0.25	2.79	1.69	2.79	1.69	2.82	2.82	3.04	1.94	4.48	4.73	3.21	2.00	4.61	5.33
3TCb	TDF	ABCb	2.30	0.86	1.91	2.30	2.47	1.92	2.47	3.16	4.22	2.77	5.08	2.97	2.82	1.88	3.42
ABCq	EVG/c	MVC	2.14	1.41	1.72	2.20	2.23	1.84	2.28	3.56	3.87	3.14	5.28	3.62	4.41	3.20	5.76
d4T	FTC	MVC	0.25	2.79	1.72	2.79	1.73	2.80	2.80	3.04	1.97	4.51	4.76	3.21	1.95	4.79	5.31
d4T	FTC	MVC	0.25	2.79	1.72	2.79	1.73	2.80	2.80	3.04	1.97	4.51	4.76	3.21	1.95	4.79	5.31
d4T	RAL	NFVt	0.25	1.69	2.76	1.69	2.76	2.87	2.87	1.94	3.01	4.44	4.69	2.01	2.92	5.85	5.51
ddIb	ABCq	ENF	0.75	2.14	2.07	2.24	2.24	2.53	2.62	2.89	2.82	4.21	4.96	2.38	2.71	3.82	4.11
AZTb	ddIEC	ABCb	0.37	2.56	1.91	2.56	1.91	2.74	2.74	2.93	2.28	4.47	4.84	3.41	2.84	3.11	6.25
3TCq	ddIb	ABCb	2.35	0.75	1.91	2.44	2.51	2.04	2.59	3.10	4.26	2.66	5.01	2.59	2.86	2.17	3.11
TDF	ABCq	ENF	0.86	2.14	2.07	2.14	2.08	2.53	2.53	3.00	2.93	4.21	5.07	2.11	2.62	3.82	3.88
AZTt	ddIEC	ABCb	0.39	2.56	1.91	2.56	1.91	2.74	2.74	2.95	2.31	4.47	4.87	3.46	2.91	3.11	6.31
3TCb	ddIq	ABCb	2.30	0.84	1.91	2.41	2.47	2.06	2.56	3.14	4.22	2.75	5.06	2.58	2.82	2.20	3.09
3TCq	TDF	ABCb	2.35	0.86	1.91	2.35	2.51	1.92	2.51	3.21	4.26	2.77	5.12	3.02	2.86	1.88	3.47
AZTb	FTC	RAL	0.37	2.79	1.69	2.79	1.69	2.82	2.82	3.16	2.05	4.48	4.84	3.55	2.07	4.61	5.70
d4T	RAL	NFVb	0.25	1.69	2.80	1.69	2.80	2.93	2.93	1.94	3.05	4.49	4.74	2.01	2.96	5.88	5.54
ddIq	ABCq	ENF	0.84	2.14	2.07	2.25	2.26	2.53	2.63	2.98	2.91	4.21	5.05	2.41	2.79	3.82	4.17
AZTb	FTC	MVC	0.37	2.79	1.72	2.79	1.72	2.80	2.80	3.16	2.09	4.51	4.88	3.55	2.06	4.79	5.77
AZTb	RAL	NFVt	0.37	1.69	2.76	1.69	2.76	2.87	2.87	2.05	3.12	4.44	4.81	2.08	3.20	5.85	5.86
AZTt	FTC	RAL	0.39	2.79	1.69	2.79	1.69	2.82	2.82	3.18	2.08	4.48	4.87	3.60	2.10	4.61	5.74
3TCq	ddIq	ABCb	2.35	0.84	1.91	2.45	2.51	2.06	2.59	3.19	4.26	2.75	5.10	2.62	2.86	2.20	3.13
AZTt	FTC	MVC	0.39	2.79	1.72	2.79	1.72	2.80	2.80	3.18	2.12	4.51	4.91	3.60	2.09	4.79	5.81
AZTt	RAL	NFVt	0.39	1.69	2.76	1.69	2.76	2.87	2.87	2.08	3.15	4.44	4.84	2.11	3.23	5.85	5.90
ddIEC	TDF	MVC	2.56	0.86	1.72	2.56	2.62	1.73	2.62	3.42	4.28	2.58	5.14	2.51	4.48	2.95	4.93
ddIEC	TDF	RAL	2.56	0.86	1.69	2.56	2.66	1.69	2.66	3.42	4.25	2.55	5.11	2.51	4.11	2.71	4.45
d4T	ddIEC	ABCq	0.25	2.56	2.14	2.56	2.14	2.82	2.82	2.81	2.39	4.70	4.95	3.29	2.64	3.21	6.46
AZTb	RAL	NFVb	0.37	1.69	2.80	1.69	2.80	2.93	2.93	2.05	3.17	4.49	4.86	2.08	3.25	5.88	5.90
FTC	ddIb	EVG/c	2.79	0.75	1.41	2.85	2.80	1.60	2.86	3.54	4.20	2.16	4.95	3.06	4.28	2.25	4.63
AZTt	RAL	NFVb	0.39	1.69	2.80	1.69	2.80	2.93	2.93	2.08	3.19	4.49	4.88	2.11	3.28	5.88	5.94

Regimen[a]			IIP_{ave}															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
d4T	FTC	ABCb	0.25	2.79	1.91	2.79	1.92	2.86	2.86	3.04	2.16	4.70	4.95	3.21	2.41	2.92	5.40
d4T	ddIEC	ENF	0.25	2.56	2.07	2.56	2.07	2.94	2.94	2.81	2.32	4.63	4.88	3.29	2.33	4.33	6.00
3TCb	ddIb	ABCq	2.30	0.75	2.14	2.39	2.56	2.24	2.63	3.05	4.45	2.89	5.19	2.55	2.93	2.38	3.18
3TCb	ddIb	ENF	2.30	0.75	2.07	2.39	2.63	2.24	2.71	3.05	4.37	2.82	5.12	2.55	4.55	2.71	4.64
3TCb	EVG/c	MVC	2.30	1.41	1.72	2.35	2.36	1.84	2.40	3.72	4.03	3.14	5.44	4.06	5.28	3.20	6.69
3TCb	EVG/c	MVC	2.30	1.41	1.72	2.35	2.36	1.84	2.40	3.72	4.03	3.14	5.44	4.06	5.28	3.20	6.69
TDF	EVG/c	NFVt	0.86	1.41	2.76	1.43	2.76	2.82	2.82	2.27	3.62	4.17	5.03	2.25	3.16	4.61	4.97
ENF	RAL	MVC	2.07	1.69	1.72	2.29	2.26	1.94	2.37	3.76	3.79	3.41	5.48	3.96	4.70	3.94	6.65
ABCb	ENF	EVG/c	1.91	2.07	1.41	2.41	2.02	2.20	2.46	3.98	3.33	3.48	5.40	3.62	3.39	3.46	5.19
3TCb	TDF	ABCq	2.30	0.86	2.14	2.30	2.56	2.14	2.56	3.16	4.45	3.00	5.31	2.97	2.93	2.11	3.52
3TCb	TDF	ENF	2.30	0.86	2.07	2.30	2.63	2.08	2.63	3.16	4.37	2.93	5.23	2.97	4.55	2.62	4.94
FTC	TDF	EVG/c	2.79	0.86	1.41	2.79	2.80	1.43	2.80	3.65	4.20	2.27	5.06	3.07	4.28	2.24	4.62
ddIb	EVG/c	NFVt	0.75	1.41	2.76	1.60	2.92	2.82	2.95	2.16	3.50	4.17	4.92	2.25	3.29	4.61	5.04
ABCq	RAL	MVC	2.14	1.69	1.72	2.26	2.23	1.94	2.33	3.83	3.87	3.41	5.55	3.68	4.41	3.94	6.23
ABCq	RAL	MVC	2.14	1.69	1.72	2.26	2.23	1.94	2.33	3.83	3.87	3.41	5.55	3.68	4.41	3.94	6.23
d4T	ABCb	NFVt	0.25	1.91	2.76	1.92	2.76	2.96	2.96	2.16	3.01	4.67	4.92	2.42	2.92	4.36	5.06
AZTb	ddIEC	ABCq	0.37	2.56	2.14	2.56	2.14	2.82	2.82	2.93	2.51	4.70	5.07	3.41	3.07	3.21	6.59
3TCq	ddIb	ABCq	2.35	0.75	2.14	2.44	2.59	2.24	2.65	3.10	4.49	2.89	5.24	2.59	2.96	2.38	3.21
3TCq	ddIb	ENF	2.35	0.75	2.07	2.44	2.67	2.24	2.74	3.10	4.42	2.82	5.17	2.59	4.60	2.71	4.68
AZTt	ddIEC	ABCq	0.39	2.56	2.14	2.56	2.14	2.82	2.82	2.95	2.54	4.70	5.10	3.46	3.13	3.21	6.66
FTC	ddIq	EVG/c	2.79	0.84	1.41	2.86	2.80	1.62	2.87	3.63	4.20	2.25	5.04	3.10	4.28	2.36	4.71
3TCb	ddIq	ABCq	2.30	0.84	2.14	2.41	2.56	2.25	2.64	3.14	4.45	2.98	5.29	2.58	2.93	2.40	3.20
3TCq	EVG/c	MVC	2.35	1.41	1.72	2.39	2.41	1.84	2.44	3.76	4.07	3.14	5.49	4.10	5.32	3.20	6.74
3TCb	ddIq	ENF	2.30	0.84	2.07	2.41	2.63	2.26	2.72	3.14	4.37	2.91	5.21	2.58	4.55	2.79	4.71
AZTb	FTC	ABCb	0.37	2.79	1.91	2.79	1.91	2.86	2.86	3.16	2.28	4.70	5.07	3.55	2.84	2.92	6.33
AZTb	ddIEC	ENF	0.37	2.56	2.07	2.56	2.07	2.94	2.94	2.93	2.44	4.63	5.00	3.41	2.51	4.33	5.83
3TCq	TDF	ABCq	2.35	0.86	2.14	2.35	2.59	2.14	2.59	3.21	4.49	3.00	5.35	3.02	2.96	2.11	3.56
3TCq	TDF	ENF	2.35	0.86	2.07	2.35	2.67	2.08	2.67	3.21	4.42	2.93	5.28	3.02	4.60	2.62	4.99
TDF	EVG/c	NFVb	0.86	1.41	2.80	1.43	2.80	2.88	2.88	2.27	3.66	4.22	5.08	2.25	3.20	4.65	5.02
AZTt	FTC	ABCb	0.39	2.79	1.91	2.79	1.91	2.86	2.86	3.18	2.31	4.70	5.10	3.60	2.91	2.92	6.39
AZTt	ddIEC	ENF	0.39	2.56	2.07	2.56	2.07	2.94	2.94	2.95	2.46	4.63	5.02	3.46	2.54	4.33	5.88
ddIb	EVG/c	NFVb	0.75	1.41	2.80	1.60	2.96	2.88	3.01	2.16	3.55	4.22	4.96	2.25	3.33	4.65	5.09
ddIq	EVG/c	NFVt	0.84	1.41	2.76	1.62	2.93	2.82	2.97	2.25	3.60	4.17	5.01	2.36	3.35	4.61	5.14
d4T	ABCb	NFVb	0.25	1.91	2.80	1.92	2.80	3.03	3.03	2.16	3.05	4.72	4.96	2.42	2.96	4.41	5.09
3TCq	ddIq	ABCq	2.35	0.84	2.14	2.45	2.59	2.25	2.66	3.19	4.49	2.98	5.33	2.62	2.96	2.40	3.23
AZTb	ABCb	NFVt	0.37	1.91	2.76	1.91	2.76	2.96	2.96	2.28	3.12	4.67	5.04	2.84	3.20	4.36	5.88
3TCq	ddIq	ENF	2.35	0.84	2.07	2.45	2.67	2.26	2.75	3.19	4.42	2.91	5.26	2.62	4.60	2.79	4.75
d4T	3TCb	ddIEC	0.25	2.30	2.56	2.31	2.56	2.91	2.91	2.55	2.81	4.86	5.11	2.72	3.29	3.38	6.42
AZTt	ABCb	NFVt	0.39	1.91	2.76	1.91	2.76	2.96	2.96	2.31	3.15	4.67	5.06	2.91	3.23	4.36	5.93
ddIq	EVG/c	NFVb	0.84	1.41	2.80	1.62	2.98	2.88	3.02	2.25	3.64	4.22	5.05	2.36	3.40	4.65	5.18
ddIEC	TDF	ABCb	2.56	0.86	1.91	2.56	2.74	1.92	2.74	3.42	4.47	2.77	5.33	2.51	3.11	1.88	2.90
d4T	3TCq	ddIEC	0.25	2.35	2.56	2.35	2.56	2.92	2.92	2.60	2.81	4.91	5.16	2.77	3.29	3.40	6.48
d4T	FTC	ABCq	0.25	2.79	2.14	2.79	2.14	2.90	2.90	3.04	2.39	4.93	5.18	3.21	2.64	2.97	5.70
d4T	FTC	ENF	0.25	2.79	2.07	2.79	2.07	2.99	2.99	3.04	2.32	4.86	5.11	3.21	2.33	4.39	5.37
FTC	ddIb	RAL	2.79	0.75	1.69	2.85	2.82	1.83	2.88	3.54	4.48	2.43	5.22	3.06	4.61	2.38	4.77
AZTb	ABCb	NFVb	0.37	1.91	2.80	1.91	2.80	3.03	3.03	2.28	3.17	4.72	5.08	2.84	3.25	4.41	5.91
FTC	ddIb	MVC	2.79	0.75	1.72	2.85	2.80	1.83	2.86	3.54	4.51	2.47	5.26	3.06	4.79	2.54	5.02
AZTt	ABCb	NFVb	0.39	1.91	2.80	1.91	2.80	3.03	3.03	2.31	3.19	4.72	5.11	2.91	3.28	4.41	5.96
3TCb	ABCb	EVG/c	2.30	1.91	1.41	2.47	2.35	2.02	2.50	4.22	3.72	3.33	5.63	2.82	4.06	3.39	5.29
AZTb	3TCb	ddIEC	0.37	2.30	2.56	2.30	2.56	2.91	2.91	2.67	2.93	4.86	5.23	2.91	3.40	3.38	6.12
3TCb	RAL	MVC	2.30	1.69	1.72	2.39	2.36	1.94	2.44	3.99	4.03	3.41	5.71	4.00	5.28	3.94	7.06
FTC	TDF	RAL	2.79	0.86	1.69	2.79	2.82	1.69	2.82	3.65	4.48	2.55	5.34	3.07	4.61	2.71	5.05
AZTt	3TCb	ddIEC	0.39	2.30	2.56	2.30	2.56	2.91	2.91	2.70	2.95	4.86	5.26	2.95	3.46	3.38	6.17
ABCb	ENF	RAL	1.91	2.07	1.69	2.41	2.10	2.29	2.50	3.98	3.60	3.76	5.67	3.62	3.45	3.96	5.49
FTC	TDF	MVC	2.79	0.86	1.72	2.79	2.80	1.73	2.80	3.65	4.51	2.58	5.37	3.07	4.79	2.95	5.37
TDF	RAL	NFVt	0.86	1.69	2.76	1.69	2.76	2.87	2.87	2.55	3.62	4.44	5.30	2.71	3.16	5.85	6.15
ABCb	ENF	MVC	1.91	2.07	1.72	2.41	2.07	2.26	2.47	3.98	3.64	3.79	5.71	3.62	4.16	4.70	6.57
d4T	ABCq	NFVt	0.25	2.14	2.76	2.14	2.76	3.04	3.04	2.39	3.01	4.90	5.15	2.65	2.92	4.56	5.33
ddIb	RAL	NFVt	0.75	1.69	2.76	1.83	2.92	2.87	2.99	2.43	3.50	4.44	5.19	2.38	3.29	5.85	5.92
ABCq	ENF	EVG/c	2.14	2.07	1.41	2.53	2.20	2.20	2.56	4.21	3.56	3.48	5.63	3.82	3.62	3.46	5.41
AZTb	3TCq	ddIEC	0.37	2.35	2.56	2.35	2.56	2.92	2.92	2.72	2.93	4.91	5.28	2.95	3.40	3.40	6.18
FTC	ddIq	RAL	2.79	0.84	1.69	2.86	2.82	1.85	2.89	3.63	4.48	2.53	5.32	3.10	4.61	2.47	4.84
AZTb	FTC	ABCq	0.37	2.79	2.14	2.79	2.14	2.90	2.90	3.16	2.51	4.93	5.30	3.55	3.07	2.97	6.71
3TCq	ABCb	EVG/c	2.35	1.91	1.41	2.51	2.39	2.02	2.54	4.26	3.76	3.33	5.68	2.86	4.10	3.39	5.33
AZTb	FTC	ENF	0.37	2.79	2.07	2.79	2.07	2.99	2.99	3.16	2.44	4.86	5.23	3.55	2.51	4.39	5.91
FTC	ddIq	MVC	2.79	0.84	1.72	2.86	2.80	1.85	2.87	3.63	4.51	2.56	5.35	3.10	4.79	2.64	5.10
AZTt	3TCq	ddIEC	0.39	2.35	2.56	2.35	2.56	2.92	2.92	2.74	2.95	4.91	5.30	2.99	3.46	3.40	6.22
AZTt	FTC	ABCq	0.39	2.79	2.14	2.79	2.14	2.90	2.90	3.18	2.54	4.93	5.33	3.60	3.13	2.97	6.77
3TCq	RAL	MVC	2.35	1.69	1.72	2.44	2.41	1.94	2.48	4.04	4.07	3.41	5.76	4.04	5.32	3.94	7.10
d4T	ENF	NFVt	0.25	2.07	2.76	2.07	2.76	3.16	3.16	2.32	3.01	4.83	5.08	2.34	2.92	5.11	5.09

Regimen[a]			IIP_{ave}															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTt	FTC	ENF	0.39	2.79	2.07	2.79	2.07	2.99	2.99	3.18	2.46	4.86	5.25	3.60	2.54	4.39	5.95
d4T	ENF	NFVb	0.25	2.07	2.80	2.07	2.80	3.15	3.15	2.32	3.05	4.87	5.12	2.34	2.96	5.17	5.13
ddIb	RAL	NFVb	0.75	1.69	2.80	1.83	2.96	2.93	3.04	2.43	3.55	4.49	5.23	2.38	3.33	5.88	5.96
TDF	RAL	NFVb	0.86	1.69	2.80	1.69	2.80	2.93	2.93	2.55	3.66	4.49	5.35	2.71	3.20	5.88	6.18
ddIq	RAL	NFVt	0.84	1.69	2.76	1.85	2.93	2.87	3.00	2.53	3.60	4.44	5.28	2.47	3.35	5.85	6.02
d4T	ABCq	NFVb	0.25	2.14	2.80	2.14	2.80	3.10	3.10	2.39	3.05	4.94	5.19	2.65	2.96	4.61	5.36
AZTb	ABCq	NFVt	0.37	2.14	2.76	2.14	2.76	3.04	3.04	2.51	3.12	4.90	5.27	3.07	3.20	4.56	6.20
AZTt	ABCq	NFVt	0.39	2.14	2.76	2.14	2.76	3.04	3.04	2.54	3.15	4.90	5.29	3.13	3.23	4.56	6.25
ddIEC	EVG/c	MVC	2.56	1.41	1.72	2.60	2.62	1.84	2.65	3.97	4.28	3.14	5.70	4.20	4.48	3.20	6.05
AZTb	ENF	NFVt	0.37	2.07	2.76	2.07	2.76	3.16	3.16	2.44	3.12	4.83	5.19	2.51	3.20	5.11	5.58
FTC	ddIb	ABCb	2.79	0.75	1.91	2.85	2.86	2.04	2.92	3.54	4.70	2.66	5.45	3.06	2.92	2.17	3.38
ddIEC	TDF	ABCq	2.56	0.86	2.14	2.56	2.82	2.14	2.82	3.42	4.70	3.00	5.56	2.51	3.21	2.11	2.98
AZTt	ENF	NFVt	0.39	2.07	2.76	2.07	2.76	3.16	3.16	2.46	3.15	4.83	5.22	2.54	3.23	5.11	5.61
ddIq	RAL	NFVb	0.84	1.69	2.80	1.85	2.98	2.93	3.06	2.53	3.64	4.49	5.33	2.47	3.40	5.88	6.06
AZTb	ENF	NFVb	0.37	2.07	2.80	2.07	2.80	3.15	3.15	2.44	3.17	4.87	5.24	2.51	3.25	5.17	5.63
AZTb	ABCq	NFVb	0.37	2.14	2.80	2.14	2.80	3.10	3.10	2.51	3.17	4.94	5.31	3.07	3.25	4.61	6.22
AZTt	ENF	NFVb	0.39	2.07	2.80	2.07	2.80	3.15	3.15	2.46	3.19	4.87	5.26	2.54	3.28	5.17	5.66
FTC	TDF	ABCb	2.79	0.86	1.91	2.79	2.86	1.92	2.86	3.65	4.70	2.77	5.56	3.07	2.92	1.88	3.22
ddIEC	TDF	ENF	2.56	0.86	2.07	2.56	2.94	2.08	2.94	3.42	4.63	2.93	5.49	2.51	4.33	2.62	4.32
d4T	3TCb	NFVt	0.25	2.30	2.76	2.31	2.76	3.12	3.12	2.55	3.01	5.06	5.31	2.72	2.92	4.32	5.13
3TCb	ABCb	RAL	2.30	1.91	1.69	2.47	2.39	2.10	2.53	4.22	3.99	3.60	5.91	2.82	4.00	3.45	5.06
AZTt	ABCq	NFVb	0.39	2.14	2.80	2.14	2.80	3.10	3.10	2.54	3.19	4.94	5.34	3.13	3.28	4.61	6.27
3TCb	ABCq	EVG/c	2.30	2.14	1.41	2.56	2.35	2.20	2.58	4.45	3.72	3.56	5.86	2.93	4.06	3.62	5.49
3TCb	ENF	EVG/c	2.30	2.07	1.41	2.63	2.35	2.20	2.66	4.37	3.72	3.48	5.79	4.55	4.06	3.46	6.15
3TCb	ABCb	MVC	2.30	1.91	1.72	2.47	2.36	2.07	2.51	4.22	4.03	3.64	5.94	2.82	5.28	4.16	6.81
FTC	ddIq	ABCb	2.79	0.84	1.91	2.86	2.86	2.06	2.92	3.63	4.70	2.75	5.54	3.10	2.92	2.20	3.41
ddIb	ABCb	NFVt	0.75	1.91	2.76	2.04	2.92	2.96	3.07	2.66	3.50	4.67	5.42	2.17	3.29	4.36	4.53
d4T	3TCq	NFVt	0.25	2.35	2.76	2.35	2.76	3.14	3.14	2.60	3.01	5.11	5.36	2.77	2.92	4.35	5.18
ABCq	ENF	RAL	2.14	2.07	1.69	2.53	2.26	2.29	2.59	4.21	3.83	3.76	5.90	3.82	3.68	3.96	5.70
TDF	ABCb	NFVt	0.86	1.91	2.76	1.92	2.76	2.96	2.96	2.77	3.62	4.67	5.53	1.89	3.16	4.36	4.32
ABCq	ENF	MVC	2.14	2.07	1.72	2.53	2.23	2.26	2.57	4.21	3.87	3.79	5.94	3.82	4.41	4.70	6.81
3TCq	ABCq	EVG/c	2.35	2.14	1.41	2.59	2.39	2.20	2.61	4.49	3.76	3.56	5.91	2.96	4.10	3.62	5.53
3TCq	ABCb	RAL	2.35	1.91	1.69	2.51	2.44	2.10	2.57	4.26	4.04	3.60	5.95	2.86	4.04	3.45	5.10
3TCq	ENF	EVG/c	2.35	2.07	1.41	2.67	2.39	2.20	2.69	4.42	3.76	3.48	5.83	4.60	4.10	3.46	6.20
d4T	3TCb	NFVb	0.25	2.30	2.80	2.31	2.80	3.17	3.17	2.55	3.05	5.11	5.35	2.72	2.96	4.36	5.17
3TCq	ABCb	MVC	2.35	1.91	1.72	2.51	2.41	2.07	2.55	4.26	4.07	3.64	5.99	2.86	5.32	4.16	6.85
AZTb	3TCb	NFVt	0.37	2.30	2.76	2.30	2.76	3.12	3.12	2.67	3.12	5.06	5.43	2.91	3.20	4.32	5.62
AZTt	3TCb	NFVt	0.39	2.30	2.76	2.30	2.76	3.12	3.12	2.70	3.15	5.06	5.45	2.95	3.23	4.32	5.66
ddIb	ABCb	NFVb	0.75	1.91	2.80	2.04	2.96	3.03	3.12	2.66	3.55	4.72	5.46	2.17	3.33	4.41	4.58
ddIq	ABCb	NFVt	0.84	1.91	2.76	2.06	2.93	2.96	3.08	2.75	3.60	4.67	5.51	2.20	3.35	4.36	4.59
d4T	3TCq	NFVb	0.25	2.35	2.80	2.35	2.80	3.20	3.20	2.60	3.05	5.15	5.40	2.77	2.96	4.40	5.21
TDF	ABCb	NFVb	0.86	1.91	2.80	1.92	2.80	3.03	3.03	2.77	3.66	4.72	5.57	1.89	3.20	4.41	4.38
AZTb	3TCq	NFVt	0.37	2.35	2.76	2.35	2.76	3.14	3.14	2.72	3.12	5.11	5.47	2.95	3.20	4.35	5.67
FTC	ddIb	ABCq	2.79	0.75	2.14	2.85	2.90	2.24	2.95	3.54	4.93	2.89	5.68	3.06	2.97	2.38	3.45
3TCb	ddIEC	TDF	2.30	2.56	0.86	2.91	2.30	2.56	2.91	4.86	3.16	3.42	5.72	3.38	2.97	2.51	3.86
AZTt	3TCq	NFVt	0.39	2.35	2.76	2.35	2.76	3.14	3.14	2.74	3.15	5.11	5.50	2.99	3.23	4.35	5.71
AZTb	3TCb	NFVb	0.37	2.30	2.80	2.30	2.80	3.17	3.17	2.67	3.17	5.11	5.47	2.91	3.25	4.36	5.66
FTC	ddIb	ENF	2.79	0.75	2.07	2.85	2.99	2.24	3.04	3.54	4.86	2.82	5.61	3.06	4.39	2.71	4.68
ddIEC	ABCb	EVG/c	2.56	1.91	1.41	2.74	2.60	2.02	2.77	4.47	3.97	3.33	5.89	3.11	4.20	3.39	5.42
ddIEC	RAL	MVC	2.56	1.69	1.72	2.66	2.62	1.94	2.69	4.25	4.28	3.41	5.97	4.11	4.48	3.94	6.39
AZTt	3TCb	NFVb	0.39	2.30	2.80	2.30	2.80	3.17	3.17	2.70	3.19	5.11	5.50	2.95	3.28	4.36	5.70
ddIq	ABCb	NFVb	0.84	1.91	2.80	2.06	2.98	3.03	3.14	2.75	3.64	4.72	5.55	2.20	3.40	4.41	4.64
3TCq	ddIEC	TDF	2.35	2.56	0.86	2.92	2.35	2.56	2.92	4.91	3.21	3.42	5.77	3.40	3.02	2.51	3.88
FTC	TDF	ABCq	2.79	0.86	2.14	2.79	2.90	2.14	2.90	3.65	4.93	3.00	5.79	3.07	2.97	2.11	3.27
FTC	TDF	ENF	2.79	0.86	2.07	2.79	2.99	2.08	2.99	3.65	4.86	2.93	5.72	3.07	4.39	2.62	4.61
AZTb	3TCq	NFVb	0.37	2.35	2.80	2.35	2.80	3.20	3.20	2.72	3.17	5.15	5.52	2.95	3.25	4.40	5.71
FTC	ddIq	ABCq	2.79	0.84	2.14	2.86	2.90	2.25	2.96	3.63	4.93	2.98	5.77	3.10	2.97	2.40	3.48
AZTt	3TCq	NFVb	0.39	2.35	2.80	2.35	2.80	3.20	3.20	2.74	3.19	5.15	5.54	2.99	3.28	4.40	5.74
3TCb	ABCq	RAL	2.30	2.14	1.69	2.56	2.39	2.26	2.61	4.45	3.99	3.83	6.13	2.93	4.00	3.68	5.24
3TCb	ENF	RAL	2.30	2.07	1.69	2.63	2.39	2.29	2.68	4.37	3.99	3.76	6.06	4.55	4.00	3.96	6.34
FTC	EVG/c	MVC	2.79	1.41	1.72	2.80	2.80	1.84	2.82	4.20	4.51	3.14	5.93	4.28	4.79	3.20	6.22
FTC	ddIq	ENF	2.79	0.84	2.07	2.86	2.99	2.26	3.05	3.63	4.86	2.91	5.70	3.10	4.39	2.79	4.74
3TCb	ABCq	MVC	2.30	2.14	1.72	2.56	2.36	2.23	2.59	4.45	4.03	3.87	6.17	2.93	5.28	4.41	7.05
3TCb	ENF	MVC	2.30	2.07	1.72	2.63	2.36	2.26	2.66	4.37	4.03	3.79	6.10	4.55	5.28	4.70	7.81
ddIb	ABCq	NFVt	0.75	2.14	2.76	2.24	2.92	3.04	3.12	2.89	3.50	4.90	5.65	2.38	3.29	4.56	4.68
d4T	FTC	ddIEC	0.25	2.79	2.56	2.79	2.56	3.19	3.19	3.04	2.81	5.35	5.60	3.21	3.29	3.86	6.96
TDF	ABCq	NFVt	0.86	2.14	2.76	2.14	2.76	3.04	3.04	3.00	3.62	4.90	5.76	2.11	3.16	4.56	4.46
3TCq	ABCq	RAL	2.35	2.14	1.69	2.59	2.44	2.26	2.63	4.49	4.04	3.83	6.18	2.96	4.04	3.68	5.28
3TCq	ENF	RAL	2.35	2.07	1.69	2.67	2.44	2.29	2.71	4.42	4.04	3.76	6.11	4.60	4.04	3.96	6.39
ddIb	ENF	NFVt	0.75	2.07	2.76	2.24	2.92	3.16	3.25	2.82	3.50	4.83	5.57	2.71	3.29	5.11	5.41

Regimen[a]			IIP_{ave}															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
3TCq	ABCq	MVC	2.35	2.14	1.72	2.59	2.41	2.23	2.61	4.49	4.07	3.87	6.22	2.96	5.32	4.41	7.09
3TCq	ENF	MVC	2.35	2.07	1.72	2.67	2.41	2.26	2.70	4.42	4.07	3.79	6.14	4.60	5.32	4.70	7.85
TDF	ENF	NFVt	0.86	2.07	2.76	2.08	2.76	3.16	3.16	2.93	3.62	4.83	5.69	2.63	3.16	5.11	5.29
ddIb	ENF	NFVb	0.75	2.07	2.80	2.24	2.96	3.15	3.25	2.82	3.55	4.87	5.62	2.71	3.33	5.17	5.45
ddIq	ABCq	NFVt	0.84	2.14	2.76	2.25	2.93	3.04	3.13	2.98	3.60	4.90	5.74	2.41	3.35	4.56	4.74
ddIb	ABCq	NFVb	0.75	2.14	2.80	2.24	2.96	3.10	3.19	2.89	3.55	4.94	5.69	2.38	3.33	4.61	4.74
TDF	ENF	NFVb	0.86	2.07	2.80	2.08	2.80	3.15	3.15	2.93	3.66	4.87	5.73	2.63	3.20	5.17	5.32
TDF	ABCq	NFVb	0.86	2.14	2.80	2.14	2.80	3.10	3.10	3.00	3.66	4.94	5.80	2.11	3.20	4.61	4.52
AZTb	FTC	ddIEC	0.37	2.79	2.56	2.79	2.56	3.19	3.19	3.16	2.93	5.35	5.72	3.55	3.40	3.86	7.02
ddIq	ENF	NFVt	0.84	2.07	2.76	2.26	2.93	3.16	3.26	2.91	3.60	4.83	5.67	2.79	3.35	5.11	5.49
AZTt	FTC	ddIEC	0.39	2.79	2.56	2.79	2.56	3.19	3.19	3.18	2.95	5.35	5.74	3.60	3.46	3.86	7.07
ddIEC	ABCq	EVG/c	2.56	2.14	1.41	2.82	2.60	2.20	2.83	4.70	3.97	3.56	6.12	3.21	4.20	3.62	5.62
ddIEC	ABCb	RAL	2.56	1.91	1.69	2.74	2.66	2.10	2.80	4.47	4.25	3.60	6.16	3.11	4.11	3.45	5.17
ddIEC	ABCb	MVC	2.56	1.91	1.72	2.74	2.62	2.07	2.77	4.47	4.28	3.64	6.20	3.11	4.48	4.16	6.04
ddIq	ENF	NFVb	0.84	2.07	2.80	2.26	2.98	3.15	3.26	2.91	3.64	4.87	5.71	2.79	3.40	5.17	5.53
ddIq	ABCq	NFVb	0.84	2.14	2.80	2.25	2.98	3.10	3.19	2.98	3.64	4.94	5.78	2.41	3.40	4.61	4.79
FTC	ABCb	EVG/c	2.79	1.91	1.41	2.86	2.80	2.02	2.87	4.70	4.20	3.33	6.12	2.92	4.28	3.39	5.37
ddIEC	ENF	EVG/c	2.56	2.07	1.41	2.94	2.60	2.20	2.95	4.63	3.97	3.48	6.04	4.33	4.20	3.46	6.01
3TCb	ddIb	NFVt	2.30	0.75	2.76	2.39	3.12	2.92	3.20	3.05	5.06	3.50	5.81	2.55	4.32	3.29	4.58
3TCb	ABCb	ENF	2.30	1.91	2.07	2.47	2.63	2.41	2.74	4.22	4.37	3.98	6.29	2.82	4.55	3.61	5.43
FTC	RAL	MVC	2.79	1.69	1.72	2.82	2.80	1.94	2.83	4.48	4.51	3.41	6.20	4.61	4.79	3.94	6.84
3TCb	TDF	NFVt	2.30	0.86	2.76	2.30	3.12	2.76	3.12	3.16	5.06	3.62	5.92	2.97	4.32	3.16	4.85
d4T	ddIEC	NFVt	0.25	2.56	2.76	2.56	2.76	3.48	3.48	2.81	3.01	5.32	5.57	3.29	2.92	4.64	6.26
3TCq	ddIb	NFVt	2.35	0.75	2.76	2.44	3.14	2.92	3.21	3.10	5.11	3.50	5.85	2.59	4.35	3.29	4.60
ABCb	EVG/c	NFVt	1.91	1.41	2.76	2.02	2.96	2.82	2.99	3.33	4.67	4.17	6.09	3.39	4.36	4.61	6.30
3TCb	ddIb	NFVb	2.30	0.75	2.80	2.39	3.17	2.96	3.25	3.05	5.11	3.55	5.85	2.55	4.36	3.33	4.62
3TCq	TDF	NFVt	2.35	0.86	2.76	2.35	3.14	2.76	3.14	3.21	5.11	3.62	5.97	3.02	4.35	3.16	4.89
3TCq	ABCb	ENF	2.35	1.91	2.07	2.51	2.67	2.41	2.77	4.26	4.42	3.98	6.33	2.86	4.60	3.61	5.47
3TCb	ddIq	NFVt	2.30	0.84	2.76	2.41	3.12	2.93	3.21	3.14	5.06	3.60	5.90	2.58	4.32	3.35	4.63
d4T	ddIEC	NFVb	0.25	2.56	2.80	2.56	2.80	3.53	3.53	2.81	3.05	5.36	5.61	3.29	2.96	4.69	6.28
3TCb	TDF	NFVb	2.30	0.86	2.80	2.30	3.17	2.80	3.17	3.16	5.11	3.66	5.96	2.97	4.36	3.20	4.90
3TCq	ddIb	NFVb	2.35	0.75	2.80	2.44	3.20	2.96	3.27	3.10	5.15	3.55	5.90	2.59	4.40	3.33	4.65
AZTb	ddIEC	NFVt	0.37	2.56	2.76	2.56	2.76	3.48	3.48	2.93	3.12	5.32	5.68	3.41	3.20	4.64	6.35
3TCq	ddIq	NFVt	2.35	0.84	2.76	2.45	3.14	2.93	3.22	3.19	5.11	3.60	5.94	2.62	4.35	3.35	4.65
ABCb	EVG/c	NFVb	1.91	1.41	2.80	2.02	3.03	2.88	3.05	3.33	4.72	4.22	6.13	3.39	4.41	4.65	6.34
d4T	FTC	NFVt	0.25	2.79	2.76	2.79	2.76	3.38	3.38	3.04	3.01	5.55	5.80	3.21	2.92	4.99	5.77
AZTt	ddIEC	NFVt	0.39	2.56	2.76	2.56	2.76	3.48	3.48	2.95	3.15	5.32	5.71	3.46	3.23	4.64	6.39
3TCb	ddIq	NFVb	2.30	0.84	2.80	2.41	3.17	2.98	3.25	3.14	5.11	3.64	5.94	2.58	4.36	3.40	4.68
3TCb	ddIEC	EVG/c	2.30	2.56	1.41	2.91	2.35	2.60	2.92	4.86	3.72	3.97	6.28	3.38	4.06	4.20	6.03
3TCq	TDF	NFVb	2.35	0.86	2.80	2.35	3.20	2.80	3.20	3.21	5.15	3.66	6.01	3.02	4.40	3.20	4.93
ddIEC	ABCq	RAL	2.56	2.14	1.69	2.82	2.66	2.26	2.86	4.70	4.25	3.83	6.39	3.21	4.11	3.68	5.35
AZTb	ddIEC	NFVb	0.37	2.56	2.80	2.56	2.80	3.53	3.53	2.93	3.17	5.36	5.73	3.41	3.25	4.69	6.38
FTC	ABCq	EVG/c	2.79	2.14	1.41	2.90	2.80	2.20	2.91	4.93	4.20	3.56	6.35	2.97	4.28	3.62	5.57
3TCq	ddIEC	EVG/c	2.35	2.56	1.41	2.92	2.39	2.60	2.94	4.91	3.76	3.97	6.32	3.40	4.10	4.20	6.07
ddIEC	ABCq	MVC	2.56	2.14	1.72	2.82	2.62	2.23	2.84	4.70	4.28	3.87	6.43	3.21	4.48	4.41	6.27
ddIEC	ABCq	MVC	2.56	2.14	1.72	2.82	2.62	2.23	2.84	4.70	4.28	3.87	6.43	3.21	4.48	4.41	6.27
3TCq	ddIq	NFVb	2.35	0.84	2.80	2.45	3.20	2.98	3.28	3.19	5.15	3.64	5.99	2.62	4.40	3.40	4.71
FTC	ENF	EVG/c	2.79	2.07	1.41	2.99	2.80	2.20	3.00	4.86	4.20	3.48	6.28	4.39	4.28	3.46	6.02
FTC	ABCb	RAL	2.79	1.91	1.69	2.86	2.82	2.10	2.89	4.70	4.48	3.60	6.39	2.92	4.61	3.45	5.50
AZTt	ddIEC	NFVb	0.39	2.56	2.80	2.56	2.80	3.53	3.53	2.95	3.19	5.36	5.75	3.46	3.28	4.69	6.42
d4T	FTC	NFVb	0.25	2.79	2.80	2.79	2.80	3.44	3.44	3.04	3.05	5.59	5.84	3.21	2.96	5.04	5.80
ddIEC	ENF	RAL	2.56	2.07	1.69	2.94	2.66	2.29	2.97	4.63	4.25	3.76	6.32	4.33	4.11	3.96	6.17
FTC	ABCb	MVC	2.79	1.91	1.72	2.86	2.80	2.07	2.87	4.70	4.51	3.64	6.43	2.92	4.79	4.16	6.23
AZTb	FTC	NFVt	0.37	2.79	2.76	2.79	2.76	3.38	3.38	3.16	3.12	5.55	5.91	3.55	3.20	4.99	6.60
ddIEC	ENF	MVC	2.56	2.07	1.72	2.94	2.62	2.26	2.95	4.63	4.28	3.79	6.35	4.33	4.48	4.70	7.00
3TCb	ABCq	ENF	2.30	2.14	2.07	2.56	2.63	2.53	2.80	4.45	4.37	4.21	6.52	2.93	4.55	3.82	5.60
AZTt	FTC	NFVt	0.39	2.79	2.76	2.79	2.76	3.38	3.38	3.18	3.15	5.55	5.94	3.60	3.23	4.99	6.64
ABCq	EVG/c	NFVt	2.14	1.41	2.76	2.20	3.04	2.82	3.05	3.56	4.90	4.17	6.31	3.62	4.56	4.61	6.52
ABCb	RAL	NFVt	1.91	1.69	2.76	2.10	2.96	2.87	3.01	3.60	4.67	4.44	6.36	3.45	4.36	5.85	7.36
3TCq	ABCq	ENF	2.35	2.14	2.07	2.59	2.67	2.53	2.82	4.49	4.42	4.21	6.56	2.96	4.60	3.82	5.64
FTC	ddIEC	TDF	2.79	2.56	0.86	3.19	2.79	2.56	3.19	5.35	3.65	3.42	6.21	3.86	3.07	2.51	3.85
AZTb	FTC	NFVb	0.37	2.79	2.80	2.79	2.80	3.44	3.44	3.16	3.17	5.59	5.96	3.55	3.25	5.04	6.64
ENF	EVG/c	NFVt	2.07	1.41	2.76	2.20	3.16	2.82	3.18	3.48	4.83	4.17	6.24	3.46	5.11	4.61	6.78
AZTt	FTC	NFVb	0.39	2.79	2.80	2.79	2.80	3.44	3.44	3.18	3.19	5.59	5.98	3.60	3.28	5.04	6.68
ENF	EVG/c	NFVb	2.07	1.41	2.80	2.20	3.15	2.88	3.18	3.48	4.87	4.22	6.29	3.46	5.17	4.65	6.83
ABCb	RAL	NFVb	1.91	1.69	2.80	2.10	3.03	2.93	3.08	3.60	4.72	4.49	6.40	3.45	4.41	5.88	7.40
ABCq	EVG/c	NFVb	2.14	1.41	2.80	2.20	3.10	2.88	3.12	3.56	4.94	4.22	6.36	3.62	4.61	4.65	6.57
AZTb	d4T	NVP	0.37	0.25	4.43	0.45	4.43	4.43	4.43	0.62	4.80	4.68	5.05	0.45	5.28	4.90	5.69
3TCb	ddIEC	RAL	2.30	2.56	1.69	2.91	2.39	2.66	2.94	4.86	3.99	4.25	6.55	3.38	4.00	4.11	5.64
AZTt	d4T	NVP	0.39	0.25	4.43	0.47	4.43	4.43	4.43	0.64	4.83	4.68	5.07	0.47	5.33	4.90	5.74

Regimen[a]			IIP_{ave}													
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
3TCb	ddIEC	MVC	2.30	2.56	1.72	2.91	2.36	2.62	2.92	4.86	4.03	4.28	6.59	3.38	5.28	4.48	7.12
FTC	ABCq	RAL	2.79	2.14	1.69	2.90	2.82	2.26	2.92	4.93	4.48	3.83	6.62	2.97	4.61	3.68	5.68
3TCq	ddIEC	RAL	2.35	2.56	1.69	2.92	2.44	2.66	2.96	4.91	4.04	4.25	6.60	3.40	4.04	4.11	5.68
FTC	ENF	RAL	2.79	2.07	1.69	2.99	2.82	2.29	3.01	4.86	4.48	3.76	6.55	4.39	4.61	3.96	6.50
FTC	ABCq	MVC	2.79	2.14	1.72	2.90	2.80	2.23	2.91	4.93	4.51	3.87	6.66	2.97	4.79	4.41	6.46
ddIEC	ABCb	ENF	2.56	1.91	2.07	2.74	2.94	2.41	3.02	4.47	4.63	3.98	6.54	3.11	4.33	3.61	5.25
3TCq	ddIEC	MVC	2.35	2.56	1.72	2.92	2.41	2.62	2.94	4.91	4.07	4.28	6.63	3.40	5.32	4.48	7.18
FTC	ENF	MVC	2.79	2.07	1.72	2.99	2.80	2.26	3.00	4.86	4.51	3.79	6.58	4.39	4.79	4.70	7.22
3TCb	EVG/c	NFVt	2.30	1.41	2.76	2.35	3.12	2.82	3.14	3.72	5.06	4.17	6.48	4.06	4.32	4.61	6.69
ddIEC	TDF	NFVt	2.56	0.86	2.76	2.56	3.48	2.76	3.48	3.42	5.32	3.62	6.18	2.51	4.64	3.16	4.60
ABCq	RAL	NFVt	2.14	1.69	2.76	2.26	3.04	2.87	3.07	3.83	4.90	4.44	6.59	3.68	4.56	5.85	7.60
3TCq	EVG/c	NFVt	2.35	1.41	2.76	2.39	3.14	2.82	3.15	3.76	5.11	4.17	6.52	4.10	4.35	4.61	6.73
3TCb	EVG/c	NFVb	2.30	1.41	2.80	2.35	3.17	2.88	3.19	3.72	5.11	4.22	6.52	4.06	4.36	4.65	6.73
ENF	RAL	NFVt	2.07	1.69	2.76	2.29	3.16	2.87	3.20	3.76	4.83	4.44	6.51	3.96	5.11	5.85	7.99
FTC	ddIb	NFVt	2.79	0.75	2.76	2.85	3.38	2.92	3.44	3.54	5.55	3.50	6.29	3.06	4.99	3.29	5.14
ddIEC	TDF	NFVb	2.56	0.86	2.80	2.56	3.53	2.80	3.53	3.42	5.36	3.66	6.22	2.51	4.69	3.20	4.65
ENF	RAL	NFVb	2.07	1.69	2.80	2.29	3.15	2.93	3.20	3.76	4.87	4.49	6.56	3.96	5.17	5.88	8.06
3TCb	ddIEC	ABCb	2.30	2.56	1.91	2.91	2.47	2.74	2.99	4.86	4.22	4.47	6.78	3.38	2.82	3.11	3.81
ABCq	RAL	NFVb	2.14	1.69	2.80	2.26	3.10	2.93	3.14	3.83	4.94	4.49	6.63	3.68	4.61	5.88	7.64
3TCq	EVG/c	NFVb	2.35	1.41	2.80	2.39	3.20	2.88	3.21	3.76	5.15	4.22	6.57	4.10	4.40	4.65	6.78
FTC	TDF	NFVt	2.79	0.86	2.76	2.79	3.38	2.76	3.38	3.65	5.55	3.62	6.41	3.07	4.99	3.16	5.05
FTC	ABCb	ENF	2.79	1.91	2.07	2.86	2.99	2.41	3.04	4.70	4.86	3.98	6.77	2.92	4.39	3.61	5.14
3TCq	ddIEC	ABCb	2.35	2.56	1.91	2.92	2.51	2.74	3.00	4.91	4.26	4.47	6.82	3.40	2.86	3.11	3.83
FTC	ddIb	NFVb	2.79	0.75	2.80	2.85	3.44	2.96	3.49	3.54	5.59	3.55	6.34	3.06	5.04	3.33	5.19
FTC	ddIq	NFVt	2.79	0.84	2.76	2.86	3.38	2.93	3.45	3.63	5.55	3.60	6.39	3.10	4.99	3.35	5.19
ddIEC	ABCq	ENF	2.56	2.14	2.07	2.82	2.94	2.53	3.07	4.70	4.63	4.21	6.77	3.21	4.33	3.82	5.41
d4T	ddIb	NVP	0.25	0.75	4.43	0.82	4.43	4.45	4.45	0.99	4.68	5.18	5.43	1.34	4.90	5.05	5.94
FTC	TDF	NFVb	2.79	0.86	2.80	2.79	3.44	2.80	3.44	3.65	5.59	3.66	6.45	3.07	5.04	3.20	5.10
3TCb	RAL	NFVt	2.30	1.69	2.76	2.39	3.12	2.87	3.15	3.99	5.06	4.44	6.75	4.00	4.32	5.85	7.66
FTC	ddIq	NFVb	2.79	0.84	2.80	2.86	3.44	2.98	3.50	3.63	5.59	3.64	6.43	3.10	5.04	3.40	5.24
3TCq	RAL	NFVt	2.35	1.69	2.76	2.44	3.14	2.87	3.17	4.04	5.11	4.44	6.79	4.04	4.35	5.85	7.71
FTC	ddIEC	EVG/c	2.79	2.56	1.41	3.19	2.80	2.60	3.20	5.35	4.20	3.97	6.76	3.86	4.28	4.20	6.27
d4T	TDF	NVP	0.25	0.86	4.43	0.87	4.43	4.43	4.43	1.11	4.68	5.29	5.54	1.67	4.90	5.32	6.30
d4T	ddIq	NVP	0.25	0.84	4.43	0.90	4.43	4.46	4.46	1.09	4.68	5.27	5.52	1.45	4.90	5.12	6.09
ABCb	ENF	NFVt	1.91	2.07	2.76	2.41	2.96	3.16	3.25	3.98	4.67	4.83	6.74	3.62	4.36	5.11	6.54
3TCb	RAL	NFVb	2.30	1.69	2.80	2.39	3.17	2.93	3.20	3.99	5.11	4.49	6.79	4.00	4.36	5.88	7.71
AZTb	ddIb	NVP	0.37	0.75	4.43	0.83	4.43	4.45	4.45	1.11	4.80	5.18	5.55	1.51	5.28	5.05	6.28
AZTt	ddIb	NVP	0.39	0.75	4.43	0.84	4.43	4.45	4.45	1.14	4.83	5.18	5.57	1.55	5.33	5.05	6.32
3TCb	ddIEC	ABCq	2.30	2.56	2.14	2.91	2.56	2.82	3.03	4.86	4.45	4.70	7.01	3.38	2.93	3.21	3.89
ABCb	ENF	NFVb	1.91	2.07	2.80	2.41	3.03	3.15	3.26	3.98	4.72	4.87	6.79	3.62	4.41	5.17	6.58
3TCq	RAL	NFVb	2.35	1.69	2.80	2.44	3.20	2.93	3.22	4.04	5.15	4.49	6.84	4.04	4.40	5.88	7.75
3TCb	ddIEC	ENF	2.30	2.56	2.07	2.91	2.63	2.94	3.13	4.86	4.37	4.63	6.93	3.38	4.55	4.33	6.04
FTC	ABCq	ENF	2.79	2.14	2.07	2.90	2.99	2.53	3.07	4.93	4.86	4.21	7.00	2.97	4.39	3.82	5.29
3TCq	ddIEC	ABCq	2.35	2.56	2.14	2.92	2.59	2.82	3.04	4.91	4.49	4.70	7.05	3.40	2.96	3.21	3.91
AZTb	TDF	NVP	0.37	0.86	4.43	0.87	4.43	4.43	4.43	1.23	4.80	5.29	5.66	1.92	5.28	5.32	6.69
AZTb	ddIq	NVP	0.37	0.84	4.43	0.91	4.43	4.46	4.46	1.21	4.80	5.27	5.64	1.61	5.28	5.12	6.43
AZTt	TDF	NVP	0.39	0.86	4.43	0.87	4.43	4.43	4.43	1.25	4.83	5.29	5.68	1.99	5.33	5.32	6.74
3TCq	ddIEC	ENF	2.35	2.56	2.07	2.92	2.67	2.94	3.14	4.91	4.42	4.63	6.98	3.40	4.60	4.33	6.08
AZTt	ddIq	NVP	0.39	0.84	4.43	0.92	4.43	4.46	4.46	1.23	4.83	5.27	5.66	1.66	5.33	5.12	6.47
3TCb	ABCb	NFVt	2.30	1.91	2.76	2.47	3.12	2.96	3.19	4.22	5.06	4.67	6.98	2.82	4.32	4.36	5.43
ddIEC	EVG/c	NFVt	2.56	1.41	2.76	2.60	3.48	2.82	3.49	3.97	5.32	4.17	6.73	4.20	4.64	4.61	6.85
3TCq	ABCb	NFVt	2.35	1.91	2.76	2.51	3.14	2.96	3.21	4.26	5.11	4.67	7.02	2.86	4.35	4.36	5.45
FTC	ddIEC	RAL	2.79	2.56	1.69	3.19	2.82	2.66	3.21	5.35	4.48	4.25	7.04	3.86	4.61	4.11	6.23
ABCq	ENF	NFVt	2.14	2.07	2.76	2.53	3.04	3.16	3.28	4.21	4.90	4.83	6.97	3.82	4.56	5.11	6.74
3TCb	ABCb	NFVb	2.30	1.91	2.80	2.47	3.17	3.03	3.24	4.22	5.11	4.72	7.02	2.82	4.36	4.41	5.48
FTC	ddIEC	MVC	2.79	2.56	1.72	3.19	2.80	2.62	3.20	5.35	4.51	4.28	7.07	3.86	4.79	4.48	6.67
ddIEC	EVG/c	NFVb	2.56	1.41	2.80	2.60	3.53	2.88	3.53	3.97	5.36	4.22	6.78	4.20	4.69	4.65	6.89
ABCq	ENF	NFVb	2.14	2.07	2.80	2.53	3.10	3.15	3.31	4.21	4.94	4.87	7.01	3.82	4.61	5.17	6.79
3TCq	ABCb	NFVb	2.35	1.91	2.80	2.51	3.20	3.03	3.27	4.26	5.15	4.72	7.06	2.86	4.40	4.41	5.51
FTC	EVG/c	NFVt	2.79	1.41	2.76	2.80	3.38	2.82	3.39	4.20	5.55	4.17	6.96	4.28	4.99	4.61	7.07
3TCb	ABCq	NFVt	2.30	2.14	2.76	2.56	3.12	3.04	3.23	4.45	5.06	4.90	7.20	2.93	4.32	4.56	5.58
FTC	EVG/c	NFVb	2.79	1.41	2.80	2.80	3.44	2.88	3.45	4.20	5.59	4.22	7.01	4.28	5.04	4.65	7.12
3TCb	ENF	NFVt	2.30	2.07	2.76	2.63	3.12	3.16	3.34	4.37	5.06	4.83	7.13	4.55	4.32	5.11	7.05
3TCq	ABCq	NFVt	2.35	2.14	2.76	2.59	3.14	3.04	3.24	4.49	5.11	4.90	7.25	2.96	4.35	4.56	5.60
ddIb	TDF	NVP	0.75	0.86	4.43	1.06	4.45	4.43	4.45	1.61	5.18	5.29	6.04	1.03	5.05	5.32	5.79
FTC	ddIEC	ABCb	2.79	2.56	1.91	3.19	2.86	2.74	3.23	5.35	4.70	4.47	7.26	3.86	2.92	3.11	4.03
ddIEC	RAL	NFVt	2.56	1.69	2.76	2.66	3.48	2.87	3.50	4.25	5.32	4.44	7.00	4.11	4.64	5.85	7.77
3TCq	ENF	NFVt	2.35	2.07	2.76	2.67	3.14	3.16	3.35	4.42	5.11	4.83	7.18	4.60	4.35	5.11	7.09
3TCb	ENF	NFVb	2.30	2.07	2.80	2.63	3.17	3.15	3.35	4.37	5.11	4.87	7.18	4.55	4.36	5.17	7.09
d4T	NVP	EVG/c	0.25	4.43	1.41	4.43	1.42	4.43	4.43	4.68	1.66	5.85	6.10	4.90	1.69	7.01	7.35

Regimen[a]			IIP_{ave}															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
3TCb	ABCq	NFVb	2.30	2.14	2.80	2.56	3.17	3.10	3.28	4.45	5.11	4.94	7.25	2.93	4.36	4.61	5.63
ddIq	TDF	NVP	0.84	0.86	4.43	1.10	4.46	4.43	4.46	1.70	5.27	5.29	6.13	1.07	5.12	5.32	5.86
ddIEC	RAL	NFVb	2.56	1.69	2.80	2.66	3.53	2.93	3.54	4.25	5.36	4.49	7.05	4.11	4.69	5.88	7.81
3TCq	ABCb	NFVb	2.35	1.91	2.80	2.59	3.20	3.03	3.30	4.49	5.15	4.94	7.29	2.96	4.40	4.61	5.66
3TCq	ENF	NFVb	2.35	2.07	2.80	2.67	3.20	3.15	3.37	4.42	5.15	4.87	7.22	4.60	4.40	5.17	7.13
FTC	RAL	NFVt	2.79	1.69	2.76	2.82	3.38	2.87	3.40	4.48	5.55	4.44	7.23	4.61	4.99	5.85	8.31
AZTb	NVP	EVG/c	0.37	4.43	1.41	4.43	1.42	4.43	4.43	4.80	1.78	5.85	6.21	5.28	1.83	7.01	7.84
AZTt	NVP	EVG/c	0.39	4.43	1.41	4.43	1.42	4.43	4.43	4.83	1.81	5.85	6.24	5.33	1.86	7.01	7.89
FTC	RAL	NFVb	2.79	1.69	2.80	2.82	3.44	2.93	3.45	4.48	5.59	4.49	7.28	4.61	5.04	5.88	8.35
FTC	ddIEC	ABCq	2.79	2.56	2.14	3.19	2.90	2.82	3.26	5.35	4.93	4.70	7.49	3.86	2.97	3.21	4.09
ddIEC	ABCb	NFVt	2.56	1.91	2.76	2.74	3.48	2.96	3.52	4.47	5.32	4.67	7.23	3.11	4.64	4.36	5.72
FTC	ddIEC	ENF	2.79	2.56	2.07	3.19	2.99	2.94	3.34	5.35	4.86	4.63	7.42	3.86	4.39	4.33	5.95
d4T	NVP	RAL	0.25	4.43	1.69	4.43	1.69	4.43	4.43	4.68	1.94	6.12	6.37	4.90	2.00	6.36	7.21
d4T	NVP	MVC	0.25	4.43	1.72	4.43	1.73	4.43	4.43	4.68	1.97	6.16	6.40	4.90	1.95	7.26	7.62
ddIEC	ABCb	NFVb	2.56	1.91	2.80	2.74	3.53	3.03	3.57	4.47	5.36	4.72	7.28	3.11	4.69	4.41	5.77
FTC	ABCb	NFVt	2.79	1.91	2.76	2.86	3.38	2.96	3.42	4.70	5.55	4.67	7.46	2.92	4.99	4.36	5.85
AZTb	NVP	RAL	0.37	4.43	1.69	4.43	1.69	4.43	4.43	4.80	2.05	6.12	6.49	5.28	2.07	6.36	7.67
AZTt	NVP	RAL	0.39	4.43	1.69	4.43	1.69	4.43	4.43	4.83	2.08	6.12	6.51	5.33	2.10	6.36	7.72
AZTb	NVP	MVC	0.37	4.43	1.72	4.43	1.72	4.43	4.43	4.80	2.09	6.16	6.52	5.28	2.06	7.26	8.15
AZTb	NVP	MVC	0.37	4.43	1.72	4.43	1.72	4.43	4.43	4.80	2.09	6.16	6.52	5.28	2.06	7.26	8.15
FTC	ABCb	NFVb	2.79	1.91	2.80	2.86	3.44	3.03	3.48	4.70	5.59	4.72	7.51	2.92	5.04	4.41	5.90
AZTt	NVP	MVC	0.39	4.43	1.72	4.43	1.72	4.43	4.43	4.83	2.12	6.16	6.55	5.33	2.09	7.26	8.20
ddIEC	ABCq	NFVt	2.56	2.14	2.76	2.82	3.48	3.04	3.55	4.70	5.32	4.90	7.46	3.21	4.64	4.56	5.86
ddIEC	ENF	NFVt	2.56	2.07	2.76	2.94	3.48	3.16	3.64	4.63	5.32	4.83	7.39	4.33	4.64	5.11	6.97
d4T	ABCb	NVP	0.25	1.91	4.43	1.92	4.43	4.44	4.44	2.16	4.68	6.35	6.60	2.42	4.90	5.63	7.36
ddIb	NVP	EVG/c	0.75	4.43	1.41	4.45	1.60	4.43	4.45	5.18	2.16	5.85	6.59	5.05	2.25	7.01	7.37
ddIEC	ENF	NFVb	2.56	2.07	2.80	2.94	3.53	3.15	3.66	4.63	5.36	4.87	7.43	4.33	4.69	5.17	7.01
ddIEC	ABCq	NFVb	2.56	2.14	2.80	2.82	3.53	3.10	3.59	4.70	5.36	4.94	7.50	3.21	4.69	4.61	5.91
FTC	ABCq	NFVt	2.79	2.14	2.76	2.90	3.38	3.04	3.44	4.93	5.55	4.90	7.69	2.97	4.99	4.56	6.00
TDF	NVP	EVG/c	0.86	4.43	1.41	4.43	1.43	4.43	4.43	5.29	2.27	5.85	6.71	5.32	2.24	7.01	7.62
ddIq	NVP	EVG/c	0.84	4.43	1.41	4.46	1.62	4.43	4.46	5.27	2.25	5.85	6.69	5.12	2.36	7.01	7.48
FTC	ENF	NFVt	2.79	2.07	2.76	2.99	3.38	3.16	3.53	4.86	5.55	4.83	7.62	4.39	4.99	5.11	7.19
AZTb	ABCb	NVP	0.37	1.91	4.43	1.91	4.43	4.44	4.44	2.28	4.80	6.35	6.71	2.84	5.28	5.63	8.22
AZTt	ABCb	NVP	0.39	1.91	4.43	1.91	4.43	4.44	4.44	2.31	4.83	6.35	6.74	2.91	5.33	5.63	8.27
3TCb	ddIEC	NFVt	2.30	2.56	2.76	2.91	3.12	3.48	3.59	4.86	5.06	5.32	7.62	3.38	4.32	4.64	5.68
d4T	NVP	ENF	0.25	4.43	2.07	4.43	2.07	4.47	4.47	4.68	2.32	6.50	6.75	4.90	2.33	6.17	7.33
FTC	ENF	NFVb	2.79	2.07	2.80	2.99	3.44	3.15	3.56	4.86	5.59	4.87	7.66	4.39	5.04	5.17	7.24
FTC	ABCq	NFVb	2.79	2.14	2.80	2.90	3.44	3.10	3.49	4.93	5.59	4.94	7.73	2.97	5.04	4.61	6.05
3TCq	ddIEC	NFVt	2.35	2.56	2.76	2.92	3.14	3.48	3.59	4.91	5.11	5.32	7.67	3.40	4.35	4.64	5.71
d4T	ABCq	NVP	0.25	2.14	4.43	2.14	4.43	4.44	4.44	2.39	4.68	6.58	6.82	2.65	4.90	5.77	7.68
3TCb	ddIEC	NFVb	2.30	2.56	2.80	2.91	3.17	3.53	3.63	4.86	5.11	5.36	7.67	3.38	4.36	4.69	5.73
ddIb	NVP	RAL	0.75	4.43	1.69	4.45	1.83	4.43	4.45	5.18	2.43	6.12	6.87	5.05	2.38	6.36	6.83
3TCq	ddIEC	NFVb	2.35	2.56	2.80	2.92	3.20	3.53	3.63	4.91	5.15	5.36	7.71	3.40	4.40	4.69	5.75
AZTb	NVP	ENF	0.37	4.43	2.07	4.43	2.07	4.47	4.47	4.80	2.44	6.50	6.87	5.28	2.51	6.17	7.95
ddIb	NVP	MVC	0.75	4.43	1.72	4.45	1.83	4.43	4.45	5.18	2.47	6.16	6.90	5.05	2.54	7.26	7.56
ddIb	NVP	MVC	0.75	4.43	1.72	4.45	1.83	4.43	4.45	5.18	2.47	6.16	6.90	5.05	2.54	7.26	7.56
AZTt	NVP	ENF	0.39	4.43	2.07	4.43	2.07	4.47	4.47	4.83	2.46	6.50	6.90	5.33	2.54	6.17	8.00
AZTb	ABCq	NVP	0.37	2.14	4.43	2.14	4.43	4.44	4.44	2.51	4.80	6.58	6.94	3.07	5.28	5.77	8.60
AZTt	ABCq	NVP	0.39	2.14	4.43	2.14	4.43	4.44	4.44	2.54	4.83	6.58	6.97	3.13	5.33	5.77	8.66
TDF	NVP	RAL	0.86	4.43	1.69	4.43	1.69	4.43	4.43	5.29	2.55	6.12	6.98	5.32	2.71	6.36	7.26
ddIq	NVP	RAL	0.84	4.43	1.69	4.46	1.85	4.43	4.46	5.27	2.53	6.12	6.96	5.12	2.47	6.36	6.92
d4T	3TCb	NVP	0.25	2.30	4.43	2.31	4.43	4.45	4.45	2.55	4.68	6.74	6.99	2.72	4.90	5.71	7.66
TDF	NVP	MVC	0.86	4.43	1.72	4.43	1.73	4.43	4.43	5.29	2.58	6.16	7.01	5.32	2.95	7.26	8.02
ddIq	NVP	MVC	0.84	4.43	1.72	4.46	1.85	4.43	4.46	5.27	2.56	6.16	6.99	5.12	2.64	7.26	7.67
d4T	3TCq	NVP	0.25	2.35	4.43	2.35	4.43	4.45	4.45	2.60	4.68	6.78	7.03	2.77	4.90	5.74	7.72
ddIb	ABCb	NVP	0.75	1.91	4.43	2.04	4.45	4.44	4.46	2.66	5.18	6.35	7.09	2.17	5.05	5.63	6.12
AZTb	3TCb	NVP	0.37	2.30	4.43	2.30	4.43	4.45	4.45	2.67	4.80	6.74	7.10	2.91	5.28	5.71	8.28
AZTt	3TCb	NVP	0.39	2.30	4.43	2.30	4.43	4.45	4.45	2.70	4.83	6.74	7.13	2.95	5.33	5.71	8.33
AZTb	3TCq	NVP	0.37	2.35	4.43	2.35	4.43	4.45	4.45	2.72	4.80	6.78	7.15	2.95	5.28	5.74	8.35
AZTt	3TCq	NVP	0.39	2.35	4.43	2.35	4.43	4.45	4.45	2.74	4.83	6.78	7.17	2.99	5.33	5.74	8.39
TDF	ABCb	NVP	0.86	1.91	4.43	1.92	4.43	4.44	4.44	2.77	5.29	6.35	7.21	1.89	5.32	5.63	6.36
ddIq	ABCb	NVP	0.84	1.91	4.43	2.06	4.46	4.44	4.46	2.75	5.27	6.35	7.19	2.20	5.12	5.63	6.18
ddIb	NVP	ENF	0.75	4.43	2.07	4.45	2.24	4.47	4.49	5.18	2.82	6.50	7.25	5.05	2.71	6.17	6.77
ddIb	ABCq	NVP	0.75	2.14	4.43	2.24	4.45	4.44	4.46	2.89	5.18	6.58	7.32	2.38	5.05	5.77	6.24
d4T	ddIEC	NVP	0.25	2.56	4.43	2.56	4.43	4.57	4.57	2.81	4.68	6.99	7.24	3.29	4.90	6.55	8.94
FTC	ddIEC	NFVt	2.79	2.56	2.76	3.19	3.38	3.48	3.73	5.35	5.55	5.32	8.11	3.86	4.99	4.64	6.27
TDF	NVP	ENF	0.86	4.43	2.07	4.43	2.08	4.47	4.47	5.29	2.93	6.50	7.36	5.32	2.62	6.17	6.99
ddIq	NVP	ENF	0.84	4.43	2.07	4.46	2.26	4.47	4.50	5.27	2.91	6.50	7.34	5.12	2.79	6.17	6.85
TDF	ABCq	NVP	0.86	2.14	4.43	2.14	4.43	4.44	4.44	3.00	5.29	6.58	7.43	2.11	5.32	5.77	6.48
ddIq	ABCq	NVP	0.84	2.14	4.43	2.25	4.46	4.44	4.46	2.98	5.27	6.58	7.41	2.41	5.12	5.77	6.30

| Regimen[a] | | | IIP_{ave} | | | | | | | | | | | | | | |
| | | | Single drug | | | Loewe[b] | | | | Bliss[c] | | | | DI Index[d] | | | |
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
FTC	ddIEC	NFVb	2.79	2.56	2.80	3.19	3.44	3.53	3.77	5.35	5.59	5.36	8.15	3.86	5.04	4.69	6.32
AZTb	ddIEC	NVP	0.37	2.56	4.43	2.56	4.43	4.57	4.57	2.93	4.80	6.99	7.36	3.41	5.28	6.55	9.21
d4T	FTC	NVP	0.25	2.79	4.43	2.79	4.43	4.48	4.48	3.04	4.68	7.22	7.47	3.21	4.90	6.21	8.34
3TCb	ddIb	NVP	2.30	0.75	4.43	2.39	4.45	4.45	4.47	3.05	6.74	5.18	7.48	2.55	5.71	5.05	6.25
AZTt	ddIEC	NVP	0.39	2.56	4.43	2.56	4.43	4.57	4.57	2.95	4.83	6.99	7.39	3.46	5.33	6.55	9.26
3TCq	ddIb	NVP	2.35	0.75	4.43	2.44	4.45	4.45	4.47	3.10	6.78	5.18	7.53	2.59	5.74	5.05	6.28
NVP	EVG/c	MVC	4.43	1.41	1.72	4.43	4.43	1.84	4.43	5.85	6.16	3.14	7.57	7.01	7.26	3.20	9.46
NVP	EVG/c	MVC	4.43	1.41	1.72	4.43	4.43	1.84	4.43	5.85	6.16	3.14	7.57	7.01	7.26	3.20	9.46
3TCb	TDF	NVP	2.30	0.86	4.43	2.30	4.45	4.43	4.45	3.16	6.74	5.29	7.60	2.97	5.71	5.32	6.91
3TCb	ddIq	NVP	2.30	0.84	4.43	2.41	4.45	4.46	4.47	3.14	6.74	5.27	7.58	2.58	5.71	5.12	6.31
AZTb	FTC	NVP	0.37	2.79	4.43	2.79	4.43	4.48	4.48	3.16	4.80	7.22	7.59	3.55	5.28	6.21	9.33
3TCq	TDF	NVP	2.35	0.86	4.43	2.35	4.45	4.43	4.45	3.21	6.78	5.29	7.64	3.02	5.74	5.32	6.94
3TCq	ddIq	NVP	2.35	0.84	4.43	2.45	4.45	4.46	4.47	3.19	6.78	5.27	7.62	2.62	5.74	5.12	6.33
AZTt	FTC	NVP	0.39	2.79	4.43	2.79	4.43	4.48	4.48	3.18	4.83	7.22	7.62	3.60	5.33	6.21	9.38
d4T	NVP	NFVt	0.25	4.43	2.76	4.43	2.76	4.73	4.73	4.68	3.01	7.19	7.44	4.90	2.92	7.39	8.12
ABCb	NVP	EVG/c	1.91	4.43	1.41	4.44	2.02	4.43	4.44	6.35	3.33	5.85	7.76	5.63	3.39	7.01	8.54
d4T	NVP	NFVb	0.25	4.43	2.80	4.43	2.80	4.75	4.75	4.68	3.05	7.23	7.48	4.90	2.96	7.44	8.16
NVP	RAL	MVC	4.43	1.69	1.72	4.43	4.43	1.94	4.43	6.12	6.16	3.41	7.84	6.36	7.26	3.94	9.20
NVP	RAL	MVC	4.43	1.69	1.72	4.43	4.43	1.94	4.43	6.12	6.16	3.41	7.84	6.36	7.26	3.94	9.20
AZTb	NVP	NFVt	0.37	4.43	2.76	4.43	2.76	4.73	4.73	4.80	3.12	7.19	7.56	5.28	3.20	7.39	9.00
AZTt	NVP	NFVt	0.39	4.43	2.76	4.43	2.76	4.73	4.73	4.83	3.15	7.19	7.58	5.33	3.23	7.39	9.05
AZTb	NVP	NFVb	0.37	4.43	2.80	4.43	2.80	4.75	4.75	4.80	3.17	7.23	7.60	5.28	3.25	7.44	9.05
AZTt	NVP	NFVb	0.39	4.43	2.80	4.43	2.80	4.75	4.75	4.83	3.19	7.23	7.63	5.33	3.28	7.44	9.09
NVP	ENF	EVG/c	4.43	2.07	1.41	4.47	4.43	2.20	4.47	6.50	5.85	3.48	7.92	6.17	7.01	3.46	8.88
ddIEC	TDF	NVP	2.56	0.86	4.43	2.56	4.57	4.43	4.57	3.42	6.99	5.29	7.85	2.51	6.55	5.32	7.01
ABCq	NVP	EVG/c	2.14	4.43	1.41	4.44	2.20	4.43	4.44	6.58	3.56	5.85	7.99	5.77	3.62	7.01	8.80
FTC	ddIb	NVP	2.79	0.75	4.43	2.85	4.48	4.45	4.50	3.54	7.22	5.18	7.97	3.06	6.21	5.05	6.68
ABCb	NVP	RAL	1.91	4.43	1.69	4.44	2.10	4.43	4.44	6.35	3.60	6.12	8.03	5.63	3.45	6.36	7.68
ABCb	NVP	MVC	1.91	4.43	1.72	4.44	2.07	4.43	4.44	6.35	3.64	6.16	8.07	5.63	4.16	7.26	8.90
ABCb	NVP	MVC	1.91	4.43	1.72	4.44	2.07	4.43	4.44	6.35	3.64	6.16	8.07	5.63	4.16	7.26	8.90
AZTb	d4T	ATV	0.37	0.25	5.97	0.45	5.97	5.97	5.97	0.62	6.33	6.22	6.58	0.45	6.09	6.06	6.18
FTC	TDF	NVP	2.79	0.86	4.43	2.79	4.48	4.43	4.48	3.65	7.22	5.29	8.08	3.07	6.21	5.32	7.04
FTC	ddIq	NVP	2.79	0.84	4.43	2.86	4.48	4.46	4.50	3.63	7.22	5.27	8.06	3.10	6.21	5.12	6.74
AZTt	d4T	ATV	0.39	0.25	5.97	0.47	5.97	5.97	5.97	0.64	6.36	6.22	6.61	0.47	6.10	6.06	6.19
3TCb	NVP	EVG/c	2.30	4.43	1.41	4.45	2.35	4.43	4.45	6.74	3.72	5.85	8.15	5.71	4.06	7.01	9.08
3TCq	NVP	EVG/c	2.35	4.43	1.41	4.45	2.39	4.43	4.45	6.78	3.76	5.85	8.20	5.74	4.10	7.01	9.13
NVP	ENF	RAL	4.43	2.07	1.69	4.47	4.43	2.29	4.47	6.50	6.12	3.76	8.19	6.17	6.36	3.96	8.29
ddIb	NVP	NFVt	0.75	4.43	2.76	4.45	2.92	4.73	4.74	5.18	3.50	7.19	7.94	5.05	3.29	7.39	7.63
NVP	ENF	MVC	4.43	2.07	1.72	4.47	4.43	2.26	4.47	6.50	6.16	3.79	8.23	6.17	7.26	4.70	9.55
NVP	ENF	MVC	4.43	2.07	1.72	4.47	4.43	2.26	4.47	6.50	6.16	3.79	8.23	6.17	7.26	4.70	9.55
ABCq	NVP	RAL	2.14	4.43	1.69	4.44	2.26	4.43	4.44	6.58	3.83	6.12	8.26	5.77	3.68	6.36	7.87
ABCq	NVP	MVC	2.14	4.43	1.72	4.44	2.23	4.43	4.44	6.58	3.87	6.16	8.30	5.77	4.41	7.26	9.17
ABCq	NVP	MVC	2.14	4.43	1.72	4.44	2.23	4.43	4.44	6.58	3.87	6.16	8.30	5.77	4.41	7.26	9.17
ddIb	NVP	NFVb	0.75	4.43	2.80	4.45	2.96	4.75	4.77	5.18	3.55	7.23	7.98	5.05	3.33	7.44	7.67
ddIq	NVP	NFVt	0.84	4.43	2.76	4.46	2.93	4.73	4.75	5.27	3.60	7.19	8.03	5.12	3.35	7.39	7.71
TDF	NVP	NFVt	0.86	4.43	2.76	4.43	2.76	4.73	4.73	5.29	3.62	7.19	8.05	5.32	3.16	7.39	7.86
ddIq	NVP	NFVb	0.84	4.43	2.80	4.46	2.98	4.75	4.77	5.27	3.64	7.23	8.07	5.12	3.40	7.44	7.75
TDF	NVP	NFVb	0.86	4.43	2.80	4.43	2.80	4.75	4.75	5.29	3.66	7.23	8.09	5.32	3.20	7.44	7.89
3TCb	NVP	RAL	2.30	4.43	1.69	4.45	2.39	4.43	4.45	6.74	3.99	6.12	8.42	5.71	4.00	6.36	8.02
ABCb	NVP	ENF	1.91	4.43	2.07	4.44	2.41	4.47	4.48	6.35	3.98	6.50	8.42	5.63	3.61	6.17	7.40
3TCb	NVP	MVC	2.30	4.43	1.72	4.45	2.36	4.43	4.45	6.74	4.03	6.16	8.46	5.71	5.28	7.26	9.79
3TCq	NVP	RAL	2.35	4.43	1.69	4.45	2.44	4.43	4.45	6.78	4.04	6.12	8.47	5.74	4.04	6.36	8.06
d4T	ddIb	ATV	0.25	0.75	5.97	0.82	5.97	5.98	5.98	0.99	6.22	6.71	6.96	1.34	6.06	6.50	6.74
3TCq	NVP	MVC	2.35	4.43	1.72	4.45	2.41	4.43	4.45	6.78	4.07	6.16	8.51	5.74	5.32	7.26	9.85
ddIEC	NVP	EVG/c	2.56	4.43	1.41	4.57	2.60	4.43	4.57	6.99	3.97	5.85	8.41	6.55	4.20	7.01	9.54
d4T	ddIq	ATV	0.25	0.84	5.97	0.90	5.97	5.98	5.98	1.09	6.22	6.80	7.05	1.45	6.06	6.57	6.83
d4T	TDF	ATV	0.25	0.86	5.97	0.87	5.97	5.97	5.97	1.11	6.22	6.83	7.07	1.67	6.06	6.32	6.78
AZTb	ddIb	ATV	0.37	0.75	5.97	0.83	5.97	5.98	5.98	1.11	6.33	6.71	7.08	1.51	6.09	6.50	6.78
AZTt	ddIb	ATV	0.39	0.75	5.97	0.84	5.97	5.98	5.98	1.14	6.36	6.71	7.10	1.55	6.10	6.50	6.80
3TCb	ABCb	NVP	2.30	1.91	4.43	2.47	4.45	4.44	4.45	4.22	6.74	6.35	8.65	2.82	5.71	5.63	6.59
FTC	NVP	EVG/c	2.79	4.43	1.41	4.48	2.80	4.43	4.48	7.22	4.20	5.85	8.64	6.21	4.28	7.01	9.51
ABCq	NVP	ENF	2.14	4.43	2.07	4.44	2.53	4.47	4.48	6.58	4.21	6.50	8.65	5.77	3.82	6.17	7.57
3TCq	ABCb	NVP	2.35	1.91	4.43	2.51	4.45	4.44	4.45	4.26	6.78	6.35	8.70	2.86	5.74	5.63	6.61
AZTb	ddIq	ATV	0.37	0.84	5.97	0.91	5.97	5.98	5.98	1.21	6.33	6.80	7.17	1.61	6.09	6.57	6.85
AZTb	TDF	ATV	0.37	0.86	5.97	0.87	5.97	5.97	5.97	1.23	6.33	6.83	7.19	1.92	6.09	6.32	6.84
AZTt	ddIq	ATV	0.39	0.84	5.97	0.92	5.97	5.98	5.98	1.23	6.36	6.80	7.20	1.66	6.10	6.57	6.88
AZTt	TDF	ATV	0.39	0.86	5.97	0.87	5.97	5.97	5.97	1.25	6.36	6.83	7.22	1.99	6.10	6.32	6.87
AZTb	d4T	ETR	0.37	0.25	6.31	0.45	6.30	6.30	6.30	0.62	6.67	6.55	6.92	0.45	7.69	6.75	8.02
AZTt	d4T	ETR	0.39	0.25	6.31	0.47	6.30	6.30	6.30	0.64	6.70	6.55	6.95	0.47	7.78	6.75	8.09
ddIEC	NVP	RAL	2.56	4.43	1.69	4.57	2.66	4.43	4.57	6.99	4.25	6.12	8.68	6.55	4.11	6.36	8.53

Regimen[a]			IIP$_{ave}$														
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
ddIEC	NVP	MVC	2.56	4.43	1.72	4.57	2.62	4.43	4.57	6.99	4.28	6.16	8.72	6.55	4.48	7.26	9.61
3TCb	NVP	ENF	2.30	4.43	2.07	4.45	2.63	4.47	4.49	6.74	4.37	6.50	8.81	5.71	4.55	6.17	7.99
NVP	EVG/c	NFVt	4.43	1.41	2.76	4.43	4.73	2.82	4.73	5.85	7.19	4.17	8.60	7.01	7.39	4.61	10.20
3TCb	ABCq	NVP	2.30	2.14	4.43	2.56	4.45	4.44	4.45	4.45	6.74	6.58	8.88	2.93	5.71	5.77	6.70
3TCq	NVP	ENF	2.35	4.43	2.07	4.45	2.67	4.47	4.49	6.78	4.42	6.50	8.85	5.74	4.60	6.17	8.03
3TCq	ABCq	NVP	2.35	2.14	4.43	2.59	4.45	4.44	4.45	4.49	6.78	6.58	8.92	2.96	5.74	5.77	6.73
FTC	NVP	RAL	2.79	4.43	1.69	4.48	2.82	4.43	4.48	7.22	4.48	6.12	8.91	6.21	4.61	6.36	8.65
NVP	EVG/c	NFVb	4.43	1.41	2.80	4.43	4.75	2.88	4.75	5.85	7.23	4.22	8.65	7.01	7.44	4.65	10.25
FTC	NVP	MVC	2.79	4.43	1.72	4.48	2.80	4.43	4.48	7.22	4.51	6.16	8.95	6.21	4.79	7.26	9.71
ddIEC	ABCb	NVP	2.56	1.91	4.43	2.74	4.57	4.44	4.58	4.47	6.99	6.35	8.91	3.11	6.55	5.63	7.27
ddIb	TDF	ATV	0.75	0.86	5.97	1.06	5.98	5.97	5.98	1.61	6.71	6.83	7.57	1.03	6.50	6.32	6.81
d4T	EVG/c	ATV	0.25	1.41	5.97	1.42	5.97	5.97	5.97	1.66	6.22	7.38	7.63	1.70	6.06	8.10	7.68
NVP	RAL	NFVt	4.43	1.69	2.76	4.43	4.73	2.87	4.73	6.12	7.19	4.44	8.88	6.36	7.39	5.85	10.31
d4T	ddIb	ETR	0.25	0.75	6.31	0.82	6.30	6.31	6.31	0.99	6.55	7.05	7.30	1.34	6.75	6.28	7.41
FTC	ABCb	NVP	2.79	1.91	4.43	2.86	4.48	4.44	4.48	4.70	7.22	6.35	9.14	2.92	6.21	5.63	6.85
ddIq	TDF	ATV	0.84	0.86	5.97	1.10	5.98	5.97	5.98	1.70	6.80	6.83	7.66	1.07	6.57	6.32	6.86
ddIEC	NVP	ENF	2.56	4.43	2.07	4.57	2.94	4.47	4.61	6.99	4.63	6.50	9.06	6.55	4.33	6.17	8.29
NVP	RAL	NFVb	4.43	1.69	2.80	4.43	4.75	2.93	4.75	6.12	7.23	4.49	8.92	6.36	7.44	5.88	10.37
d4T	ddIq	ETR	0.25	0.84	6.31	0.90	6.30	6.31	6.31	1.09	6.55	7.14	7.39	1.45	6.75	6.28	7.53
ddIEC	ABCq	NVP	2.56	2.14	4.43	2.82	4.57	4.44	4.58	4.70	6.99	6.58	9.14	3.21	6.55	5.77	7.40
AZTb	EVG/c	ATV	0.37	1.41	5.97	1.42	5.97	5.97	5.97	1.78	6.33	7.38	7.75	1.84	6.09	8.10	7.79
d4T	TDF	ETR	0.25	0.86	6.31	0.87	6.30	6.30	6.30	1.11	6.55	7.16	7.41	1.67	6.75	6.44	7.69
AZTb	ddIb	ETR	0.37	0.75	6.31	0.83	6.30	6.31	6.31	1.11	6.67	7.05	7.42	1.51	7.69	6.28	8.61
AZTt	EVG/c	ATV	0.39	1.41	5.97	1.42	5.97	5.97	5.97	1.81	6.36	7.38	7.77	1.87	6.10	8.10	7.81
AZTt	ddIb	ETR	0.39	0.75	6.31	0.84	6.30	6.31	6.31	1.14	6.70	7.05	7.44	1.55	7.78	6.28	8.67
FTC	NVP	ENF	2.79	4.43	2.07	4.48	2.99	4.47	4.51	7.22	4.86	6.50	9.29	6.21	4.39	6.17	8.03
AZTb	ddIq	ETR	0.37	0.84	6.31	0.91	6.30	6.31	6.31	1.21	6.67	7.14	7.51	1.61	7.69	6.28	8.81
ABCb	NVP	NFVt	1.91	4.43	2.76	4.44	2.96	4.73	4.73	6.35	4.67	7.19	9.10	5.63	4.36	7.39	8.53
AZTb	TDF	ETR	0.37	0.86	6.31	0.87	6.30	6.30	6.30	1.23	6.67	7.16	7.53	1.92	7.69	6.44	9.00
AZTt	ddIq	ETR	0.39	0.84	6.31	0.92	6.30	6.31	6.31	1.23	6.70	7.14	7.54	1.66	7.78	6.28	8.87
FTC	ABCq	NVP	2.79	2.14	4.43	2.90	4.48	4.44	4.48	4.93	7.22	6.58	9.37	2.97	6.21	5.77	6.97
AZTt	TDF	ETR	0.39	0.86	6.31	0.87	6.30	6.30	6.30	1.25	6.70	7.16	7.56	1.99	7.78	6.44	9.07
d4T	RAL	ATV	0.25	1.69	5.97	1.69	5.97	5.97	5.97	1.94	6.22	7.65	7.90	2.01	6.06	8.52	8.03
3TCb	ddIEC	NVP	2.30	2.56	4.43	2.91	4.45	4.57	4.58	4.86	6.74	6.99	9.30	3.38	5.71	6.55	7.39
AZTb	d4T	LPV/rq	0.37	0.25	6.64	0.45	6.64	6.64	6.64	0.62	7.01	6.89	7.26	0.45	7.14	6.80	7.25
ABCb	NVP	NFVb	1.91	4.43	2.80	4.44	3.03	4.75	4.75	6.35	4.72	7.23	9.15	5.63	4.41	7.44	8.57
AZTt	d4T	LPV/rq	0.39	0.25	6.64	0.47	6.64	6.64	6.64	0.64	7.03	6.89	7.28	0.47	7.17	6.80	7.27
3TCq	ddIEC	NVP	2.35	2.56	4.43	2.92	4.45	4.57	4.58	4.91	6.78	6.99	9.34	3.40	5.74	6.55	7.41
AZTb	RAL	ATV	0.37	1.69	5.97	1.69	5.97	5.97	5.97	2.05	6.33	7.65	8.02	2.08	6.09	8.52	8.09
AZTt	RAL	ATV	0.39	1.69	5.97	1.69	5.97	5.97	5.97	2.08	6.36	7.65	8.05	2.11	6.10	8.52	8.11
NVP	ENF	NFVt	4.43	2.07	2.76	4.47	4.73	3.16	4.76	6.50	7.19	4.83	9.26	6.17	7.39	5.11	9.38
ABCq	NVP	NFVt	2.14	4.43	2.76	4.44	3.04	4.73	4.73	6.58	4.90	7.19	9.33	5.77	4.56	7.39	8.71
NVP	ENF	NFVb	4.43	2.07	2.80	4.47	4.75	3.15	4.78	6.50	7.23	4.87	9.30	6.17	7.44	5.17	9.43
d4T	ABCb	ATV	0.25	1.91	5.97	1.92	5.97	5.97	5.97	2.16	6.22	7.88	8.13	2.42	6.06	7.02	7.50
ddIb	EVG/c	ATV	0.75	1.41	5.97	1.60	5.98	5.97	5.98	2.16	6.71	7.38	8.13	2.25	6.50	8.10	8.46
ABCq	NVP	NFVb	2.14	4.43	2.80	4.44	3.10	4.75	4.75	6.58	4.94	7.23	9.38	5.77	4.61	7.44	8.76
ddIq	EVG/c	ATV	0.84	1.41	5.97	1.62	5.98	5.97	5.98	2.25	6.80	7.38	8.22	2.36	6.57	8.10	8.56
TDF	EVG/c	ATV	0.86	1.41	5.97	1.43	5.97	5.97	5.97	2.27	6.83	7.38	8.24	2.25	6.32	8.10	8.29
AZTb	ABCb	ATV	0.37	1.91	5.97	1.91	5.97	5.97	5.97	2.28	6.33	7.88	8.25	2.84	6.09	7.02	7.85
ddIb	TDF	ETR	0.75	0.86	6.31	1.06	6.31	6.30	6.31	1.61	7.05	7.16	7.91	1.03	6.28	6.44	6.40
3TCb	NVP	NFVt	2.30	4.43	2.76	4.45	3.12	4.73	4.74	6.74	5.06	7.19	9.49	5.71	4.32	7.39	8.51
AZTt	ABCb	ATV	0.39	1.91	5.97	1.91	5.97	5.97	5.97	2.31	6.36	7.88	8.27	2.91	6.10	7.02	7.89
d4T	ENF	ATV	0.25	2.07	5.97	2.07	5.97	5.98	5.98	2.32	6.22	8.04	8.29	2.34	6.06	7.65	7.55
d4T	ETR	EVG/c	0.25	6.31	1.41	6.30	1.42	6.30	6.30	6.55	1.66	7.72	7.97	6.75	1.69	7.55	8.46
3TCq	NVP	NFVt	2.35	4.43	2.76	4.45	3.14	4.73	4.74	6.78	5.11	7.19	9.54	5.74	4.35	7.39	8.54
d4T	ddIb	LPV/rq	0.25	0.75	6.64	0.82	6.64	6.64	6.64	0.99	6.89	7.39	7.63	1.34	6.80	7.20	7.52
3TCb	NVP	NFVb	2.30	4.43	2.80	4.45	3.17	4.75	4.76	6.74	5.11	7.23	9.54	5.71	4.36	7.44	8.55
ddIq	TDF	ETR	0.84	0.86	6.31	1.10	6.31	6.30	6.31	1.70	7.14	7.16	8.00	1.07	6.28	6.44	6.40
d4T	ABCq	ATV	0.25	2.14	5.97	2.14	5.97	5.97	5.97	2.39	6.22	8.11	8.36	2.65	6.06	7.14	7.70
3TCq	NVP	NFVb	2.35	4.43	2.80	4.45	3.20	4.75	4.76	6.78	5.15	7.23	9.58	5.74	4.40	7.44	8.58
d4T	ddIq	LPV/rq	0.25	0.84	6.64	0.90	6.64	6.64	6.64	1.09	6.89	7.48	7.73	1.45	6.80	7.26	7.62
ddIb	RAL	ATV	0.75	1.69	5.97	1.83	5.98	5.97	5.98	2.43	6.71	7.65	8.40	2.38	6.50	8.52	8.72
AZTb	ENF	ATV	0.37	2.07	5.97	2.07	5.97	5.98	5.98	2.44	6.33	8.04	8.40	2.51	6.09	7.65	7.67
d4T	TDF	LPV/rq	0.25	0.86	6.64	0.87	6.64	6.64	6.64	1.11	6.89	7.50	7.75	1.67	6.80	7.07	7.59
FTC	ddIEC	NVP	2.79	2.56	4.43	3.19	4.48	4.57	4.61	5.35	7.22	6.99	9.78	3.86	6.21	6.55	7.87
AZTb	ETR	EVG/c	0.37	6.31	1.41	6.30	1.42	6.30	6.30	6.67	1.78	7.72	8.09	7.69	1.83	7.55	10.23
AZTb	ddIb	LPV/rq	0.37	0.75	6.64	0.83	6.64	6.64	6.64	1.11	7.01	7.39	7.75	1.51	7.14	7.20	7.94
AZTt	ENF	ATV	0.39	2.07	5.97	2.07	5.97	5.98	5.98	2.46	6.36	8.04	8.43	2.54	6.10	7.65	7.69
AZTt	ETR	EVG/c	0.39	6.31	1.41	6.30	1.42	6.30	6.30	6.70	1.81	7.72	8.11	7.78	1.86	7.55	10.30
AZTt	ddIb	LPV/rq	0.39	0.75	6.64	0.84	6.64	6.64	6.64	1.14	7.03	7.39	7.78	1.55	7.17	7.20	7.98

Regimen[a]			IIP_ave															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTb	ABCq	ATV	0.37	2.14	5.97	2.14	5.97	5.97	5.97	2.51	6.33	8.11	8.48	3.07	6.09	7.14	8.09
ddIq	RAL	ATV	0.84	1.69	5.97	1.85	5.98	5.97	5.98	2.53	6.80	7.65	8.49	2.47	6.57	8.52	8.82
AZTt	ABCq	ATV	0.39	2.14	5.97	2.14	5.97	5.97	5.97	2.54	6.36	8.11	8.50	3.13	6.10	7.14	8.13
TDF	RAL	ATV	0.86	1.69	5.97	1.69	5.97	5.97	5.97	2.55	6.83	7.65	8.51	2.71	6.32	8.52	8.69
AZTb	ddIq	LPV/rq	0.37	0.84	6.64	0.91	6.64	6.64	6.64	1.21	7.01	7.48	7.85	1.61	7.14	7.26	8.06
d4T	3TCb	ATV	0.25	2.30	5.97	2.31	5.97	5.97	5.97	2.55	6.22	8.27	8.52	2.72	6.06	6.90	7.53
AZTb	TDF	LPV/rq	0.37	0.86	6.64	0.87	6.64	6.64	6.64	1.23	7.01	7.50	7.87	1.92	7.14	7.07	8.06
AZTt	ddIq	LPV/rq	0.39	0.84	6.64	0.92	6.64	6.64	6.64	1.23	7.03	7.48	7.87	1.66	7.17	7.26	8.09
AZTt	TDF	LPV/rq	0.39	0.86	6.64	0.87	6.64	6.64	6.64	1.25	7.03	7.50	7.89	1.99	7.17	7.07	8.10
d4T	3TCq	ATV	0.25	2.35	5.97	2.35	5.97	5.97	5.97	2.60	6.22	8.32	8.57	2.77	6.06	6.92	7.56
d4T	ETR	RAL	0.25	6.31	1.69	6.30	1.69	6.30	6.30	6.55	1.94	7.99	8.24	6.75	2.00	7.73	8.80
AZTb	d4T	LPV/rb	0.37	0.25	6.97	0.45	6.97	6.97	6.97	0.62	7.34	7.22	7.59	0.45	7.47	7.13	7.58
d4T	ETR	MVC	0.25	6.31	1.72	6.30	1.73	6.30	6.30	6.55	1.97	8.03	8.28	6.75	1.95	9.41	9.67
AZTt	d4T	LPV/rb	0.39	0.25	6.97	0.47	6.97	6.97	6.97	0.64	7.37	7.22	7.62	0.47	7.51	7.13	7.61
ddIEC	NVP	NFVt	2.56	4.43	2.76	4.57	3.48	4.73	4.84	6.99	5.32	7.19	9.75	6.55	4.64	7.39	9.15
ddIb	ABCb	ATV	0.75	1.91	5.97	2.04	5.98	5.97	5.98	2.66	6.71	7.88	8.63	2.17	6.50	7.02	7.49
AZTb	3TCb	ATV	0.37	2.30	5.97	2.30	5.97	5.97	5.97	2.67	6.33	8.27	8.64	2.91	6.09	6.90	7.60
AZTt	3TCb	ATV	0.39	2.30	5.97	2.30	5.97	5.97	5.97	2.70	6.36	8.27	8.66	2.95	6.10	6.90	7.62
AZTb	3TCq	ATV	0.37	2.35	5.97	2.35	5.97	5.97	5.97	2.72	6.33	8.32	8.68	2.95	6.09	6.92	7.63
ddIEC	NVP	NFVb	2.56	4.43	2.80	4.57	3.53	4.75	4.86	6.99	5.36	7.23	9.79	6.55	4.69	7.44	9.19
AZTb	ETR	RAL	0.37	6.31	1.69	6.30	1.69	6.30	6.30	6.67	2.05	7.99	8.36	7.69	2.07	7.73	10.72
AZTt	3TCq	ATV	0.39	2.35	5.97	2.35	5.97	5.97	5.97	2.74	6.36	8.32	8.71	2.99	6.10	6.92	7.65
AZTt	ETR	RAL	0.39	6.31	1.69	6.30	1.69	6.30	6.30	6.70	2.08	7.99	8.39	7.78	2.10	7.73	10.79
ddIq	ABCb	ATV	0.84	1.91	5.97	2.06	5.98	5.97	5.98	2.75	6.80	7.88	8.72	2.20	6.57	7.02	7.54
AZTb	ETR	MVC	0.37	6.31	1.72	6.30	1.72	6.30	6.30	6.67	2.09	8.03	8.40	7.69	2.06	9.41	11.52
AZTb	ETR	MVC	0.37	6.31	1.72	6.30	1.72	6.30	6.30	6.67	2.09	8.03	8.40	7.69	2.06	9.41	11.52
TDF	ABCb	ATV	0.86	1.91	5.97	1.92	5.97	5.97	5.97	2.77	6.83	7.88	8.74	1.89	6.32	7.02	7.13
AZTt	ETR	MVC	0.39	6.31	1.72	6.30	1.72	6.30	6.30	6.70	2.12	8.03	8.42	7.78	2.09	9.41	11.59
FTC	NVP	NFVt	2.79	4.43	2.76	4.48	3.38	4.73	4.76	7.22	5.55	7.19	9.98	6.21	4.99	7.39	9.15
ddIb	ENF	ATV	0.75	2.07	5.97	2.24	5.98	5.99	5.99	2.82	6.71	8.04	8.78	2.71	6.50	7.65	8.16
d4T	ABCb	ETR	0.25	1.91	6.31	1.92	6.30	6.31	6.31	2.16	6.55	8.22	8.47	2.42	6.75	6.62	8.79
ddIb	ETR	EVG/c	0.75	6.31	1.41	6.31	1.60	6.30	6.31	7.05	2.16	7.72	8.47	6.28	2.25	7.55	7.52
FTC	NVP	NFVb	2.79	4.43	2.80	4.48	3.44	4.75	4.78	7.22	5.59	7.23	10.02	6.21	5.04	7.44	9.19
d4T	ddIEC	ATV	0.25	2.56	5.97	2.56	5.97	6.03	6.03	2.81	6.22	8.53	8.78	3.29	6.06	7.81	8.81
ddIb	ABCq	ATV	0.75	2.14	5.97	2.24	5.98	5.97	5.98	2.89	6.71	8.11	8.86	2.38	6.50	7.14	7.60
ddIq	ENF	ATV	0.84	2.07	5.97	2.26	5.98	5.98	5.99	2.91	6.80	8.04	8.88	2.79	6.57	7.65	8.23
ddIq	ETR	EVG/c	0.84	6.31	1.41	6.31	1.62	6.30	6.31	7.14	2.25	7.72	8.56	6.28	2.36	7.55	7.59
TDF	ENF	ATV	0.86	2.07	5.97	2.08	5.97	5.98	5.98	2.93	6.83	8.04	8.90	2.63	6.32	7.65	7.83
TDF	ETR	EVG/c	0.86	6.31	1.41	6.30	1.43	6.30	6.30	7.16	2.27	7.72	8.58	6.44	2.24	7.55	7.69
ddIb	TDF	LPV/rq	0.75	0.86	6.64	1.06	6.64	6.64	6.64	1.61	7.39	7.50	8.24	1.03	7.20	7.07	7.57
AZTb	ABCb	ETR	0.37	1.91	6.31	1.91	6.30	6.31	6.31	2.28	6.67	8.22	8.59	2.84	7.69	6.62	11.24
AZTt	ABCb	ETR	0.39	1.91	6.31	1.91	6.30	6.31	6.31	2.31	6.70	8.22	8.61	2.91	7.78	6.62	11.32
AZTb	ddIEC	ATV	0.37	2.56	5.97	2.56	5.97	6.03	6.03	2.93	6.33	8.53	8.89	3.41	6.09	7.81	8.59
ddIq	ABCq	ATV	0.84	2.14	5.97	2.25	5.98	5.97	5.98	2.98	6.80	8.11	8.95	2.41	6.57	7.14	7.66
d4T	ETR	ENF	0.25	6.31	2.07	6.30	2.07	6.31	6.31	6.55	2.32	8.38	8.62	6.75	2.33	8.20	9.27
TDF	ABCq	ATV	0.86	2.14	5.97	2.14	5.97	5.97	5.97	3.00	6.83	8.11	8.97	2.11	6.32	7.14	7.22
d4T	EVG/c	LPV/rq	0.25	1.41	6.64	1.42	6.64	6.64	6.64	1.66	6.89	8.05	8.30	1.70	6.80	8.86	8.57
d4T	ddIb	LPV/rb	0.25	0.75	6.97	0.82	6.97	6.98	6.98	0.99	7.22	7.72	7.97	1.34	7.13	7.53	7.85
AZTt	ddIEC	ATV	0.39	2.56	5.97	2.56	5.97	6.03	6.03	2.95	6.36	8.53	8.92	3.46	6.10	7.81	8.63
ddIq	TDF	LPV/rq	0.84	0.86	6.64	1.10	6.64	6.64	6.64	1.70	7.48	7.50	8.34	1.07	7.26	7.07	7.63
d4T	FTC	ATV	0.25	2.79	5.97	2.79	5.97	5.98	5.98	3.04	6.22	8.76	9.01	3.21	6.06	7.53	8.11
3TCb	ddIb	ATV	2.30	0.75	5.97	2.39	5.97	5.98	5.98	3.05	8.27	6.71	9.02	2.55	6.90	6.50	7.51
d4T	ABCq	ETR	0.25	2.14	6.31	2.14	6.30	6.31	6.31	2.39	6.55	8.45	8.70	2.65	6.75	6.66	9.07
d4T	ddIq	LPV/rb	0.25	0.84	6.97	0.90	6.97	6.98	6.98	1.09	7.22	7.81	8.06	1.45	7.13	7.60	7.95
3TCq	ddIb	ATV	2.35	0.75	5.97	2.44	5.97	5.98	5.98	3.10	8.32	6.71	9.06	2.59	6.92	6.50	7.53
ddIb	ETR	RAL	0.75	6.31	1.69	6.31	1.83	6.30	6.31	7.05	2.43	7.99	8.74	6.28	2.38	7.73	7.56
AZTb	ETR	ENF	0.37	6.31	2.07	6.30	2.07	6.31	6.31	6.67	2.44	8.38	8.74	7.69	2.51	8.20	11.51
d4T	TDF	LPV/rb	0.25	0.86	6.97	0.87	6.97	6.97	6.97	1.11	7.22	7.83	8.08	1.67	7.13	7.41	7.91
AZTb	EVG/c	LPV/rq	0.37	1.41	6.64	1.42	6.64	6.64	6.64	1.78	7.01	8.05	8.42	1.84	7.14	8.86	9.21
AZTb	ddIb	LPV/rb	0.37	0.75	6.97	0.83	6.97	6.98	6.98	1.11	7.34	7.72	8.09	1.51	7.47	7.53	8.27
AZTt	ETR	ENF	0.39	6.31	2.07	6.30	2.07	6.31	6.31	6.70	2.46	8.38	8.77	7.78	2.54	8.20	11.57
ddIb	ETR	MVC	0.75	6.31	1.72	6.31	1.83	6.30	6.31	7.05	2.47	8.03	8.77	6.28	2.54	9.41	8.95
AZTt	EVG/c	LPV/rq	0.39	1.41	6.64	1.42	6.64	6.64	6.64	1.81	7.03	8.05	8.45	1.87	7.17	8.86	9.25
AZTt	ddIb	LPV/rb	0.39	0.75	6.97	0.84	6.97	6.98	6.98	1.14	7.37	7.72	8.11	1.55	7.51	7.53	8.30
3TCb	ddIq	ATV	2.30	0.84	5.97	2.41	5.97	5.98	5.98	3.14	8.27	6.80	9.11	2.58	6.90	6.57	7.56
3TCb	TDF	ATV	2.30	0.86	5.97	2.30	5.97	5.97	5.97	3.16	8.27	6.83	9.13	2.97	6.90	6.32	7.48
AZTb	FTC	ATV	0.37	2.79	5.97	2.79	5.97	5.98	5.98	3.16	6.33	8.76	9.12	3.55	6.09	7.53	8.49
AZTb	ABCq	ETR	0.37	2.14	6.31	2.14	6.30	6.31	6.31	2.51	6.67	8.45	8.82	3.07	7.69	6.66	11.74
AZTt	FTC	ATV	0.39	2.79	5.97	2.79	5.97	5.98	5.98	3.18	6.36	8.76	9.15	3.60	6.10	7.53	8.53
3TCq	ddIq	ATV	2.35	0.84	5.97	2.45	5.97	5.98	5.98	3.19	8.32	6.80	9.15	2.62	6.92	6.57	7.58

Regimen[a]			IIP$_{ave}$															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
ddIq	ETR	RAL	0.84	6.31	1.69	6.31	1.85	6.30	6.31	7.14	2.53	7.99	8.83	6.28	2.47	7.73	7.62
3TCq	TDF	ATV	2.35	0.86	5.97	2.35	5.97	5.97	5.97	3.21	8.32	6.83	9.18	3.02	6.92	6.32	7.50
AZTb	ABCq	ETR	0.39	2.14	6.31	2.14	6.30	6.31	6.31	2.54	6.70	8.45	8.84	3.13	7.78	6.66	11.82
AZTb	ddIq	LPV/rb	0.37	0.84	6.97	0.91	6.97	6.98	6.98	1.21	7.34	7.81	8.18	1.61	7.47	7.60	8.39
TDF	ETR	RAL	0.86	6.31	1.69	6.30	1.69	6.30	6.30	7.16	2.55	7.99	8.85	6.44	2.71	7.73	7.93
d4T	3TCb	ETR	0.25	2.30	6.31	2.31	6.30	6.31	6.31	2.55	6.55	8.61	8.86	2.72	6.75	6.86	9.17
AZTb	TDF	LPV/rb	0.37	0.86	6.97	0.87	6.97	6.97	6.97	1.23	7.34	7.83	8.20	1.92	7.47	7.41	8.38
ddIq	ETR	MVC	0.84	6.31	1.72	6.31	1.85	6.30	6.31	7.14	2.56	8.03	8.87	6.28	2.64	9.41	9.06
AZTt	ddIq	LPV/rb	0.39	0.84	6.97	0.92	6.97	6.98	6.98	1.23	7.37	7.81	8.20	1.66	7.51	7.60	8.42
TDF	ETR	MVC	0.86	6.31	1.72	6.30	1.73	6.30	6.30	7.16	2.58	8.03	8.89	6.44	2.95	9.41	9.35
AZTt	TDF	LPV/rb	0.39	0.86	6.97	0.87	6.97	6.97	6.97	1.25	7.37	7.83	8.23	1.99	7.51	7.41	8.42
d4T	3TCq	ETR	0.25	2.35	6.31	2.35	6.30	6.31	6.31	2.60	6.55	8.65	8.90	2.77	6.75	6.87	9.23
d4T	RAL	LPV/rq	0.25	1.69	6.64	1.69	6.64	6.64	6.64	1.94	6.89	8.33	8.58	2.01	6.80	8.86	8.68
d4T	LPV/rq	MVC	0.25	6.64	1.72	6.64	1.73	6.64	6.64	6.89	1.97	8.36	8.61	6.80	1.95	6.64	7.42
ABCb	EVG/c	ATV	1.91	1.41	5.97	2.02	5.97	5.97	5.97	3.33	7.88	7.38	9.30	3.39	7.02	8.10	9.49
ddIb	ABCb	ETR	0.75	1.91	6.31	2.04	6.31	6.31	6.31	2.66	7.05	8.22	8.97	2.17	6.28	6.62	6.54
AZTb	3TCb	ETR	0.37	2.30	6.31	2.30	6.30	6.31	6.31	2.67	6.67	8.61	8.98	2.91	7.69	6.86	11.71
AZTt	3TCb	ETR	0.39	2.30	6.31	2.30	6.30	6.31	6.31	2.70	6.70	8.61	9.00	2.95	7.78	6.86	11.78
AZTb	d4T	EFV	0.37	0.25	7.35	0.45	7.35	7.35	7.35	0.62	7.72	7.60	7.97	0.45	8.91	8.00	9.46
AZTb	3TCq	ETR	0.37	2.35	6.31	2.35	6.30	6.31	6.31	2.72	6.67	8.65	9.02	2.95	7.69	6.87	11.79
AZTb	RAL	LPV/rq	0.37	1.69	6.64	1.69	6.64	6.64	6.64	2.05	7.01	8.33	8.69	2.08	7.14	8.86	9.32
AZTt	d4T	EFV	0.39	0.25	7.35	0.47	7.35	7.35	7.35	0.64	7.75	7.60	8.00	0.47	9.02	8.00	9.54
AZTt	3TCq	ETR	0.39	2.35	6.31	2.35	6.30	6.31	6.31	2.74	6.70	8.65	9.05	2.99	7.78	6.87	11.86
AZTt	RAL	LPV/rq	0.39	1.69	6.64	1.69	6.64	6.64	6.64	2.08	7.03	8.33	8.72	2.11	7.17	8.86	9.36
ddIq	ABCb	ETR	0.84	1.91	6.31	2.06	6.31	6.31	6.31	2.75	7.14	8.22	9.06	2.20	6.28	6.62	6.55
AZTb	LPV/rq	MVC	0.37	6.64	1.72	6.64	1.72	6.64	6.64	7.01	2.09	8.36	8.73	7.14	2.06	6.64	8.18
TDF	ABCb	ETR	0.86	1.91	6.31	1.92	6.30	6.31	6.31	2.77	7.16	8.22	9.08	1.89	6.44	6.62	6.69
AZTt	LPV/rq	MVC	0.39	6.64	1.72	6.64	1.72	6.64	6.64	7.03	2.12	8.36	8.76	7.17	2.09	6.64	8.20
ddIEC	TDF	ATV	2.56	0.86	5.97	2.56	6.03	5.97	6.03	3.42	8.53	6.83	9.39	2.51	7.81	6.32	7.65
ENF	EVG/c	ATV	2.07	1.41	5.97	2.20	5.98	5.97	5.98	3.48	8.04	7.38	9.45	3.46	7.65	8.10	9.92
ddIb	ETR	ENF	0.75	6.31	2.07	6.31	2.24	6.31	6.31	7.05	2.82	8.38	9.12	6.28	2.71	8.20	7.88
d4T	ABCb	LPV/rq	0.25	1.91	6.64	1.92	6.64	6.64	6.64	2.16	6.89	8.55	8.80	2.42	6.80	7.67	8.35
ddIb	EVG/c	LPV/rq	0.75	1.41	6.64	1.60	6.64	6.64	6.64	2.16	7.39	8.05	8.80	2.25	7.20	8.86	9.22
d4T	ddIEC	ETR	0.25	2.56	6.31	2.56	6.30	6.33	6.33	2.81	6.55	8.87	9.11	3.29	6.75	6.24	10.02
ABCq	EVG/c	ATV	2.14	1.41	5.97	2.20	5.97	5.97	5.97	3.56	8.11	7.38	9.52	3.62	7.14	8.10	9.72
FTC	ddIb	ATV	2.79	0.75	5.97	2.85	5.98	5.98	5.99	3.54	8.76	6.71	9.50	3.06	7.53	6.50	8.00
AZTb	d4T	ATV/r	0.37	0.25	7.44	0.45	7.44	7.44	7.44	0.62	7.81	7.69	8.06	0.45	7.57	7.53	7.65
ddIb	ABCq	ETR	0.75	2.14	6.31	2.24	6.31	6.31	6.31	2.89	7.05	8.45	9.19	2.38	6.28	6.66	6.57
AZTt	d4T	ATV/r	0.39	0.25	7.44	0.47	7.44	7.44	7.44	0.64	7.84	7.69	8.08	0.47	7.58	7.53	7.66
ddIq	ETR	ENF	0.84	6.31	2.07	6.31	2.26	6.31	6.31	7.14	2.91	8.38	9.21	6.28	2.79	8.20	7.93
ABCb	RAL	ATV	1.91	1.69	5.97	2.10	5.97	5.97	5.97	3.60	7.88	7.65	9.57	3.45	7.02	8.52	9.74
ddIq	EVG/c	LPV/rq	0.84	1.41	6.64	1.62	6.64	6.64	6.64	2.25	7.48	8.05	8.89	2.36	7.26	8.86	9.33
TDF	ETR	ENF	0.86	6.31	2.07	6.30	2.08	6.31	6.31	7.16	2.93	8.38	9.23	6.44	2.62	8.20	8.05
TDF	EVG/c	LPV/rq	0.86	1.41	6.64	1.43	6.64	6.64	6.64	2.27	7.50	8.05	8.91	2.25	7.07	8.86	9.10
ddIb	TDF	LPV/rb	0.75	0.86	6.97	1.06	6.98	6.97	6.98	1.61	7.72	7.83	8.58	1.03	7.53	7.41	7.91
AZTb	ABCb	LPV/rq	0.37	1.91	6.64	1.91	6.64	6.64	6.64	2.28	7.01	8.55	8.92	2.84	7.14	7.67	9.36
AZTb	ddIEC	ETR	0.37	2.56	6.31	2.56	6.30	6.33	6.33	2.93	6.67	8.87	9.23	3.41	7.69	6.24	12.43
AZTt	ABCb	LPV/rq	0.39	1.91	6.64	1.91	6.64	6.64	6.64	2.31	7.03	8.55	8.95	2.91	7.17	7.67	9.40
FTC	ddIq	ATV	2.79	0.84	5.97	2.86	5.98	5.98	5.99	3.63	8.76	6.80	9.59	3.10	7.53	6.57	8.06
AZTt	ddIEC	ETR	0.39	2.56	6.31	2.56	6.30	6.33	6.33	2.95	6.70	8.87	9.26	3.46	7.78	6.24	12.51
ddIq	ABCq	ETR	0.84	2.14	6.31	2.25	6.31	6.31	6.31	2.98	7.14	8.45	9.29	2.41	6.28	6.66	6.58
FTC	TDF	ATV	2.79	0.86	5.97	2.79	5.98	5.97	5.98	3.65	8.76	6.83	9.62	3.07	7.53	6.32	7.67
d4T	ENF	LPV/rq	0.25	2.07	6.64	2.07	6.64	6.64	6.64	2.32	6.89	8.71	8.96	2.34	6.80	7.88	8.22
d4T	EVG/c	LPV/rb	0.25	1.41	6.97	1.42	6.97	6.97	6.97	1.66	7.22	8.39	8.64	1.70	7.13	9.19	8.90
TDF	ABCq	ETR	0.86	2.14	6.31	2.14	6.30	6.31	6.31	3.00	7.16	8.45	9.31	2.11	6.44	6.66	6.71
ddIq	TDF	LPV/rb	0.84	0.86	6.97	1.10	6.98	6.97	6.98	1.70	7.81	7.83	8.67	1.07	7.60	7.41	7.96
d4T	FTC	ETR	0.25	2.79	6.31	2.79	6.30	6.31	6.31	3.04	6.55	9.10	9.34	3.21	6.75	6.83	9.71
3TCb	EVG/c	ATV	2.30	1.41	5.97	2.35	5.97	5.97	5.97	3.72	8.27	7.38	9.69	4.06	6.90	8.10	9.88
3TCb	ddIb	ETR	2.30	0.75	6.31	2.39	6.31	6.31	6.31	3.05	8.61	7.05	9.36	2.55	6.86	6.28	6.70
d4T	ABCq	LPV/rq	0.25	2.14	6.64	2.14	6.64	6.64	6.64	2.39	6.89	8.78	9.03	2.65	6.80	7.79	8.56
3TCq	EVG/c	ATV	2.35	1.41	5.97	2.39	5.97	5.97	5.97	3.76	8.32	7.38	9.73	4.10	6.92	8.10	9.92
d4T	ddIb	EFV	0.25	0.75	7.35	0.82	7.35	7.35	7.35	0.99	7.60	8.10	8.35	1.34	8.00	7.77	9.05
ENF	RAL	ATV	2.07	1.69	5.97	2.29	5.98	5.97	5.98	3.76	8.04	7.65	9.72	3.96	7.65	8.52	10.37
3TCq	ddIb	ETR	2.35	0.75	6.31	2.44	6.31	6.31	6.31	3.10	8.65	7.05	9.40	2.59	6.87	6.28	6.71
d4T	ETR	NFVt	0.25	6.31	2.76	6.30	2.76	6.40	6.40	6.55	3.01	9.06	9.31	6.75	2.92	10.37	10.68
ddIb	RAL	LPV/rq	0.75	1.69	6.64	1.83	6.64	6.64	6.64	2.43	7.39	8.33	9.07	2.38	7.20	8.86	9.18
AZTb	ENF	LPV/rq	0.37	2.07	6.64	2.07	6.64	6.64	6.64	2.44	7.01	8.71	9.08	2.51	7.14	7.88	9.07
AZTb	EVG/c	LPV/rb	0.37	1.41	6.97	1.42	6.97	6.97	6.97	1.78	7.34	8.39	8.76	1.84	7.47	9.19	9.55
AZTt	ENF	LPV/rq	0.39	2.07	6.64	2.07	6.64	6.64	6.64	2.46	7.03	8.71	9.10	2.54	7.17	7.88	9.09
ETR	EVG/c	MVC	6.31	1.41	1.72	6.30	6.30	1.84	6.30	7.72	8.03	3.14	9.44	7.55	9.41	3.20	10.50

Regimen[a]			IIP_{ave}														
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
ddIb	LPV/rq	MVC	0.75	6.64	1.72	6.64	1.83	6.64	6.64	7.39	2.47	8.36	9.11	7.20	2.54	6.64	7.88
AZTt	EVG/c	LPV/rb	0.39	1.41	6.97	1.42	6.97	6.97	6.97	1.81	7.37	8.39	8.78	1.87	7.51	9.19	9.58
3TCb	ddIq	ETR	2.30	0.84	6.31	2.41	6.31	6.31	6.31	3.14	8.61	7.14	9.45	2.58	6.86	6.28	6.72
ABCq	RAL	ATV	2.14	1.69	5.97	2.26	5.97	5.97	5.97	3.83	8.11	7.65	9.80	3.68	7.14	8.52	9.96
d4T	ETR	NFVb	0.25	6.31	2.80	6.30	2.80	6.41	6.41	6.55	3.05	9.11	9.36	6.75	2.96	10.43	10.73
AZTb	FTC	ETR	0.37	2.79	6.31	2.79	6.30	6.31	6.31	3.16	6.67	9.10	9.46	3.55	7.69	6.83	12.86
3TCb	TDF	ETR	2.30	0.86	6.31	2.30	6.31	6.30	6.31	3.16	8.61	7.16	9.47	2.97	6.86	6.44	7.27
AZTb	ABCq	LPV/rq	0.37	2.14	6.64	2.14	6.64	6.64	6.64	2.51	7.01	8.78	9.15	3.07	7.14	7.79	9.66
AZTt	FTC	ETR	0.39	2.79	6.31	2.79	6.30	6.31	6.31	3.18	6.70	9.10	9.49	3.60	7.78	6.83	12.94
d4T	ddIq	EFV	0.25	0.84	7.35	0.90	7.35	7.36	7.36	1.09	7.60	8.19	8.44	1.45	8.00	7.82	9.21
3TCq	ddIq	ETR	2.35	0.84	6.31	2.45	6.31	6.31	6.31	3.19	8.65	7.14	9.49	2.62	6.87	6.28	6.73
ddIq	RAL	LPV/rq	0.84	1.69	6.64	1.85	6.64	6.64	6.64	2.53	7.48	8.33	9.17	2.47	7.26	8.86	9.27
d4T	TDF	EFV	0.25	0.86	7.35	0.87	7.35	7.35	7.35	1.11	7.60	8.21	8.46	1.67	8.00	7.97	9.36
AZTt	ABCq	LPV/rq	0.39	2.14	6.64	2.14	6.64	6.64	6.64	2.54	7.03	8.78	9.18	3.13	7.17	7.79	9.70
3TCq	TDF	ETR	2.35	0.86	6.31	2.35	6.31	6.30	6.31	3.21	8.65	7.16	9.51	3.02	6.87	6.44	7.29
AZTb	ddIb	EFV	0.37	0.75	7.35	0.83	7.35	7.35	7.35	1.11	7.72	8.10	8.47	1.51	8.91	7.77	10.14
TDF	RAL	LPV/rq	0.86	1.69	6.64	1.69	6.64	6.64	6.64	2.55	7.50	8.33	9.19	2.71	7.07	8.86	9.16
d4T	3TCb	LPV/rq	0.25	2.30	6.64	2.31	6.64	6.64	6.64	2.55	6.89	8.94	9.19	2.72	6.80	7.77	8.51
AZTb	ETR	NFVt	0.37	6.31	2.76	6.30	2.76	6.40	6.40	6.67	3.12	9.06	9.43	7.69	3.20	10.37	13.25
ddIq	LPV/rq	MVC	0.84	6.64	1.72	6.64	1.85	6.64	6.64	7.48	2.56	8.36	9.20	7.26	2.64	6.64	7.94
AZTt	ddIb	EFV	0.39	0.75	7.35	0.84	7.35	7.35	7.35	1.14	7.75	8.10	8.49	1.55	9.02	7.77	10.21
AZTt	ETR	NFVt	0.39	6.31	2.76	6.30	2.76	6.40	6.40	6.70	3.15	9.06	9.45	7.78	3.23	10.37	13.32
TDF	LPV/rq	MVC	0.86	6.64	1.72	6.64	1.73	6.64	6.64	7.50	2.58	8.36	9.22	7.07	2.95	6.64	7.85
d4T	3TCq	LPV/rq	0.25	2.35	6.64	2.35	6.64	6.64	6.64	2.60	6.89	8.99	9.24	2.77	6.80	7.79	8.55
d4T	ddIb	ATV/r	0.25	0.75	7.44	0.82	7.44	7.44	7.44	0.99	7.69	8.19	8.44	1.34	7.53	7.97	8.17
d4T	RAL	LPV/rb	0.25	1.69	6.97	1.69	6.97	6.97	6.97	1.94	7.22	8.66	8.91	2.01	7.13	9.20	9.00
AZTb	ETR	NFVb	0.37	6.31	2.80	6.30	2.80	6.41	6.41	6.67	3.17	9.11	9.47	7.69	3.25	10.43	13.31
AZTt	ETR	NFVb	0.39	6.31	2.80	6.30	2.80	6.41	6.41	6.70	3.19	9.11	9.50	7.78	3.28	10.43	13.38
AZTb	ddIq	EFV	0.37	0.84	7.35	0.91	7.35	7.36	7.36	1.21	7.72	8.19	8.56	1.61	8.91	7.82	10.36
3TCb	RAL	ATV	2.30	1.69	5.97	2.39	5.97	5.97	5.97	3.99	8.27	7.65	9.96	4.00	6.90	8.52	10.02
ABCb	ENF	ATV	1.91	2.07	5.97	2.41	5.97	5.98	5.98	3.98	7.88	8.04	9.95	3.62	7.02	7.65	8.77
AZTb	TDF	EFV	0.37	0.86	7.35	0.87	7.35	7.35	7.35	1.23	7.72	8.21	8.58	1.92	8.91	7.97	10.54
ABCb	ETR	EVG/c	1.91	6.31	1.41	6.31	2.02	6.30	6.31	8.22	3.33	7.72	9.63	6.62	3.39	7.55	8.44
AZTt	ddIq	EFV	0.39	0.84	7.35	0.92	7.35	7.36	7.36	1.23	7.75	8.19	8.58	1.66	9.02	7.82	10.43
ddIb	ABCb	LPV/rq	0.75	1.91	6.64	2.04	6.64	6.64	6.64	2.66	7.39	8.55	9.30	2.17	7.20	7.67	8.19
AZTb	3TCb	LPV/rq	0.37	2.30	6.64	2.30	6.64	6.64	6.64	2.67	7.01	8.94	9.31	2.91	7.14	7.77	9.39
AZTt	TDF	EFV	0.39	0.86	7.35	0.87	7.35	7.35	7.35	1.25	7.75	8.21	8.61	1.99	9.02	7.97	10.62
ddIEC	EVG/c	ATV	2.56	1.41	5.97	2.60	6.03	5.97	6.03	3.97	8.53	7.38	9.94	4.20	7.81	8.10	10.44
3TCq	RAL	ATV	2.35	1.69	5.97	2.44	5.97	5.97	5.97	4.04	8.32	7.65	10.00	4.04	6.92	8.52	10.07
d4T	ddIq	ATV/r	0.25	0.84	7.44	0.90	7.44	7.44	7.44	1.09	7.69	8.28	8.53	1.45	7.53	8.04	8.26
AZTt	3TCb	LPV/rq	0.39	2.30	6.64	2.30	6.64	6.64	6.64	2.70	7.03	8.94	9.34	2.95	7.17	7.77	9.42
d4T	TDF	ATV/r	0.25	0.86	7.44	0.87	7.44	7.44	7.44	1.11	7.69	8.30	8.55	1.67	7.53	7.80	8.18
AZTb	3TCq	LPV/rq	0.37	2.35	6.64	2.35	6.64	6.64	6.64	2.72	7.01	8.99	9.36	2.95	7.14	7.79	9.43
AZTb	ddIb	ATV/r	0.37	0.75	7.44	0.83	7.44	7.44	7.44	1.11	7.81	8.19	8.56	1.51	7.57	7.97	8.21
AZTb	RAL	LPV/rb	0.37	1.69	6.97	1.69	6.97	6.97	6.97	2.05	7.34	8.66	9.03	2.08	7.47	9.20	9.66
ETR	RAL	MVC	6.31	1.69	1.72	6.30	6.30	1.94	6.30	7.99	8.03	3.41	9.72	7.73	9.41	3.94	10.97
AZTt	3TCq	LPV/rq	0.39	2.35	6.64	2.35	6.64	6.64	6.64	2.74	7.03	8.99	9.38	2.99	7.17	7.79	9.46
AZTt	ddIb	ATV/r	0.39	0.75	7.44	0.84	7.44	7.44	7.44	1.14	7.84	8.19	8.58	1.55	7.58	7.97	8.23
AZTt	RAL	LPV/rb	0.39	1.69	6.97	1.69	6.97	6.97	6.97	2.08	7.37	8.66	9.05	2.11	7.51	9.20	9.69
ddIq	ABCb	LPV/rq	0.84	1.91	6.64	2.06	6.64	6.64	6.64	2.75	7.48	8.55	9.39	2.20	7.26	7.67	8.25
TDF	ABCb	LPV/rq	0.86	1.91	6.64	1.92	6.64	6.64	6.64	2.77	7.50	8.55	9.41	1.89	7.07	7.67	7.91
ddIEC	TDF	ETR	2.56	0.86	6.31	2.56	6.33	6.30	6.33	3.42	8.87	7.16	9.72	2.51	6.24	6.44	6.48
AZTb	ddIq	ATV/r	0.37	0.84	7.44	0.91	7.44	7.44	7.44	1.21	7.81	8.28	8.65	1.61	7.57	8.04	8.28
ETR	ENF	EVG/c	6.31	2.07	1.41	6.31	6.30	2.20	6.31	8.38	7.72	3.48	9.79	8.20	7.55	3.46	9.49
ddIb	ENF	LPV/rq	0.75	2.07	6.64	2.24	6.64	6.64	6.65	2.82	7.39	8.71	9.46	2.71	7.20	7.88	8.59
ddIb	EVG/c	LPV/rb	0.75	1.41	6.97	1.60	6.98	6.97	6.98	2.16	7.72	8.39	9.13	2.25	7.53	9.19	9.55
d4T	ABCb	LPV/rb	0.25	1.91	6.97	1.92	6.97	6.97	6.97	2.16	7.22	8.89	9.14	2.42	7.13	8.00	8.66
d4T	ddIEC	LPV/rq	0.25	2.56	6.64	2.56	6.64	6.66	6.66	2.81	6.89	9.20	9.45	3.29	6.80	8.55	9.69
AZTb	TDF	ATV/r	0.37	0.86	7.44	0.87	7.44	7.44	7.44	1.23	7.81	8.30	8.67	1.92	7.57	7.80	8.24
AZTt	ddIq	ATV/r	0.39	0.84	7.44	0.92	7.44	7.44	7.44	1.23	7.84	8.28	8.67	1.66	7.58	8.04	8.31
AZTt	TDF	ATV/r	0.39	0.86	7.44	0.87	7.44	7.44	7.44	1.25	7.84	8.30	8.69	1.99	7.58	7.80	8.27
FTC	ddIb	ETR	2.79	0.75	6.31	2.85	6.31	6.31	6.31	3.54	9.10	7.05	9.84	3.06	6.83	6.28	6.75
FTC	EVG/c	ATV	2.79	1.41	5.97	2.80	5.98	5.97	5.98	4.20	8.76	7.38	10.17	4.28	7.53	8.10	10.38
3TCb	ABCb	ATV	2.30	1.91	5.97	2.47	5.97	5.97	5.97	4.22	8.27	7.88	10.18	2.82	6.90	7.02	7.78
ABCq	ENF	ATV	2.14	2.07	5.97	2.53	5.97	5.98	5.98	4.21	8.11	8.04	10.18	3.82	7.14	7.65	8.93
ABCq	ETR	EVG/c	2.14	6.31	1.41	6.31	2.20	6.30	6.31	8.45	3.56	7.72	9.86	6.66	3.62	7.55	8.61
ddIb	ABCq	LPV/rq	0.75	2.14	6.64	2.24	6.64	6.64	6.64	2.89	7.39	8.78	9.53	2.38	7.20	7.79	8.31
ddIq	ENF	LPV/rq	0.84	2.07	6.64	2.26	6.64	6.64	6.65	2.91	7.48	8.71	9.55	2.79	7.26	7.88	8.66
3TCq	ABCb	ATV	2.35	1.91	5.97	2.51	5.97	5.97	5.97	4.26	8.32	7.88	10.23	2.86	6.92	7.02	7.80
ddIq	EVG/c	LPV/rb	0.84	1.41	6.97	1.62	6.98	6.97	6.98	2.25	7.81	8.39	9.23	2.36	7.60	9.19	9.66

Regimen[a]			IIP_{ave}													
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
TDF	ENF	LPV/rq	0.86	2.07	6.64	2.08	6.64	6.64	6.64	2.93	7.50	8.71	9.57	2.63	7.07	7.88	8.30
ABCb	ETR	RAL	1.91	6.31	1.69	6.31	2.10	6.30	6.31	8.22	3.60	7.99	9.91	6.62	3.45	7.73	8.47
ddIb	ETR	NFVt	0.75	6.31	2.76	6.31	2.92	6.40	6.41	7.05	3.50	9.06	9.81	6.28	3.29	10.37	9.37
TDF	EVG/c	LPV/rq	0.86	1.41	6.97	1.43	6.97	6.97	6.97	2.27	7.83	8.39	9.25	2.25	7.41	9.19	9.43
AZTb	ABCb	LPV/rb	0.37	1.91	6.97	1.91	6.97	6.97	6.97	2.28	7.34	8.89	9.26	2.84	7.47	8.00	9.67
AZTb	ddIEC	LPV/rq	0.37	2.56	6.64	2.56	6.64	6.66	6.66	2.93	7.01	9.20	9.57	3.41	7.14	8.55	10.30
ddIEC	RAL	ATV	2.56	1.69	5.97	2.66	6.03	5.97	6.03	4.25	8.53	7.65	10.21	4.11	7.81	8.52	10.58
FTC	ddIq	ETR	2.79	0.84	6.31	2.86	6.31	6.31	6.31	3.63	9.10	7.14	9.93	3.10	6.83	6.28	6.77
ABCb	ETR	MVC	1.91	6.31	1.72	6.31	2.07	6.30	6.31	8.22	3.64	8.03	9.94	6.62	4.16	9.41	10.55
AZTt	ABCb	LPV/rb	0.39	1.91	6.97	1.91	6.97	6.97	6.97	2.31	7.37	8.89	9.28	2.91	7.51	8.00	9.71
AZTt	ddIEC	LPV/rq	0.39	2.56	6.64	2.56	6.64	6.66	6.66	2.95	7.03	9.20	9.59	3.46	7.17	8.55	10.34
FTC	TDF	ETR	2.79	0.86	6.31	2.79	6.31	6.30	6.31	3.65	9.10	7.16	9.95	3.07	6.83	6.44	7.05
ddIq	ABCq	LPV/rq	0.84	2.14	6.64	2.25	6.64	6.64	6.64	2.98	7.48	8.78	9.62	2.41	7.26	7.79	8.37
ddIb	ETR	NFVb	0.75	6.31	2.80	6.31	2.96	6.41	6.41	7.05	3.55	9.11	9.85	6.28	3.33	10.43	9.42
d4T	ENF	LPV/rb	0.25	2.07	6.97	2.07	6.97	6.98	6.98	2.32	7.22	9.04	9.29	2.34	7.13	8.21	8.54
TDF	ABCq	LPV/rq	0.86	2.14	6.64	2.14	6.64	6.64	6.64	3.00	7.50	8.78	9.64	2.11	7.07	7.79	8.00
ddIq	ETR	NFVt	0.84	6.31	2.76	6.31	2.93	6.40	6.41	7.14	3.60	9.06	9.90	6.28	3.35	10.37	9.45
ddIb	TDF	EFV	0.75	0.86	7.35	1.06	7.35	7.35	7.35	1.61	8.10	8.21	8.96	1.03	7.77	7.97	8.31
d4T	FTC	LPV/rq	0.25	2.79	6.64	2.79	6.64	6.64	6.64	3.04	6.89	9.43	9.68	3.21	6.80	8.38	9.11
TDF	ETR	NFVt	0.86	6.31	2.76	6.30	2.76	6.40	6.40	7.16	3.62	9.06	9.92	6.44	3.16	10.37	9.58
3TCb	ENF	ATV	2.30	2.07	5.97	2.63	5.97	5.98	5.98	4.37	8.27	8.04	10.34	4.55	6.90	7.65	9.18
3TCb	ETR	EVG/c	2.30	6.31	1.41	6.31	2.35	6.30	6.31	8.61	3.72	7.72	10.02	6.86	4.06	7.55	8.99
3TCb	ddIb	LPV/rq	2.30	0.75	6.64	2.39	6.64	6.64	6.64	3.05	8.94	7.39	9.69	2.55	7.77	7.20	8.34
d4T	ABCq	LPV/rb	0.25	2.14	6.97	2.14	6.97	6.97	6.97	2.39	7.22	9.12	9.37	2.65	7.13	8.13	8.88
ddIq	ETR	NFVb	0.84	6.31	2.80	6.31	2.98	6.41	6.42	7.14	3.64	9.11	9.94	6.28	3.40	10.43	9.50
3TCq	ENF	ATV	2.35	2.07	5.97	2.67	5.97	5.98	5.98	4.42	8.32	8.04	10.39	4.60	6.92	7.65	9.22
d4T	EFV	EVG/c	0.25	7.35	1.41	7.35	1.42	7.35	7.35	7.60	1.66	8.77	9.02	8.00	1.69	8.86	10.25
ETR	ENF	RAL	6.31	2.07	1.69	6.31	6.30	2.29	6.31	8.38	7.99	3.76	10.06	8.20	7.73	3.96	9.81
3TCq	ETR	EVG/c	2.35	6.31	1.41	6.31	2.39	6.30	6.31	8.65	3.76	7.72	10.07	6.87	4.10	7.55	9.03
TDF	ETR	NFVb	0.86	6.31	2.80	6.30	2.80	6.41	6.41	7.16	3.66	9.11	9.97	6.44	3.20	10.43	9.62
3TCq	ddIb	LPV/rq	2.35	0.75	6.64	2.44	6.64	6.64	6.64	3.10	8.99	7.39	9.74	2.59	7.79	7.20	8.36
ddIb	RAL	LPV/rb	0.75	1.69	6.97	1.83	6.98	6.97	6.98	2.43	7.72	8.66	9.41	2.38	7.53	9.20	9.51
3TCb	ABCq	ATV	2.30	2.14	5.97	2.56	5.97	5.97	5.97	4.45	8.27	8.11	10.41	2.93	6.90	7.14	7.88
AZTb	ENF	LPV/rb	0.37	2.07	6.97	2.07	6.97	6.98	6.98	2.44	7.34	9.04	9.41	2.51	7.47	8.21	9.40
ddIq	TDF	EFV	0.84	0.86	7.35	1.10	7.36	7.35	7.36	1.70	8.19	8.21	9.05	1.07	7.82	7.97	8.36
ETR	ENF	MVC	6.31	2.07	1.72	6.31	6.30	2.26	6.31	8.38	8.03	3.79	10.10	8.20	9.41	4.70	11.73
AZTt	ENF	LPV/rb	0.39	2.07	6.97	2.07	6.97	6.98	6.98	2.46	7.37	9.04	9.44	2.54	7.51	8.21	9.43
EVG/c	LPV/rq	MVC	1.41	6.64	1.72	6.64	1.84	6.64	6.64	8.05	3.14	8.36	9.78	8.86	3.20	6.64	9.54
3TCb	ddIq	LPV/rq	2.30	0.84	6.64	2.41	6.64	6.64	6.64	3.14	8.94	7.48	9.78	2.58	7.77	7.26	8.39
FTC	RAL	ATV	2.79	1.69	5.97	2.82	5.98	5.97	5.98	4.48	8.76	7.65	10.44	4.61	7.53	8.52	10.76
3TCq	ABCq	ATV	2.35	2.14	5.97	2.59	5.97	5.97	5.97	4.49	8.32	8.11	10.46	2.96	6.92	7.14	7.90
AZTb	FTC	LPV/rq	0.37	2.79	6.64	2.79	6.64	6.64	6.64	3.16	7.01	9.43	9.80	3.55	7.14	8.38	10.34
ABCq	ETR	RAL	2.14	6.31	1.69	6.31	2.26	6.30	6.31	8.45	3.83	7.99	10.14	6.66	3.68	7.73	8.62
3TCb	TDF	LPV/rq	2.30	0.86	6.64	2.30	6.64	6.64	6.64	3.16	8.94	7.50	9.80	2.97	7.77	7.07	8.36
AZTb	ABCq	LPV/rb	0.37	2.14	6.97	2.14	6.97	6.97	6.97	2.51	7.34	9.12	9.48	3.07	7.47	8.13	9.97
AZTt	FTC	LPV/rq	0.39	2.79	6.64	2.79	6.64	6.64	6.64	3.18	7.03	9.43	9.82	3.60	7.17	8.38	10.38
ddIEC	ABCb	ATV	2.56	1.91	5.97	2.74	6.03	5.97	6.03	4.47	8.53	7.88	10.44	3.11	7.81	7.02	8.51
3TCq	ddIq	LPV/rq	2.35	0.84	6.64	2.45	6.64	6.64	6.64	3.19	8.99	7.48	9.83	2.62	7.79	7.26	8.42
ddIq	RAL	LPV/rb	0.84	1.69	6.97	1.85	6.98	6.97	6.98	2.53	7.81	8.66	9.50	2.47	7.60	9.20	9.60
ABCq	ETR	MVC	2.14	6.31	1.72	6.31	2.23	6.30	6.31	8.45	3.87	8.03	10.17	6.66	4.41	9.41	10.82
ABCq	ETR	MVC	2.14	6.31	1.72	6.31	2.23	6.30	6.31	8.45	3.87	8.03	10.17	6.66	4.41	9.41	10.82
AZTt	ABCq	LPV/rb	0.39	2.14	6.97	2.14	6.97	6.97	6.97	2.54	7.37	9.12	9.51	3.13	7.51	8.13	10.01
3TCq	TDF	LPV/rq	2.35	0.86	6.64	2.35	6.64	6.64	6.64	3.21	8.99	7.50	9.85	3.02	7.79	7.07	8.38
AZTb	EFV	EVG/c	0.37	7.35	1.41	7.35	1.42	7.35	7.35	7.72	1.78	8.77	9.14	8.91	1.83	8.86	11.83
ddIb	TDF	ATV/r	0.75	0.86	7.44	1.06	7.44	7.44	7.44	1.61	8.19	8.30	9.05	1.03	7.97	7.80	8.29
TDF	RAL	LPV/rq	0.86	1.69	6.97	1.69	6.97	6.97	6.97	2.55	7.83	8.66	9.52	2.71	7.41	9.20	9.49
d4T	3TCb	LPV/rb	0.25	2.30	6.97	2.31	6.97	6.97	6.97	2.55	7.22	9.28	9.53	2.72	7.13	8.10	8.83
AZTt	EFV	EVG/c	0.39	7.35	1.41	7.35	1.42	7.35	7.35	7.75	1.81	8.77	9.16	9.02	1.86	8.86	11.90
d4T	3TCq	LPV/rb	0.25	2.35	6.97	2.35	6.97	6.97	6.97	2.60	7.22	9.32	9.57	2.77	7.13	8.12	8.87
d4T	EVG/c	ATV/r	0.25	1.41	7.44	1.42	7.44	7.44	7.44	1.66	7.69	8.86	9.11	1.70	7.53	9.57	9.13
ddIq	TDF	ATV/r	0.84	0.86	7.44	1.10	7.44	7.44	7.44	1.70	8.28	8.30	9.14	1.07	8.04	7.80	8.34
ABCb	ETR	ENF	1.91	6.31	2.07	6.31	2.41	6.31	6.31	8.22	3.98	8.38	10.29	6.62	3.61	8.20	8.77
3TCb	ETR	RAL	2.30	6.31	1.69	6.31	2.39	6.30	6.31	8.61	3.99	7.99	10.30	6.86	4.00	7.73	8.92
ABCb	EVG/c	LPV/rq	1.91	1.41	6.64	2.02	6.64	6.64	6.64	3.33	8.55	8.05	9.97	3.39	7.67	8.86	10.24
ddIb	ABCb	LPV/rb	0.75	1.91	6.97	2.04	6.98	6.97	6.98	2.66	7.72	8.89	9.63	2.17	7.53	8.00	8.53
ddIEC	ETR	EVG/c	2.56	6.31	1.41	6.33	2.60	6.30	6.33	8.87	3.97	7.72	10.28	6.24	4.20	7.55	8.82
AZTb	3TCb	LPV/rb	0.37	2.30	6.97	2.30	6.97	6.97	6.97	2.67	7.34	9.28	9.65	2.91	7.47	8.10	9.71
ddIEC	ENF	ATV	2.56	2.07	5.97	2.94	6.03	5.98	6.04	4.63	8.53	8.04	10.60	4.33	7.81	7.65	9.57
3TCb	ETR	MVC	2.30	6.31	1.72	6.31	2.36	6.30	6.31	8.61	4.03	8.03	10.33	6.86	5.28	9.41	11.51
d4T	EFV	RAL	0.25	7.35	1.69	7.35	1.69	7.35	7.35	7.60	1.94	9.04	9.29	8.00	2.00	9.55	10.91

Regimen[a]			IIP_{ave}															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTt	3TCb	LPV/rb	0.39	2.30	6.97	2.30	6.97	6.97	6.97	2.70	7.37	9.28	9.67	2.95	7.51	8.10	9.74
3TCq	ETR	RAL	2.35	6.31	1.69	6.31	2.44	6.30	6.31	8.65	4.04	7.99	10.34	6.87	4.04	7.73	8.95
FTC	ABCb	ATV	2.79	1.91	5.97	2.86	5.98	5.97	5.98	4.70	8.76	7.88	10.67	2.92	7.53	7.02	8.17
AZTb	3TCq	LPV/rb	0.37	2.35	6.97	2.35	6.97	6.97	6.97	2.72	7.34	9.32	9.69	2.95	7.47	8.12	9.76
AZTb	EVG/c	ATV/r	0.37	1.41	7.44	1.42	7.44	7.44	7.44	1.78	7.81	8.86	9.22	1.84	7.57	9.57	9.24
d4T	EFV	MVC	0.25	7.35	1.72	7.35	1.73	7.35	7.35	7.60	1.97	9.08	9.33	8.00	1.95	10.23	11.24
3TCq	ETR	MVC	2.35	6.31	1.72	6.31	2.41	6.30	6.31	8.65	4.07	8.03	10.38	6.87	5.32	9.41	11.57
AZTt	3TCq	LPV/rb	0.39	2.35	6.97	2.35	6.97	6.97	6.97	2.74	7.37	9.32	9.72	2.99	7.51	8.12	9.79
RAL	LPV/rq	MVC	1.69	6.64	1.72	6.64	1.94	6.64	6.64	8.33	3.41	8.36	10.05	8.86	3.94	6.64	9.63
AZTt	EVG/c	ATV/r	0.39	1.41	7.44	1.42	7.44	7.44	7.44	1.81	7.84	8.86	9.25	1.87	7.58	9.57	9.26
ddIEC	ABCq	ATV	2.56	2.14	5.97	2.82	6.03	5.97	6.03	4.70	8.53	8.11	10.67	3.21	7.81	7.14	8.63
ddIq	ABCb	LPV/rb	0.84	1.91	6.97	2.06	6.98	6.97	6.98	2.75	7.81	8.89	9.73	2.20	7.60	8.00	8.59
TDF	ABCb	LPV/rb	0.86	1.91	6.97	1.92	6.97	6.97	6.97	2.77	7.83	8.89	9.75	1.89	7.41	8.00	8.25
ddIEC	TDF	LPV/rq	2.56	0.86	6.64	2.56	6.66	6.64	6.66	3.42	9.20	7.50	10.06	2.51	8.55	7.07	8.50
AZTb	EFV	RAL	0.37	7.35	1.69	7.35	1.69	7.35	7.35	7.72	2.05	9.04	9.41	8.91	2.07	9.55	12.59
ddIb	ENF	LPV/rb	0.75	2.07	6.97	2.24	6.98	6.98	6.98	2.82	7.72	9.04	9.79	2.71	7.53	8.21	8.92
ENF	EVG/c	LPV/rq	2.07	1.41	6.64	2.20	6.64	6.64	6.64	3.48	8.71	8.05	10.12	3.46	7.88	8.86	10.44
d4T	ddIEC	LPV/rb	0.25	2.56	6.97	2.56	6.97	6.99	6.99	2.81	7.22	9.53	9.78	3.29	7.13	8.88	9.99
AZTt	EFV	RAL	0.39	7.35	1.69	7.35	1.69	7.35	7.35	7.75	2.08	9.04	9.43	9.02	2.10	9.55	12.67
AZTb	EFV	MVC	0.37	7.35	1.72	7.35	1.72	7.35	7.35	7.72	2.09	9.08	9.44	8.91	2.06	10.23	12.95
AZTb	EFV	MVC	0.37	7.35	1.72	7.35	1.72	7.35	7.35	7.72	2.09	9.08	9.44	8.91	2.06	10.23	12.95
FTC	ETR	EVG/c	2.79	6.31	1.41	6.31	2.80	6.30	6.31	9.10	4.20	7.72	10.51	6.83	4.28	7.55	9.11
FTC	ddIb	LPV/rq	2.79	0.75	6.64	2.85	6.64	6.64	6.65	3.54	9.43	7.39	10.18	3.06	8.38	7.20	8.83
FTC	ENF	ATV	2.79	2.07	5.97	2.99	5.98	5.98	5.99	4.86	8.76	8.04	10.83	4.39	7.53	7.65	9.38
d4T	RAL	ATV/r	0.25	1.69	7.44	1.69	7.44	7.44	7.44	1.94	7.69	9.13	9.38	2.01	7.53	10.00	9.47
AZTt	EFV	MVC	0.39	7.35	1.72	7.35	1.72	7.35	7.35	7.75	2.12	9.08	9.47	9.02	2.09	10.23	13.02
ABCq	ETR	ENF	2.14	6.31	2.07	6.31	2.53	6.31	6.31	8.45	4.21	8.38	10.52	6.66	3.82	8.20	8.91
3TCb	ABCb	ETR	2.30	1.91	6.31	2.47	6.31	6.31	6.31	4.22	8.61	8.22	10.52	2.82	6.86	6.62	7.16
ABCq	EVG/c	LPV/rq	2.14	1.41	6.64	2.20	6.64	6.64	6.64	3.56	8.78	8.05	10.20	3.62	7.79	8.86	10.48
ddIb	ABCq	LPV/rb	0.75	2.14	6.97	2.24	6.98	6.97	6.98	2.89	7.72	9.12	9.86	2.38	7.53	8.13	8.65
ddIq	ENF	LPV/rb	0.84	2.07	6.97	2.26	6.98	6.98	6.98	2.91	7.81	9.04	9.88	2.79	7.60	8.21	8.99
3TCb	ddIEC	ATV	2.30	2.56	5.97	2.91	5.97	6.03	6.03	4.86	8.27	8.53	10.83	3.38	6.90	7.81	8.46
ddIb	EFV	EVG/c	0.75	7.35	1.41	7.35	1.60	7.35	7.35	8.10	2.16	8.77	9.51	7.77	2.25	8.86	9.23
d4T	ABCb	EFV	0.25	1.91	7.35	1.92	7.35	7.35	7.35	2.16	7.60	9.27	9.52	2.42	8.00	8.81	11.01
3TCq	ABCb	ETR	2.35	1.91	6.31	2.51	6.31	6.31	6.31	4.26	8.65	8.22	10.57	2.86	6.87	6.62	7.17
TDF	ENF	LPV/rb	0.86	2.07	6.97	2.08	6.97	6.98	6.98	2.93	7.83	9.04	9.90	2.63	7.41	8.21	8.64
ETR	EVG/c	NFVt	6.31	1.41	2.76	6.30	6.40	2.82	6.40	7.72	9.06	4.17	10.48	7.55	10.37	4.61	11.51
ABCb	RAL	LPV/rq	1.91	1.69	6.64	2.10	6.64	6.64	6.64	3.60	8.55	8.33	10.24	3.45	7.67	8.86	10.05
FTC	ABCq	ATV	2.79	2.14	5.97	2.90	5.98	5.97	5.98	4.93	8.76	8.11	10.90	2.97	7.53	7.14	8.27
ddIEC	ETR	RAL	2.56	6.31	1.69	6.33	2.66	6.30	6.33	8.87	4.25	7.99	10.55	6.24	4.11	7.73	8.68
AZTb	ddIEC	LPV/rb	0.37	2.56	6.97	2.56	6.97	6.99	6.99	2.93	7.34	9.53	9.90	3.41	7.47	8.88	10.62
3TCq	ddIEC	ATV	2.35	2.56	5.97	2.92	5.97	6.03	6.03	4.91	8.32	8.53	10.88	3.40	6.92	7.81	8.48
FTC	ddIq	LPV/rq	2.79	0.84	6.64	2.86	6.64	6.64	6.65	3.63	9.43	7.48	10.27	3.10	8.38	7.26	8.89
AZTt	ddIEC	LPV/rb	0.39	2.56	6.97	2.56	6.97	6.99	6.99	2.95	7.37	9.53	9.93	3.46	7.51	8.88	10.66
ABCb	LPV/rq	MVC	1.91	6.64	1.72	6.64	2.07	6.64	6.64	8.55	3.64	8.36	10.28	7.67	4.16	6.64	8.55
ddIEC	ETR	MVC	2.56	6.31	1.72	6.33	2.62	6.30	6.33	8.87	4.28	8.03	10.59	6.24	4.48	9.41	10.93
ddIq	ABCq	LPV/rb	0.84	2.14	6.97	2.25	6.98	6.97	6.98	2.98	7.81	9.12	9.95	2.41	7.60	8.13	8.71
FTC	TDF	LPV/rq	2.79	0.86	6.64	2.79	6.64	6.64	6.64	3.65	9.43	7.50	10.29	3.07	8.38	7.07	8.57
ETR	EVG/c	NFVb	6.31	1.41	2.80	6.30	6.41	2.88	6.41	7.72	9.11	4.22	10.52	7.55	10.43	4.65	11.57
AZTb	RAL	ATV/r	0.37	1.69	7.44	1.69	7.44	7.44	7.44	2.05	7.81	9.13	9.50	2.08	7.57	10.00	9.53
TDF	ABCq	LPV/rb	0.86	2.14	6.97	2.14	6.97	6.97	6.97	3.00	7.83	9.12	9.98	2.11	7.41	8.13	8.34
d4T	NVP	ATV	0.25	4.43	5.97	4.43	5.97	6.31	6.31	4.68	6.22	10.40	10.65	4.90	6.06	8.91	10.02
ddIq	EFV	EVG/c	0.84	7.35	1.41	7.36	1.62	7.35	7.36	8.19	2.25	8.77	9.61	7.82	2.36	8.86	9.31
AZTt	RAL	ATV/r	0.39	1.69	7.44	1.69	7.44	7.44	7.44	2.08	7.84	9.13	9.52	2.11	7.58	10.00	9.56
TDF	EFV	EVG/c	0.86	7.35	1.41	7.35	1.43	7.35	7.35	8.21	2.27	8.77	9.63	7.97	2.24	8.86	9.42
d4T	FTC	LPV/rb	0.25	2.79	6.97	2.79	6.97	6.97	6.97	3.04	7.22	9.76	10.01	3.21	7.13	8.72	9.42
AZTb	ABCb	EFV	0.37	1.91	7.35	1.91	7.35	7.35	7.35	2.28	7.72	9.27	9.64	2.84	8.91	8.81	13.08
3TCb	ETR	ENF	2.30	6.31	2.07	6.31	2.63	6.31	6.31	8.61	4.37	8.38	10.68	6.86	4.55	8.20	9.47
3TCb	ddIb	LPV/rb	2.30	0.75	6.97	2.39	6.97	6.98	6.98	3.05	9.28	7.72	10.02	2.55	8.10	7.53	8.68
3TCb	EVG/c	LPV/rq	2.30	1.41	6.64	2.35	6.64	6.64	6.64	3.72	8.94	8.05	10.36	4.06	7.77	8.86	10.73
AZTt	ABCb	EFV	0.39	1.91	7.35	1.91	7.35	7.35	7.35	2.31	7.75	9.27	9.66	2.91	9.02	8.81	13.16
d4T	EFV	ENF	0.25	7.35	2.07	7.35	2.07	7.35	7.35	7.60	2.32	9.42	9.67	8.00	2.33	9.20	11.10
3TCq	ETR	ENF	2.35	6.31	2.07	6.31	2.67	6.31	6.31	8.65	4.42	8.38	10.73	6.87	4.60	8.20	9.51
ENF	RAL	LPV/rq	2.07	1.69	6.64	2.29	6.64	6.64	6.64	3.76	8.71	8.33	10.40	3.96	7.88	8.86	10.44
3TCq	EVG/c	LPV/rq	2.35	1.41	6.64	2.39	6.64	6.64	6.64	3.76	8.99	8.05	10.40	4.10	7.79	8.86	10.78
3TCq	ddIb	LPV/rb	2.35	0.75	6.97	2.44	6.97	6.98	6.98	3.10	9.32	7.72	10.07	2.59	8.12	7.53	8.70
ddIb	EVG/c	ATV/r	0.75	1.41	7.44	1.60	7.44	7.44	7.44	2.16	8.19	8.86	9.60	2.25	7.97	9.57	9.92
d4T	ABCb	ATV/r	0.25	1.91	7.44	1.92	7.44	7.44	7.44	2.16	7.69	9.36	9.61	2.42	7.53	8.49	8.88
3TCb	ABCq	ETR	2.30	2.14	6.31	2.56	6.31	6.31	6.31	4.45	8.61	8.45	10.75	2.93	6.86	6.66	7.20
ENF	LPV/rq	MVC	2.07	6.64	1.72	6.64	2.26	6.64	6.64	8.71	3.79	8.36	10.43	7.88	4.70	6.64	9.06

| Regimen[a] | | | IIP_ave | | | | | | | | | | | | | | | | |
| | | | Single drug | | | Loewe[b] | | | | Bliss[c] | | | | DI Index[d] | | | |
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTb	NVP	ATV	0.37	4.43	5.97	4.43	5.97	6.31	6.31	4.80	6.33	10.40	10.77	5.28	6.09	8.91	10.68
FTC	ETR	RAL	2.79	6.31	1.69	6.31	2.82	6.30	6.31	9.10	4.48	7.99	10.78	6.83	4.61	7.73	9.29
3TCb	ddIq	LPV/rb	2.30	0.84	6.97	2.41	6.97	6.98	6.98	3.14	9.28	7.81	10.12	2.58	8.10	7.60	8.73
d4T	ABCq	EFV	0.25	2.14	7.35	2.14	7.35	7.35	7.35	2.39	7.60	9.50	9.75	2.65	8.00	8.98	11.38
3TCq	ABCq	ETR	2.35	2.14	6.31	2.59	6.31	6.31	6.31	4.49	8.65	8.45	10.80	2.96	6.87	6.66	7.21
AZTt	NVP	ATV	0.39	4.43	5.97	4.43	5.97	6.31	6.31	4.83	6.36	10.40	10.79	5.33	6.10	8.91	10.72
AZTb	FTC	LPV/rb	0.37	2.79	6.97	2.79	6.97	6.97	6.97	3.16	7.34	9.76	10.13	3.55	7.47	8.72	10.65
ABCq	RAL	LPV/rq	2.14	1.69	6.64	2.26	6.64	6.64	6.64	3.83	8.78	8.33	10.47	3.68	7.79	8.86	10.26
3TCb	TDF	LPV/rb	2.30	0.86	6.97	2.30	6.97	6.97	6.97	3.16	9.28	7.83	10.14	2.97	8.10	7.41	8.69
ddIEC	ABCb	ETR	2.56	1.91	6.31	2.74	6.33	6.31	6.33	4.47	8.87	8.22	10.78	3.11	6.24	6.62	6.76
FTC	ETR	MVC	2.79	6.31	1.72	6.31	2.80	6.30	6.31	9.10	4.51	8.03	10.82	6.83	4.79	9.41	11.41
AZTt	FTC	LPV/rb	0.39	2.79	6.97	2.79	6.97	6.97	6.97	3.18	7.37	9.76	10.16	3.60	7.51	8.72	10.69
3TCq	ddIq	LPV/rb	2.35	0.84	6.97	2.45	6.97	6.98	6.98	3.19	9.32	7.81	10.16	2.62	8.12	7.60	8.76
ddIq	EVG/c	ATV/r	0.84	1.41	7.44	1.62	7.44	7.44	7.44	2.25	8.28	8.86	9.70	2.36	8.04	9.57	10.02
ddIb	EFV	RAL	0.75	7.35	1.69	7.35	1.83	7.35	7.35	8.10	2.43	9.04	9.79	7.77	2.38	9.55	9.69
ABCq	LPV/rq	MVC	2.14	6.64	1.72	6.64	2.23	6.64	6.64	6.78	3.87	8.36	10.51	7.79	4.41	6.64	8.71
AZTb	EFV	ENF	0.37	7.35	2.07	7.35	2.07	7.35	7.35	7.72	2.44	9.42	9.79	8.91	2.51	9.20	13.12
ETR	RAL	NFVt	6.31	1.69	2.76	6.30	6.40	2.87	6.40	7.99	9.06	4.44	10.75	7.73	10.37	5.85	12.41
3TCq	TDF	LPV/rb	2.35	0.86	6.97	2.35	6.97	6.97	6.97	3.21	9.32	7.83	10.18	3.02	8.12	7.41	8.71
TDF	EVG/c	ATV/r	0.86	1.41	7.44	1.43	7.44	7.44	7.44	2.27	8.30	8.86	9.72	2.25	7.80	9.57	9.74
AZTb	ABCb	ATV/r	0.37	1.91	7.44	1.91	7.44	7.44	7.44	2.28	7.81	9.36	9.72	2.84	7.57	8.49	9.19
AZTt	EFV	ENF	0.39	7.35	2.07	7.35	2.07	7.35	7.35	7.75	2.46	9.42	9.82	9.02	2.54	9.20	13.20
ddIb	EFV	MVC	0.75	7.35	1.72	7.35	1.83	7.35	7.35	8.10	2.47	9.08	9.82	7.77	2.54	10.23	10.26
ddIb	EFV	MVC	0.75	7.35	1.72	7.35	1.83	7.35	7.35	8.10	2.47	9.08	9.82	7.77	2.54	10.23	10.26
AZTt	ABCb	ATV/r	0.39	1.91	7.44	1.91	7.44	7.44	7.44	2.31	7.84	9.36	9.75	2.91	7.58	8.49	9.22
d4T	ENF	ATV/r	0.25	2.07	7.44	2.07	7.44	7.44	7.44	2.32	7.69	9.51	9.76	2.34	7.53	9.12	8.99
ETR	RAL	NFVb	6.31	1.69	2.80	6.30	6.41	2.93	6.41	7.99	9.11	4.49	10.79	7.73	10.43	5.88	12.48
AZTb	ABCq	EFV	0.37	2.14	7.35	2.14	7.35	7.35	7.35	2.51	7.72	9.50	9.86	3.07	8.91	8.98	13.61
ddIq	EFV	RAL	0.84	7.35	1.69	7.36	1.85	7.35	7.36	8.19	2.53	9.04	9.88	7.82	2.47	9.55	9.78
AZTt	ABCq	EFV	0.39	2.14	7.35	2.14	7.35	7.35	7.35	2.54	7.75	9.50	9.89	3.13	9.02	8.98	13.70
TDF	EFV	RAL	0.86	7.35	1.69	7.35	1.69	7.35	7.35	8.21	2.55	9.04	9.90	7.97	2.71	9.55	10.04
d4T	3TCb	EFV	0.25	2.30	7.35	2.31	7.35	7.35	7.35	2.55	7.60	9.66	9.91	2.72	8.00	8.38	11.26
ABCb	ENF	LPV/rq	1.91	2.07	6.64	2.41	6.64	6.64	6.64	3.98	8.55	8.71	10.62	3.62	7.67	7.88	9.06
ddIq	EFV	MVC	0.84	7.35	1.72	7.36	1.85	7.35	7.36	8.19	2.56	9.08	9.91	7.82	2.64	10.23	10.37
3TCb	RAL	LPV/rq	2.30	1.69	6.64	2.39	6.64	6.64	6.64	3.99	8.94	8.33	10.63	4.00	7.77	8.86	10.41
ddIEC	ETR	ENF	2.56	6.31	2.07	6.33	2.94	6.31	6.34	8.87	4.63	8.38	10.94	6.24	4.33	8.20	9.00
ABCb	EVG/c	LPV/rb	1.91	1.41	6.97	2.02	6.97	6.97	6.97	3.33	8.89	8.39	10.30	3.39	8.00	9.19	10.58
ddIEC	EVG/c	LPV/rq	2.56	1.41	6.64	2.60	6.66	6.64	6.66	3.97	9.20	8.05	10.61	4.20	8.55	8.86	11.26
d4T	ABCq	ATV/r	0.25	2.14	7.44	2.14	7.44	7.44	7.44	2.39	7.69	9.59	9.83	2.65	7.53	8.62	9.07
TDF	EFV	MVC	0.86	7.35	1.72	7.35	1.73	7.35	7.35	8.21	2.58	9.08	9.94	7.97	2.95	10.23	10.65
d4T	3TCq	EFV	0.25	2.35	7.35	2.35	7.35	7.35	7.35	2.60	7.60	9.70	9.95	2.77	8.00	8.40	11.32
3TCb	LPV/rq	MVC	2.30	6.64	1.72	6.64	2.36	6.64	6.64	8.94	4.03	8.36	10.67	7.77	5.28	6.64	9.32
FTC	ABCb	ETR	2.79	1.91	6.31	2.86	6.31	6.31	6.31	4.70	9.10	8.22	11.01	2.92	6.83	6.62	7.02
3TCq	RAL	LPV/rq	2.35	1.69	6.64	2.44	6.64	6.64	6.64	4.04	8.99	8.33	10.68	4.04	7.79	8.86	10.46
ddIb	RAL	ATV/r	0.75	1.69	7.44	1.83	7.44	7.44	7.44	2.43	8.19	9.13	9.88	2.38	7.97	10.00	10.19
AZTb	ENF	ATV/r	0.37	2.07	7.44	2.07	7.44	7.44	7.44	2.44	7.81	9.51	9.88	2.51	7.57	9.12	9.10
ddIEC	ABCq	ETR	2.56	2.14	6.31	2.82	6.33	6.31	6.33	4.70	8.87	8.45	11.01	3.21	6.24	6.66	6.78
AZTt	ENF	ATV/r	0.39	2.07	7.44	2.07	7.44	7.44	7.44	2.46	7.84	9.51	9.91	2.54	7.58	9.12	9.11
3TCq	LPV/rq	MVC	2.35	6.64	1.72	6.64	2.41	6.64	6.64	8.99	4.07	8.36	10.71	7.79	5.32	6.64	9.35
FTC	ddIEC	ATV	2.79	2.56	5.97	3.19	5.98	6.03	6.04	5.35	8.76	8.53	11.32	3.86	7.53	7.81	9.06
ddIb	ABCb	EFV	0.75	1.91	7.35	2.04	7.35	7.35	7.35	2.66	8.10	9.27	10.01	2.17	7.77	8.81	8.98
AZTb	3TCb	EFV	0.37	2.30	7.35	2.30	7.35	7.35	7.35	2.67	7.72	9.66	10.03	2.91	8.91	8.38	13.47
ABCb	ETR	NFVt	1.91	6.31	2.76	6.31	2.96	6.40	6.40	8.22	4.67	9.06	10.98	6.62	4.36	10.37	10.72
ddIEC	TDF	LPV/rb	2.56	0.86	6.97	2.56	6.99	6.97	6.99	3.42	9.53	7.83	10.39	2.51	8.88	7.41	8.84
AZTb	ABCq	ATV/r	0.37	2.14	7.44	2.14	7.44	7.44	7.44	2.51	7.81	9.59	9.95	3.07	7.57	8.62	9.41
AZTt	3TCb	EFV	0.39	2.30	7.35	2.30	7.35	7.35	7.35	2.70	7.75	9.66	10.05	2.95	9.02	8.38	13.55
ddIq	RAL	ATV/r	0.84	1.69	7.44	1.85	7.44	7.44	7.44	2.53	8.28	9.13	9.97	2.47	8.04	10.00	10.29
AZTt	ABCq	ATV/r	0.39	2.14	7.44	2.14	7.44	7.44	7.44	2.54	7.84	9.59	9.98	3.13	7.58	8.62	9.44
AZTb	3TCq	EFV	0.37	2.35	7.35	2.35	7.35	7.35	7.35	2.72	7.72	9.70	10.07	2.95	8.91	8.40	13.56
TDF	RAL	ATV/r	0.86	1.69	7.44	1.69	7.44	7.44	7.44	2.55	8.30	9.13	9.99	2.71	7.80	10.00	10.13
ABCb	ETR	NFVb	1.91	6.31	2.80	6.31	3.03	6.41	6.41	8.22	4.72	9.11	11.02	6.62	4.41	10.43	10.77
ENF	EVG/c	LPV/rb	2.07	1.41	6.97	2.20	6.98	6.97	6.98	3.48	9.04	8.39	10.46	3.46	8.21	9.19	10.77
d4T	3TCb	ATV/r	0.25	2.30	7.44	2.31	7.44	7.44	7.44	2.55	7.69	9.75	10.00	2.72	7.53	8.37	8.90
AZTt	3TCq	EFV	0.39	2.35	7.35	2.35	7.35	7.35	7.35	2.74	7.75	9.70	10.10	2.99	9.02	8.40	13.64
ddIq	ABCb	EFV	0.84	1.91	7.35	2.06	7.36	7.35	7.36	2.75	8.19	9.27	10.11	2.20	7.82	8.81	9.03
ddIb	NVP	ATV	0.75	4.43	5.97	4.45	5.98	6.31	6.32	5.18	6.71	10.40	11.14	5.05	6.50	8.91	9.72
FTC	ETR	ENF	2.79	6.31	2.07	6.31	2.99	6.31	6.31	9.10	4.86	8.38	11.17	6.83	4.39	8.20	9.33
TDF	ABCb	EFV	0.86	1.91	7.35	1.92	7.35	7.35	7.35	2.77	8.21	9.27	10.13	1.89	7.97	8.81	9.19
d4T	3TCq	ATV/r	0.25	2.35	7.44	2.35	7.44	7.44	7.44	2.60	7.69	9.79	10.04	2.77	7.53	8.39	8.93
FTC	ddIb	LPV/rb	2.79	0.75	6.97	2.85	6.97	6.98	6.98	3.54	9.76	7.72	10.51	3.06	8.72	7.53	9.17

Regimen[a]			IIP$_{ave}$													
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
FTC	EVG/c	LPV/rq	2.79	1.41	6.64	2.80	6.64	6.64	6.64	4.20	9.43	8.05	10.84	4.28	8.38	8.86	11.26
ABCq	ENF	LPV/rq	2.14	2.07	6.64	2.53	6.64	6.64	6.64	4.21	8.78	8.71	10.85	3.82	7.79	7.88	9.20
3TCb	ABCb	LPV/rq	2.30	1.91	6.64	2.47	6.64	6.64	6.64	4.22	8.94	8.55	10.86	2.82	7.77	7.67	8.60
3TCb	ddIEC	ETR	2.30	2.56	6.31	2.91	6.31	6.33	6.33	4.86	8.61	8.87	11.17	3.38	6.86	6.24	6.99
ABCq	EVG/c	LPV/rb	2.14	1.41	6.97	2.20	6.97	6.97	6.97	3.56	9.12	8.39	10.53	3.62	8.13	9.19	10.81
d4T	ddIEC	EFV	0.25	2.56	7.35	2.56	7.35	7.36	7.36	2.81	7.60	9.91	10.16	3.29	8.00	8.77	12.30
ddIb	EFV	ENF	0.75	7.35	2.07	7.35	2.24	7.35	7.36	8.10	2.82	9.42	10.17	7.77	2.71	9.20	9.46
ETR	ENF	NFVt	6.31	2.07	2.76	6.31	6.40	3.16	6.41	8.38	9.06	4.83	11.13	8.20	10.37	5.11	12.19
3TCq	ABCb	LPV/rq	2.35	1.91	6.64	2.51	6.64	6.64	6.64	4.26	8.99	8.55	10.90	2.86	7.79	7.67	8.62
FTC	ABCq	ETR	2.79	2.14	6.31	2.90	6.31	6.31	6.31	4.93	9.10	8.45	11.24	2.97	6.83	6.66	7.05
ddIb	ABCb	ATV/r	0.75	1.91	7.44	2.04	7.44	7.44	7.44	2.66	8.19	9.36	10.10	2.17	7.97	8.49	8.99
3TCq	ddIEC	ETR	2.35	2.56	6.31	2.92	6.31	6.33	6.33	4.91	8.65	8.87	11.21	3.40	6.87	6.24	7.00
ABCb	RAL	LPV/rb	1.91	1.69	6.97	2.10	6.97	6.97	6.97	3.60	8.89	8.66	10.57	3.45	8.00	9.20	10.38
ddIEC	RAL	LPV/rq	2.56	1.69	6.64	2.66	6.66	6.64	6.66	4.25	9.20	8.33	10.89	4.11	8.55	8.86	10.94
AZTb	3TCb	ATV/r	0.37	2.30	7.44	2.30	7.44	7.44	7.44	2.67	7.81	9.75	10.11	2.91	7.57	8.37	8.97
ddIq	NVP	ATV	0.84	4.43	5.97	4.46	5.98	6.31	6.32	5.27	6.80	10.40	11.24	5.12	6.57	8.91	9.79
TDF	NVP	ATV	0.86	4.43	5.97	4.43	5.97	6.31	6.31	5.29	6.83	10.40	11.26	5.32	6.32	8.91	9.63
FTC	ddIq	LPV/rb	2.79	0.84	6.97	2.86	6.97	6.98	6.98	3.63	9.76	7.81	10.60	3.10	8.72	7.60	9.23
AZTt	3TCb	ATV/r	0.39	2.30	7.44	2.30	7.44	7.44	7.44	2.70	7.84	9.75	10.14	2.95	7.58	8.37	8.99
ddIEC	LPV/rq	MVC	2.56	6.64	1.72	6.66	2.62	6.64	6.66	9.20	4.28	8.36	10.92	8.55	4.48	6.64	9.13
ETR	ENF	NFVb	6.31	2.07	2.80	6.31	6.41	3.15	6.41	8.38	9.11	4.87	11.18	8.20	10.43	5.17	12.25
FTC	TDF	LPV/rb	2.79	0.86	6.97	2.79	6.97	6.97	6.97	3.65	9.76	7.83	10.62	3.07	8.72	7.41	8.91
ddIb	ABCq	EFV	0.75	2.14	7.35	2.24	7.35	7.35	7.35	2.89	8.10	9.50	10.24	2.38	7.77	8.98	9.11
AZTb	3TCq	ATV/r	0.37	2.35	7.44	2.35	7.44	7.44	7.44	2.72	7.81	9.79	10.16	2.95	7.57	8.39	9.00
ABCq	ETR	NFVt	2.14	6.31	2.76	6.31	3.04	6.40	6.40	8.45	4.90	9.06	11.20	6.66	4.56	10.37	10.93
ddIq	EFV	ENF	0.84	7.35	2.07	7.36	2.26	7.35	7.36	8.19	2.91	9.42	10.26	7.82	2.79	9.20	9.53
AZTt	3TCq	ATV/r	0.39	2.35	7.44	2.35	7.44	7.44	7.44	2.74	7.84	9.79	10.18	2.99	7.58	8.39	9.02
TDF	EFV	ENF	0.86	7.35	2.07	7.35	2.08	7.35	7.35	8.21	2.93	9.42	10.28	7.97	2.62	9.20	9.66
ddIq	ABCb	ATV/r	0.84	1.91	7.44	2.06	7.44	7.44	7.44	2.75	8.28	9.36	10.20	2.20	8.04	8.49	9.04
AZTb	ddIEC	EFV	0.37	2.56	7.35	2.56	7.35	7.36	7.36	2.93	7.72	9.91	10.28	3.41	8.91	8.77	14.33
3TCb	ENF	LPV/rq	2.30	2.07	6.64	2.63	6.64	6.64	6.64	4.37	8.94	8.71	11.01	4.55	7.77	7.88	9.57
TDF	ABCb	ATV/r	0.86	1.91	7.44	1.92	7.44	7.44	7.44	2.77	8.30	9.36	10.22	1.89	7.80	8.49	8.64
ABCq	ETR	NFVb	2.14	6.31	2.80	6.31	3.10	6.41	6.41	8.45	4.94	9.11	11.25	6.66	4.61	10.43	10.98
3TCb	EVG/c	LPV/rb	2.30	1.41	6.97	2.35	6.97	6.97	6.97	3.72	9.28	8.39	10.69	4.06	8.10	9.19	11.06
AZTt	ddIEC	EFV	0.39	2.56	7.35	2.56	7.35	7.36	7.36	2.95	7.75	9.91	10.31	3.46	9.02	8.77	14.42
ddIq	ABCq	EFV	0.84	2.14	7.35	2.25	7.36	7.35	7.36	2.98	8.19	9.50	10.33	2.41	7.82	8.98	9.16
3TCq	ENF	LPV/rq	2.35	2.07	6.64	2.67	6.64	6.64	6.64	4.42	8.99	8.71	11.06	4.60	7.79	7.88	9.61
ddIb	ENF	ATV/r	0.75	2.07	7.44	2.24	7.44	7.44	7.45	2.82	8.19	9.51	10.26	2.71	7.97	9.12	9.62
ENF	RAL	LPV/rb	2.07	1.69	6.97	2.29	6.98	6.97	6.98	3.76	9.04	8.66	10.73	3.96	8.21	9.20	10.76
d4T	ddIEC	ATV/r	0.25	2.56	7.44	2.56	7.44	7.45	7.45	2.81	7.69	10.00	10.25	3.29	7.53	9.27	10.09
TDF	ABCq	EFV	0.86	2.14	7.35	2.14	7.35	7.35	7.35	3.00	8.21	9.50	10.36	2.11	7.97	8.98	9.32
3TCq	EVG/c	LPV/rb	2.35	1.41	6.97	2.39	6.97	6.97	6.97	3.76	9.32	8.39	10.74	4.10	8.12	9.19	11.11
3TCb	ABCq	LPV/rq	2.30	2.14	6.64	2.56	6.64	6.64	6.64	4.45	8.94	8.78	11.09	2.93	7.77	7.79	8.70
d4T	FTC	EFV	0.25	2.79	7.35	2.79	7.35	7.35	7.35	3.04	7.60	10.14	10.39	3.21	8.00	8.63	11.98
d4T	EFV	NFVt	0.25	7.35	2.76	7.35	2.76	7.39	7.39	7.60	3.01	10.11	10.36	8.00	2.92	10.85	12.36
3TCb	ddIb	EFV	2.30	0.75	7.35	2.39	7.35	7.35	7.35	3.05	9.66	8.10	10.40	2.55	8.38	7.77	8.76
FTC	RAL	LPV/rq	2.79	1.69	6.64	2.82	6.64	6.64	6.64	4.48	9.43	8.33	11.12	4.61	8.38	8.86	11.13
3TCb	ETR	NFVt	2.30	6.31	2.76	6.31	3.12	6.40	6.40	8.61	5.06	9.06	11.37	6.86	4.32	10.37	10.97
3TCq	ABCq	LPV/rq	2.35	2.14	6.64	2.59	6.64	6.64	6.64	4.49	8.99	8.78	11.13	2.96	7.79	7.79	8.72
ddIb	ABCq	ATV/r	0.75	2.14	7.44	2.24	7.44	7.44	7.44	2.89	8.19	9.59	10.33	2.38	7.97	8.62	9.11
ddIEC	ABCb	LPV/rq	2.56	1.91	6.64	2.74	6.66	6.64	6.66	4.47	9.20	8.55	11.11	3.11	8.55	7.67	9.23
ABCq	RAL	LPV/rb	2.14	1.69	6.97	2.26	6.97	6.97	6.97	3.83	9.12	8.66	10.80	3.68	8.13	9.20	10.59
FTC	LPV/rq	MVC	2.79	6.64	1.72	6.64	2.80	6.64	6.64	9.43	4.51	8.36	11.15	8.38	4.79	6.64	9.10
ddIq	ENF	ATV/r	0.84	2.07	7.44	2.26	7.44	7.44	7.45	2.91	8.28	9.51	10.35	2.79	8.04	9.12	9.69
d4T	EFV	NFVb	0.25	7.35	2.80	7.35	2.80	7.40	7.40	7.60	3.05	10.15	10.40	8.00	2.96	10.90	12.42
3TCq	ddIb	EFV	2.35	0.75	7.35	2.44	7.35	7.35	7.35	3.10	9.70	8.10	10.45	2.59	8.40	7.77	8.78
3TCq	ETR	NFVt	2.35	6.31	2.76	6.31	3.14	6.40	6.40	8.65	5.11	9.06	11.41	6.87	4.35	10.37	11.00
TDF	ENF	ATV/r	0.86	2.07	7.44	2.08	7.44	7.44	7.44	2.93	8.30	9.51	10.37	2.63	7.80	9.12	9.29
3TCb	ETR	NFVb	2.30	6.31	2.80	6.31	3.17	6.41	6.41	8.61	5.11	9.11	11.41	6.86	4.36	10.43	11.02
AZTb	ddIEC	ATV/r	0.37	2.56	7.44	2.56	7.44	7.45	7.45	2.93	7.81	10.00	10.37	3.41	7.57	9.27	9.91
EFV	EVG/c	MVC	7.35	1.41	1.72	7.35	7.35	1.84	7.35	8.77	9.08	3.14	10.49	8.86	10.23	3.20	11.56
EFV	EVG/c	MVC	7.35	1.41	1.72	7.35	7.35	1.84	7.35	8.77	9.08	3.14	10.49	8.86	10.23	3.20	11.56
AZTt	ddIEC	ATV/r	0.39	2.56	7.44	2.56	7.44	7.45	7.45	2.95	7.84	10.00	10.40	3.46	7.58	9.27	9.94
3TCb	ddIq	EFV	2.30	0.84	7.35	2.41	7.35	7.36	7.36	3.14	9.66	8.19	10.50	2.58	8.38	7.82	8.81
AZTb	FTC	EFV	0.37	2.79	7.35	2.79	7.35	7.35	7.35	3.16	7.72	10.14	10.51	3.55	8.91	8.63	14.69
ddIq	ABCq	ATV/r	0.84	2.14	7.44	2.25	7.44	7.44	7.44	2.98	8.28	9.59	10.42	2.41	8.04	8.62	9.16
3TCq	ETR	NFVb	2.35	6.31	2.80	6.31	3.20	6.41	6.41	8.65	5.15	9.11	11.46	6.87	4.40	10.43	11.05
3TCb	TDF	EFV	2.30	0.86	7.35	2.30	7.35	7.35	7.35	3.16	9.66	8.21	10.52	2.97	8.38	7.97	9.28
AZTb	EFV	NFVt	0.37	7.35	2.76	7.35	2.76	7.39	7.39	7.72	3.12	10.11	10.48	8.91	3.20	10.85	14.81
TDF	ABCq	ATV/r	0.86	2.14	7.44	2.14	7.44	7.44	7.44	3.00	8.30	9.59	10.44	2.11	7.80	8.62	8.72

Regimen[a]			IIP$_{ave}$																
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTt	FTC	EFV	0.39	2.79	7.35	2.79	7.35	7.35	7.35	3.18	7.75	10.14	10.54	3.60	9.02	8.63	14.78
3TCq	ddIq	EFV	2.35	0.84	7.35	2.45	7.35	7.36	7.36	3.19	9.70	8.19	10.54	2.62	8.40	7.82	8.83
AZTt	EFV	NFVt	0.39	7.35	2.76	7.35	2.76	7.39	7.39	7.75	3.15	10.11	10.50	9.02	3.23	10.85	14.89
3TCq	TDF	EFV	2.35	0.86	7.35	2.35	7.35	7.35	7.35	3.21	9.70	8.21	10.56	3.02	8.40	7.97	9.30
AZTb	EFV	NFVb	0.37	7.35	2.80	7.35	2.80	7.40	7.40	7.72	3.17	10.15	10.52	8.91	3.25	10.90	14.88
d4T	FTC	ATV/r	0.25	2.79	7.44	2.79	7.44	7.44	7.44	3.04	7.69	10.23	10.48	3.21	7.53	9.00	9.46
ABCb	ENF	LPV/rb	1.91	2.07	6.97	2.41	6.97	6.98	6.98	3.98	8.89	9.04	10.96	3.62	8.00	8.21	9.38
ddIEC	ENF	LPV/rq	2.56	2.07	6.64	2.94	6.66	6.64	6.66	4.63	9.20	8.71	11.27	4.33	8.55	7.88	9.92
3TCb	ddIb	ATV/r	2.30	0.75	7.44	2.39	7.44	7.44	7.44	3.05	9.75	8.19	10.49	2.55	8.37	7.97	9.00
ddIEC	EVG/c	LPV/rb	2.56	1.41	6.97	2.60	6.99	6.97	6.99	3.97	9.53	8.39	10.95	4.20	8.88	9.19	11.60
3TCb	RAL	LPV/rb	2.30	1.69	6.97	2.39	6.97	6.97	6.97	3.99	9.28	8.66	10.97	4.00	8.10	9.20	10.74
AZTt	EFV	NFVb	0.39	7.35	2.80	7.35	2.80	7.40	7.40	7.75	3.19	10.15	10.55	9.02	3.28	10.90	14.96
3TCq	ddIb	ATV/r	2.35	0.75	7.44	2.44	7.44	7.44	7.44	3.10	9.79	8.19	10.54	2.59	8.39	7.97	9.03
3TCq	RAL	LPV/rb	2.35	1.69	6.97	2.44	6.97	6.97	6.97	4.04	9.32	8.66	11.01	4.04	8.12	9.20	10.78
FTC	ABCb	LPV/rq	2.79	1.91	6.64	2.86	6.64	6.64	6.64	4.70	9.43	8.55	11.34	2.92	8.38	7.67	8.98
FTC	ddIEC	ETR	2.79	2.56	6.31	3.19	6.31	6.33	6.34	5.35	9.10	8.87	11.66	3.86	6.83	6.24	7.05
ddIEC	ABCq	LPV/rq	2.56	2.14	6.64	2.82	6.66	6.64	6.66	4.70	9.20	8.78	11.34	3.21	8.55	7.79	9.35
3TCb	ddIq	ATV/r	2.30	0.84	7.44	2.41	7.44	7.44	7.44	3.14	9.75	8.28	10.59	2.58	8.37	8.04	9.05
ABCb	EFV	EVG/c	1.91	7.35	1.41	7.35	2.02	7.35	7.35	9.27	3.33	8.77	10.68	8.81	3.39	8.86	10.47
AZTb	FTC	ATV/r	0.37	2.79	7.44	2.79	7.44	7.44	7.44	3.16	7.81	10.23	10.60	3.55	7.57	9.00	9.80
3TCb	TDF	ATV/r	2.30	0.86	7.44	2.30	7.44	7.44	7.44	3.16	9.75	8.30	10.61	2.97	8.37	7.80	8.92
ddIEC	ETR	NFVt	2.56	6.31	2.76	6.33	3.48	6.40	6.43	8.87	5.32	9.06	11.62	6.24	4.64	10.37	10.88
AZTt	FTC	ATV/r	0.39	2.79	7.44	2.79	7.44	7.44	7.44	3.18	7.84	10.23	10.63	3.60	7.58	9.00	9.83
3TCq	ddIq	ATV/r	2.35	0.84	7.44	2.45	7.44	7.44	7.44	3.19	9.79	8.28	10.63	2.62	8.39	8.04	9.07
3TCq	TDF	ATV/r	2.35	0.86	7.44	2.35	7.44	7.44	7.44	3.21	9.79	8.30	10.65	3.02	8.39	7.80	8.94
ddIEC	ETR	NFVb	2.56	6.31	2.80	6.33	3.53	6.41	6.44	8.87	5.36	9.11	11.67	6.24	4.69	10.43	10.93
EFV	RAL	MVC	7.35	1.69	1.72	7.35	7.35	1.94	7.35	9.04	9.08	3.41	10.76	9.55	10.23	3.94	12.37
EFV	RAL	MVC	7.35	1.69	1.72	7.35	7.35	1.94	7.35	9.04	9.08	3.41	10.76	9.55	10.23	3.94	12.37
d4T	NVP	LPV/rq	0.25	4.43	6.64	4.43	6.64	6.80	6.80	4.68	6.89	11.07	11.32	4.90	6.80	10.51	11.40
NVP	EVG/c	ATV	4.43	1.41	5.97	4.43	6.31	5.97	6.31	5.85	10.40	7.38	11.81	7.01	8.91	8.10	13.32
ddIEC	TDF	EFV	2.56	0.86	7.35	2.56	7.36	7.35	7.36	3.42	9.91	8.21	10.77	2.51	8.77	7.97	9.20
FTC	ENF	LPV/rq	2.79	2.07	6.64	2.99	6.64	6.64	6.64	4.86	9.43	8.71	11.50	4.39	8.38	7.88	9.76
FTC	EVG/c	LPV/rb	2.79	1.41	6.97	2.80	6.97	6.97	6.97	4.20	9.76	8.39	11.18	4.28	8.72	9.19	11.59
ABCq	ENF	LPV/rb	2.14	2.07	6.97	2.53	6.97	6.98	6.98	4.21	9.12	9.04	11.19	3.82	8.13	8.21	9.53
3TCb	ABCb	LPV/rb	2.30	1.91	6.97	2.47	6.97	6.97	6.97	4.22	9.28	8.89	11.19	2.82	8.10	8.00	8.94
3TCb	ddIEC	LPV/rq	2.30	2.56	6.64	2.91	6.64	6.66	6.66	4.86	8.94	9.20	11.50	3.38	7.77	8.55	9.36
EFV	ENF	EVG/c	7.35	2.07	1.41	7.35	7.35	2.20	7.35	9.42	8.77	3.48	10.84	9.20	8.86	3.46	10.76
3TCq	ABCb	LPV/rb	2.35	1.91	6.97	2.51	6.97	6.97	6.97	4.26	9.32	8.89	11.24	2.86	8.12	8.00	8.96
ddIEC	RAL	LPV/rb	2.56	1.69	6.97	2.66	6.99	6.97	6.99	4.25	9.53	8.66	11.22	4.11	8.88	9.20	11.28
3TCq	ddIEC	LPV/rq	2.35	2.56	6.64	2.92	6.64	6.66	6.66	4.91	8.99	9.20	11.55	3.40	7.79	8.55	9.38
ABCb	EVG/c	ATV/r	1.91	1.41	7.44	2.02	7.44	7.44	7.44	3.33	9.36	8.86	10.77	3.39	8.49	9.57	10.95
FTC	ABCq	LPV/rq	2.79	2.14	6.64	2.90	6.64	6.64	6.64	4.93	9.43	8.78	11.57	2.97	8.38	7.79	9.10
AZTb	NVP	LPV/rq	0.37	4.43	6.64	4.43	6.64	6.80	6.80	4.80	7.01	11.07	11.44	5.28	7.14	10.51	13.07
FTC	ddIb	EFV	2.79	0.75	7.35	2.85	7.35	7.35	7.35	3.54	10.14	8.10	10.89	3.06	8.63	7.77	9.03
ddIb	EFV	NFVt	0.75	7.35	2.76	7.35	2.92	7.39	7.40	8.10	3.50	10.11	10.86	7.77	3.29	10.85	10.58
FTC	ETR	NFVt	2.79	6.31	2.76	6.31	3.38	6.40	6.41	9.10	5.55	9.06	11.85	6.83	4.99	10.37	11.43
AZTt	NVP	LPV/rq	0.39	4.43	6.64	4.43	6.64	6.80	6.80	4.83	7.03	11.07	11.46	5.33	7.17	10.51	13.12
ABCq	EFV	EVG/c	2.14	7.35	1.41	7.35	2.20	7.35	7.35	9.50	3.56	8.77	10.91	8.98	3.62	8.86	10.68
ddIb	EFV	NFVb	0.75	7.35	2.80	7.35	2.96	7.40	7.40	8.10	3.55	10.15	10.90	7.77	3.33	10.90	10.63
ABCb	EFV	RAL	1.91	7.35	1.69	7.35	2.10	7.35	7.35	9.27	3.60	9.04	10.95	8.81	3.45	9.55	11.03
FTC	ETR	NFVb	2.79	6.31	2.80	6.31	3.44	6.41	6.41	9.10	5.59	9.11	11.90	6.83	5.04	10.43	11.48
ddIEC	TDF	ATV/r	2.56	0.86	7.44	2.56	7.45	7.44	7.45	3.42	10.00	8.30	10.86	2.51	9.27	7.80	9.15
3TCb	ENF	LPV/rb	2.30	2.07	6.97	2.63	6.97	6.98	6.98	4.37	9.28	9.04	11.35	4.55	8.10	8.21	9.89
FTC	ddIq	EFV	2.79	0.84	7.35	2.86	7.35	7.36	7.36	3.63	10.14	8.19	10.98	3.10	8.63	7.82	9.07
ABCb	EFV	MVC	1.91	7.35	1.72	7.35	2.07	7.35	7.35	9.27	3.64	9.08	10.99	8.81	4.16	10.23	11.95
ABCb	EFV	MVC	1.91	7.35	1.72	7.35	2.07	7.35	7.35	9.27	3.64	9.08	10.99	8.81	4.16	10.23	11.95
ddIq	EFV	NFVt	0.84	7.35	2.76	7.36	2.93	7.39	7.40	8.19	3.60	10.11	10.95	7.82	3.35	10.85	10.66
FTC	TDF	EFV	2.79	0.86	7.35	2.79	7.35	7.35	7.35	3.65	10.14	8.21	11.00	3.07	8.63	7.97	9.33
TDF	EFV	NFVt	0.86	7.35	2.76	7.35	2.76	7.39	7.39	8.21	3.62	10.11	10.97	7.97	3.16	10.85	10.80
3TCq	ENF	LPV/rb	2.35	2.07	6.97	2.67	6.97	6.98	6.98	4.42	9.32	9.04	11.39	4.60	8.12	8.21	9.92
ENF	EVG/c	ATV/r	2.07	1.41	7.44	2.20	7.44	7.44	7.44	3.48	9.51	8.86	10.93	3.46	9.12	9.57	11.40
ddIq	EFV	NFVb	0.84	7.35	2.80	7.36	2.98	7.40	7.40	8.19	3.64	10.15	10.99	7.82	3.40	10.90	10.71
3TCb	ABCq	LPV/rb	2.30	2.14	6.97	2.56	6.97	6.97	6.97	4.45	9.28	9.12	11.42	2.93	8.10	8.13	9.04
NVP	RAL	ATV	4.43	1.69	5.97	4.43	6.31	5.97	6.31	6.12	10.40	7.65	12.09	6.36	8.91	8.52	12.59
TDF	EFV	NFVb	0.86	7.35	2.80	7.35	2.80	7.40	7.40	8.21	3.66	10.15	11.01	7.97	3.20	10.90	10.85
FTC	ddIb	ATV/r	2.79	0.75	7.44	2.85	7.44	7.44	7.45	3.54	10.23	8.19	10.98	3.06	9.00	7.97	9.50
FTC	RAL	LPV/rb	2.79	1.69	6.97	2.82	6.97	6.97	6.97	4.48	9.76	8.66	11.45	4.61	8.72	9.20	11.46
3TCb	EFV	EVG/c	2.30	7.35	1.41	7.35	2.35	7.35	7.35	9.66	3.72	8.77	11.07	8.38	4.06	8.86	10.54
ddIEC	ABCb	LPV/rb	2.56	1.91	6.97	2.74	6.99	6.97	6.99	4.47	9.53	8.89	11.45	3.11	8.88	8.00	9.57
3TCq	ABCq	LPV/rb	2.35	2.14	6.97	2.59	6.97	6.97	6.97	4.49	9.32	9.12	11.47	2.96	8.12	8.13	9.06

Regimen[a]			IIP_ave														
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
ABCq	EVG/c	ATV/r	2.14	1.41	7.44	2.20	7.44	7.44	7.44	3.56	9.59	8.86	11.00	3.62	8.62	9.57	11.18
EFV	ENF	RAL	7.35	2.07	1.69	7.35	7.35	2.29	7.35	9.42	9.04	3.76	11.11	9.20	9.55	3.96	11.52
3TCq	EFV	EVG/c	2.35	7.35	1.41	7.35	2.39	7.35	7.35	9.70	3.76	8.77	11.12	8.40	4.10	8.86	10.58
ABCb	RAL	ATV/r	1.91	1.69	7.44	2.10	7.44	7.44	7.44	3.60	9.36	9.13	11.04	3.45	8.49	10.00	11.21
EFV	ENF	MVC	7.35	2.07	1.72	7.35	7.35	2.26	7.35	9.42	9.08	3.79	11.15	9.20	10.23	4.70	12.50
EFV	ENF	MVC	7.35	2.07	1.72	7.35	7.35	2.26	7.35	9.42	9.08	3.79	11.15	9.20	10.23	4.70	12.50
FTC	ddIq	ATV/r	2.79	0.84	7.44	2.86	7.44	7.44	7.45	3.63	10.23	8.28	11.07	3.10	9.00	8.04	9.56
FTC	TDF	ATV/r	2.79	0.86	7.44	2.79	7.44	7.44	7.44	3.65	10.23	8.30	11.09	3.07	9.00	7.80	9.15
ABCq	EFV	RAL	2.14	7.35	1.69	7.35	2.26	7.35	7.35	9.50	3.83	9.04	11.18	8.98	3.68	9.55	11.25
ABCq	EFV	MVC	2.14	7.35	1.72	7.35	2.23	7.35	7.35	9.50	3.87	9.08	11.22	8.98	4.41	10.23	12.23
ABCq	EFV	MVC	2.14	7.35	1.72	7.35	2.23	7.35	7.35	9.50	3.87	9.08	11.22	8.98	4.41	10.23	12.23
ddIEC	ENF	LPV/rb	2.56	2.07	6.97	2.94	6.99	6.98	6.99	4.63	9.53	9.04	11.60	4.33	8.88	8.21	10.24
3TCb	EVG/c	ATV/r	2.30	1.41	7.44	2.35	7.44	7.44	7.44	3.72	9.75	8.86	11.16	4.06	8.37	9.57	11.30
ddIb	NVP	LPV/rq	0.75	4.43	6.64	4.45	6.64	6.80	6.80	5.18	7.39	11.07	11.82	5.05	7.20	10.51	10.91
ABCb	NVP	ATV	1.91	4.43	5.97	4.44	5.97	6.31	6.31	6.35	7.88	10.40	12.31	5.63	7.02	8.91	9.94
ENF	RAL	ATV/r	2.07	1.69	7.44	2.29	7.44	7.44	7.44	3.76	9.51	9.13	11.20	3.96	9.12	10.00	11.85
3TCq	EVG/c	ATV/r	2.35	1.41	7.44	2.39	7.44	7.44	7.44	3.76	9.79	8.86	11.21	4.10	8.39	9.57	11.35
FTC	ABCb	LPV/rb	2.79	1.91	6.97	2.86	6.97	6.97	6.97	4.70	9.76	8.89	11.68	2.92	8.72	8.00	9.33
FTC	ddIEC	LPV/rq	2.79	2.56	6.64	3.19	6.64	6.66	6.66	5.35	9.43	9.20	11.99	3.86	8.38	8.55	9.94
ddIEC	ABCq	LPV/rb	2.56	2.14	6.97	2.82	6.99	6.97	6.99	4.70	9.53	9.12	11.68	3.21	8.88	8.13	9.69
ddIEC	EFV	EVG/c	2.56	7.35	1.41	7.36	2.60	7.35	7.36	9.91	3.97	8.77	11.33	8.77	4.20	8.86	10.85
ABCb	EFV	ENF	1.91	7.35	2.07	7.35	2.41	7.35	7.35	9.27	3.98	9.42	11.34	8.81	3.61	9.20	10.61
3TCb	EFV	RAL	2.30	7.35	1.69	7.35	2.39	7.35	7.35	9.66	3.99	9.04	11.35	8.38	4.00	9.55	11.03
ddIq	NVP	LPV/rq	0.84	4.43	6.64	4.46	6.64	6.80	6.80	5.27	7.48	11.07	11.91	5.12	7.26	10.51	10.98
ABCq	RAL	ATV/r	2.14	1.69	7.44	2.26	7.44	7.44	7.44	3.83	9.59	9.13	11.27	3.68	8.62	10.00	11.43
TDF	NVP	LPV/rq	0.86	4.43	6.64	4.43	6.64	6.80	6.80	5.29	7.50	11.07	11.93	5.32	7.07	10.51	10.87
3TCb	EFV	MVC	2.30	7.35	1.72	7.35	2.36	7.35	7.35	9.66	4.03	9.08	11.38	8.38	5.28	10.23	12.42
d4T	NVP	LPV/rb	0.25	4.43	6.97	4.43	6.97	7.09	7.09	4.68	7.22	11.41	11.66	4.90	7.13	10.84	11.70
3TCq	EFV	RAL	2.35	7.35	1.69	7.35	2.44	7.35	7.35	9.70	4.04	9.04	11.39	8.40	4.04	9.55	11.07
3TCq	EFV	MVC	2.35	7.35	1.72	7.35	2.41	7.35	7.35	9.70	4.07	9.08	11.43	8.40	5.32	10.23	12.48
NVP	ENF	ATV	4.43	2.07	5.97	4.47	6.31	5.98	6.32	6.50	10.40	8.04	12.47	6.17	8.91	7.65	10.92
FTC	ENF	LPV/rb	2.79	2.07	6.97	2.99	6.97	6.98	6.98	4.86	9.76	9.04	11.83	4.39	8.72	8.21	10.08
3TCb	ddIEC	LPV/rb	2.30	2.56	6.97	2.91	6.97	6.99	6.99	4.86	9.28	9.53	11.84	3.38	8.10	8.88	9.70
ABCq	NVP	ATV	2.14	4.43	5.97	4.44	5.97	6.31	6.31	6.58	8.11	10.40	12.54	5.77	7.14	8.91	10.08
AZTb	NVP	LPV/rb	0.37	4.43	6.97	4.43	6.97	7.09	7.09	4.80	7.34	11.41	11.77	5.28	7.47	10.84	13.39
ABCb	ENF	ATV/r	1.91	2.07	7.44	2.41	7.44	7.44	7.44	3.98	9.36	9.51	11.43	3.62	8.49	9.12	10.23
ddIEC	EVG/c	ATV/r	2.56	1.41	7.44	2.60	7.45	7.44	7.45	3.97	10.00	8.86	11.42	4.20	9.27	9.57	11.91
3TCq	ddIEC	LPV/rb	2.35	2.56	6.97	2.92	6.97	6.99	6.99	4.91	9.32	9.53	11.88	3.40	8.12	8.88	9.72
3TCb	RAL	ATV/r	2.30	1.69	7.44	2.39	7.44	7.44	7.44	3.99	9.75	9.13	11.43	4.00	8.37	10.00	11.47
FTC	ABCq	LPV/rb	2.79	2.14	6.97	2.90	6.97	6.97	6.97	4.93	9.76	9.12	11.91	2.97	8.72	8.13	9.44
AZTt	NVP	LPV/rb	0.39	4.43	6.97	4.43	6.97	7.09	7.09	4.83	7.37	11.41	11.80	5.33	7.51	10.84	13.44
FTC	EFV	EVG/c	2.79	7.35	1.41	7.35	2.80	7.35	7.35	10.14	4.20	8.77	11.56	8.63	4.28	8.77	10.82
EFV	EVG/c	NFVt	7.35	1.41	2.76	7.35	7.39	2.82	7.39	8.77	10.11	4.17	11.52	8.86	10.85	4.61	12.38
ABCq	EFV	ENF	2.14	7.35	2.07	7.35	2.53	7.35	7.35	9.50	4.21	9.42	11.57	8.98	3.82	9.20	10.79
3TCq	RAL	ATV/r	2.35	1.69	7.44	2.44	7.44	7.44	7.44	4.04	9.79	9.13	11.48	4.04	8.39	10.00	11.51
3TCb	ABCb	EFV	2.30	1.91	7.35	2.47	7.35	7.35	7.35	4.22	9.66	9.27	11.57	2.82	8.38	8.81	9.67
ddIEC	EFV	RAL	2.56	7.35	1.69	7.36	2.66	7.35	7.36	9.91	4.25	9.04	11.60	8.77	4.11	9.55	11.34
EFV	EVG/c	NFVb	7.35	1.41	2.80	7.35	7.40	2.88	7.40	8.77	10.15	4.22	11.57	8.86	10.90	4.65	12.43
3TCq	ABCb	EFV	2.35	1.91	7.35	2.51	7.35	7.35	7.35	4.26	9.70	9.27	11.62	2.86	8.40	8.81	9.69
ddIEC	EFV	MVC	2.56	7.35	1.72	7.36	2.62	7.35	7.36	9.91	4.28	9.08	11.64	8.77	4.48	10.23	12.26
3TCb	NVP	ATV	2.30	4.43	5.97	4.45	5.97	6.31	6.31	6.74	8.27	10.40	12.70	5.71	6.90	8.91	9.76
3TCq	NVP	ATV	2.35	4.43	5.97	4.45	5.97	6.31	6.31	6.78	8.32	10.40	12.75	5.74	6.92	8.91	9.78
3TCb	EFV	ENF	2.30	7.35	2.07	7.35	2.63	7.35	7.35	9.66	4.37	9.42	11.73	8.38	4.55	9.20	10.71
FTC	EVG/c	ATV/r	2.79	1.41	7.44	2.80	7.44	7.44	7.44	4.20	10.23	8.86	11.65	4.28	9.00	9.57	11.85
ABCq	ENF	ATV/r	2.14	2.07	7.44	2.53	7.44	7.44	7.44	4.21	9.59	9.51	11.66	3.82	8.62	9.12	10.38
3TCb	ABCb	ATV/r	2.30	1.91	7.44	2.47	7.44	7.44	7.44	4.22	9.75	9.36	11.66	2.82	8.37	8.49	9.29
3TCq	EFV	ENF	2.35	7.35	2.07	7.35	2.67	7.35	7.35	9.70	4.42	9.42	11.77	8.40	4.60	9.20	10.75
ddIEC	RAL	ATV/r	2.56	1.69	7.44	2.66	7.45	7.44	7.45	4.25	10.00	9.13	11.69	4.11	9.27	10.00	12.08
3TCq	ABCb	ATV/r	2.35	1.91	7.44	2.51	7.44	7.44	7.44	4.26	9.79	9.36	11.71	2.86	8.39	8.49	9.30
3TCb	ABCq	EFV	2.30	2.14	7.35	2.56	7.35	7.35	7.35	4.45	9.66	9.50	11.80	2.93	8.38	8.98	9.80
FTC	EFV	RAL	2.79	7.35	1.69	7.35	2.82	7.35	7.35	10.14	4.48	9.04	11.83	8.63	4.61	9.55	11.56
ddIEC	ABCb	EFV	2.56	1.91	7.35	2.74	7.36	7.35	7.36	4.47	9.91	9.27	11.83	3.11	8.77	8.81	10.00
EFV	RAL	NFVt	7.35	1.69	2.76	7.35	7.39	2.87	7.39	9.04	10.11	4.44	11.80	9.55	10.85	5.85	13.66
3TCq	ABCq	EFV	2.35	2.14	7.35	2.59	7.35	7.35	7.35	4.49	9.70	9.50	11.85	2.96	8.40	8.98	9.82
FTC	EFV	MVC	2.79	7.35	1.72	7.35	2.80	7.35	7.35	10.14	4.51	9.08	11.87	8.63	4.79	10.23	12.43
EFV	RAL	NFVb	7.35	1.69	2.80	7.35	7.40	2.93	7.40	9.04	10.15	4.49	11.84	9.55	10.90	5.88	13.73
ddIb	NVP	LPV/rb	0.75	4.43	6.97	4.45	6.98	7.09	7.09	5.18	7.72	11.41	12.15	5.05	7.53	10.84	11.23
3TCb	ENF	ATV/r	2.30	2.07	7.44	2.63	7.44	7.44	7.44	4.37	9.75	9.51	11.82	4.55	8.37	9.12	10.58
NVP	EVG/c	LPV/rq	4.43	1.41	6.64	4.43	6.80	6.64	6.80	5.85	11.07	8.05	12.49	7.01	10.51	8.86	14.52
3TCq	ENF	ATV/r	2.35	2.07	7.44	2.67	7.44	7.44	7.44	4.42	9.79	9.51	11.86	4.60	8.39	9.12	10.61

Regimen[a]			IIP_{ave}																
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
ddIEC	NVP	ATV	2.56	4.43	5.97	4.57	6.03	6.31	6.35	6.99	8.53	10.40	12.96	6.55	7.81	8.91	11.06
FTC	ddIEC	LPV/rb	2.79	2.56	6.97	3.19	6.97	6.99	6.99	5.35	9.76	9.53	12.32	3.86	8.72	8.88	10.28
3TCb	ABCq	ATV/r	2.30	2.14	7.44	2.56	7.44	7.44	7.44	4.45	9.75	9.59	11.89	2.93	8.37	8.62	9.38
ddIq	NVP	LPV/rb	0.84	4.43	6.97	4.46	6.98	7.09	7.09	5.27	7.81	11.41	12.24	5.12	7.60	10.84	11.30
ddIEC	EFV	ENF	2.56	7.35	2.07	7.36	2.94	7.35	7.36	9.91	4.63	9.42	11.98	8.77	4.33	9.20	10.81
TDF	NVP	LPV/rb	0.86	4.43	6.97	4.43	6.97	7.09	7.09	5.29	7.83	11.41	12.27	5.32	7.41	10.84	11.18
FTC	RAL	ATV/r	2.79	1.69	7.44	2.82	7.44	7.44	7.44	4.48	10.23	9.13	11.92	4.61	9.00	10.00	12.22
ddIEC	ABCb	ATV/r	2.56	1.91	7.44	2.74	7.45	7.44	7.45	4.47	10.00	9.36	11.92	3.11	9.27	8.49	10.00
3TCq	ABCq	ATV/r	2.35	2.14	7.44	2.59	7.44	7.44	7.44	4.49	9.79	9.59	11.93	2.96	8.39	8.62	9.40
FTC	ABCb	EFV	2.79	1.91	7.35	2.86	7.35	7.35	7.35	4.70	10.14	9.27	12.06	2.92	8.63	8.81	9.84
ddIEC	ABCq	EFV	2.56	2.14	7.35	2.82	7.36	7.35	7.36	4.70	9.91	9.50	12.06	3.21	8.77	8.98	10.13
ABCb	EFV	NFVt	1.91	7.35	2.76	7.35	2.96	7.39	7.39	9.27	4.67	10.11	12.02	8.81	4.36	10.85	12.04
ABCb	EFV	NFVb	1.91	7.35	2.80	7.35	3.03	7.40	7.40	9.27	4.72	10.15	12.07	8.81	4.41	10.90	12.08
FTC	NVP	ATV	2.79	4.43	5.97	4.48	5.98	6.31	6.32	7.22	8.76	10.40	13.19	6.21	7.53	8.91	10.50
ddIEC	ENF	ATV/r	2.56	2.07	7.44	2.94	7.45	7.44	7.46	4.63	10.00	9.51	12.07	4.33	9.27	9.12	11.03
NVP	RAL	LPV/rq	4.43	1.69	6.64	4.43	6.80	6.64	6.80	6.12	11.07	8.33	12.76	6.36	10.51	8.86	13.31
FTC	EFV	ENF	2.79	7.35	2.07	7.35	2.99	7.35	7.35	10.14	4.86	9.42	12.21	8.63	4.39	9.20	10.73
EFV	ENF	NFVt	7.35	2.07	2.76	7.35	7.39	3.16	7.39	9.42	10.11	4.83	12.18	9.20	10.85	5.11	12.72
3TCb	ddIEC	EFV	2.30	2.56	7.35	2.91	7.35	7.36	7.36	4.86	9.66	9.91	12.22	3.38	8.38	8.77	9.58
FTC	ABCb	ATV/r	2.79	1.91	7.44	2.86	7.44	7.44	7.44	4.70	10.23	9.36	12.15	2.92	9.00	8.49	9.70
NVP	LPV/rq	MVC	4.43	6.64	1.72	6.80	4.43	6.64	6.80	11.07	6.16	8.36	12.80	10.51	7.26	6.64	11.97
ddIEC	ABCq	ATV/r	2.56	2.14	7.44	2.82	7.45	7.44	7.45	4.70	10.00	9.59	12.15	3.21	9.27	8.62	10.13
EFV	ENF	NFVb	7.35	2.07	2.80	7.35	7.40	3.15	7.40	9.42	10.15	4.87	12.23	9.20	10.90	5.17	12.77
3TCq	ddIEC	EFV	2.35	2.56	7.35	2.92	7.35	7.36	7.36	4.91	9.70	9.91	12.26	3.40	8.40	8.77	9.60
FTC	ABCq	EFV	2.79	2.14	7.35	2.90	7.35	7.35	7.35	4.93	10.14	9.50	12.29	2.97	8.63	8.98	9.97
ABCq	EFV	NFVt	2.14	7.35	2.76	7.35	3.04	7.39	7.39	9.50	4.90	10.11	12.25	8.98	4.56	10.85	12.25
d4T	NVP	ATV/r	0.25	4.43	7.44	4.43	7.44	7.53	7.53	4.68	7.69	11.88	12.12	4.90	7.53	10.29	11.25
ABCq	EFV	NFVb	2.14	7.35	2.80	7.35	3.10	7.40	7.40	9.50	4.94	10.15	12.30	8.98	4.61	10.90	12.30
d4T	ETR	ATV	0.25	6.31	5.97	6.30	5.97	7.22	7.22	6.55	6.22	12.27	12.52	6.75	6.06	11.14	12.29
FTC	ENF	ATV/r	2.79	2.07	7.44	2.99	7.44	7.44	7.44	4.86	10.23	9.51	12.30	4.39	9.00	9.12	10.83
3TCb	ddIEC	ATV/r	2.30	2.56	7.44	2.91	7.44	7.45	7.45	4.86	9.75	10.00	12.31	3.38	8.37	9.27	9.95
AZTb	NVP	ATV/r	0.37	4.43	7.44	4.43	7.44	7.53	7.53	4.80	7.81	11.88	12.24	5.28	7.57	10.29	11.86
ABCb	NVP	LPV/rq	1.91	4.43	6.64	4.44	6.64	6.80	6.80	6.35	8.55	11.07	12.99	5.63	7.67	10.51	11.16
AZTt	NVP	ATV/r	0.39	4.43	7.44	4.43	7.44	7.53	7.53	4.83	7.84	11.88	12.27	5.33	7.58	10.29	11.90
3TCq	ddIEC	ATV/r	2.35	2.56	7.44	2.92	7.44	7.45	7.45	4.91	9.79	10.00	12.35	3.40	8.39	9.27	9.97
3TCb	EFV	NFVt	2.30	7.35	2.76	7.35	3.12	7.39	7.39	9.66	5.06	10.11	12.41	8.38	4.32	10.85	11.70
FTC	ABCq	ATV/r	2.79	2.14	7.44	2.90	7.44	7.44	7.44	4.93	10.23	9.59	12.38	2.97	9.00	8.62	9.81
3TCq	EFV	NFVt	2.35	7.35	2.76	7.35	3.14	7.39	7.39	9.70	5.11	10.11	12.46	8.40	4.35	10.85	11.74
3TCb	EFV	NFVb	2.30	7.35	2.80	7.35	3.17	7.40	7.40	9.66	5.11	10.15	12.46	8.38	4.36	10.90	11.75
AZTb	ETR	ATV	0.37	6.31	5.97	6.30	5.97	7.22	7.22	6.67	6.33	12.27	12.64	7.69	6.09	11.14	15.81
AZTt	ETR	ATV	0.39	6.31	5.97	6.30	5.97	7.22	7.22	6.70	6.36	12.27	12.66	7.78	6.10	11.14	15.89
3TCq	EFV	NFVb	2.35	7.35	2.80	7.35	3.20	7.40	7.40	9.70	5.15	10.15	12.50	8.40	4.40	10.90	11.78
NVP	EVG/c	LPV/rb	4.43	1.41	6.97	4.43	7.09	6.97	7.09	5.85	11.41	8.39	12.82	7.01	10.84	9.19	14.85
NVP	ENF	LPV/rq	4.43	2.07	6.64	4.47	6.80	6.64	6.80	6.50	11.07	8.71	13.14	6.17	10.51	7.88	11.71
ABCq	NVP	LPV/rq	2.14	4.43	6.64	4.44	6.64	6.80	6.80	6.58	8.78	11.07	13.22	5.77	7.79	10.51	11.31
FTC	ddIEC	EFV	2.79	2.56	7.35	3.19	7.35	7.36	7.36	5.35	10.14	9.91	12.70	3.86	8.63	8.77	9.88
ddIEC	EFV	NFVt	2.56	7.35	2.76	7.36	3.48	7.39	7.40	9.91	5.32	10.11	12.67	8.77	4.64	10.85	12.09
ddIEC	EFV	NFVb	2.56	7.35	2.80	7.36	3.53	7.40	7.41	9.91	5.36	10.15	12.71	8.77	4.69	10.90	12.13
ddIb	NVP	ATV/r	0.75	4.43	7.44	4.45	7.44	7.53	7.53	5.18	8.19	11.88	12.62	5.05	7.97	10.29	11.10
3TCb	NVP	LPV/rq	2.30	4.43	6.64	4.45	6.64	6.80	6.80	6.74	8.94	11.07	13.38	5.71	7.77	10.51	11.21
NVP	RAL	LPV/rb	4.43	1.69	6.97	4.43	7.09	6.97	7.09	6.12	11.41	8.66	13.09	6.36	10.84	9.20	13.65
3TCq	NVP	LPV/rq	2.35	4.43	6.64	4.45	6.64	6.80	6.80	6.78	8.99	11.07	13.42	5.74	7.79	10.51	11.24
ddIb	ETR	ATV	0.75	6.31	5.97	6.31	5.98	7.22	7.23	7.05	6.71	12.27	13.02	6.28	6.50	11.14	10.39
FTC	ddIEC	ATV/r	2.79	2.56	7.44	3.19	7.44	7.45	7.46	5.35	10.23	10.00	12.79	3.86	9.00	9.27	10.55
ddIq	NVP	ATV/r	0.84	4.43	7.44	4.46	7.44	7.53	7.53	5.27	8.28	11.88	12.71	5.12	8.04	10.29	11.17
TDF	NVP	ATV/r	0.86	4.43	7.44	4.43	7.44	7.53	7.53	5.29	8.30	11.88	12.73	5.32	7.80	10.29	10.92
FTC	EFV	NFVt	2.79	7.35	2.76	7.35	3.38	7.39	7.39	10.14	5.55	10.11	12.90	8.63	4.99	10.85	12.22
ddIq	ETR	ATV	0.84	6.31	5.97	6.31	5.98	7.22	7.23	7.14	6.80	12.27	13.11	6.28	6.57	11.14	10.45
FTC	EFV	NFVb	2.79	7.35	2.80	7.35	3.44	7.40	7.40	10.14	5.59	10.15	12.94	8.63	5.04	10.90	12.27
TDF	ETR	ATV	0.86	6.31	5.97	6.30	5.97	7.22	7.22	7.16	6.83	12.27	13.13	6.44	6.32	11.14	10.27
ABCb	NVP	LPV/rb	1.91	4.43	6.97	4.44	6.97	7.09	7.09	6.35	8.89	11.41	13.32	5.63	8.00	10.84	11.48
ddIEC	NVP	LPV/rq	2.56	4.43	6.64	4.57	6.66	6.80	6.82	6.99	9.20	11.07	13.63	6.55	8.55	10.51	12.37
NVP	ENF	LPV/rb	4.43	2.07	6.97	4.47	7.09	6.98	7.09	6.50	11.41	9.04	13.48	6.17	10.84	8.21	12.02
ABCq	NVP	LPV/rb	2.14	4.43	6.97	4.44	6.97	7.09	7.09	6.58	9.12	11.41	13.55	5.77	8.13	10.84	11.63
d4T	ETR	LPV/rq	0.25	6.31	6.64	6.30	6.64	7.45	7.45	6.55	6.89	12.94	13.19	6.75	6.80	11.95	13.36
FTC	NVP	LPV/rq	2.79	4.43	6.64	4.48	6.64	6.80	6.80	7.22	9.43	11.07	13.86	6.21	8.38	10.51	11.95
AZTb	ETR	LPV/rq	0.37	6.31	6.64	6.30	6.64	7.45	7.45	6.67	7.01	12.94	13.31	7.69	7.14	11.95	18.04
AZTt	ETR	LPV/rq	0.39	6.31	6.64	6.30	6.64	7.45	7.45	6.70	7.03	12.94	13.34	7.78	7.17	11.95	18.12
3TCb	NVP	LPV/rb	2.30	4.43	6.97	4.45	6.97	7.09	7.09	6.74	9.28	11.41	13.71	5.71	8.10	10.84	11.53
NVP	EVG/c	ATV/r	4.43	1.41	7.44	4.43	7.53	7.44	7.53	5.85	11.88	8.86	13.29	7.01	10.29	9.57	14.75

Regimen[a]			IIP_ave														
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
3TCq	NVP	LPV/rb	2.35	4.43	6.97	4.45	6.97	7.09	7.09	6.78	9.32	11.41	13.76	5.74	8.12	10.84	11.56
ETR	EVG/c	ATV	6.31	1.41	5.97	6.30	7.22	5.97	7.22	7.72	12.27	7.38	13.69	7.55	11.14	8.10	13.86
ddIEC	NVP	LPV/rb	2.56	4.43	6.97	4.57	6.99	7.09	7.10	6.99	9.53	11.41	13.97	6.55	8.88	10.84	12.69
NVP	RAL	ATV/r	4.43	1.69	7.44	4.43	7.53	7.44	7.53	6.12	11.88	9.13	13.56	6.36	10.29	10.00	14.09
ddIb	ETR	LPV/rq	0.75	6.31	6.64	6.31	6.64	7.45	7.45	7.05	7.39	12.94	13.69	6.28	7.20	11.95	11.12
d4T	ETR	LPV/rb	0.25	6.31	6.97	6.30	6.97	7.61	7.61	6.55	7.22	13.28	13.53	6.75	7.13	12.26	13.66
AZTb	d4T	DRV/rq	0.37	0.25	10.28	0.45	10.28	10.28	10.28	0.62	10.64	10.53	10.89	0.45	10.51	10.50	10.74
ETR	RAL	ATV	6.31	1.69	5.97	6.30	7.22	5.97	7.22	7.99	12.27	7.65	13.96	7.73	11.14	8.52	14.13
AZTt	d4T	DRV/rq	0.39	0.25	10.28	0.47	10.28	10.28	10.28	0.64	10.67	10.53	10.92	0.47	10.52	10.50	10.75
ddIq	ETR	LPV/rq	0.84	6.31	6.64	6.31	6.64	7.45	7.45	7.14	7.48	12.94	13.78	6.28	7.26	11.95	11.17
TDF	ETR	LPV/rq	0.86	6.31	6.64	6.30	6.64	7.45	7.45	7.16	7.50	12.94	13.80	6.44	7.07	11.95	11.04
AZTb	ETR	LPV/rb	0.37	6.31	6.97	6.30	6.97	7.61	7.61	6.67	7.34	13.28	13.65	7.69	7.47	12.26	18.41
FTC	NVP	LPV/rb	2.79	4.43	6.97	4.48	6.97	7.09	7.09	7.22	9.76	11.41	14.20	6.21	8.72	10.84	12.27
AZTt	ETR	LPV/rb	0.39	6.31	6.97	6.30	6.97	7.61	7.61	6.70	7.37	13.28	13.67	7.78	7.51	12.26	18.50
ABCb	NVP	ATV/r	1.91	4.43	7.44	4.44	7.44	7.53	7.53	6.35	9.36	11.88	13.79	5.63	8.49	10.29	11.30
d4T	EFV	ATV	0.25	7.35	5.97	7.35	5.97	7.83	7.83	7.60	6.22	13.32	13.57	8.00	6.06	11.89	14.86
ABCb	ETR	ATV	1.91	6.31	5.97	6.31	5.97	7.22	7.22	8.22	7.88	12.27	14.19	6.62	7.02	11.14	11.04
NVP	ENF	ATV/r	4.43	2.07	7.44	4.47	7.53	7.44	7.53	6.50	11.88	9.51	13.95	6.17	10.29	9.12	12.32
AZTb	EFV	ATV	0.37	7.35	5.97	7.35	5.97	7.83	7.83	7.72	6.33	13.32	13.69	8.91	6.09	11.89	18.38
AZTt	EFV	ATV	0.39	7.35	5.97	7.35	5.97	7.83	7.83	7.75	6.36	13.32	13.71	9.02	6.10	11.89	18.47
d4T	ddIb	DRV/rq	0.25	0.75	10.28	0.82	10.28	10.28	10.28	0.99	10.53	11.02	11.27	1.34	10.50	10.64	11.09
ABCq	NVP	ATV/r	2.14	4.43	7.44	4.44	7.44	7.53	7.53	6.58	9.59	11.88	14.02	5.77	8.62	10.29	11.44
ETR	ENF	ATV	6.31	2.07	5.97	6.31	7.22	5.98	7.23	8.38	12.27	8.04	14.34	8.20	11.14	7.65	13.12
ABCq	ETR	ATV	2.14	6.31	5.97	6.31	5.97	7.22	7.22	8.45	8.11	12.27	14.41	6.66	7.14	11.14	11.17
ddIb	ETR	LPV/rb	0.75	6.31	6.97	6.31	6.98	7.61	7.62	7.05	7.72	13.28	14.02	6.28	7.53	12.26	11.41
d4T	ddIq	DRV/rq	0.25	0.84	10.28	0.90	10.28	10.28	10.28	1.09	10.53	11.12	11.36	1.45	10.50	10.68	11.18
d4T	TDF	DRV/rq	0.25	0.86	10.28	0.87	10.28	10.28	10.28	1.11	10.53	11.14	11.39	1.67	10.50	10.66	11.22
AZTb	ddIb	DRV/rq	0.37	0.75	10.28	0.83	10.28	10.28	10.28	1.11	10.64	11.02	11.39	1.51	10.51	10.64	11.03
AZTt	ddIb	DRV/rq	0.39	0.75	10.28	0.84	10.28	10.28	10.28	1.14	10.67	11.02	11.42	1.55	10.52	10.64	11.05
3TCb	NVP	ATV/r	2.30	4.43	7.44	4.45	7.44	7.53	7.53	6.74	9.75	11.88	14.18	5.71	8.37	10.29	11.10
ddIq	ETR	LPV/rb	0.84	6.31	6.97	6.31	6.98	7.61	7.62	7.14	7.81	13.28	14.12	6.28	7.60	12.26	11.47
TDF	ETR	LPV/rb	0.86	6.31	6.97	6.30	6.97	7.61	7.61	7.16	7.83	13.28	14.14	6.44	7.41	12.26	11.32
3TCq	NVP	ATV/r	2.35	4.43	7.44	4.45	7.44	7.53	7.53	6.78	9.79	11.88	14.22	5.74	8.39	10.29	11.12
AZTb	ddIq	DRV/rq	0.37	0.84	10.28	0.91	10.28	10.28	10.28	1.21	10.64	11.12	11.48	1.61	10.51	10.68	11.10
AZTb	TDF	DRV/rq	0.37	0.86	10.28	0.87	10.28	10.28	10.28	1.23	10.64	11.14	11.50	1.92	10.51	10.66	11.17
AZTt	ddIq	DRV/rq	0.39	0.84	10.28	0.92	10.28	10.28	10.28	1.23	10.67	11.12	11.51	1.66	10.52	10.68	11.12
3TCb	ETR	ATV	2.30	6.31	5.97	6.31	5.97	7.22	7.22	8.61	8.27	12.27	14.58	6.86	6.90	11.14	11.09
AZTt	TDF	DRV/rq	0.39	0.86	10.28	0.87	10.28	10.28	10.28	1.25	10.67	11.14	11.53	1.99	10.52	10.66	11.19
ETR	EVG/c	LPV/rq	6.31	1.41	6.64	6.30	7.45	6.64	7.45	7.72	12.94	8.05	14.36	7.55	11.95	8.86	14.84
3TCq	ETR	ATV	2.35	6.31	5.97	6.31	5.97	7.22	7.22	8.65	8.32	12.27	14.62	6.87	6.92	11.14	11.11
ddIb	EFV	ATV	0.75	7.35	5.97	7.35	5.98	7.83	7.83	8.10	6.71	13.32	14.07	7.77	6.50	11.89	12.06
ddIEC	NVP	ATV/r	2.56	4.43	7.44	4.57	7.45	7.53	7.54	6.99	10.00	11.88	14.44	6.55	9.27	10.29	12.43
ddIq	EFV	ATV	0.84	7.35	5.97	7.36	5.98	7.83	7.83	8.19	6.80	13.32	14.16	7.82	6.57	11.89	12.12
d4T	ETR	ATV/r	0.25	6.31	7.44	6.30	7.44	8.00	8.00	6.55	7.69	13.75	14.00	6.75	7.53	12.46	13.50
TDF	EFV	ATV	0.86	7.35	5.97	7.35	5.97	7.83	7.83	8.21	6.83	13.32	14.18	7.97	6.32	11.89	11.98
ddIEC	ETR	ATV	2.56	6.31	5.97	6.33	6.03	7.22	7.24	8.87	8.53	12.27	14.83	6.24	7.81	11.14	11.46
ETR	RAL	LPV/rq	6.31	1.69	6.64	6.30	7.45	6.64	7.45	7.99	12.94	8.33	14.63	7.73	11.95	8.86	14.49
AZTb	ETR	ATV/r	0.37	6.31	7.44	6.30	7.44	8.00	8.00	6.67	7.81	13.75	14.12	7.69	7.57	12.46	17.08
ETR	LPV/rq	MVC	6.31	6.64	1.72	7.45	6.30	6.64	7.45	12.94	8.03	8.36	14.67	11.95	9.41	6.64	14.34
AZTt	ETR	ATV/r	0.39	6.31	7.44	6.30	7.44	8.00	8.00	6.70	7.84	13.75	14.14	7.78	7.58	12.46	17.16
ddIb	TDF	DRV/rq	0.75	0.86	10.28	1.06	10.28	10.28	10.28	1.61	11.02	11.14	11.88	1.03	10.64	10.66	10.99
d4T	EFV	LPV/rq	0.25	7.35	6.64	7.35	6.64	7.95	7.95	7.60	6.89	13.99	14.24	8.00	6.80	13.56	16.33
FTC	NVP	ATV/r	2.79	4.43	7.44	4.48	7.44	7.53	7.53	7.22	10.23	11.88	14.67	6.21	9.00	10.29	11.86
d4T	EVG/c	DRV/rq	0.25	1.41	10.28	1.42	10.28	10.28	10.28	1.66	10.53	11.69	11.94	1.70	10.50	11.74	11.90
ddIq	TDF	DRV/rq	0.84	0.86	10.28	1.10	10.28	10.28	10.28	1.70	11.12	11.14	11.97	1.07	10.68	10.66	11.03
FTC	EFV	ATV	2.79	7.35	5.97	7.35	5.98	7.22	7.22	9.10	8.76	12.27	15.06	6.83	7.53	11.14	11.57
ETR	EVG/c	LPV/rb	6.31	1.41	6.97	6.30	7.61	6.97	7.61	7.72	13.28	8.39	14.69	7.55	12.26	9.19	15.21
ABCb	ETR	LPV/rq	1.91	6.31	6.64	6.31	6.64	7.45	7.45	8.22	8.55	12.94	14.86	6.62	7.67	11.95	11.69
AZTb	EFV	LPV/rq	0.37	7.35	6.64	7.35	6.64	7.95	7.95	7.72	7.01	13.99	14.36	8.91	7.14	13.56	20.94
AZTt	EFV	LPV/rq	0.39	7.35	6.64	7.35	6.64	7.95	7.95	7.75	7.03	13.99	14.39	9.02	7.17	13.56	21.04
AZTb	EVG/c	DRV/rq	0.37	1.41	10.28	1.42	10.28	10.28	10.28	1.78	10.64	11.69	12.06	1.84	10.51	11.74	11.82
AZTb	d4T	DRV/rb	0.37	0.25	10.87	0.45	10.87	10.87	10.87	0.62	11.23	11.12	11.48	0.45	11.10	11.08	11.32
AZTt	EVG/c	DRV/rq	0.39	1.41	10.28	1.42	10.28	10.28	10.28	1.81	10.67	11.69	12.08	1.87	10.52	11.74	11.84
AZTt	d4T	DRV/rb	0.39	0.25	10.87	0.47	10.87	10.87	10.87	0.64	11.26	11.12	11.51	0.47	11.11	11.08	11.34
ETR	ENF	LPV/rq	6.31	2.07	6.64	6.31	7.45	6.64	7.45	8.38	12.94	8.71	15.02	8.20	11.95	7.88	13.39
d4T	RAL	DRV/rq	0.25	1.69	10.28	1.69	10.28	10.28	10.28	1.94	10.53	11.96	12.21	2.01	10.50	12.17	12.28
ddIb	ETR	ATV/r	0.75	6.31	7.44	6.31	7.44	8.00	8.00	7.05	8.19	13.75	14.49	6.28	7.97	12.46	11.68
ABCq	ETR	LPV/rq	2.14	6.31	6.64	6.31	6.64	7.45	7.45	8.45	8.78	12.94	15.09	6.66	7.79	11.95	11.82
EFV	EVG/c	ATV	7.35	1.41	5.97	7.35	7.83	5.97	7.83	8.77	13.32	7.38	14.73	8.86	11.89	8.10	15.12
ETR	RAL	LPV/rb	6.31	1.69	6.97	6.30	7.61	6.97	7.61	7.99	13.28	8.66	14.97	7.73	12.26	9.20	14.84

| Regimen[a] | | | IIP_{ave} | | | | | | | | | | | | | | | |
| | | | Single drug | | | Loewe[b] | | | | Bliss[c] | | | | DI Index[d] | | | |
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
ddIq	ETR	ATV/r	0.84	6.31	7.44	6.31	7.44	8.00	8.00	7.14	8.28	13.75	14.59	6.28	8.04	12.46	11.74
TDF	ETR	ATV/r	0.86	6.31	7.44	6.30	7.44	8.00	8.00	7.16	8.30	13.75	14.61	6.44	7.80	12.46	11.45
AZTb	RAL	DRV/rq	0.37	1.69	10.28	1.69	10.28	10.28	10.28	2.05	10.64	11.96	12.33	2.08	10.51	12.17	12.15
d4T	EFV	LPV/rb	0.25	7.35	6.97	7.35	6.97	8.06	8.06	7.60	7.22	14.33	14.58	8.00	7.13	13.88	16.66
AZTt	RAL	DRV/rq	0.39	1.69	10.28	1.69	10.28	10.28	10.28	2.08	10.67	11.96	12.36	2.11	10.52	12.17	12.17
ddIb	EFV	LPV/rq	0.75	7.35	6.64	7.35	6.64	7.95	7.95	8.10	7.39	13.99	14.74	7.77	7.20	13.56	13.24
3TCb	ETR	LPV/rq	2.30	6.31	6.64	6.31	6.64	7.45	7.45	8.61	8.94	12.94	15.25	6.86	7.77	11.95	11.92
ddIb	EVG/c	DRV/rq	0.75	1.41	10.28	1.60	10.28	10.28	10.28	2.16	11.02	11.69	12.44	2.25	10.64	11.74	12.03
d4T	ABCb	DRV/rq	0.25	1.91	10.28	1.92	10.28	10.28	10.28	2.16	10.53	12.19	12.44	2.42	10.50	11.77	12.31
d4T	ddIb	DRV/rb	0.25	0.75	10.87	0.82	10.87	10.87	10.87	0.99	11.12	11.61	11.86	1.34	11.08	11.23	11.67
3TCq	ETR	LPV/rq	2.35	6.31	6.64	6.31	6.64	7.45	7.45	8.65	8.99	12.94	15.29	6.87	7.79	11.95	11.95
AZTb	EFV	LPV/rb	0.37	7.35	6.97	7.35	6.97	8.06	8.06	7.72	7.34	14.33	14.69	8.91	7.47	13.88	21.39
AZTt	EFV	LPV/rb	0.39	7.35	6.97	7.35	6.97	8.06	8.06	7.75	7.37	14.33	14.72	9.02	7.51	13.88	21.48
ddIq	EFV	LPV/rq	0.84	7.35	6.64	7.36	6.64	7.95	7.95	8.19	7.48	13.99	14.83	7.82	7.26	13.56	13.31
TDF	EFV	LPV/rq	0.86	7.35	6.64	7.35	6.64	7.95	7.95	8.21	7.50	13.99	14.85	7.97	7.07	13.56	13.22
ddIq	EVG/c	DRV/rq	0.84	1.41	10.28	1.62	10.28	10.28	10.28	2.25	11.12	11.69	12.53	2.36	10.68	11.74	12.11
ABCb	ETR	LPV/rq	1.91	6.31	6.97	6.31	6.97	7.61	7.61	8.22	8.89	13.28	15.19	6.62	8.00	12.26	11.97
d4T	ddIq	DRV/rb	0.25	0.84	10.87	0.90	10.87	10.87	10.87	1.09	11.12	11.70	11.95	1.45	11.08	11.27	11.76
TDF	EVG/c	DRV/rq	0.86	1.41	10.28	1.43	10.28	10.28	10.28	2.27	11.14	11.69	12.55	2.25	10.66	11.74	12.04
AZTb	ABCb	DRV/rq	0.37	1.91	10.28	1.91	10.28	10.28	10.28	2.28	10.64	12.19	12.56	2.84	10.51	11.77	12.36
d4T	TDF	DRV/rb	0.25	0.86	10.87	0.87	10.87	10.87	10.87	1.11	11.12	11.73	11.97	1.67	11.08	11.25	11.80
EFV	RAL	ATV	7.35	1.69	5.97	7.35	7.83	5.97	7.83	9.04	13.32	7.65	15.01	9.55	11.89	8.52	16.02
AZTb	ddIb	DRV/rb	0.37	0.75	10.87	0.83	10.87	10.87	10.87	1.11	11.23	11.61	11.98	1.51	11.10	11.23	11.61
AZTt	ABCb	DRV/rq	0.39	1.91	10.28	1.91	10.28	10.28	10.28	2.31	10.67	12.19	12.58	2.91	10.52	11.77	12.39
AZTt	ddIb	DRV/rb	0.39	0.75	10.87	0.84	10.87	10.87	10.87	1.14	11.26	11.61	12.00	1.55	11.11	11.23	11.63
d4T	ENF	DRV/rq	0.25	2.07	10.28	2.07	10.28	10.28	10.28	2.32	10.53	12.35	12.60	2.34	10.50	10.39	11.51
AZTb	ddIq	DRV/rb	0.37	0.84	10.87	0.91	10.87	10.87	10.87	1.21	11.23	11.70	12.07	1.61	11.10	11.27	11.68
d4T	ABCq	DRV/rq	0.25	2.14	10.28	2.14	10.28	10.28	10.28	2.39	10.53	12.42	12.67	2.65	10.50	11.94	12.55
AZTb	TDF	DRV/rb	0.37	0.86	10.87	0.87	10.87	10.87	10.87	1.23	11.23	11.73	12.09	1.92	11.10	11.25	11.75
AZTt	ddIq	DRV/rb	0.39	0.84	10.87	0.92	10.87	10.87	10.87	1.23	11.26	11.70	12.10	1.66	11.11	11.27	11.70
ddIEC	ETR	LPV/rq	2.56	6.31	6.64	6.33	6.66	7.45	7.46	8.87	9.20	12.94	15.50	6.24	8.55	11.95	12.26
ETR	ENF	LPV/rb	6.31	2.07	6.97	6.31	7.61	6.98	7.62	8.38	13.28	9.04	15.35	8.20	12.26	8.21	13.68
AZTt	TDF	DRV/rb	0.39	0.86	10.87	0.87	10.87	10.87	10.87	1.25	11.26	11.73	12.12	1.99	11.11	11.25	11.77
ddIb	RAL	DRV/rq	0.75	1.69	10.28	1.83	10.28	10.28	10.28	2.43	11.02	11.96	12.71	2.38	10.64	12.17	12.31
AZTb	ENF	DRV/rq	0.37	2.07	10.28	2.07	10.28	10.28	10.28	2.44	10.64	12.35	12.72	2.51	10.51	10.39	11.34
AZTt	ENF	DRV/rq	0.39	2.07	10.28	2.07	10.28	10.28	10.28	2.46	10.67	12.35	12.74	2.54	10.52	10.39	11.35
ABCq	ETR	LPV/rb	2.14	6.31	6.97	6.31	6.97	7.61	7.61	8.45	9.12	13.28	15.42	6.66	8.13	12.26	12.10
AZTb	ABCq	DRV/rq	0.37	2.14	10.28	2.14	10.28	10.28	10.28	2.51	10.64	12.42	12.79	3.07	10.51	11.94	12.60
ABCb	EFV	ATV	1.91	7.35	5.97	7.35	5.97	7.83	7.83	9.27	7.88	13.32	15.23	8.81	7.02	11.89	13.00
ddIq	RAL	DRV/rq	0.84	1.69	10.28	1.85	10.28	10.28	10.28	2.53	11.12	11.96	12.80	2.47	10.68	12.17	12.38
AZTt	ABCq	DRV/rq	0.39	2.14	10.28	2.14	10.28	10.28	10.28	2.54	10.67	12.42	12.81	3.13	10.52	11.94	12.63
TDF	RAL	DRV/rq	0.86	1.69	10.28	1.69	10.28	10.28	10.28	2.55	11.14	11.96	12.82	2.71	10.66	12.17	12.44
d4T	3TCb	DRV/rq	0.25	2.30	10.28	2.31	10.28	10.28	10.28	2.55	10.53	12.58	12.83	2.72	10.50	11.71	12.44
ddIb	EFV	LPV/rb	0.75	7.35	6.97	7.35	6.98	8.06	8.06	8.10	7.72	14.33	15.07	7.77	7.53	13.88	13.54
d4T	3TCq	DRV/rq	0.25	2.35	10.28	2.35	10.28	10.28	10.28	2.60	10.53	12.63	12.88	2.77	10.50	11.74	12.48
ETR	EVG/c	ATV/r	6.31	1.41	7.44	6.30	8.00	7.44	8.00	7.72	13.75	8.86	15.16	7.55	12.46	9.57	15.44
FTC	ETR	LPV/rq	2.79	6.31	6.64	6.31	6.64	7.45	7.45	9.10	9.43	12.94	15.73	6.83	8.38	11.95	12.43
3TCb	ETR	LPV/rb	2.30	6.31	6.97	6.31	6.97	7.61	7.61	8.61	9.28	13.28	15.58	6.86	8.10	12.26	12.20
ddIb	ABCb	DRV/rq	0.75	1.91	10.28	2.04	10.28	10.28	10.28	2.66	11.02	12.19	12.94	2.17	10.64	11.77	11.88
ddIq	EFV	LPV/rb	0.84	7.35	6.97	7.36	6.98	8.06	8.06	8.19	7.81	14.33	15.17	7.82	7.60	13.88	13.60
EFV	ENF	ATV	7.35	2.07	5.97	7.35	7.83	5.98	7.83	9.42	13.32	8.04	15.39	9.20	11.89	7.65	13.93
AZTb	3TCb	DRV/rq	0.37	2.30	10.28	2.30	10.28	10.28	10.28	2.67	10.64	12.58	12.95	2.91	10.51	11.71	12.26
TDF	EFV	LPV/rb	0.86	7.35	6.97	7.35	6.97	8.06	8.06	8.21	7.83	14.33	15.19	7.97	7.41	13.88	13.49
3TCq	ETR	LPV/rb	2.35	6.31	6.97	6.31	6.97	7.61	7.61	8.65	9.32	13.28	15.63	6.87	8.12	12.26	12.22
AZTt	3TCb	DRV/rq	0.39	2.30	10.28	2.30	10.28	10.28	10.28	2.70	10.67	12.58	12.97	2.95	10.52	11.71	12.29
AZTb	3TCq	DRV/rq	0.37	2.35	10.28	2.35	10.28	10.28	10.28	2.72	10.64	12.63	12.99	2.95	10.51	11.74	12.30
ABCq	EFV	ATV	2.14	7.35	5.97	7.35	5.97	7.83	7.83	9.50	8.11	13.32	15.46	8.98	7.14	11.89	13.16
AZTt	3TCq	DRV/rq	0.39	2.35	10.28	2.35	10.28	10.28	10.28	2.74	10.67	12.63	13.02	2.99	10.52	11.74	12.32
ddIq	ABCb	DRV/rq	0.84	1.91	10.28	2.06	10.28	10.28	10.28	2.75	11.12	12.19	13.03	2.20	10.68	11.77	11.93
TDF	ABCb	DRV/rq	0.86	1.91	10.28	1.92	10.28	10.28	10.28	2.77	11.14	12.19	13.05	1.89	10.66	11.77	11.86
ddIb	TDF	DRV/rb	0.75	0.86	10.87	1.06	10.87	10.87	10.87	1.61	11.61	11.73	12.47	1.03	11.23	11.25	11.58
EFV	EVG/c	LPV/rq	7.35	1.41	6.64	7.35	7.95	6.64	7.95	8.77	13.99	8.05	15.41	8.86	13.56	8.86	16.52
d4T	ddIEC	DRV/rq	0.25	2.56	10.28	2.56	10.28	10.28	10.28	2.81	10.53	12.84	13.09	3.29	10.50	11.52	12.99
ddIb	ENF	DRV/rq	0.75	2.07	10.28	2.24	10.28	10.28	10.28	2.82	11.02	12.35	13.09	2.71	10.64	10.39	11.22
d4T	EFV	ATV/r	0.25	7.35	7.44	7.35	7.44	8.35	8.35	7.60	7.69	14.80	15.05	8.00	7.53	13.12	16.13
d4T	EVG/c	DRV/rb	0.25	1.41	10.87	1.42	10.87	10.87	10.87	1.66	11.12	12.28	12.53	1.70	11.08	12.33	12.49
ddIq	TDF	DRV/rb	0.84	0.86	10.87	1.10	10.87	10.87	10.87	1.70	11.70	11.73	12.56	1.07	11.27	11.25	11.62
ETR	RAL	ATV/r	6.31	1.69	7.44	6.30	8.00	7.44	8.00	7.99	13.75	9.13	15.43	7.73	12.46	10.00	15.72
ddIb	ABCq	DRV/rq	0.75	2.14	10.28	2.24	10.28	10.28	10.28	2.89	11.02	12.42	13.17	2.38	10.64	11.94	12.01
3TCb	EFV	ATV	2.30	7.35	5.97	7.35	5.97	7.83	7.83	9.66	8.27	13.32	15.62	8.38	6.90	11.89	12.23

Regimen[a]			IIP_{ave}																
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
ddIEC	ETR	LPV/rb	2.56	6.31	6.97	6.33	6.99	7.61	7.62	8.87	9.53	13.28	15.84	6.24	8.88	12.26	12.56
ddIq	ENF	DRV/rq	0.84	2.07	10.28	2.26	10.28	10.28	10.28	2.91	11.12	12.35	13.19	2.79	10.68	10.39	11.26
AZTb	ddIEC	DRV/rq	0.37	2.56	10.28	2.56	10.28	10.28	10.28	2.93	10.64	12.84	13.20	3.41	10.51	11.52	12.58
TDF	ENF	DRV/rq	0.86	2.07	10.28	2.08	10.28	10.28	10.28	2.93	11.14	12.35	13.21	2.63	10.66	10.39	11.15
3TCq	EFV	ATV	2.35	7.35	5.97	7.35	5.97	7.83	7.83	9.70	8.32	13.32	15.67	8.40	6.92	11.89	12.25
AZTt	ddIEC	DRV/rq	0.39	2.56	10.28	2.56	10.28	10.28	10.28	2.95	10.67	12.84	13.23	3.46	10.52	11.52	12.61
AZTb	EFV	ATV/r	0.37	7.35	7.44	7.35	7.44	8.35	8.35	7.72	7.81	14.80	15.16	8.91	7.57	13.12	19.86
AZTb	EVG/c	DRV/rb	0.37	1.41	10.87	1.42	10.87	10.87	10.87	1.78	11.23	12.28	12.65	1.84	11.10	12.33	12.41
ddIq	ABCq	DRV/rq	0.84	2.14	10.28	2.25	10.28	10.28	10.28	2.98	11.12	12.42	13.26	2.41	10.68	11.94	12.06
AZTt	EFV	ATV/r	0.39	7.35	7.44	7.35	7.44	8.35	8.35	7.75	7.84	14.80	15.19	9.02	7.58	13.12	19.96
AZTt	EVG/c	DRV/rb	0.39	1.41	10.87	1.42	10.87	10.87	10.87	1.81	11.26	12.28	12.67	1.87	11.11	12.33	12.43
TDF	ABCq	DRV/rq	0.86	2.14	10.28	2.14	10.28	10.28	10.28	3.00	11.14	12.42	13.28	2.11	10.66	11.94	11.98
d4T	FTC	DRV/rq	0.25	2.79	10.28	2.79	10.28	10.28	10.28	3.04	10.53	13.07	13.32	3.21	10.50	11.67	12.72
3TCb	ddIb	DRV/rq	2.30	0.75	10.28	2.39	10.28	10.28	10.28	3.05	12.58	11.02	13.33	2.55	11.71	10.64	11.88
EFV	RAL	LPV/rq	7.35	1.69	6.64	7.35	7.95	6.64	7.95	9.04	13.99	8.33	15.68	9.55	13.56	8.86	16.83
3TCq	ddIb	DRV/rq	2.35	0.75	10.28	2.44	10.28	10.28	10.28	3.10	12.63	11.02	13.37	2.59	11.74	10.64	11.90
ABCb	ETR	ATV/r	1.91	6.31	7.44	6.31	7.44	8.00	8.00	8.22	9.36	13.75	15.66	6.62	8.49	12.46	12.29
EFV	LPV/rq	MVC	7.35	6.64	1.72	7.95	7.35	6.64	7.95	13.99	9.08	8.36	15.72	13.56	10.23	6.64	15.52
d4T	RAL	DRV/rb	0.25	1.69	10.87	1.69	10.87	10.87	10.87	1.94	11.12	12.55	12.80	2.01	11.08	12.76	12.86
FTC	ETR	LPV/rb	2.79	6.31	6.97	6.31	6.97	7.61	7.61	9.10	9.76	13.28	16.07	6.83	8.72	12.26	12.72
3TCb	ddIq	DRV/rq	2.30	0.84	10.28	2.41	10.28	10.28	10.28	3.14	12.58	11.12	13.42	2.58	11.71	10.68	11.93
AZTb	FTC	DRV/rq	0.37	2.79	10.28	2.79	10.28	10.28	10.28	3.16	10.64	13.07	13.43	3.55	10.51	11.67	12.71
ddIEC	EFV	ATV	2.56	7.35	5.97	7.36	6.03	7.83	7.84	9.91	8.53	13.32	15.88	8.77	7.81	11.89	13.27
3TCb	TDF	DRV/rq	2.30	0.86	10.28	2.30	10.28	10.28	10.28	3.16	12.58	11.14	13.44	2.97	11.71	10.66	12.07
AZTt	FTC	DRV/rq	0.39	2.79	10.28	2.79	10.28	10.28	10.28	3.18	10.67	13.07	13.46	3.60	10.52	11.67	12.73
3TCq	ddIq	DRV/rq	2.35	0.84	10.28	2.45	10.28	10.28	10.28	3.19	12.63	11.12	13.47	2.62	11.74	10.68	11.95
3TCq	TDF	DRV/rq	2.35	0.86	10.28	2.35	10.28	10.28	10.28	3.21	12.63	11.14	13.49	3.02	11.74	10.66	12.10
AZTb	RAL	DRV/rb	0.37	1.69	10.87	1.69	10.87	10.87	10.87	2.05	11.23	12.55	12.92	2.08	11.10	12.76	12.73
EFV	EVG/c	LPV/rb	7.35	1.41	6.97	7.35	8.06	6.97	8.06	8.77	14.33	8.39	15.74	8.86	13.88	9.19	16.90
AZTt	RAL	DRV/rb	0.39	1.69	10.87	1.69	10.87	10.87	10.87	2.08	11.26	12.55	12.95	2.11	11.11	12.76	12.75
ETR	ENF	ATV/r	6.31	2.07	7.44	6.31	8.00	7.44	8.00	8.38	13.75	9.51	15.82	8.20	12.46	9.12	14.45
ABCb	EFV	LPV/rq	1.91	7.35	6.64	7.35	6.64	7.95	7.95	9.27	8.55	13.99	15.91	8.81	7.67	13.56	14.16
ABCb	EVG/c	DRV/rq	1.91	1.41	10.28	2.02	10.28	10.28	10.28	3.33	12.19	11.69	13.61	3.39	11.77	11.74	13.35
ABCq	ETR	ATV/r	2.14	6.31	7.44	6.31	7.44	8.00	8.00	8.45	9.59	13.75	15.89	6.66	8.62	12.46	12.41
ddIb	EVG/c	DRV/rb	0.75	1.41	10.87	1.60	10.87	10.87	10.87	2.16	11.61	12.28	13.03	2.25	11.23	12.33	12.61
ddIb	EFV	ATV/r	0.75	7.35	7.44	7.35	7.44	8.35	8.35	8.10	8.19	14.80	15.54	7.77	7.97	13.12	13.26
d4T	ABCb	DRV/rb	0.25	1.91	10.87	1.92	10.87	10.87	10.87	2.16	11.12	12.78	13.03	2.42	11.08	12.35	12.89
FTC	EFV	ATV	2.79	7.35	5.97	7.35	5.98	7.83	7.83	10.14	8.76	13.32	16.11	8.63	7.53	11.89	12.84
ddIEC	TDF	DRV/rq	2.56	0.86	10.28	2.56	10.28	10.28	10.28	3.42	12.84	11.14	13.70	2.51	11.52	10.66	11.69
ddIq	EVG/c	DRV/rb	0.84	1.41	10.87	1.62	10.87	10.87	10.87	2.25	11.70	12.28	13.12	2.36	11.27	12.33	12.69
ddIq	EFV	ATV/r	0.84	7.35	7.44	7.36	7.44	8.35	8.35	8.19	8.28	14.80	15.63	7.82	8.04	13.12	13.32
TDF	EFV	ATV/r	0.86	7.35	7.44	7.35	7.44	8.35	8.35	8.21	8.30	14.80	15.66	7.97	7.80	13.12	13.06
TDF	EVG/c	DRV/rb	0.86	1.41	10.87	1.43	10.87	10.87	10.87	2.27	11.73	12.28	13.14	2.25	11.25	12.33	12.63
EFV	ENF	LPV/rq	7.35	2.07	6.64	7.35	7.95	6.64	7.95	9.42	13.99	8.71	16.06	9.20	13.56	7.88	14.70
AZTb	ABCb	DRV/rb	0.37	1.91	10.87	1.91	10.87	10.87	10.87	2.28	11.23	12.78	13.15	2.84	11.10	12.35	12.93
AZTt	ABCb	DRV/rb	0.39	1.91	10.87	1.91	10.87	10.87	10.87	2.31	11.26	12.78	13.17	2.91	11.11	12.35	12.96
ENF	EVG/c	DRV/rq	2.07	1.41	10.28	2.20	10.28	10.28	10.28	3.48	12.35	11.69	13.76	3.46	10.39	11.74	12.47
d4T	ENF	DRV/rb	0.25	2.07	10.87	2.07	10.87	10.87	10.87	2.32	11.12	12.94	13.19	2.34	11.08	10.97	12.09
3TCb	ETR	ATV/r	2.30	6.31	7.44	6.31	7.44	8.00	8.00	8.61	9.75	13.75	16.05	6.86	8.37	12.46	12.27
EFV	RAL	LPV/rb	7.35	1.69	6.97	7.35	8.06	6.97	8.06	9.04	14.33	8.66	16.01	9.55	13.88	9.20	17.20
ABCq	EFV	LPV/rq	2.14	7.35	6.64	7.35	6.64	7.95	7.95	9.50	8.78	13.99	16.14	8.98	7.79	13.56	14.32
FTC	ddIb	DRV/rq	2.79	0.75	10.28	2.85	10.28	10.28	10.28	3.54	13.07	11.02	13.81	3.06	11.67	10.64	11.94
3TCq	ETR	ATV/r	2.35	6.31	7.44	6.31	7.44	8.00	8.00	8.65	9.79	13.75	16.10	6.87	8.39	12.46	12.30
ABCq	EVG/c	DRV/rq	2.14	1.41	10.28	2.20	10.28	10.28	10.28	3.56	12.42	11.69	13.83	3.62	11.94	11.74	13.56
d4T	ABCq	DRV/rb	0.25	2.14	10.87	2.14	10.87	10.87	10.87	2.39	11.12	13.01	13.26	2.65	11.08	12.53	13.12
ABCb	RAL	DRV/rq	1.91	1.69	10.28	2.10	10.28	10.28	10.28	3.60	12.19	11.96	13.88	3.45	11.77	11.96	13.69
ddIb	RAL	DRV/rb	0.75	1.69	10.87	1.83	10.87	10.87	10.87	2.43	11.61	12.55	13.30	2.38	11.23	12.76	12.89
AZTb	ENF	DRV/rb	0.37	2.07	10.87	2.07	10.87	10.87	10.87	2.44	11.23	12.94	13.30	2.51	11.10	10.97	11.92
FTC	ddIq	DRV/rq	2.79	0.84	10.28	2.86	10.28	10.28	10.28	3.63	13.07	11.12	13.91	3.10	11.67	10.68	11.98
AZTt	ENF	DRV/rb	0.39	2.07	10.87	2.07	10.87	10.87	10.87	2.46	11.26	12.94	13.33	2.54	11.11	10.97	11.93
FTC	TDF	DRV/rq	2.79	0.86	10.28	2.79	10.28	10.28	10.28	3.65	13.07	11.14	13.93	3.07	11.67	10.66	11.94
AZTb	ABCq	DRV/rb	0.37	2.14	10.87	2.14	10.87	10.87	10.87	2.51	11.23	13.01	13.38	3.07	11.10	12.53	13.17
3TCb	EFV	LPV/rq	2.30	7.35	6.64	7.35	6.64	7.95	7.95	9.66	8.94	13.99	16.30	8.38	7.77	13.56	13.61
ddIq	RAL	DRV/rb	0.84	1.69	10.87	1.85	10.87	10.87	10.87	2.53	11.70	12.55	13.39	2.47	11.27	12.76	12.97
AZTt	ABCq	DRV/rb	0.39	2.14	10.87	2.14	10.87	10.87	10.87	2.54	11.26	13.01	13.40	3.13	11.11	12.53	13.20
3TCb	EVG/c	DRV/rq	2.30	1.41	10.28	2.35	10.28	10.28	10.28	3.72	12.58	11.69	14.00	4.06	11.71	11.74	13.59
TDF	RAL	DRV/rb	0.86	1.69	10.87	1.69	10.87	10.87	10.87	2.55	11.73	12.55	13.41	2.71	11.25	12.76	13.02
d4T	3TCb	DRV/rb	0.25	2.30	10.87	2.31	10.87	10.87	10.87	2.55	11.12	13.17	13.42	2.72	11.08	12.30	13.01
3TCq	EFV	LPV/rq	2.35	7.35	6.64	7.35	6.64	7.95	7.95	9.70	8.99	13.99	16.34	8.40	7.79	13.56	13.63
ABCb	EFV	LPV/rb	1.91	7.35	6.97	7.35	6.97	8.06	8.06	9.27	8.89	14.33	16.24	8.81	8.00	13.88	14.43

Regimen[a]			IIP_{ave}															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
ENF	RAL	DRV/rq	2.07	1.69	10.28	2.29	10.28	10.28	10.28	3.76	12.35	11.96	14.03	3.96	10.39	12.17	12.94
ddIEC	ETR	ATV/r	2.56	6.31	7.44	6.33	7.45	8.00	8.01	8.87	10.00	13.75	16.31	6.24	9.27	12.46	12.77
3TCq	EVG/c	DRV/rq	2.35	1.41	10.28	2.39	10.28	10.28	10.28	3.76	12.63	11.69	14.04	4.10	11.74	11.74	13.63
d4T	3TCq	DRV/rb	0.25	2.35	10.87	2.35	10.87	10.87	10.87	2.60	11.12	13.22	13.46	2.77	11.08	12.33	13.05
ABCq	RAL	DRV/rq	2.14	1.69	10.28	2.26	10.28	10.28	10.28	3.83	12.42	11.96	14.11	3.68	11.94	12.17	13.90
ddIb	ABCb	DRV/rb	0.75	1.91	10.87	2.04	10.87	10.87	10.87	2.66	11.61	12.78	13.53	2.17	11.23	12.35	12.47
AZTb	3TCb	DRV/rb	0.37	2.30	10.87	2.30	10.87	10.87	10.87	2.67	11.23	13.17	13.54	2.91	11.10	12.30	12.84
AZTt	3TCb	DRV/rb	0.39	2.30	10.87	2.30	10.87	10.87	10.87	2.70	11.26	13.17	13.56	2.95	11.11	12.30	12.86
AZTb	3TCq	DRV/rb	0.37	2.35	10.87	2.35	10.87	10.87	10.87	2.72	11.23	13.22	13.58	2.95	11.10	12.33	12.88
EFV	ENF	LPV/rb	7.35	2.07	6.97	7.35	8.06	6.98	8.06	9.42	14.33	9.04	16.40	9.20	13.88	8.21	14.99
AZTt	3TCq	DRV/rb	0.39	2.35	10.87	2.35	10.87	10.87	10.87	2.74	11.26	13.22	13.61	2.99	11.11	12.33	12.90
ddIq	ABCb	DRV/rb	0.84	1.91	10.87	2.06	10.87	10.87	10.87	2.75	11.70	12.78	13.62	2.20	11.27	12.35	12.52
TDF	ABCb	DRV/rb	0.86	1.91	10.87	1.92	10.87	10.87	10.87	2.77	11.73	12.78	13.64	1.89	11.25	12.35	12.45
ddIEC	EFV	LPV/rq	2.56	7.35	6.64	7.36	6.66	7.95	7.95	9.91	9.20	13.99	16.55	8.77	8.55	13.56	14.58
ABCq	EFV	LPV/rb	2.14	7.35	6.97	7.35	6.97	8.06	8.06	9.50	9.12	14.33	16.47	8.98	8.13	13.88	14.60
ddIEC	EVG/c	DRV/rq	2.56	1.41	10.28	2.60	10.28	10.28	10.28	3.97	12.84	11.69	14.25	4.20	11.52	11.74	13.56
ABCb	ENF	DRV/rq	1.91	2.07	10.28	2.41	10.28	10.28	10.28	3.98	12.19	12.35	14.26	3.62	11.77	10.39	12.21
FTC	ETR	ATV/r	2.79	6.31	7.44	6.31	7.44	8.00	8.00	9.10	10.23	13.75	16.54	6.83	9.00	12.46	12.83
d4T	ddIEC	DRV/rb	0.25	2.56	10.87	2.56	10.87	10.87	10.87	2.81	11.12	13.43	13.68	3.29	11.08	12.11	13.54
3TCb	RAL	DRV/rq	2.30	1.69	10.28	2.39	10.28	10.28	10.28	3.99	12.58	11.96	14.27	4.00	11.71	12.17	13.86
ddIb	ENF	DRV/rb	0.75	2.07	10.87	2.24	10.87	10.87	10.87	2.82	11.61	12.94	13.68	2.71	11.23	10.97	11.80
EFV	EVG/c	ATV/r	7.35	1.41	7.44	7.35	8.35	7.44	8.35	8.77	14.80	8.86	16.21	8.86	13.12	9.57	16.71
3TCq	RAL	DRV/rq	2.35	1.69	10.28	2.44	10.28	10.28	10.28	4.04	12.63	11.96	14.31	4.04	11.74	12.17	13.90
ddIb	ABCq	DRV/rb	0.75	2.14	10.87	2.24	10.87	10.87	10.87	2.89	11.61	13.01	13.75	2.38	11.23	12.53	12.60
ddIq	ENF	DRV/rb	0.84	2.07	10.87	2.26	10.87	10.87	10.87	2.91	11.70	12.94	13.77	2.79	11.27	10.97	11.84
AZTb	ddIEC	DRV/rb	0.37	2.56	10.87	2.56	10.87	10.87	10.87	2.93	11.23	13.43	13.79	3.41	11.10	12.11	13.14
TDF	ENF	DRV/rb	0.86	2.07	10.87	2.08	10.87	10.87	10.87	2.93	11.73	12.94	13.80	2.63	11.25	10.97	11.73
AZTt	ddIEC	DRV/rb	0.39	2.56	10.87	2.56	10.87	10.87	10.87	2.95	11.26	13.43	13.82	3.46	11.11	12.11	13.17
3TCb	EFV	LPV/rb	2.30	7.35	6.97	7.35	6.97	8.06	8.06	9.66	9.28	14.33	16.63	8.38	8.10	13.88	13.87
ddIq	ABCq	DRV/rb	0.84	2.14	10.87	2.25	10.87	10.87	10.87	2.98	11.70	13.01	13.85	2.41	11.27	12.53	12.65
FTC	EFV	LPV/rq	2.79	7.35	6.64	7.35	6.64	7.95	7.95	10.14	9.43	13.99	16.78	8.63	8.38	13.56	14.24
3TCq	EFV	LPV/rb	2.35	7.35	6.97	7.35	6.97	8.06	8.06	9.70	9.32	14.33	16.68	8.40	8.12	13.88	13.90
TDF	ABCq	DRV/rb	0.86	2.14	10.87	2.14	10.87	10.87	10.87	3.00	11.73	13.01	13.87	2.11	11.25	12.53	12.57
FTC	EVG/c	DRV/rq	2.79	1.41	10.28	2.80	10.28	10.28	10.28	4.20	13.07	11.69	14.48	4.28	11.67	11.74	13.69
ABCq	ENF	DRV/rq	2.14	2.07	10.28	2.53	10.28	10.28	10.28	4.21	12.42	12.35	14.49	3.82	11.94	10.39	12.33
d4T	FTC	DRV/rb	0.25	2.79	10.87	2.79	10.87	10.87	10.87	3.04	11.12	13.66	13.91	3.21	11.08	12.26	13.29
3TCb	ABCb	DRV/rq	2.30	1.91	10.28	2.47	10.28	10.28	10.28	4.22	12.58	12.19	14.50	2.82	11.71	11.77	13.01
3TCb	ddIb	DRV/rb	2.30	0.75	10.87	2.39	10.87	10.87	10.87	3.05	13.17	11.61	13.92	2.55	12.30	11.23	12.47
ddIEC	RAL	DRV/rq	2.56	1.69	10.28	2.66	10.28	10.28	10.28	4.25	12.84	11.96	14.52	4.11	11.52	12.17	13.80
3TCq	ABCb	DRV/rq	2.35	1.91	10.28	2.51	10.28	10.28	10.28	4.26	12.63	12.19	14.54	2.86	11.74	11.77	13.03
3TCq	ddIb	DRV/rb	2.35	0.75	10.87	2.44	10.87	10.87	10.87	3.10	13.22	11.61	13.96	2.59	12.33	11.23	12.49
EFV	RAL	ATV/r	7.35	1.69	7.44	7.35	8.35	7.44	8.35	9.04	14.80	9.13	16.48	9.55	13.12	10.00	17.64
3TCb	ddIq	DRV/rb	2.30	0.84	10.87	2.41	10.87	10.87	10.87	3.14	13.17	11.70	14.01	2.58	12.30	11.27	12.52
AZTb	FTC	DRV/rb	0.37	2.79	10.87	2.79	10.87	10.87	10.87	3.16	11.23	13.66	14.02	3.55	11.10	12.26	13.27
3TCb	TDF	DRV/rb	2.30	0.86	10.87	2.30	10.87	10.87	10.87	3.16	13.17	11.73	14.03	2.97	12.30	11.25	12.66
AZTt	FTC	DRV/rb	0.39	2.79	10.87	2.79	10.87	10.87	10.87	3.18	11.26	13.66	14.05	3.60	11.11	12.26	13.29
3TCq	ddIq	DRV/rb	2.35	0.84	10.87	2.45	10.87	10.87	10.87	3.19	13.22	11.70	14.05	2.62	12.33	11.27	12.54
3TCb	ENF	DRV/rq	2.30	2.07	10.28	2.63	10.28	10.28	10.28	4.37	12.58	12.35	14.65	4.55	11.71	10.39	12.39
3TCq	TDF	DRV/rb	2.35	0.86	10.87	2.35	10.87	10.87	10.87	3.21	13.22	11.73	14.07	3.02	12.33	11.25	12.68
ddIEC	EFV	LPV/rb	2.56	7.35	6.97	7.36	6.99	8.06	8.06	9.91	9.53	14.33	16.89	8.77	8.88	13.88	14.87
3TCq	ENF	DRV/rq	2.35	2.07	10.28	2.67	10.28	10.28	10.28	4.42	12.63	12.35	14.70	4.60	11.74	10.39	12.42
3TCb	ABCq	DRV/rq	2.30	2.14	10.28	2.56	10.28	10.28	10.28	4.45	12.58	12.42	14.72	2.93	11.71	11.94	13.15
ddIEC	ABCb	DRV/rq	2.56	1.91	10.28	2.74	10.28	10.28	10.28	4.47	12.84	12.19	14.75	3.11	11.52	11.77	12.89
FTC	RAL	DRV/rq	2.79	1.69	10.28	2.82	10.28	10.28	10.28	4.48	13.07	11.96	14.75	4.61	11.67	12.17	14.13
3TCq	ABCq	DRV/rq	2.35	2.14	10.28	2.59	10.28	10.28	10.28	4.49	12.63	12.42	14.77	2.96	11.74	11.94	13.18
ABCb	EFV	ATV/r	1.91	7.35	7.44	7.35	7.44	8.35	8.35	9.27	9.36	14.80	16.71	8.81	8.49	13.12	14.14
ABCb	EVG/c	DRV/rb	1.91	1.41	10.87	2.02	10.87	10.87	10.87	3.33	12.78	12.28	14.19	3.39	12.35	12.33	13.94
ddIEC	TDF	DRV/rb	2.56	0.86	10.87	2.56	10.87	10.87	10.87	3.42	13.43	11.73	14.29	2.51	12.11	11.25	12.29
FTC	EFV	LPV/rb	2.79	7.35	6.97	7.35	6.97	8.06	8.06	10.14	9.76	14.33	17.12	8.63	8.72	13.88	14.52
ddIEC	ENF	DRV/rq	2.56	2.07	10.28	2.94	10.28	10.28	10.28	4.63	12.84	12.35	14.91	4.33	11.52	10.39	11.99
EFV	ENF	ATV/r	7.35	2.07	7.44	7.35	8.35	7.44	8.35	9.42	14.80	9.51	16.87	9.20	13.12	9.12	15.20
ENF	EVG/c	DRV/rb	2.07	1.41	10.87	2.20	10.87	10.87	10.87	3.48	12.94	12.28	14.35	3.46	10.97	12.33	13.05
d4T	NVP	DRV/rq	0.25	4.43	10.28	4.43	10.28	10.28	10.28	4.68	10.53	14.71	14.96	4.90	10.50	12.19	14.28
ddIEC	ABCq	DRV/rq	2.56	2.14	10.28	2.82	10.28	10.28	10.28	4.70	12.84	12.42	14.98	3.21	11.52	11.94	13.02
FTC	ABCb	DRV/rq	2.79	1.91	10.28	2.86	10.28	10.28	10.28	4.70	13.07	12.19	14.98	2.92	11.67	11.77	12.97
FTC	ddIb	DRV/rb	2.79	0.75	10.87	2.85	10.87	10.87	10.87	3.54	13.66	11.61	14.40	3.06	12.26	11.23	12.53
ABCq	EFV	ATV/r	2.14	7.35	7.44	7.35	7.44	8.35	8.35	9.50	9.59	14.80	16.94	8.98	8.62	13.12	14.30
ABCq	EVG/c	DRV/rb	2.14	1.41	10.87	2.20	10.87	10.87	10.87	3.56	13.01	12.28	14.42	3.62	12.53	12.33	14.15
ABCb	RAL	DRV/rb	1.91	1.69	10.87	2.10	10.87	10.87	10.87	3.60	12.78	12.55	14.47	3.45	12.35	12.76	14.28
FTC	ddIq	DRV/rb	2.79	0.84	10.87	2.86	10.87	10.87	10.87	3.63	13.66	11.70	14.49	3.10	12.26	11.27	12.58

Regimen[a]			IIP_{ave}															
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
AZTb	NVP	DRV/rq	0.37	4.43	10.28	4.43	10.28	10.28	10.28	4.80	10.64	14.71	15.08	5.28	10.51	12.19	14.39
FTC	TDF	DRV/rb	2.79	0.86	10.87	2.79	10.87	10.87	10.87	3.65	13.66	11.73	14.52	3.07	12.26	11.25	12.53
AZTt	NVP	DRV/rq	0.39	4.43	10.28	4.43	10.28	10.28	10.28	4.83	10.67	14.71	15.10	5.33	10.52	12.19	14.43
FTC	ENF	DRV/rq	2.79	2.07	10.28	2.99	10.28	10.28	10.28	4.86	13.07	12.35	15.14	4.39	11.67	10.39	12.05
3TCb	ddIEC	DRV/rq	2.30	2.56	10.28	2.91	10.28	10.28	10.28	4.86	12.58	12.84	15.14	3.38	11.71	11.52	12.78
3TCb	EFV	ATV/r	2.30	7.35	7.44	7.35	7.44	8.35	8.35	9.66	9.75	14.80	17.10	8.38	8.37	13.12	13.28
3TCb	EVG/c	DRV/rb	2.30	1.41	10.87	2.35	10.87	10.87	10.87	3.72	13.17	12.28	14.59	4.06	12.30	12.33	14.17
3TCq	ddIEC	DRV/rq	2.35	2.56	10.28	2.92	10.28	10.28	10.28	4.91	12.63	12.84	15.19	3.40	11.74	11.52	12.81
FTC	ABCq	DRV/rq	2.79	2.14	10.28	2.90	10.28	10.28	10.28	4.93	13.07	12.42	15.21	2.97	11.67	11.94	13.10
ENF	RAL	DRV/rb	2.07	1.69	10.87	2.29	10.87	10.87	10.87	3.76	12.94	12.55	14.62	3.96	10.97	12.76	13.51
3TCq	EFV	ATV/r	2.35	7.35	7.44	7.35	7.44	8.35	8.35	9.70	9.79	14.80	17.15	8.40	8.39	13.12	13.30
3TCq	EVG/c	DRV/rb	2.35	1.41	10.87	2.39	10.87	10.87	10.87	3.76	13.22	12.28	14.63	4.10	12.33	12.33	14.21
ABCq	RAL	DRV/rb	2.14	1.69	10.87	2.26	10.87	10.87	10.87	3.83	13.01	12.55	14.70	3.68	12.53	12.76	14.49
ddIEC	EVG/c	DRV/rb	2.56	1.41	10.87	2.60	10.87	10.87	10.87	3.97	13.43	12.28	14.84	4.20	12.11	12.33	14.14
ddIEC	EFV	ATV/r	2.56	7.35	7.44	7.36	7.45	8.35	8.35	9.91	10.00	14.80	17.36	8.77	9.27	13.12	14.47
ABCb	ENF	DRV/rb	1.91	2.07	10.87	2.41	10.87	10.87	10.87	3.98	12.78	12.94	14.85	3.62	12.35	10.97	12.78
3TCb	RAL	DRV/rb	2.30	1.69	10.87	2.39	10.87	10.87	10.87	3.99	13.17	12.55	14.86	4.00	12.30	12.76	14.44
ddIb	NVP	DRV/rq	0.75	4.43	10.28	4.45	10.28	10.28	10.28	5.18	11.02	14.71	15.46	5.05	10.64	12.19	12.98
3TCq	RAL	DRV/rb	2.35	1.69	10.87	2.44	10.87	10.87	10.87	4.04	13.22	12.55	14.90	4.04	12.33	12.76	14.48
ddIq	NVP	DRV/rq	0.84	4.43	10.28	4.46	10.28	10.28	10.28	5.27	11.12	14.71	15.55	5.12	10.68	12.19	13.03
TDF	NVP	DRV/rq	0.86	4.43	10.28	4.43	10.28	10.28	10.28	5.29	11.14	14.71	15.57	5.32	10.66	12.19	13.19
FTC	ddIEC	DRV/rq	2.79	2.56	10.28	3.19	10.28	10.28	10.28	5.35	13.07	12.84	15.63	3.86	11.67	11.52	12.77
FTC	EFV	ATV/r	2.79	7.35	7.44	7.35	7.44	8.35	8.35	10.14	10.23	14.80	17.59	8.63	9.00	13.12	13.97
FTC	EVG/c	DRV/rb	2.79	1.41	10.87	2.80	10.87	10.87	10.87	4.20	13.66	12.28	15.07	4.28	12.26	12.33	14.28
ABCq	ENF	DRV/rb	2.14	2.07	10.87	2.53	10.87	10.87	10.87	4.21	13.01	12.94	15.08	3.82	12.53	10.97	12.91
3TCb	ABCb	DRV/rb	2.30	1.91	10.87	2.47	10.87	10.87	10.87	4.22	13.17	12.78	15.08	2.82	12.30	12.35	13.60
ddIEC	RAL	DRV/rb	2.56	1.69	10.87	2.66	10.87	10.87	10.87	4.25	13.43	12.55	15.11	4.11	12.11	12.76	14.38
3TCq	ABCb	DRV/rb	2.35	1.91	10.87	2.51	10.87	10.87	10.87	4.26	13.22	12.78	15.13	2.86	12.33	12.35	13.63
3TCb	ENF	DRV/rb	2.30	2.07	10.87	2.63	10.87	10.87	10.87	4.37	13.17	12.94	15.24	4.55	12.30	10.97	12.95
3TCq	ENF	DRV/rb	2.35	2.07	10.87	2.67	10.87	10.87	10.87	4.42	13.22	12.94	15.29	4.60	12.33	10.97	12.98
3TCb	ABCq	DRV/rb	2.30	2.14	10.87	2.56	10.87	10.87	10.87	4.45	13.17	13.01	15.31	2.93	12.30	12.53	13.75
ddIEC	ABCb	DRV/rb	2.56	1.91	10.87	2.74	10.87	10.87	10.87	4.47	13.43	12.78	15.34	3.11	12.11	12.35	13.48
FTC	RAL	DRV/rb	2.79	1.69	10.87	2.82	10.87	10.87	10.87	4.48	13.66	12.55	15.34	4.61	12.26	12.76	14.71
3TCq	ABCq	DRV/rb	2.35	2.14	10.87	2.59	10.87	10.87	10.87	4.49	13.22	13.01	15.36	2.96	12.33	12.53	13.77
ddIEC	ENF	DRV/rb	2.56	2.07	10.87	2.94	10.87	10.87	10.87	4.63	13.43	12.94	15.50	4.33	12.11	10.97	12.56
NVP	EVG/c	DRV/rq	4.43	1.41	10.28	4.43	10.28	10.28	10.28	5.85	14.71	11.69	16.12	7.01	12.19	11.74	15.98
d4T	NVP	DRV/rb	0.25	4.43	10.87	4.43	10.87	10.87	10.87	4.68	11.12	15.30	15.55	4.90	11.08	12.77	14.83
ddIEC	ABCq	DRV/rb	2.56	2.14	10.87	2.82	10.87	10.87	10.87	4.70	13.43	13.01	15.57	3.21	12.11	12.53	13.62
FTC	ABCb	DRV/rb	2.79	1.91	10.87	2.86	10.87	10.87	10.87	4.70	13.66	12.78	15.57	2.92	12.26	12.35	13.57
AZTb	NVP	DRV/rb	0.37	4.43	10.87	4.43	10.87	10.87	10.87	4.80	11.23	15.30	15.67	5.28	11.10	12.77	14.92
AZTt	NVP	DRV/rb	0.39	4.43	10.87	4.43	10.87	10.87	10.87	4.83	11.26	15.30	15.69	5.33	11.11	12.77	14.96
FTC	ENF	DRV/rb	2.79	2.07	10.87	2.99	10.87	10.87	10.87	4.86	13.66	12.94	15.73	4.39	12.26	10.97	12.62
3TCb	ddIEC	DRV/rb	2.30	2.56	10.87	2.91	10.87	10.87	10.87	4.86	13.17	13.43	15.73	3.38	12.30	12.11	13.38
3TCq	ddIEC	DRV/rb	2.35	2.56	10.87	2.92	10.87	10.87	10.87	4.91	13.22	13.43	15.78	3.40	12.33	12.11	13.40
FTC	ABCq	DRV/rb	2.79	2.14	10.87	2.90	10.87	10.87	10.87	4.93	13.66	13.01	15.80	2.97	12.26	12.53	13.70
NVP	RAL	DRV/rq	4.43	1.69	10.28	4.43	10.28	10.28	10.28	6.12	14.71	11.96	16.40	6.36	12.19	12.17	15.50
ABCb	NVP	DRV/rq	1.91	4.43	10.28	4.44	10.28	10.28	10.28	6.35	12.19	14.71	16.62	5.63	11.77	12.19	14.12
ddIb	NVP	DRV/rb	0.75	4.43	10.87	4.45	10.87	10.87	10.87	5.18	11.61	15.30	16.04	5.05	11.23	12.77	13.55
ddIq	NVP	DRV/rb	0.84	4.43	10.87	4.46	10.87	10.87	10.87	5.27	11.70	15.30	16.14	5.12	11.27	12.77	13.61
TDF	NVP	DRV/rb	0.86	4.43	10.87	4.43	10.87	10.87	10.87	5.29	11.73	15.30	16.16	5.32	11.25	12.77	13.75
NVP	ENF	DRV/rq	4.43	2.07	10.28	4.47	10.28	10.28	10.28	6.50	14.71	12.35	16.78	6.17	12.19	10.39	12.76
FTC	ddIEC	DRV/rb	2.79	2.56	10.87	3.19	10.87	10.87	10.87	5.35	13.66	13.43	16.22	3.86	12.26	12.11	13.37
ABCq	NVP	DRV/rq	2.14	4.43	10.28	4.44	10.28	10.28	10.28	6.58	12.42	14.71	16.85	5.77	11.94	12.19	14.27
d4T	ETR	DRV/rq	0.25	6.31	10.28	6.30	10.28	10.36	10.36	6.55	10.53	16.58	16.83	6.75	10.50	16.55	17.60
3TCb	NVP	DRV/rq	2.30	4.43	10.28	4.45	10.28	10.28	10.28	6.74	12.58	14.71	17.01	5.71	11.71	12.19	13.85
AZTb	ETR	DRV/rq	0.37	6.31	10.28	6.30	10.28	10.36	10.36	6.67	10.64	16.58	16.95	7.69	10.51	16.55	20.21
AZTt	ETR	DRV/rq	0.39	6.31	10.28	6.30	10.28	10.36	10.36	6.70	10.67	16.58	16.98	7.78	10.52	16.55	20.28
3TCq	NVP	DRV/rq	2.35	4.43	10.28	4.45	10.28	10.28	10.28	6.78	12.63	14.71	17.06	5.74	11.74	12.19	13.88
ddIEC	NVP	DRV/rq	2.56	4.43	10.28	4.57	10.28	10.28	10.28	6.99	12.84	14.71	17.27	6.55	11.52	12.19	14.02
NVP	EVG/c	DRV/rb	4.43	1.41	10.87	4.43	10.87	10.87	10.87	5.85	15.30	12.28	16.71	7.01	12.77	12.33	16.52
ddIb	ETR	DRV/rq	0.75	6.31	10.28	6.31	10.28	10.36	10.36	7.05	11.02	16.58	17.33	6.28	10.64	16.55	14.82
FTC	NVP	DRV/rq	2.79	4.43	10.28	4.48	10.28	10.28	10.28	7.22	13.07	14.71	17.50	6.21	11.67	12.19	13.88
ddIq	ETR	DRV/rq	0.84	6.31	10.28	6.31	10.28	10.36	10.36	7.14	11.12	16.58	17.42	6.28	10.68	16.55	14.87
TDF	ETR	DRV/rq	0.86	6.31	10.28	6.30	10.28	10.36	10.36	7.16	11.14	16.58	17.44	6.44	10.66	16.55	15.04
NVP	RAL	DRV/rb	4.43	1.69	10.87	4.43	10.87	10.87	10.87	6.12	15.30	12.55	16.99	6.36	12.77	12.76	16.07
ABCb	NVP	DRV/rb	1.91	4.43	10.87	4.44	10.87	10.87	10.87	6.35	12.78	15.30	17.21	5.63	12.35	12.77	14.71
NVP	ENF	DRV/rb	4.43	2.07	10.87	4.47	10.87	10.87	10.87	6.50	15.30	12.94	17.37	6.17	12.77	10.97	13.31
d4T	EFV	DRV/rq	0.25	7.35	10.28	7.35	10.28	10.41	10.41	7.60	10.53	17.63	17.88	8.00	10.50	15.46	19.41
ABCq	NVP	DRV/rb	2.14	4.43	10.87	4.44	10.87	10.87	10.87	6.58	13.01	15.30	17.44	5.77	12.53	12.77	14.85
d4T	ETR	DRV/rb	0.25	6.31	10.87	6.30	10.87	10.92	10.92	6.55	11.12	17.17	17.42	6.75	11.08	17.14	18.15

Regimen[a]			IIP_{ave}																
			Single drug			Loewe[b]				Bliss[c]				DI Index[d]			
Drug 1	Drug 2	Drug 3	1	2	3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3	1,2	1,3	2,3	1,2,3
ETR	EVG/c	DRV/rq	6.31	1.41	10.28	6.30	10.36	10.28	10.36	7.72	16.58	11.69	18.00	7.55	16.55	11.74	17.87
AZTb	EFV	DRV/rq	0.37	7.35	10.28	7.35	10.28	10.41	10.41	7.72	10.64	17.63	18.00	8.91	10.51	15.46	22.41
AZTt	EFV	DRV/rq	0.39	7.35	10.28	7.35	10.28	10.41	10.41	7.75	10.67	17.63	18.02	9.02	10.52	15.46	22.51
AZTb	ETR	DRV/rq	0.37	6.31	10.87	6.30	10.87	10.92	10.92	6.67	11.23	17.17	17.54	7.69	11.10	17.14	20.66
3TCb	NVP	DRV/rb	2.30	4.43	10.87	4.45	10.87	10.87	10.87	6.74	13.17	15.30	17.60	5.71	12.30	12.77	14.44
AZTt	ETR	DRV/rb	0.39	6.31	10.87	6.30	10.87	10.92	10.92	6.70	11.26	17.17	17.56	7.78	11.11	17.14	20.74
3TCq	NVP	DRV/rb	2.35	4.43	10.87	4.45	10.87	10.87	10.87	6.78	13.22	15.30	17.65	5.74	12.33	12.77	14.46
ETR	RAL	DRV/rq	6.31	1.69	10.28	6.30	10.36	10.28	10.36	7.99	16.58	11.96	18.27	7.73	16.55	12.17	18.31
ddIEC	NVP	DRV/rb	2.56	4.43	10.87	4.57	10.87	10.87	10.87	6.99	13.43	15.30	17.86	6.55	12.11	12.77	14.59
ddIb	EFV	DRV/rq	0.75	7.35	10.28	7.35	10.28	10.41	10.41	8.10	11.02	17.63	18.38	7.77	10.64	15.46	15.18
ddIb	ETR	DRV/rb	0.75	6.31	10.87	6.31	10.87	10.92	10.92	7.05	11.61	17.17	17.92	6.28	11.23	17.14	15.42
ABCb	ETR	DRV/rq	1.91	6.31	10.28	6.31	10.28	10.36	10.36	8.22	12.19	16.58	18.50	6.62	11.77	16.55	16.58
ddIq	EFV	DRV/rq	0.84	7.35	10.28	7.36	10.28	10.41	10.41	8.19	11.12	17.63	18.47	7.82	10.68	15.46	15.23
TDF	EFV	DRV/rq	0.86	7.35	10.28	7.35	10.28	10.41	10.41	8.21	11.14	17.63	18.49	7.97	10.66	15.46	15.45
ddIq	ETR	DRV/rb	0.84	6.31	10.87	6.31	10.87	10.92	10.92	7.14	11.70	17.17	18.01	6.28	11.27	17.14	15.47
TDF	ETR	DRV/rb	0.86	6.31	10.87	6.31	10.87	10.92	10.92	7.16	11.73	17.17	18.03	6.44	11.25	17.14	15.63
FTC	NVP	DRV/rb	2.79	4.43	10.87	4.48	10.87	10.87	10.87	7.22	13.66	15.30	18.09	6.21	12.26	12.77	14.46
ETR	ENF	DRV/rq	6.31	2.07	10.28	6.31	10.36	10.28	10.36	8.38	16.58	12.35	18.65	8.20	16.55	10.39	16.15
ABCq	ETR	DRV/rq	2.14	6.31	10.28	6.31	10.28	10.36	10.36	8.45	12.42	16.58	18.73	6.66	11.94	16.55	16.75
3TCb	ETR	DRV/rq	2.30	6.31	10.28	6.31	10.28	10.36	10.36	8.61	12.58	16.58	18.89	6.86	11.71	16.55	16.53
3TCq	ETR	DRV/rq	2.35	6.31	10.28	6.31	10.28	10.36	10.36	8.65	12.63	16.58	18.93	6.87	11.74	16.55	16.56
d4T	EFV	DRV/rb	0.25	7.35	10.87	7.35	10.87	10.94	10.94	7.60	11.12	18.22	18.47	8.00	11.08	16.03	19.90
EFV	EVG/c	DRV/rq	7.35	1.41	10.28	7.35	10.41	10.28	10.41	8.77	17.63	11.69	19.05	8.86	15.46	11.74	18.17
ETR	EVG/c	DRV/rb	6.31	1.41	10.87	6.30	10.92	10.87	10.92	7.72	17.17	12.28	18.59	7.55	17.14	12.33	18.47
ddIEC	ETR	DRV/rq	2.56	6.31	10.28	6.33	10.28	10.36	10.36	8.87	12.84	16.58	19.14	6.24	11.52	16.55	15.95
AZTb	EFV	DRV/rb	0.37	7.35	10.87	7.35	10.87	10.94	10.94	7.72	11.23	18.22	18.59	8.91	11.10	16.03	22.80
AZTt	EFV	DRV/rb	0.39	7.35	10.87	7.35	10.87	10.94	10.94	7.75	11.26	18.22	18.61	9.02	11.11	16.03	22.90
EFV	RAL	DRV/rq	7.35	1.69	10.28	7.35	10.41	10.28	10.41	9.04	17.63	11.96	19.32	9.55	15.46	12.17	19.27
FTC	ETR	DRV/rq	2.79	6.31	10.28	6.31	10.28	10.36	10.36	9.10	13.07	16.58	19.37	6.83	11.67	16.55	16.42
ETR	RAL	DRV/rb	6.31	1.69	10.87	6.30	10.92	10.87	10.92	7.99	17.17	12.55	18.86	7.73	17.14	12.76	18.92
ddIb	EFV	DRV/rb	0.75	7.35	10.87	7.35	10.87	10.94	10.94	8.10	11.61	18.22	18.97	7.77	11.23	16.03	15.74
ABCb	EFV	DRV/rq	1.91	7.35	10.28	7.35	10.28	10.41	10.41	9.27	12.19	17.63	19.54	8.81	11.77	15.46	17.17
ddIq	EFV	DRV/rb	0.84	7.35	10.87	7.36	10.87	10.94	10.94	8.19	11.70	18.22	19.06	7.82	11.27	16.03	15.80
ABCb	ETR	DRV/rb	1.91	6.31	10.87	6.31	10.87	10.92	10.92	8.22	12.78	17.17	19.09	6.62	12.35	17.14	17.19
TDF	EFV	DRV/rb	0.86	7.35	10.87	7.35	10.87	10.94	10.94	8.21	11.73	18.22	19.08	7.97	11.25	16.03	16.00
EFV	ENF	DRV/rq	7.35	2.07	10.28	7.35	10.41	10.28	10.41	9.42	17.63	12.35	19.70	9.20	15.46	10.39	15.60
ETR	ENF	DRV/rb	6.31	2.07	10.87	6.31	10.92	10.87	10.92	8.38	17.17	12.94	19.24	8.20	17.14	10.97	16.68
ABCq	EFV	DRV/rq	2.14	7.35	10.28	7.35	10.28	10.41	10.41	9.50	12.42	17.63	19.77	8.98	11.94	15.46	17.34
ABCq	ETR	DRV/rb	2.14	6.31	10.87	6.31	10.87	10.92	10.92	8.45	13.01	17.17	19.31	6.66	12.53	17.14	17.36
3TCb	EFV	DRV/rq	2.30	7.35	10.28	7.35	10.28	10.41	10.41	9.66	12.58	17.63	19.94	8.38	11.71	15.46	16.27
3TCq	EFV	DRV/rq	2.35	7.35	10.28	7.35	10.28	10.41	10.41	9.70	12.63	17.63	19.98	8.40	11.74	15.46	16.29
3TCb	ETR	DRV/rb	2.30	6.31	10.87	6.31	10.87	10.92	10.92	8.61	13.17	17.17	19.48	6.86	12.30	17.14	17.13
3TCq	ETR	DRV/rb	2.35	6.31	10.87	6.31	10.87	10.92	10.92	8.65	13.22	17.17	19.52	6.87	12.33	17.14	17.16
EFV	EVG/c	DRV/rb	7.35	1.41	10.87	7.35	10.94	10.87	10.94	8.77	18.22	12.28	19.63	8.86	16.03	12.33	18.75
ddIEC	EFV	DRV/rq	2.56	7.35	10.28	7.36	10.28	10.41	10.41	9.91	12.84	17.63	20.19	8.77	11.52	15.46	16.22
ddIEC	ETR	DRV/rb	2.56	6.31	10.87	6.33	10.87	10.92	10.92	8.87	13.43	17.17	19.73	6.24	12.11	17.14	16.55
FTC	EFV	DRV/rq	2.79	7.35	10.28	7.35	10.28	10.41	10.41	10.14	13.07	17.63	20.42	8.63	11.67	15.46	16.18
EFV	RAL	DRV/rb	7.35	1.69	10.87	7.35	10.94	10.87	10.94	9.04	18.22	12.55	19.91	9.55	16.03	12.76	19.83
FTC	ETR	DRV/rb	2.79	6.31	10.87	6.31	10.87	10.92	10.92	9.10	13.66	17.17	19.96	6.83	12.26	17.14	17.02
ABCb	EFV	DRV/rb	1.91	7.35	10.87	7.35	10.87	10.94	10.94	9.27	12.78	18.22	20.13	8.81	12.35	16.03	17.74
EFV	ENF	DRV/rb	7.35	2.07	10.87	7.35	10.94	10.87	10.94	9.42	18.22	12.94	20.29	9.20	16.03	10.97	16.10
ABCq	EFV	DRV/rb	2.14	7.35	10.87	7.35	10.87	10.94	10.94	9.50	13.01	18.22	20.36	8.98	12.53	16.03	17.92
3TCb	EFV	DRV/rb	2.30	7.35	10.87	7.35	10.87	10.94	10.94	9.66	13.17	18.22	20.52	8.38	12.30	16.03	16.85
3TCq	EFV	DRV/rb	2.35	7.35	10.87	7.35	10.87	10.94	10.94	9.70	13.22	18.22	20.57	8.40	12.33	16.03	16.88
ddIEC	EFV	DRV/rb	2.56	7.35	10.87	7.36	10.87	10.94	10.94	9.91	13.43	18.22	20.78	8.77	12.11	16.03	16.79
FTC	EFV	DRV/rb	2.79	7.35	10.87	7.35	10.87	10.94	10.94	10.14	13.66	18.22	21.01	8.63	12.26	16.03	16.75

[a]Regimens with more than one drug from the NNRTI, PI, or InSTI classes or NRTI subclasses were excluded. In the case

of drugs for which multiple dosing schedules are used, calculations were done separately for each dosing schedule (q=

once daily, b= twice daily, t= thrice daily, EC= enteric coated, /r=dosing with RTV, /c=dosing with cobicistat). Some

listed regimens may have unfavorable pharmacokinetic interactions not accounted for in the present analysis. Regimens are sorted based on the midpoint of the Loewe-Bliss range of IIP_{ave} values

[b]The Loewe prediction for IIP_{ave} for two or three drugs was computed using the area under the curve for the IIP vs. time curves, where $IIP = \log(1/f_u)$ and f_u is determined from the Loewe formula for two drugs (**Equation 4**) or 3 drugs (**Fig. 3b**), with m and IC_{50} values chosen to represent the shape of the dose-response curve for each drug in the clinical concentration range (m' and IC_{50}', **Supplementary Table S1**).

[c]The Bliss prediction for IIP_{ave} for two or three drugs was computed using the area under the curve for the IIP vs. time curves, where $IIP=\log(1/f_u)$ and f_u is determined from the Bliss formula for two drugs (**Equation 3**) or 3 drugs (**Fig. 3a**), with m and IC_{50} values chosen to represent the shape of the dose-response curve for each drug in the clinical concentration range (m' and IC_{50}', Supplementary Table S1).

[d]Predictions based on the DI index were computed using mean pairwise DI index values (**Supplementary Table S5**) for two drug combinations. For three drug combinations, we used a weighted average of pairwise DI values as described in **Supplemental Information, Methods**.

Supplementary Table S7. Relationship between experimental values of IIP_{1+2+3} and values predictd by three different methods for representative three drug regimens.

Regimen[a]			Expected mode of interaction[b]			IIP_{1+2+3} values[c]			
Drug 1	Drug 2	Drug 3	Drugs 1+2	Drugs 1+3	Drugs 2+3	Exper.	Bliss	Loewe	*DI* Index
TDF	FTC	EFV	inter	inter	inter	2.63	4.30	1.88	2.67
TDF	FTC	RAL	inter	synergy	Bliss	2.70	4.46	1.91	3.47
ABC	3TC	EFV	Loewe	inter	inter	1.95	3.73	1.78	2.04
ABC	3TC	NVP	Loewe	inter	inter	1.87	3.65	1.73	2.12
ETR[d]	NVP[d]	EFV[d]	Loewe	Loewe	Loewe	1.71	2.80	2.09	1.76
NVP[d]	ENF[d]	RAL[d]	Bliss	Bliss	Bliss	3.10	3.38	1.50	3.40
FTC	EFV	RAL	inter	Bliss	synergy	2.71	4.22	1.98	2.93
TDF	EFV	RAL	inter	Bliss	synergy	3.18	4.28	1.91	3.33
3TC	EFV	NVP	inter	inter	Loewe	2.06	3.75	1.88	2.16
ABC	EFV	NVP	inter	inter	Loewe	1.91	3.69	1.78	2.20

[a]Regimens were chosen to include common used combinations as well as combinations that reflect particular modes of interaction. Some combinations, such as the ETR/NVP/EFV combination chosen to reflect Loewe additivity, would not be used clinically.

[b]Mode of interaction (syngery, Bliss independence, intermediate, Loewe additivity, or antagonism) based on experiments summarized in **Fig. 2f**.

[c]IIP_{1+2+3} values here reflect inhibition at the drug ratios selected to given the highest combined effect within the dynamic range of the assay with equal contribution from each drug. Under these conditions, the differences between the Loewe and Bliss predictions are maximized. Because the drug concentrations used in these experiment are different (and generally lower than) the clinical concentrations, the IIP_{1+2+3} values in this table do not reflect IIP_{1+2+3} values at clinical drug concentrations. Estimated IIP_{1+2+3} values at clinical concentrations are shown in **Fig. 4** and **Supplementary Table S6**.

[d]These experiments were carried out with CCR5-tropic virus.

Supplementary Table S8. Comparison of IC_{50}' and m' values obtained using R5 and X4 viruses.

Drug	log IC_{50}' [a]			m' [b]		
	R5[c]	X4[d]	P value	R5[c]	X4[d]	P value
AZT	0.43 ± 0.59	0.20 ± 0.69	0.4756	0.48 ± 0.17	0.63 ± 0.21	0.1770
d4T	-0.01 ± 0.35	0.07 ± 0.42	0.6864	0.75 ± 0.15	0.85 ± 0.20	0.1743
3TC	-1.29 ± 0.25	-1.25 ± 0.23	0.7638	1.23 ± 0.30	1.12 ± 0.25	0.5241
FTC	-1.34 ± 0.52	-1.56 ± 0.47	0.5424	1.19 ± 0.19	1.26 ± 0.44	0.6229
TDF	-0.99 ± 1.02	-1.91 ± 0.63	0.2581	0.50 ± 0.14	0.41 ± 0.13	0.3853
ABC	-0.69 ± 0.38	-1.14 ± 0.66	0.1578	1.20 ± 0.22	1.04 ± 0.23	0.3423
NVP	-0.58 ± 0.18	-0.65 ± 0.22	0.5703	2.06 ± 0.29	2.40 ± 0.64	0.1624
EFV	-1.77 ± 0.13	-1.84 ± 0.18	0.4521	2.30 ± 0.26	2.57 ± 0.51	0.2082
RAL	-1.36 ± 0.07	-1.38 ± 0.31	0.7833	0.91 ± 0.08	0.91 ± 0.15	0.9207
ELV	-1.28 ± 0.17	-1.22 ± 0.33	0.5941	0.88 ± 0.22	0.87 ± 0.27	0.9202

[a] IC_{50}' is determined from m' and the y-intercept of a linear regression line best representing the dose-response curve in the clinical concentration range as described in Methods.

[b] m' is the slope of a linear regression line best representing the dose-response curve in the clinical concentration range (see Methods).

[c] Data from infectivity assays carried out with recombinant HIV-1 vector (pNL43-ΔE-EGFP) pseudotyped with an R5 envelope (SF162).

[d] Data from infectivity assays carried out with recombinant HIV-1 vector pseudotypes with an X4 envelope (HXB2).

Supplementary Material

Methods

Antiretroviral drugs. Drugs were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS at the National Institute of Allergy and Infectious Diseases, US National Institutes of Health, except for EVG which was provided by D. Hazuda (Merck). 3TC, AZT, ABC, ddI, EFV, NVP, ETR, EVG, ATV DRV, LPV, NFV, RTV, and MVC were dissolved in DMSO. d4T, FTC, TDF, and RAL were dissolved in tissue culture media (DMEM + 50% human serum + 10% fetal calf serum). ENF was reconstituted in a 0.1 M sodium bicarbonate buffer solution, pH 8.6. Stock solutions were at 50 mM except for TDF (40 mM), RAL (10 mM), and ENF (1 mM). Stocks were aliquoted and stored at -20°C except for ENF which was stored at -80°C. Concentrations of the DMSO vehicle were constant for all drug dilutions.

Virus stocks. HEK 293 T cells were propagated in DMEM with 10% fetal bovine serum in tissue culture flasks to 90% confluence. Cells were transfected with a previously described[1,2] HIV-1 vector (pNL43-ΔE-EGFP) containing a GFP-tagged, defective envelope. The envelope was provided in trans by co-transfection with a CXCR4 envelope expression vector except that in the case of experiments involving MVC, a CCR5 envelope expression vector was used. Transfections were done using Lipofectamine 2000 following the manufacturer's instructions (Invitrogen). After 7-8 hours, medium was replaced with RPMI1640 supplemented with 10% fetal bovine serum (FBS). After incubation for 48 hours, supernatants were collected and centrifuged at 1200 rpm for 10 minutes to pellet cellular debris. Supernatants were then filtered through a 0.22 μm membrane. Virus was pelleted by ultracentrifugation at 100,000 g for 2 hours. The viral pellets were resuspended in RPMI1640, aliquoted to appropriate volume, and stored at -80 °C. Viral stocks were standardized based on level of HIV-1 p24 determined using an enzyme-linked immunosorbent assay (Perkin-Elmer). For each virus preparation, titrations were done to determine the amount of virus needed to give 20% infection of 1×10^5 cells. For experiments containing PIs, the medium was replaced 7-8 h after transfection with RPMI1640 containing the PIs and

50% human serum plus 10% FBS. The transfected cells were incubated for 48 hours, and the virus was collected and used for infection without concentration at concentrations giving ~20% infection.

Infectivity assays. Inhibition of HIV-1 infection was measured in a single round infectivity assay as previously described[1,2]. To accurately mimic infection events *in vivo*, infections were carried out in primary CD4[+] T lymphoblasts. To account for individual variation in cellular uptake and metabolism of drugs, assays were carried out in lymphoblasts from 10-60 donors, and average levels of inhibition were computed. High serum concentrations were used to account for protein binding. For protein bound drugs, titrations of drug effect vs. serum concentration demonstrated that inclusion of 50% human serum and 10% fetal calf serum provided a close approximation for *in vivo* drug binding. Lots of human serum were preselected for low toxicity to CD4[+] T lymphoblasts. Drugs were added to lymphoblast targets, and cells were incubated at 37°C for 16 hours before infection to allow sufficient time for triphosphorylation of NRTIs. Longer preincubations did not enhance antiviral activity. PIs were also added at the stage of viral production in 293T cells[2]. After spin infection in 96 well plates, targets incubated for 3 days at 37 °C. Cells were then fixed in 2% formaldehyde, and GFP expression was analyzed by flow cytometry. After gating for viable cells, the fraction of infection events unaffected by drug (f_u) was determined as the % GFP[+] cells in the presence of drug divided by the % GFP[+] cells in control wells set up without drug.

Calculation of *IIP*$_{ave}$ for single drugs. For single drugs, *IIP*$_{ave}$ was computed from the area under the curve (*AUC*) of the *IIP* vs. time curve over a dosing interval (τ):

$$IIP_{ave} = \frac{AUC\,[IIP(t)]}{\tau}$$

IIP at a given time (*t*) was computed using the median-effect equation for f_u (Equation 1):

$$IIP(t) = \log\,[1/f_u(t)] = \log\,[1+(D(t)/IC_{50}')^{m'}]$$

where *m'* and *IC*$_{50}$' represent values that best approximate the shape of the dose-response curve in the clinical concentration range (**Supplementary Table S1**). In cases where clinical concentrations

produced levels of inhibition within the dynamic range of the assay ($IIP<3$), m' and IC_{50}' were directly determined from the experimental data. m' was taken as the slope of a linear regression line through these data points on a median-effect plot, and IC_{50}' was calculated as:

$$IC_{50}'=10^{-b/m'}$$

where b is the y-intercept of the regression line. In cases where clinical concentrations produce levels of inhibition beyond the dynamic range of the assay ($IIP>3$ at C_{min}), m' was taken to be the slope of a linear regression line through the three data points closest to the clinical concentration range (**Supplementary Figure S7**). IC_{50}' was determined as above. For drugs with sharply infected dose-response curves, m' and IC_{50}' are expected to differ from previously reported values[1] which were based on minimal estimates of m. Values for m' and IC_{50}' for each donor were used to compute $IIP(t)$. To estimate D as a function of time t, we assumed exponentially decay from C_{max} and rapid absorption and distribution of the drug. We used published values for C_{max} and $t_{1/2}$ (see **Supplementary Table S3**). For NRTIs, half-lives of the active intracellular triphosphate forms were used. The mean and SD of IIP_{ave} values for each drug are shown in **Fig. 1g** and **Supplementary Table S3**. Note that this analysis assumes that upwardly infecting curves for NNRTIs and PIs do not undergo an additional downward inflection at high D. Support for this assumption comes from a theoretical analysis of the molecular basis for upwardly infecting dose-response curves (see **Supplementary Note 2** and reference 3). Importantly, this calculation takes into account both the complex shapes of the dose-response curves revealed here and pharmacokinetic differences between drugs. Although individual variability in pharmacodynamic parameters gives rise to variability in IIP_{ave} (**Fig. 1g**), the differences in IIP_{ave} values for different drugs are highly significant for most comparisons (**Supplementary Table S4**). This analysis does not consider individual variation in pharmacokinetics, which is likely to provide additional variation. Nevertheless, the striking multilog differences in IIP_{ave} provide insight into the general activity of these drugs in populations of patients.

Combination experiments. To determine whether the combined effect of two antiretroviral drugs followed the predictions of the Bliss or Loewe models, we tested pairs of drugs at constant molar ratios chosen to maximize the difference between the levels of inhibition predicted by the two models. Drug

combinations are often evaluated in surface experiments in which all possible combinations of several different concentrations of each drug are tested[4,5]. However, the difference between the inhibition predicted by the two models increases with drug concentration (**Fig. 2b**) and is maximal when both drugs contribute equally to the observed suppression (R. Siliciano, unpublished observation). Therefore, we chose drug concentrations such that at the highest concentrations used, the total inhibition predicted by the Bliss model would be within the dynamic range of the assay (*IIP*<3), with each drug contributing equally. Drugs were mixed at these concentrations and serially diluted. Experimental analysis was carried out in cells from 5-15 donors/combination.

Two drug interactions were characterized with respect to model predictions using two methods. For both methods, predicted dose-response curves were constructed using **Equations 3** and **4**. Because the dose-response curves for some drugs showed pronounced inflections in the measured concentration range, we used local average m and IC_{50} values computed with three data points centered on the point of interest. To determine whether experimental results from combination experiments fit predictions of the Bliss or Loewe models, R^2 values were computed for the fit with experimental data. A combination was considered to fit the Bliss or Loewe prediction if the relevant R^2 value was > 0.9. An intermediate pattern was defined as inhibition between the predictions of the Loewe and Bliss models, with R^2 < 0.9 for both models and $F_L < F_E < F_B$, where F_L, F_E, and F_B are logarithmic measures of inhibition, log [(1−f_u)/f_u], for the Loewe prediction, the experimental data, and the Bliss prediction, respectively. An intermediate pattern was also assigned in cases where $F_L < F_E < F_B$ and $R^2 > 0.9$ for both models. Synergy was defined as R^2<0.9 for Bliss and $F_E > F_B > F_L$. Antagonism, defined as $R^2 < 0.9$ for Loewe and $F_E < F_L < F_B$, was not observed.

In a second approach to characterizing drug combinations, a *DI* index was computed using Equation 5. Because the difference between the Bliss and Loewe predictions increases with drug concentration, the *DI* index was computed using the highest concentration in the measurable range. In general, differences between the *DI* index at this concentration and at the next lowest concentration were not significant, suggesting that the index reflects the degree to which the drugs behave independently, a

4

feature that should remain constant over a wide range of drug concentrations. This analysis assumes that $F_B > F_L$, which is true over a wide range of m and IC_{50} values and can be formally proven for $m_1 = m_2 = 1$.

Calculation of IIP_{ave} for drug combinations. For three drug combinations, $IIP_{ave_{1+2+3}}$ values were computed from the area under the curve of the IIP_{1+2+3} vs. time plot over a 24 hr period. Drug levels achieved with standard dosing for each drug and published plasma and intracellular (for NRTIs) half-lives were used to calculate $IIP_{ave_{1+2+3}}$ for each model. Formulas for the three drug forms of the Bliss and Loewe models are given in **Fig. 3a**. The m and IC_{50} values for each component drug were chosen to best represent the shapes of the single drug dose-response curves in the clinical concentration range (m' and I IC_{50}', **Supplementary Table S1**). We assumed that three drugs were taken simultaneously at the beginning of this period, reached C_{max} quickly, and then decayed exponentially as described above. For *bid* and *tid* drugs, the effects of the additional doses were included after the appropriate interval. For a given time t, the concentrations of drugs 1, 2, and 3 were used to compute $IIP_{ave_{1+2+3}}$ using three drug forms of the Bliss and Loewe equations. In each case, $IIP_{ave_{1+2+3}} = \log (1/f_{u_{1+2+3}})$ where $f_{u_{1+2+3}}$ is given by the relevant formulas (**Fig. 3a**). The Loewe formula is based on the idea the inhibitors act in a mutually exclusive way or compete for the same binding site as discussed by Chou[5]. It is derived from the general expression for an n drug combination with no synergy or antagonism:

$$1 = \sum_{i=1}^{n} \frac{D_i}{(D_x)_i}$$

where D_i is the concentration of drug i in a combination giving x % inhibition and $(D_x)_i$ is the concentration of drug i alone that produces the same degree of inhibition. Using the convention of positive slopes for inhibitory drugs, Equation 1 for any given value of f_u can be written as:

$$(D_x)_i = IC_{50}\left(\frac{f_u}{1-f_u}\right)^{-1/m}$$

This substitution can be used for each drug to obtain the Loewe three drug expression given in **Fig. 3a**.

To obtain a more precise estimate of IIP_{ave} for three drug combinations, we used experimentally determined DI values (**Supplementary Table S5**) to map inhibition at clinical concentrations in relation to the predictions of the Bliss and Loewe estimates calculated from the above formulas. A weighted average of the three relevant pairwise DI values was used. Weighting was based on the predicted degree of inhibition produced by each pair and was allowed to vary with time as drug concentrations changed. The following formula was used:

$$F_{\text{predicted}_{1+2+3}} = F_{L_{1+2+3}} + [DI_{1+2+3} \; x \; (F_{B_{1+2+3}} - F_{L_{1+2+3}})]$$

where $DI_{1+2+3} = [(DI_{1+2} \; x \; F_{1+2}) + (DI_{1+3} \; x \; F_{1+3}) + (DI_{2+3} \; x \; F_{2+3})]/(F_{1+2} + F_{1+3} + F_{2+3})$. Note that at higher levels of inhibition, F approaches $\log(1/f_u)$, which is the IIP. The precise relationship is:

$$IIP = \log(1/f_u) = \log(1 + 10^F)$$

References

1. Shen, L. *et al*. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. *Nat. Med.* 14, 762-766 (2008).

2. Sampah, M. E., Shen, L., Jilek, B. L. & Siliciano, R. F. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. *Proc. Natl. Acad. Sci. U. S. A.* 108, 7613-7618 (2011).

3. Shen, L. *et al*. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. *Sci. Transl. Med.* 3, 91ra63 (2011).

4. Greco, W. R., Bravo, G. & Parsons, J. C. The search for synergy: a critical review from a response surface perspective. *Pharmacol. Rev.* 47, 331-385 (1995).

5. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol. Rev.* 58, 621-681 (2006).

Supplementary Note 1. **Non-linearity of median-effect plots for certain antitretroviral drugs.** For every donor tested (n=35), median-effect plots of the dose-response curves for the PI ATV showed a striking upward inflection **(Fig. 1c)**. The tangent slopes below the IC_{50} (m^*) were much lower than the tangent slopes in the region of the dose-response curve closest to the clinical concentration range (m'). m^* was calculated from the slope of a best fit line through the data points for which log $[(1-f_u)/f_u] < 0$. m' was taken to be the slope of a linear regression line through the three data points closest to the clinical concentration range. The difference was highly significant ($m^* = 0.98 \pm 0.50$, $m' = 3.52 \pm 0.41$, $P < 0.0001$). The same was true for all other PIs studied (**Supplementary Fig. S1**). For every donor, median-effect curves for each PI inflected sharply upward above the IC_{50}, with m' significantly greater than m^* (**Supplementary Table S1**).

Supplementary Note 2. Extrapolating median-effect plots to high *D*. In cases where the inhibition produced by clinical concentrations of a drug is high (*IIP*>3) and beyond the dynamic range of the infectivity assay, extrapolation of the median-effect plot from the upper end of the measurable concentration range was used to estimate inhibition at clinical concentrations. This approach assumes that these transformed dose-response curves do not show a saturation effect or downward inflection at high *D*. This assumption is supported by several lines of evidence:

1) We have recently described a new model for drug action that explains the upward inflections observed for PIs and NNRTIs[1]. For these drugs, multiple copies of the drug target are involved in the relevant step in the virus life cycle. For example, multiple copies of protease simultaneously participate in virus maturation. If a certain critical number (*c*) of these enzyme molecules out of a total of n_T protease enzyme molecules per virion must be in an unbound state for virus maturation to be completed, then it is possible to derive from the law of mass action the following expression for f_a, the fraction of infection events blocked by drug, as a function of, *c*, n_T, the drug concentration *D*, the unbound virus concentration *V*, and K_d, dissociation constant for the drug-target binding:

$$f_a(n_T) = \frac{\displaystyle\sum_{i=n_T-c+1}^{n_T} \binom{n_T}{i}\left(\frac{D}{K_d}\right)^i}{\displaystyle\sum_{i=0}^{n_T} \binom{n_T}{i}\left(\frac{D}{K_d}\right)^i}$$

This equation simply states that f_a is the sum of all viruses having subthreshold numbers of unbound enzymes divided by the total number of viruses. We have shown that for values of *c* and n_T that fit the NNRTI and PI dose response curves, the logarithmic measures of inhibition based on this function do not show saturation or downward inflection as *D* increases above the IC_{50}, even at very high *D* (**Fig. S2a and S2b**). The NNRTI curves show a slight upward inflection (**Fig. S2a**). The pronounced upward inflection in the experimental PI dose response curves (**Fig. 1c-f**) is further explained in point 2. Importantly, in no case do the curves inflect downward at concentrations above substantially above the IC_{50}.

2) We have recently shown that the sharp upward inflection in the PI dose response curves (**Fig. 1c-f**) results from the fact that the inhibition of virus maturation affects multiple downstream steps in the virus life cycle (Rabi et al, manuscript in preparation). In this sense, individual PIs behave as drug combinations. As shown here, when different steps in the life cycle are targeted, the combined effects follow Bliss independence (**Fig. 2a and b**). In this situation, the logarithmic measures of inhibition inflect upward.

3) Downward inflections are not apparent when infectivity assays are done with an extended 6 log dynamic range allowing[2].

References

1. Shen, L. *et al*. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. *Sci. Transl. Med.* 3, 91ra63 (2011).

2. Shen, L. *et al*. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. *Nat. Med.* 14, 762-766 (2008).

Supplementary Note 3. Complex shapes of dose-response curves for antiretroviral drugs.

As shown in **Fig. 1e**, PIs and NNRTIs have steep, upwardly inflected dose-response curves. Complex curves were also noted for other antiretrovirals. The fusion inhibitor enfuvirtide (ENF) has a steep, slightly inflected dose-response curve ($m = 1.53 \pm 0.24$). Complex dose-response curves were also observed for the deoxyadenosine analogs didanosine (ddI) and tenofovir disoproxil fumarate (TDF), the deoxyguanosine analogue abacavir (ABC), and the deoxythymidine analogue stavudine (d4T). The other deoxythymidine analogue, zidovudine (AZT), has a very low slope ($m = 0.62 \pm 0.21$). The atypical nature of these curves may reflect complexities in conversion from prodrugs to active triphosphate forms as well as the excision reaction that reverses inhibition. Standard, non-cooperative dose-response curves (linear median effect plot with $m \approx 1$) were observed only for two deoxycytidine analogs, lamivudine (3TC) and emtricitabine (FTC), and for InSTIs. The CCR5 antagonist maraviroc (MVC), the only drug targeting a host protein, had a linear curve with a low slope ($m = 0.61 \pm 0.17$).